---
document_datetime: 2023-11-09 19:37:47
document_pages: 116
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003820-ii-0121-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-003820-ii-0121-epar-assessment-report-variation_en.pdf
version: success
processing_time: 333.5150865
conversion_datetime: 2025-12-29 19:51:52.249481
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
14 September 2023 EMA/451876/2023

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Keytruda

International non-proprietary name: pembrolizumab

Procedure No. EMEA/H/C/003820/II/0121

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................6                                                          |
|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ................................................................................................ | 6                                                                                                        |
| 1.2. Steps taken for the assessment of the product                                                                      | ....................................................... 6                                                |
| 2. Scientific discussion                                                                                                | ................................................................................8                        |
| 2.1. Introduction                                                                                                       | ...................................................................................................... 8 |
| 2.1.1. Problem statement                                                                                                | .......................................................................................... 8             |
| 2.1.2. About the product .........................................................................................      | 12                                                                                                       |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                        | ..... 12                                                                                                 |
| 2.1.4. General comments on compliance with GCP                                                                          | ...................................................... 13                                                |
| 2.2. Non-clinical aspects..........................................................................................     | 13                                                                                                       |
| 2.2.1. Ecotoxicity/environmental risk assessment........................................................                | 13                                                                                                       |
| 2.3. Clinical aspects                                                                                                   | ................................................................................................ 13      |
| 2.3.1. Introduction                                                                                                     | ................................................................................................. 13     |
| 2.3.2. Pharmacokinetics ..........................................................................................      | 14                                                                                                       |
| 2.3.3. Discussion on clinical pharmacology                                                                              | ................................................................. 19                                     |
| 2.3.4. Conclusions on clinical pharmacology ...............................................................             | 20                                                                                                       |
| 2.4. Clinical efficacy                                                                                                  | ................................................................................................ 20      |
| 2.4.1. Dose response study(ies) ...............................................................................         | 20                                                                                                       |
| 2.4.2. Main study                                                                                                       | ................................................................................................... 20   |
| 2.4.3. Discussion on clinical efficacy ..........................................................................       | 68                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy...................................................................          | 73                                                                                                       |
| 2.5. Clinical safety                                                                                                    | .................................................................................................. 74    |
| 2.5.1. Discussion on clinical safety                                                                                    | ...........................................................................102                           |
| 2.5.2. Conclusions on clinical safety .........................................................................106      |                                                                                                          |
| 2.5.3. PSUR cycle                                                                                                       | ..................................................................................................107    |
| 2.6. Risk management plan.....................................................................................107       |                                                                                                          |
| 2.7. Update of the Product information                                                                                  | .....................................................................109                                 |
| 2.7.1. User consultation..........................................................................................109   |                                                                                                          |
| 3. Benefit-Risk Balance............................................................................110                  |                                                                                                          |
| 3.1. Therapeutic Context                                                                                                | ........................................................................................110              |
| 3.1.1. Disease or condition......................................................................................110    |                                                                                                          |
| 3.1.2. Available therapies and unmet medical need                                                                       | ....................................................110                                                  |
| 3.1.3. Main clinical studies                                                                                            | ......................................................................................110                |
| 3.2. Favourable effects...........................................................................................110   |                                                                                                          |
| 3.3. Uncertainties and limitations about favourable effects                                                             | ..........................................111                                                            |
| 3.4. Unfavourable effects........................................................................................111    |                                                                                                          |
| 3.5. Uncertainties and limitations about unfavourable effects                                                           | .......................................112                                                               |
| 3.6. Effects Table                                                                                                      | ..................................................................................................113    |
| 3.7. Benefit-risk assessment and discussion                                                                             | ..............................................................113                                        |
| 3.7.1. Importance of favourable and unfavourable effects                                                                | ...........................................113                                                           |
| 3.7.2. Balance of benefits and risks..........................................................................114       |                                                                                                          |
| 3.7.3. Additional considerations on the benefit-risk balance                                                            | .........................................114                                                             |
| 3.8. Conclusions....................................................................................................114 |                                                                                                          |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations ...............................................................................  115 5. EPAR changes  ......................................................................................  116

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                                      |
|----------------|-----------------------------------------------------------------|
| ADA            | antidrug antibodies                                             |
| AE             | adverse event                                                   |
| AEOSI          | adverse event of special interest                               |
| AJCC           | American Joint Committee on Cancer                              |
| APaT           | All Participants as Treated                                     |
| cHL            | classical Hodgkin lymphoma                                      |
| CHMP           | Committee for Medicinal Products                                |
| CI             | confidence interval                                             |
|                | coronavirus disease caused by severe acute respiratory syndrome |
| COVID-19       | coronavirus 2                                                   |
| CRC            | colorectal carcinoma                                            |
| CSCC           | cutaneous squamous cell carcinoma                               |
| DFS            | Disease-free survival                                           |
| DILI           | drug-induced liver injury                                       |
| ECOG           | Eastern Cooperative Oncology Group                              |
| EFS            | event-free survival                                             |
| EGFR           | epidermal growth factor receptor                                |
| EMA            | European Medicines Agency                                       |
| E-R            | exposure-response                                               |
| EU             | European Union                                                  |
| FDA            | Food and Drug Administration                                    |
| GCP            | Good Clinical Practice                                          |
| HCC            | hepatocellular carcinoma                                        |
| HNSCC          | head and neck squamous cell carcinoma                           |
| HR             | hazard ratio                                                    |
| IA             | interim analysis                                                |
| IASLC          | International Association for the Study of Lung Cancer          |
| IB             | Investigator Brochure                                           |
| IFN γ          | interferon gamma                                                |
| IL-2           | interleukin 2                                                   |
| ITT            | Intention-to-treat                                              |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                   |
|----------------|----------------------------------------------|
| KM             | Kaplan-Meier                                 |
| mAb            | monoclonal antibody                          |
| MAH            | marketing authorization holder               |
| MCC            | Merkel cell carcinoma                        |
| MSI-H          | microsatellite instability-high              |
| NSCLC          | non-small-cell lung cancer                   |
| OS             | overall survival                             |
| PD-1           | programmed cell death 1                      |
| PD-L1/2        | programmed cell death ligand 1 or 2          |
| PK             | pharmacokinetics                             |
| PMBCL          | primary mediastinal large B-cell lymphoma    |
| Q3W            | every 3 weeks                                |
| Q6W            | every 6 weeks                                |
| RCC            | renal cell carcinoma                         |
| RECIST         | Response Evaluation Criteria in Solid Tumors |
| RSD            | Reference Safety Dataset                     |
| SAE            | serious adverse event                        |
| SAP            | Statistical Analysis Plan                    |
| sBLA           | supplemental Biologics License Application   |
| SCLC           | small-cell lung cancer                       |
| SmPC           | Summary of Products Characteristics          |
| TC             | tumor cells                                  |
| TMB-H          | tumor mutational burden-high                 |
| TNF α          | tumor necrosis factor alpha                  |
| TNM            | tumor-node-metastases                        |
| TPS            | tumor proportion score                       |
| UICC           | Union for International Cancer Control       |
| UK             | United Kingdom                               |
| US             | United States                                |
| USPI           | US Prescribing Information                   |
| Vs             | versus                                       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 6 April 2022 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include Keytruda as monotherapy for the adjuvant treatment of adults with Stage IB (T2a ≥ 4 cm), II or IIIA non -small cell lung carcinoma (NSCLC) who have undergone complete resection, based on study KEYNOTE-091; an ongoing Phase 3, randomized, triple-blinded, placebo-controlled, multicentre study of pembrolizumab versus placebo in patients with early-stage NSCLC after resection and completion of standard adjuvant therapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are being updated and the Package Leaflet is updated in accordance. An updated RMP version 39.1 was also submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0043/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0043/2018 was completed.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH received Scientific Advice from the CHMP on 22 January 2015 (EMA/H/SA/2437/7/2014/II). The Scientific Advice pertained to clinical aspects of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Paolo Gasparini

Co-Rapporteur:

N/A

<div style=\"page-break-after: always\"></div>

| Timetable                                                                            | Actual dates      |
|--------------------------------------------------------------------------------------|-------------------|
| Submission date                                                                      | 6 April 2022      |
| Start of procedure                                                                   | 23 April 2022     |
| CHMP Rapporteur's preliminary assessment report circulated on                        | 24 June 2022      |
| PRAC Rapporteur's preliminary assessment report circulated on                        | 29 June 2022      |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | 7 July 2022       |
| CHMP Rapporteur's updated assessment report circulated on                            | 15 July 2022      |
| Request for supplementary information adopted by the CHMP on                         | 21 July 2022      |
| MAH's responses submitted to the CHMP on                                             | 11 August 2022    |
| Re-start of procedure                                                                | 15 August 2022    |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on | 15 September 2022 |
| PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on | 14 September 2022 |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | 29 September 2022 |
| CHMP Rapporteur's updated assessment report on the MAH's responses circulated on     | 7 October 2022    |
| 2 nd Request for supplementary information adopted by the CHMP on                    | 13 October 2022   |
| MAH's responses submitted to the CHMP on                                             | 6 July 2023       |
| Re-start of procedure                                                                | 17 July 2023      |
| PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on | 3 August 2023     |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on | 11 August 2023    |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | 31 August 2023    |
| CHMP Rapporteur's updated assessment report on the MAH's responses circulated on     | 9 September 2023  |
| CHMP opinion adopted on                                                              | 14 September 2023 |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Lung cancer is one of the most common malignancies in the world, with an estimated global incidence of 2.2 million in 2020 and an associated 1.8 million deaths. In Europe, age standardized incidence rates (per 100.000) vary between 33.3 - 49 in male, and between 11.6 - 26.8 in female, while age standardized mortality rates vary between 26.9 - 32.7 in male, and between 20.1 - 23.8 in female. 1 NSCLC accounts for approximately 85% of all lung cancers, the most common histological subtypes being adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma 2 .

At the time of diagnosis, approximately 19% of patients with NSCLC have localized disease (Stage I), 22% have locally advanced or regional disease (Stages II and III), and 55% have metastatic disease (Stage IV). Stage is a main prognostic factor. According to stage, 5-years relative survival ranges between 61.2% in localized, 33.5% in regional, and 7% in distant disease 3 .

## State the claimed the therapeutic indication

The MAH's sought indication is: 'KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with Stage IB (T2a ≥ 4 cm), II or IIIA non-small cell lung carcinoma who have undergone complete resection.'

## Risk factors, screening tools/prevention

Global statistics estimate that 15% of lung cancers in men and 53% in women are not attributable to smoking. To date, there are no specific recommendation for screening for lung cancer. 4

## Biologic features

## Molecular characteristics

Histological diagnosis of NSCLC is crucial to many treatment decisions and should be as exact and detailed as the samples and available technology allow. After morphological diagnosis, the next consideration is therapy-predictive biomarker testing. Several molecular drivers for oncogene addiction represent strong predictive biomarkers and excellent therapeutic targets. They are generally mutually exclusive of each other. The vast majority of oncogene-addicted lung cancers are adenocarcinomas.

1  International Agency for Research on Cancer. Lung. Lyon (France): International Agency for Research on Cancer (IARC); 2020. 2p. Available from: https://gco.iarc.fr/today/fact-sheets-cancers.

2  National Cancer Institute. SEER Cancer Statistics Review 1975-2017: cancer of the lung and bronchus (invasive). Bethesda (MD): National Cancer Institute (NCI); 2020.

3  Surveillance, Epidemiology, and End Results Program [Internet]. Bethesda (MD): National Cancer Institute (NCI). Cancer stat facts: lung and bronchus cancer; [cited 2021 Sep 20]; [about 18 screens]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html

4  Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl\\_4):iv1-iv21.

<div style=\"page-break-after: always\"></div>

Patients, in general, tend to be younger, female gender and East Asian ethnicity. To date, relevant biomarkers for NSCLC are EGFR mutations, rearrangements involving the ALK and ROS1 genes, BRAF V600E mutations, NTRK1 fusion, HER2 and MET exon 14 mutations and fusion genes involving RET 5 . To date, the only approved targeted treatment in the EU in the adjuvant setting is osimertinib (see section 'management' below).

## Clinical presentation, diagnosis and stage/prognosis

## Update to AJCC Staging Guidelines

Study KEYNOTE-091 was initiated in 2015. The study enrolled participants who had Stages IB (T2a ≥ 4 cm), II, or IIIA NSCLC under the AJCC 7th edition. The tumour stage was also used as a stratification factor. During the conduct of the study in January 2017, a major update to staging guidelines was provided with the release of the 8th edition of the UICC/IASLC and was implemented clinically in January 2018. In order to maintain consistency in participant eligibility and stratification, use of the AJCC 7th edition staging system was continued throughout the study.

The key feature of this update was changes in determination of the T (primary tumour) component of the staging system, which led to migration in certain overall stages 6 . For example, some participants enrolled in KEYNOTE-091 with Stage IB (T2a&gt;4 cm) in the 7th edition would be considered to have Stage IIA (T2b) in 8th edition. Participants with Stage IB (T2a =4 cm) in the 7th edition would remain Stage IB (T2a) in the 8th edition. Additionally, some participants with Stage IIIA [T (2-3) N2] under the 7th edition would become Stage IIIB [T (3-4) N2] under the 8th edition.

In summary, KEYNOTE-091 enrolled participants with Stages IB (T2a ≥ 4 cm), II, or IIIA NSCLC under the AJCC 7th edition. This is equivalent to Stage IB (T2a = 4 cm) through IIIB [(T3-4 (&gt;7cm), N2] under the AJCC 8th edition.

<!-- image -->

Stage groups for NSCLC. Overall survival in pa�ents with NSCLC according to the eighth edi�on stage groups in the Interna�onal Associa�on for the Study of Lung Cancer (IASLC) data sets. (A) Clinically staged (cTNM) tumors. ( B ) Pathologically staged (pTNM) tumors. MST, median survival �me (months). From Chansky K, 2017.

5  Planchard D, et al, on behalf of the ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4): iv192-iv237 - Updated version published 15 September 2020 by the ESMO Guidelines Committee.

6  Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallieres E, Groome P, et al. The IASLC Lung Cancer Staging Project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017 Jul;12(7):1109-21.

<div style=\"page-break-after: always\"></div>

## Management

In early-stage NSCLC, both prognosis and the treatment strategy, particularly with regards to surgical intervention and the use of adjuvant chemotherapy, are dependent on disease stage 7 . The cornerstone of treatment of potentially resectable lung cancer is surgical removal of the tumour, which includes lobectomy, pneumonectomy, and mediastinal lymph node dissection/sampling depending on the extent of the disease and the cardiopulmonary reserve of the patient 6, 8 . The management of lymph nodes during surgery is mainly dictated by the staging requirements for guaranteed 'R0 resection' status 6 . For those who are not willing to accept the risks, or are at very high risk, curative RT should be offered, either SABR or hypofractionated high-dose RT 6 .

Adjuvant chemotherapy with up to 4 cycles of a platinum-based doublet has been utilized to reduce the risk of disease recurrence. The most frequently studied regimen is cisplatin-vinorelbine. According to ESMO guidelines, adjuvant ChT should be offered to patients with resected stage II and III NSCLC and can be considered in patients with resected stage IB disease and a primary tumour &gt; 4 cm. Preexisting comorbidity, time from surgery and postoperative recovery need to be taken into account in this decision taken in a multidisciplinary tumour board 6 . Meta-analyses have shown an absolute OS and DFS benefit at 5 years of approximately 5% with adjuvant chemotherapy in early-stage NSCLC  9 . ESMO guidelines underline that in view of the equivalence of neoadjuvant and adjuvant chemotherapy for OS, the consistent results and broad evidence base support adjuvant chemotherapy as the timing of choice 6 .

For patients with actionable EGFR tumour mutations, results from the Phase 3 ADAURA study showed that osimertinib improved DFS in patients with Stage IB-IIIA (AJCC 7 th  ed) NSCLC as compared to placebo 10 . In the EU, Tagrisso was approved in May 2021 for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations 13 . The subsequent final analysis of ADAURA study, at median follow-up of about 60 months, demonstrated also statistical significant improvement in OS: in patients with stage II to IIIA disease, the 5-year OS was 85% (95% CI, 79 to 89) in the osimertinib group and 73% (95% CI, 66 to 78) in the placebo group (overall HR 0.49; 95.03% CI, 0.33 to 0.73; P&lt;0.001). In the overall population (stage IB to IIIA disease) the 5-year OS was 88% (95% CI, 83 to 91) in the osimertinib group and 78% (95% CI, 73 to 82) in the placebo group (overall HR for death, 0.49; 95.03% CI, 0.34 to 0.70; P&lt;0.001) 11 .

Checkpoint inhibitors have proven clinical benefits in advanced lung cancer. A recent study IMpower010 evaluating the anti-PD-L1 antibody atezolizumab (every 3 weeks for 16 cycles) demonstrated improvement in DFS compared with best supportive care when given as adjuvant therapy following surgery and chemotherapy in participants with Stage II-IIIA (AJCC 7 th  ed) NSCLC 12 . At data cutoff of 21 January 2021, median follow-up was 32.2 months in the ITT population. In hierarchical testing, atezolizumab showed statistically significant DFS benefit vs BSC in the PD-L1 TC ≥ 1% (SP263 assay) Stage II-IIIA (median DFS not reached versus 35.3 months, HR 0.66, 95% CI 0.50-0.88, p=0.0039) and in all randomized Stage II-IIIA populations (median DFS 42.3 versus 35.3

7  Heineman DJ, Daniels JM, Schreurs WH. Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy. Ther Adv Med Oncol. 2017;9(9):599-609.

8  National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer; version 8.2020. Plymouth Meeting (PA): National Comprehensive Cancer Network (NCCN); 2020. 254 p.

9  Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008 Jul 20;26(21):3552-9.

10  Wu YL, Tsuboi M, He J, John T, et al; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723.

11  Tsuboi M, Herbst RS, John T, et al; ADAURA Investigators. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137-147.

12  Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398:1344-57.

<div style=\"page-break-after: always\"></div>

months, (HR 0.79, 95% CI 0.64-0.96, p=0.0205); on the contrary the significance boundary was not crossed for DFS in the ITT population that included stage IB ( ≥ 4 cm) disease (HR 0.81, 95% CI 0.670.99, p=0.04) 14, 13 . OS data were immature and not formally tested. IMpower010 study did not show a consistent benefit in DFS by PD-L1 subgroups: PD-L1 TC &lt;1% (HR 0.97; 95% CI: 0.72, 1.31) (about 45% of the population), 1-49% (HR 0.87; 95% CI: 0.60, 1.26), PDL1 TC≥50% (HR 0.43; 95%CI: 0·27-0·68) 14 . In the EU, Tecentriq was approved in June 2022 for patients whose tumours express PDL1 TC ≥ 50%, with the following indication: 'Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK -positive NSCLC (see section 5.1 for selection criteria)' 14 . Recent updated data from IMpower010 showed improved OS for adjuvant atezolizumab with HR of 0.43 in the PD-L1 TC ≥ 50% 15

The immune-checkpoint inhibitors were also explored in the neoadjuvant NSCLC setting. In the openlabel, phase 3 CheckMate 816 trial, patients with stage IB (≥4cm) to IIIA (AJCC 7 th  ed) resectable NSCLC were randomized to receive nivolumab plus platinum-based chemotherapy or platinum-based chemotherapy alone, followed by resection. The primary end points were event-free survival and pathological complete response by blinded independent review. At the prespecified interim analysis 1 of (minimum follow-up, 21 months; median follow-up, 29.5 months) the median EFS was 31.6 months (95%CI, 30.2 to NR) with nivolumab plus chemotherapy and 20.8 months (95% CI, 14.0 to 26.7) with chemotherapy alone (HR 0.63; 97.38% CI, 0.43 to 0.91; P=0.005). The percentage of patients with a pathological complete response at the final analysis for pCR was 24% (95% CI, 18 to 31) and 2.2% (95% CI, 0.6 to 5.6), respectively.  16  Based on this study, Opdivo in combination with platinum-based chemotherapy was approved in the EU in June 2023 for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1% 17 .

In addition, the strategy including both neoadjuvant and adjuvant treatment (i.e. perioperative) regimens for early-stage NSCLC with anti-PD(L)1 drugs is currently under investigation, although none is approved to date. KEYNOTE-671 study evaluated, in 786 participants with resectable stage II, IIIA, or IIIB (N2 stage) NSCLC, neoadjuvant pembrolizumab or placebo plus 4 cycles of cisplatin-based chemotherapy followed by surgery and adjuvant pembrolizumab or placebo for up to 13 cycles. The first IA, with a median follow-up of 25.2 months, showed statistically significant improvement in EFS (HR for progression, recurrence, or death, 0.58; 95% CI, 0.46 to 0.72; P&lt;0.001; EFS at 24 months 62.4% vs 40.6%). A major pathological response occurred in 30.2% vs 11% and a pathological complete response occurred in 18.1% and 4% of patients in the experimental vs control arm, respectively 18 . The double-blind phase III study AEGEAN assessing neoadjuvant durvalumab + chemotherapy followed by surgery and adjuvant durvalumab in patients with resectable NSCLC (stage II-IIIB[N2]; AJCC 8th ed) was reported to have met its primary endpoints of pCR (17.2% vs 4.3%) and EFS (HR 0.68, 95%CI 0.53-0.88, median EFS NR vs 25.9 months) at the first interim analysis of

13  Wakelee HA, Altorki NK, Zhou C, Csoszi T, Vynnychenko IO, Goloborodko O, et al. IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC) [abstract]. Presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; 2021 Jun 4-8; [online meeting]. J Clin Oncol. 2021;39(15 suppl).

14  EMA/CHMP/219365/2022 CHMP Summary of Opinion Tecentriq

15  Wakelee H, et al: IMpower010: Overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC. 2022 World Conference on Lung Cancer. Abstract PL03.09. Presented August 8, 2022.

16  Forde PM, Spicer J, Lu S, et al; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985.

17  EMA/287093/2023 EPAR CHMP Assessment Report Opdivo EMEA/H/C/003985/II/0117

18  Wakelee H, Liberman M, Kato T, et al; KEYNOTE-671 Investigators. Perioperative Pembrolizumab for Early-Stage NonSmall-Cell Lung Cancer. N Engl J Med. 2023 Jun 3.

<div style=\"page-break-after: always\"></div>

after a median EFS follow-up of 11.7 months 19 .

An unmet need for introducing tolerable treatments in earlier stages of disease in order to provide the best chance of survival by decreasing the risk of recurrence is recognised.

## 2.1.2. About the product

Pembrolizumab is humanized mAb of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and, ultimately, immune rejection. The antibody potentiates existing immune responses in the presence of antigen only; it does not nonspecifically activate T cells.

Keytruda was granted first approval by the European Commission on 17-JUL-2015 for patients with advanced melanoma. At the time of submission, in the EU, Keytruda is currently approved as monotherapy and in combination with other agents in adults in several tumor types: melanoma, NSCLC, HNSCC, TNBC, RCC, cHL, urothelial carcinoma, esophageal cancer, gastric or gastrooesophageal junction adnocarcinoma, endometrial carcinoma, MSI-H selected tumor types (colorectal cancer, gastric, biliary and small intestine cancer). In the pediatric setting, it is approved in 3 years and older cHL and in 12 years and older melanoma.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

EU CHMP scientific advice was obtained on the clinical development program for adjuvant NSCLC (EMEA/H/SA/2437/7/2014/II). The CHMP generally agreed to the overall study design for study KEYNOTE-091, patient population, DFS as primary endpoint, and the choice of placebo as a comparator.

The patient population was considered rather heterogeneous, and subgroup analyses according to stratification/minimisation factors are expected. The impact on the final indication of any potential contrasting results will be a matter of assessment at time of evaluation. This is true not only for PD-L1 expression levels (a factor already taken into account for the main statistical analysis), but for other important factors (e.g. stage, histology, nature of background adjuvant treatment).

The CHMP suggested a minimum enrolment for each subgroup to at least allow meaningful analysis of trends. In this respect, a larger study with more stringent hypotheses should be considered. The CHMP also noted that study maturity will progress differently across prognostic subgroups. Further, the Applicant was advised to consider limiting the number of patients with stage IB disease ( A cap of 35% to stage IB subgroup was implemented).

According to the CHMP, taking into account the size of the planned study and the significant number of patients harbouring EGFR mutations or ALK rearrangements expected, the Applicant should consider genotyping the tumours of all patients to enable future exploratory analysis in different specific subgroups of patients defined by these aberrations (this was not implemented).

The CHMP commented that the second interim analysis (for efficacy) may limit the feasibility of a final powerful analysis if enrolment is not achieved, which conditions the acceptability of this interim analysis. Study maturity will progress differently across prognostic subgroups. This is true for the

19  Heymach JV, et al. AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. In: Proceedings of the 114th Annual Meeting of the American Association for Cancer Research; 2023 April 14-19; Orlando, FL. Philadelphia (PA): AACR; 2023. Abstract nr CT005.

<div style=\"page-break-after: always\"></div>

interim efficacy analysis with an overrepresentation of patients with early progressive disease and limited relevance in patients with relatively late progression and good prognosis. For the final analysis, any conclusion on cure rates that could be obtained by discussion on the terminal plateau should incorporate all subgroups, including those with less mature observation.

## 2.1.4. General comments on compliance with GCP

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Keytruda is a protein and is therefore exempt from the ERA requirements. This is compliant with the current Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00).

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Study ID                                  |   Phase | Country/Region                                                                                                                                                                                                                                                                                                               | Study Title                                                                                                                                                                                                           | Study design                                                                                                                                                                                                                                                   | Dosingregimen                                                                                                                                                                             | Study population                                                                                                                                                              | Participant exposure            |
|-------------------------------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| KEYNOTE-091 [Ref. 5.3.5.1: P091V01MK3475] |       3 | Australia Asia (Japan, South Europe (Austria, Korea) Republic,Denmark, Belgium,Czech Israel, Italy, Latvia, Germany, Greece, Hungary,Ireland, Estonia, France, Netherlands,Poland, Portugal, Slovenia, Spain,Switzerland Turkey,United Kingdom) North America (Canada) Russia Federation South America (Brazil, Chile, Peru) | A randomized,phase 3 trial with anti-PD-1 pembrolizumab(MK- monoclonalantibody 3475)versus placebo for patientswith early stage NSCLC after therapy (PEARLS) standardadjuvant resection and completion of KEYNOTE-091 | A phase3,randomized, triple-blinded, evaluate the efficacy and multicenterstudy to placebo-controlled, safety of withearly stageNSCLC completeresectionwith placeboinparticipants whohaveundergone pembrolizumab vs or without standard adjuvant chemotherapy. | Pembrolizumab: 200 mgby intravenous for approximately 1 year infusion every 3 weeks (18 infusions) Placebo: for approximately1 year infusionevery3weeks O mgby intravenous (18 infusions) | Males and females Age: 31 to 87 Stage IB (T2a ≥4 Participants with NSCLC,whohave cm), II, or IIIA complete resection standard adjuvant with orwithout undergone chemotherapy. | Pembrolizumab: 590 Placebo: 587 |

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

Pembrolizumab PK disposition has been characterized via pooled population PK analyses using serum concentration-time data contributed from subjects across various clinical studies using a timedependent PK (TDPK) model. The PK reference dataset for monotherapy includes all available PK data from subjects enrolled on KEYNOTE-001, KEYNOTE-002, KEYNOTE-006, KEYNOTE-010, and KEYNOTE024, with an overall sample size of 2993. This serves as the PK reference analysis to support descriptions of pembrolizumab pharmacokinetics in the EU SmPC.

Within this Application, the MAH proposes an extension of indication for ' KEYTRUDA as monotherapy for the adjuvant treatment of patients with Stage IB (T2a ≥ 4 cm), II, or IIIA non-small cell lung carcinoma (NSCLC) who have undergone complete resection.'

The focus of the clinical pharmacology data submitted with this application is on the integrated immunogenicity assessment from studies KEYNOTE-054 and KEYNOTE-091, to characterize the immunogenicity profile of pembrolizumab in the adjuvant setting in patients with completely resected lymph node-positive stage III melanoma or completely resected stages IB, II, or IIIA NSCLC, respectively.

## Absorption

Pembrolizumab is dosed via the intravenous route and therefore is immediately and completely bioavailable.

## Distribution

Consistent with a limited extravascular distribution, the volume of distribution of pembrolizumab at steady state is small (6.0 L; coefficient of variation [CV]: 20%). As expected for an antibody, pembrolizumab does not bind to plasma proteins in a specific manner.

## Elimination

Pembrolizumab CL is approximately 23% lower (geometric mean, 195 mL/day [CV%: 40%]) after achieving maximal change at steady state compared with the first dose (252 mL/day [CV%: 37%]); this decrease in CL with time is not considered clinically meaningful. The geometric mean value (CV%) for the terminal half-life is 22 days (32%) at steady-state.

## Pharmacokinetic data submitted within this EoI

The existing immunogenicity assessment for pembrolizumab for the monotherapy in the non-adjuvant setting is based on a sufficiently large dataset of patients across several indications, with very low observed rates of total treatment ADA across different pembrolizumab regimens (1.4 - 3.8%) as well as of neutralizing antibodies (0.4 - 1.6%). This analysis has not demonstrated impact on efficacy or safety. The low rate of immunogenicity has been shown to be consistent across tumour type and no clinically meaningful consequences have been observed in the subjects with a positive immunogenicity reading.

The incidence of ADA has not been impacted by the presence of another small molecule or chemotherapy in combination with pembrolizumab.

<div style=\"page-break-after: always\"></div>

However, as immunogenicity has not been characterized in the adjuvant setting, it was agreed to assess the immunogenicity of pembrolizumab in this setting in studies KEYNOTE-054 (most recent ADA sample of 2 October 2017) and KEYNOTE-091 (most recent ADA sample of 2 June 2021).

KEYNOTE-054 / EORTC-1325-MG is a phase 3 trial with pembrolizumab monotherapy administration (MK-3475, 200 mg Q3W) as adjuvant treatment in participants with completely resected lymph nodepositive stage III melanoma. KEYNOTE-091/EORTC-1416-LCG is a phase 3 trial with pembrolizumab monotherapy administration (MK-3475, 200 mg Q3W) as adjuvant treatment in participants with completely resected stages IB, II, or IIIA NSCLC.

## IMMUNOGENICITY DATA and EVALUATION

ADA samples were available from 1067 participants. A subset of the participants was not assessable for drug induced immunogenicity analysis, because only a pre-treatment ADA sample was available (N=10). The remaining 1057 participants were assessable for drug-induced immunogenicity analysis.

An overview of the participants included in the analysis is summarized in Table 1.

Table 1: Overview of participants included in the immunogenicity analysis after pembrolizumab adjuvant treatment (200 mg pembrolizumab Q3W) in participants with completely resected lymph node-positive stage III melanoma (KEYNOTE-054/ EORTC-1325-MG) or completely resected early stage NSCLC (KEYNOTE-091/EORTC-1416-LCG)

<!-- image -->

|                            | Participants                      | Participants                         | Participants                                                                       |
|----------------------------|-----------------------------------|--------------------------------------|------------------------------------------------------------------------------------|
| Study                      | Participants Providing ADASamples | Participants Dosed withPembrolizumab | AssessableParticipants ParticipantsDosedwith Pembrolizumab andPostTreatmentSamples |
| Pembrolizumab Therapy      | Pembrolizumab Therapy             | Pembrolizumab Therapy                | Pembrolizumab Therapy                                                              |
| Keynote 054 EORTC-1325-MG  | 500                               | 500                                  | 496                                                                                |
| Keynote 091 EORTC-1416-LCG | 567                               | 566                                  | 561                                                                                |
| Total                      | 1067                              | 1066                                 | 1057                                                                               |

Data source -07Z6N3: analysis-p054pkada03 and analysis-adada

The overall immunogenicity was defined as the proportion of treatment emergent positive participants to the total number of evaluable participants (treatment emergent positive, non-treatment emergent positive and negative immunogenicity status).

Table 2 presents an overview of the immunogenicity status of all assessable participants:

<div style=\"page-break-after: always\"></div>

Table 2: Summary of subject immunogenicity results after pembrolizumab adjuvant treatment (200 mg pembrolizumab Q3W) in participants with completely resected lymph node-positive stage III melanoma (KEYNOTE-054/ EORTC-1325-MG) or completely resected early stage NSCLC (KEYNOTE-091/EORTC1416-LCG)

| PembrolizumabTherapy             | PembrolizumabTherapy   | PembrolizumabTherapy                | PembrolizumabTherapy              |
|----------------------------------|------------------------|-------------------------------------|-----------------------------------|
| Immunogenicitystatus             | Total                  | Melanoma KEYNOTE-054/ EORTC-1325-MG | NSCLC KEYNOTE-091/ EORTC-1416-LCG |
| Assessable participantsa         | 1057                   | 496                                 | 561                               |
| Inconclusive participantsb       | 4                      | 1                                   | 3                                 |
| Evaluable participantsc          | 1053                   | 495                                 | 558                               |
| Negatived                        | 1011 (96.0%)           | 473 (95.6%)                         | 538 (96.4%)                       |
| Non-Treatment emergent positived | 12 (1.1%)              | 5 (1.0%)                            | 7 (1.3%)                          |
| Neutralizing negative            | 9 (0.8%)               | 5 (1.0%)                            | 4 (0.7%)                          |
| Neutralizing positive            | 3 (0.3%)               | 0                                   | 3 (0.5%)                          |
| Treatment emergent positived     | 30 (2.8%)              | 17 (3.4%)                           | 13 (2.3%)                         |
| Neutralizing negative            | 30 (2.8%)              | 17 (3.4%)                           | 13 (2.3%)                         |
| Neutralizing positive            | 0                      | 0                                   | 0                                 |

- c:Evaluable participants are the total number of negative and positive participants (non-treatment emergent and treatment emergent.

d: Denominator was total number ofevaluable participants.

Data source - 07Z6N3: analysis-p054pkada03 and analysis-adada

Out of the 1057 participants included in the immunogenicity assessment, 4 participants were inconclusive, resulting in 1053 evaluable participants. The observed incidence of treatment emergent ADA in evaluable participants with completely resected lymph-node positive stage III melanoma or completely resected early-stage NSCLC and completion of standard adjuvant therapy is 2.8% (30 out of 1053), based on 30 participants with treatment emergent positive status, 12 participants with nontreatment emergent positive status and 1011 with negative immunogenicity status.

None of the 30 treatment-emergent positive participants had antibodies with neutralizing capacity.

## IMPACT OF ANTI-DRUG ANTIBODIES ON EXPOSURE

The effect of ADA on pembrolizumab levels, for the participants with ADA positive samples, is compared with the participants treated with the same regimen that only have ADA negative samples. For the ADA positive participants, the pembrolizumab exposure was comparable with the exposures observed for the negative participants treated with the same regimen [Figure 1] and [Figure 2].

<div style=\"page-break-after: always\"></div>

Figure 1: Effect of ADA on pembrolizumab exposure after pembrolizumab adjuvant treatment (200 mg pembrolizumab Q3W) in participants with completely resected lymph node-positive stage III melanoma (KEYNOTE-054/ EORTC-1325-MG) Linear scale (top) and Log scale (bottom)

<!-- image -->

Footnote:Figure includesADAsampleswithcorrespondingPKconcentrations.Samples taken&gt;42days after last dose(&gt; 2 times the scheduled time) are excluded.

Individual pembrolizumab concentrations for the ADA negative participants (grey circles), mean value of the negative participants (grey line),non-treatment emergent neutralizing negative participants (green dot),

Mean pembrolizumab concentration is calculated based on nominal time after first dose.GivenEOT is not concentration was not included in thefigure.

Ifa subject is determined tobeADApositive (non-TE orTE,based on one or more positive samples),all datapoints belonging to that subject are shown in the color of the corresponding ADA status group.

<div style=\"page-break-after: always\"></div>

Figure 2: Effect of ADA on pembrolizumab exposure after pembrolizumab adjuvant treatment (200 mg pembrolizumab Q3W) in participants with completely resected early stage NSCLC (KEYNOTE091/EORTC-1416-LCG) Linear scale (top) and Log scale (bottom)

<!-- image -->

Footnote:FigureincludesADAsampleswithcorrespondingPKconcentrations.Samplestaken&gt;42daysafter last dose(&gt;2 times the scheduled time) are excluded.Pembrolizumabconcentrations for sampleswith Cycle1 predose PK concentrations &gt;0 were set to missing as their results are unreliable.

Individual pembrolizumabconcentrationsfor theADAnegative participants(grey circles),meanvalue of the negative participants(greyline),non-treatment emergentneutralizingnegativeparticipants(green dot),nontreatment emergent neutralizingpositive participants(blue dot),treatmentemergentneutralizing negative participants (orange dot).

Meanpembrolizumabconcentration is calculatedbased onnominal time afterfirst dose.GivenEOTis not concentration was not included in the figure.

Ifa subject is determined tobe ADA positive (non-TE or TE,based on one or more positive samples),all datapoints belonging to that subject are shown in the color of the corresponding ADA status group.

non-TEnABNeg:non-treatment emergent positive neutralizingantibodynegativesubject. non-TE nAB Pos: non-treatment emergent positive neutralizing antibody positive subject.

TEnABNeg:treatmentemergentpositiveneutralizingantibodynegativesubject.

## Bioanalytical methods

## KEYNOTE-091 bioanalytical report for ADA and nAB

The samples were assayed for anti-pembrolizumab antibodies presence using a validated electrochemiluminescence (ECL) immunoassay on the Meso-Scale Discovery (MSD) platform. Bioanalysis of pembrolizumab ADA was carried out using the standard 3-tiered assay approach that consisted of screening (Tier 1), confirmation (Tier 2) and antibody titer assessment (Tier 3). Only Tier 2 confirmed ADA positive samples were moved to Tier 3 and reported with a titer value and a neutralizing antibody (nAB) result.

The DTL for the ADA assay, executed at the vendor PPD, is 124 µg/mL.

ADA : Human serum samples were analysed for the presence of MK-3475 antibodies in support of Protocol Number MK-3475-091. This interim report covers the analysis of samples received through 22 September 2021 and analysed in runs 1RFWC through 142RFWC.

Five thousand eight hundred seventy-four (5874) original and six thousand thirty-six (6036) replicate human serum samples were received frozen and in good condition. Project samples were analysed according to the bioanalytical plan and Method ICDIM 201 V 1.01, entitled 'An

<div style=\"page-break-after: always\"></div>

Electrochemiluminescent (ECL) Method for the Detection of Anti MK 3475 Antibodies in Human Serum,' which was validated under Project Code 'RCZO2.'

Analysis of human serum samples began on 27 September 2016 and was completed on 22 December 2021. Sample results for 2821 samples were provided. Forty-eight samples screened potentially positive for anti-MK-3475 antibodies. Twenty-four out of the 48 samples that screened potentially positive for anti-MK-3475 antibodies were confirmed positive.

Reassayed samples for this project were provided and listed with reasons for reanalysis. All sample analysis runs conducted for this study were showed. Data for the positive and negative controls used for run acceptance and data for the confirmatory positive controls used for run acceptance were also provided.

nAB: Human serum samples were analysed to detect anti-MK-3475 neutralizing antibodies (NAb) in support of Protocol Number MK-3475-091. This interim report covers sample analysis through 06 January 2022. The samples were analysed in runs 1RFWD through 10RFWD.

Five thousand eight hundred seventy-four (5874) original and six thousand thirty-six (6036) replicate human serum samples were received frozen and in good condition between 17 February 2016 and 22 September 2021. These samples were first tested in the electrochemiluminescent immunoassay for the detection of anti-MK-3475 antibodies. All samples from project RFWC which confirmed positive in the ADA immunoassay were analysed for the presence of neutralizing antibodies. Sample analysis was conducted under Project Code 'RFWD' using Method ICDIM 202 V 2.01, entitled 'An ECL Method for the Detection of Anti-MK-3475 Neutralizing Antibodies in Human Serum,' which was validated under Project Code 'RFRI2.' During the course of analysis, the method was manually modified to give the ability to use the Avidien for reagent transfers, effective 09 December 2021.

Analysis of human serum samples took place in ten runs beginning on 18 December 2018 and ending on 06 January 2022. The submitted report contains NAb results from a total of 24 ADA-positive samples. Four samples were positive for the presence of anti-MK-3475 neutralizing antibodies. Sample analysis runs sample results and data for positive and negative controls used for run acceptance were provided.

## 2.3.3. Discussion on clinical pharmacology

The immunogenicity profile of pembrolizumab was previously not well characterized in the adjuvant setting.  The  MAH  has  provided  a  comprehensive  immunogenicity  assessment  including  data  of pembrolizumab at 200 mg Q3W as adjuvant treatment from KEYNOTE-091 and KEYNOTE-054.

All the ADA samples, and the actual time after first dose and time after last dose, from ADA positive participants were provided for both studies.

The integrated immunogenicity incidence rate for pembrolizumab monotherapy as adjuvant treatment in participants with completely resected stages IB (T2a ≥ 4 cm), II, or IIIA NSCLC in KEYNOTE-091 and in participants with completely resected, lymph node-positive, stage III melanoma in KEYNOTE-054 is 2.8% (30 out of 1053 evaluable subjects). In particular, the immunogenicity rate observed in each study population was 3.4% (17 out of 495) for KEYNOTE-054 and 2.3% (13 out of 558) for KEYNOTE-091. This  is  similar  to  the  historical  incidence  rate  of  treatment  emergent  positive  subjects  reported  for monotherapy at 2.1% (27 out of 1289 evaluable subjects; range 1.4 to 3.8%).

Overall,  this  immunogenicity  analysis  shows  that  the  ADA  incidence  rates  for  pembrolizumab  in  the adjuvant setting are similar to ADA incidence rates for pembrolizumab in the metastatic and locally advanced settings.

<div style=\"page-break-after: always\"></div>

The impact of ADA on pembrolizumab PK profiles indicate that pembrolizumab exposures in ADA positive participants do not differ from pembrolizumab exposures in ADA negative participants.

## 2.3.4. Conclusions on clinical pharmacology

The ADA incidence rates for pembrolizumab in the adjuvant setting are similar to ADA incidence rates for pembrolizumab in the metastatic and locally advanced settings.

Treatment-emergent ADA  status in KEYNOTE-091  and KEYNOTE-054  is not found to affect pembrolizumab exposures, excluding a possible effect on safety and efficacy.

## 2.4. Clinical efficacy

The efficacy data in this submission is based on Interim analysis 2 (IA2, data cutoff of 20-SEP-2021) of KEYNOTE-091 , a phase 3 randomized triple blind clinical trial which evaluated the efficacy and safety of pembrolizumab versus placebo as adjuvant therapy in participants with Stage IB (T2a ≥ 4 cm), II, or IIIA NSCLC , as defined by the AJCC 7 th  edition, who have undergone complete resection with or without standard adjuvant chemotherapy. The results of the Interim analysis 3 (IA3, data cutoff of 24-JAN-2023) were also submitted during the procedure per CHMP's request.

KEYNOTE-091 is an Intergroup Trial, jointly conducted with ETOP in different countries of EU and third countries. Merck was the Sponsor in all participating countries. The EORTC was the coordinating group in this trial and centrally managed trial design and activation, data collection and quality control of data, statistical analysis and publication.

## 2.4.1. Dose response study(ies)

No dose-response studies were submitted as part of this application.

## 2.4.2. Main study

KEYNOTE-091: A randomized Phase 3 trial with pembrolizumab versus placebo for patients with early-stage non-small cell lung cancer (NSCLC) after resection and completion of standard adjuvant therapy - PEARLS study (EORTC-1416/ETOP-8-15)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Methods

## Study participants

## Key inclusion/exclusion criteria

- At least 18 years; ECOG Performance status 0-1
- Pathological diagnosis of NSCLC confirmed at surgery, any histology is eligible;
- Confirmed UICC v7 stage IB with T ≥ 4 cm, II -IIIA NSCLC after complete surgical resection (lobectomy, sleeve lobectomy, bi-lobectomy or pneumonectomy) as documented in the pathology report;
- Resection margins proved microscopically free (R0)

<div style=\"page-break-after: always\"></div>

- A systematic complete mediastinal lymph node dissection or a lobe-specific mediastinal lymph node dissection is recommended. At a minimum, the pathology and/or operative report must include the examination of at least two different mediastinal lymph node (N2) levels, one of which is the subcarinal (level 7) and the second of which is lobe-specific.
- No extracapsular extension of tumor in resected mediastinal (N2) lymph nodes. Extracapsular tumor extension is permitted in resected N1 lymph nodes
- Availability of tumor sample obtained at surgical resection for PD-L1. Patients must submit the tumor sample during screening for PDL1 IHC expression testing at a central pathology laboratory. Patients were eligible to participate regardless of the level of PD-L1 status, however tissue must be considered satisfactory for characterization of PD-L1 status. Patients whose samples are inadequate for PD-L1 determination were not randomized;
- No evidence of disease (NED) at clinical examination and baseline radiological assessment as documented by contrast enhanced chest/upper abdomen CT scan, brain CT/MRI and clinical examination within 12 weeks prior to the randomization date.
- Adequate organ function performed within 10 days of treatment initiation.
- Adjuvant chemotherapy is not mandatory but considered for patients with stage IB (T ≥ 4 cm) and strongly recommended for stage II and IIIA, and was administered according to national and local guidelines. Patients who received more than 4 cycles of adjuvant therapy are not eligible.
- o Patients not receiving adjuvant chemotherapy must be randomized and dosed with pembrolizumab/placebo within 12 weeks of their surgery date.
- o Participants who receive adjuvant chemotherapy must begin adjuvant chemotherapy within 12 weeks of their surgery date. Patients receiving adjuvant chemotherapy must be randomized and dosed with pembrolizumab/placebo at least 3 weeks but no more than 12 weeks from the last dose of chemotherapy (Day 1 of last cycle).
- No prior or planned neoadjuvant or adjuvant radiotherapy and/or neoadjuvant chemotherapy for the current malignancy is allowed;
- No prior treatment with anti-PD-1, anti-PD-L1/2, anti-CD137, CTLA-4 modulators or any other immune-modulating agents.
- If of childbearing potential, female patients must be willing to use two adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last infusion of study treatment. Male patients with a female partner(s) of child-bearing potential must agree to use two adequate barrier methods throughout the trial starting with the screening visit through 120 days after the last infusion of study treatment is received.
- Female patients who are breast feeding must discontinue nursing prior to the first infusion of study medication and until 120 days after the last study treatment.
- No known history of HIV, active Hepatitis B or C.
- No chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in the last 3 days prior to the first infusion of trial treatment (corticosteroid use on study for management of pembrolizumab event of clinical interest (ECIs) as premedication for the administration of chemotherapies, and/or a premedication for IV contrast allergies/reactions is allowed). Daily prednisone at doses of 5-7.5 mg is allowed as an example of replacement therapy. Equivalent hydrocortisone doses are also permitted if administered as a replacement therapy;

<div style=\"page-break-after: always\"></div>

- No history of interstitial lung disease (ILD) OR a history of (non-infectious) pneumonitis that required oral or IV steroids (other than COPD exacerbation) or current pneumonitis;
- No active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Any replacement therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed. Patients with hyperthyroidism or hypothyroidism but that are stable on hormone replacement are also allowed;
- No history of a hematologic or primary solid tumor malignancy, unless in remission for at least 5 years. A pT1-2 prostatic cancer Gleason &lt; 6, superficial bladder cancer, non melanomatous skin cancer or carcinoma in situ of the cervix is eligible; Note: prior radiotherapy and prior anti-cancer systemic chemotherapy for another malignancy is not exclusion criteria;
- No previous allogeneic tissue/solid organ transplant;
- No active infection requiring therapy;
- No surgery or chemotherapy related toxicity (nonhematological, toxicity resolved to grade 1 with the exception of alopecia, fatigue, neuropathy and lack of appetite /nausea);
- Absence of severe comorbidities that in the opinion of the Investigator might hamper the participation to the study and/or the treatment administration.

## PD-L1 assay testing

PD-L1 22C3 testing for KEYNOTE-091 was conducted at a central laboratory (Q2 Solutions). The PD-L1 22C3 pharmDx kit (investigational use only, IUO) was used. The IUO version and the CE-marked invitro diagnostic (IVD) version of the PD-L1 22C3 pharmDx kit are identical from a reagent perspective and protocol perspective, and IFU closely worded. Training and testing of the pathologists were conducted by Agilent to ensure accuracy of these stained slides scored at both the TPS ≥1% and the TPS ≥50% cut -offs. An assay validation including sensitivity and precision was then successfully conducted at Q2 Solutions, specificity was not repeated.

## Treatments

| Study intervention   | Dose                      | Route of administration   |
|----------------------|---------------------------|---------------------------|
| Pembrolizumab        | 200 mg, Q3W, 18 infusions | IV                        |
| Placebo **           | Q3W, 18 infusions         | IV                        |

Discontinuation criteria: Treatment is discontinued for the completion of the treatment plan, for patient's decision and based on other key criteria for discontinuation: unacceptable adverse events; progression or recurrence of any malignancy that require active treatment; inter-current illness that warrants patient's withdrawal, as per investigator's opinion; treatment-related toxicity prompting drug discontinuation, as per study protocol; positivity of pregnancy test; non-compliance with study requirements.

Tumour assessment: Disease evaluation by imaging (Contrast-enhanced chest and upper abdomen CT scan, and brain CT scan or MRI) was performed at baseline at screening. Patients were monitored with scans every 12 weeks until disease recurrence. Imaging work up (to be based on calendar) included

<div style=\"page-break-after: always\"></div>

contrast-enhanced chest and upper abdomen CT scan; contrast-enhanced brain CT scan or MRI only if clinically indicated (new evidence of headache or neurologic symptoms). Patients who receive treatment beyond 1 year from randomization (to compensate for missed or delayed doses), should have imaging performed every 12 weeks until discontinuation of treatment and then will follow the ESMO guidelines.

## Objectives

## Primary objectives (dual primary)

- To prospectively investigate whether adjuvant treatment with pembrolizumab after completion of radical surgery (lobectomy/pneumonectomy) with or without standard adjuvant chemotherapy for stage IB (T≥4 cm), II -IIIA (7 th  ed) NSCLC patients improves Disease-Free Survival (DFS), as assessed locally by the investigator, compared to placebo in the PD-L1 strong positive subgroup (i.e., PD-L1 ≥ 50%) or overall population.

## Secondary objectives

- To prospectively compare DFS as assessed by the investigator in the PD-L1 positive population (TPS ≥ 1%);
- To prospectively determine and compare OS in the PD-L1 strong positive and overall population;
- To prospectively determine and compare OS in the PD-L1 positive population;
- To prospectively determine and compare the Lung Cancer Specific Survival (LCSS) in the whole population irrespective of PD-L1 status;
- To prospectively assess the safety of pembrolizumab after radical surgery followed by standard adjuvant chemotherapy.

## Exploratory Objectives

- To assess outcome according to stratification factors and other prognostic and predictive markers for NSCLC;
- To evaluate these treatments in the elderly (age ≥70 years old);
- To prospectively study the influence of dose and duration of adjuvant chemotherapy on outcome;
- To prospectively assess genetic alterations and biomarkers of immunological pathways with outcome;
- To prospectively assess DNA mutational burden and nanostring RNA analysis with outcome;
- To prospectively assess EQ-5D health state profiles at pre-specified time points;
- To prospectively assess Health-Related Quality of Life (HRQOL);
- To evaluate the pharmacokinetics (PK) of pembrolizumab in this patient population to determine the pembrolizumab exposure-response relationships for measures of effectiveness, toxicity, and pharmacodynamic biomarkers in the study population;
- To evaluate the development of anti-drug antibodies (ADA) against pembrolizumab (immunogenicity evaluation);

<div style=\"page-break-after: always\"></div>

- To assess and describe the quality assurance for surgery.

## Outcomes/endpoints

## Primary endpoints (dual primary)

- DFS in the PDL1 ≥50% subgroup
- DFS in the overall population.

## Secondary endpoints

- DFS in the PD-L1 positive population (TPS ≥ 1%);
- OS in the overall population;
- OS in the PD-L1 strong positive subgroup (TPS ≥50 %);
- OS in the PD-L1 positive population (TPS ≥ 1%);
- Lung cancer specific survival (LCSS) in the overall population;
- Toxicity according to CTCAE version 4.03.

## Exploratory endpoints

- Health-Related Quality of Life (HRQOL);
- Pharmacokinetics (PK) of pembrolizumab in this patient population;
- Anti-drug antibodies (ADA) against pembrolizumab (immunogenicity evaluation);
- Quality assurance for surgery;
- Exploratory assessment of predictive biomarkers and immune dynamics (Translational research).

## Endpoint definitions:

DFS : DFS is calculated as the time from randomization to either the date of disease recurrence or the date of death (whatever the cause). The date of first documented disease recurrence (if applicable) will be used as the date of event. Patients alive with no evidence of disease recurrence at the time of their last visit are censored at the time of the last examination. Recurrence of disease can be a loco-regional recurrence, a distant (metastatic) recurrence or a second primary. NSCLC and secondary malignancies were considered to be events.

Recurrence is defined as the first day when the RECIST version 1.1 criteria for disease recurrence are met. The first date when recurrence was observed is taken into account regardless of the method of assessment (imaging and/or pathology).

OS: OS is defined as the time from the date of randomization to the date of death, whatever the cause. The follow-up of patients still alive will be censored at the moment of last visit/contact.

LCSS : LCSS is defined as the time from randomization to the date of death (due to lung cancer specifically). (LCSS was not analyzed at IA2 according to the SAP).

<div style=\"page-break-after: always\"></div>

## Sample size

The study was designed with dual-primary endpoints (DFS in the whole population and DFS in the PDL1 strong positive sub-population). Based on the data from ECOG 1505 study, median DFS in the placebo arm was assumed to be equal to 42 months and median OS approximately 86 months. Assumptions and the testing strategy were:

- -Overall, an improvement of 14 months in median DFS (from 42 months to 56 months) or equivalent to HR = 0.75 was aimed for the whole population. Improvements of 34.4 and 18 months in median DFS (from 42 months to 76.4 and 60 months) or equivalent to HR=0.55 and 0.7 are the effects targeted in PD-L1 strong positive and PD-L1 positive subgroups, respectively.
- -The HRs for OS between the experimental and control arms are 0.6, 0.7 and 0.765, for PD-L1 strong positive, PD-L1 positive and the whole population, respectively.
- -It is assumed that approximately 28% of participants are PD-L1 strong positive and approximately 61% are PD-L1 positive. The enrolment duration was expected to be 52 months, with a yearly drop-out rate of 2.5% and 1% for DFS and OS, respectively.

Two interim analyses (IAs) and one final analysis (FA) for DFS were planned. At the time of each DFS analysis, OS analysis was to be performed as well. There are three additional analyses for OS alone after DFS FA.

Approximately 1180 participants were to be randomized in a 1:1 ratio into the experimental arm and the control arm. For DFS, based on a target number of ~551 events at FA, the study has ~86% power at alpha=1.25% (one-sided) and ~92% power at alpha=2.5% (one-sided) for the whole population.

## Amendment on Sample Size Calculation

In the initial protocol, sample size was based on the data from Radiant study, where median DFS was approximately 48 months in the placebo arm. The study is designed with primary/co-primary endpoints: DFS in the whole population and DFS in the PD-L1 strong positive subgroup. It was expected:

- -an improvement of 13.5 months in median DFS (from 48 months to 61.5 months) or equivalent to HR = 0.78 in the whole population
- -An improvement of 39.3 months in median DFS (from 48 months to 87.3 months) or equivalent to HR=0.55 in the PD-L1 strong positive population

It was assumed that around 15% of DFS events at the final analysis were to be in the PD-L1 strong positive population (based on the available limited epidemiology data). Taking into account a dropout rate of 2.5% per year due to loss to follow up, enrollment and total study durations are assumed to be 87 and 100 months based on a total of 640 disease free survival events and a sample size of 1380 randomized patients were required.

In the second amendment, assumption for sample size calculation has been changed. Based on the data from ECOG 1505 study, median DFS was approximately 42 months in the placebo arm. Moreover, it was expected:

- -an improvement of 14 months in median DFS (from 42 months to 56 months) or equivalent to HR = 0.75 is aimed for the whole population;
- -an improvement of 34.4 and 18 months in median DFS (from 42 months to 76.4 and 60 months) in PD-L1 strong positive and positive patients.

<div style=\"page-break-after: always\"></div>

It was assumed that around 30% of patients were PD-L1 strongly positive and 60% PD-L1 positive. With this design, a sample size of 1080 patients was required for the whole population to achieve 83% power for DFS under the assigned alpha at final analysis.

## Randomisation

All participants entered have been centrally registered at the EORTC Headquarters. Patient randomization in a 1:1 ratio has been performed automatically in the Interactive Voice Response System (IVRS). IVRS assign to each patient a treatment dynamically, based on the other patients randomized in the study and the stratification factors.

The Pocock and Simon Minimization with Biased-coin Assignment methodology has been utilized to perform participant randomization for this study. Per suggestion of the ICH E9 statistical guidelines, the algorithm has been modified to incorporate a random allocation component in order to ensure 15% of completely random assignments.

Stratification factors were:

- stage (IB vs II vs IIIA),
- adjuvant chemotherapy (no adjuvant chemotherapy versus adjuvant chemotherapy)
- PD-L1 status: negative (TPS=0%) versus weak positive (TPS = 1- 49%) versus strong positive (TPS ≥ 50%)
- region (Western Europe versus Eastern Europe versus Rest of the world versus Asia).

Minimization algorithm was separately applied for each PD-L1 status, to ensure an optimal balance of treatment arms within each PD-L1 level. Treatment allocation was blinded.

The proportion of patients with stage IB has been closely monitored by the study steering committee to ensure that this proportion does not exceed 35% of the study population.

## Blinding (masking)

This is a triple blind study. The patient, the investigator and study team at site, the EORTC Headquarters study team, the Sponsor and CRO remained blinded to treatment allocation up to the database lock for the final analysis of the primary/dual-primary endpoints. Only an on-site pharmacist and limited CRO personnel remained unblinded to treatment assignment.

The unblinded Statistician, an independent Statistician at the EORTC Headquarters not involved in the conduct of the trial and the Pharmacovigilance Physician wrote the unblinded interim/safety report for the IDMC.

## Statistical methods

## Multiplicity

The family-wise error rate for DFS and OS hypotheses was strongly controlled at the overall one-sided α = 0.0125. The alpha was initially equally split to test DFS in the overall study population and in the TPS ≥ 50% subgroup. If the null hypothesis for DFS was rejected in the TPS ≥ 50% subgroup, its alpha would be fully reallocated to DFS testing in the TPS ≥ 1% subgroup. Hypotheses for OS in the overall study population and in the TPS ≥ 50% subgroup were to be tested once DFS in the overall study

<div style=\"page-break-after: always\"></div>

population was rejected. The Hwang-Shih-DeCani spending function with gamma = -4 was used to control the type I error in the interim/final analysis for each DFS and OS endpoint.

Figure 4: Multiplicity Graph for Alpha Re-allocation Strategy

<!-- image -->

## Interim analysis

Two interim analyses (IAs) and one final analysis (FA) for DFS were planned in the study. At the time of each DFS analysis, OS analysis was to be performed as well. There were three additional analyses for OS alone after DFS FA.

Table 3: Interim and final analyses for DFS: number of events, p-values boundaries and power

<!-- image -->

|                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      | PD-Ll+patients (DFSHR=0.55)                                                                                                                                                                                                                                                          | PD-Ll+patients (DFSHR=0.55)                                                                                                                                                                                                                                                          | PD-Ll+patients (DFSHR=0.7)                                                                                                                                                                                                                                                           | PD-Ll+patients (DFSHR=0.7)                                                                                                                                                                                                                                                           | All patients (DFS HR=0.75)                                                                                                                                                                                                                                                           | All patients (DFS HR=0.75)                                                                                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                      | DFS                                                                                                                                                                                                                                                                                  | Alpha=0.0125                                                                                                                                                                                                                                                                         | Alpha=0.025                                                                                                                                                                                                                                                                          | Alpha=0.0125                                                                                                                                                                                                                                                                         | Alpha=0.025                                                                                                                                                                                                                                                                          | Alpha=0.0125                                                                                                                                                                                                                                                                         | Alpha=0.025                                                                                                                                                                                                                                                                          |
| IA1 (~57months)                                                                                                                                                                                                                                                                      | Events Nominalp HR bound                                                                                                                                                                                                                                                             | 90 0.0028 0.5571                                                                                                                                                                                                                                                                     | 90 0.0055 0.5852                                                                                                                                                                                                                                                                     | 210 0.0028 0.6824                                                                                                                                                                                                                                                                    | 210 0.0057 0.7048                                                                                                                                                                                                                                                                    | 355 0.0028 0.7454                                                                                                                                                                                                                                                                    | 355 0.0057 0.7641                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      | 0.5211                                                                                                                                                                                                                                                                               | 0.6099                                                                                                                                                                                                                                                                               | 0.4269                                                                                                                                                                                                                                                                               | 0.5188                                                                                                                                                                                                                                                                               | 0.4769                                                                                                                                                                                                                                                                               | 0.5691                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                      | Power                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      |
| IA2                                                                                                                                                                                                                                                                                  | Events                                                                                                                                                                                                                                                                               | 118                                                                                                                                                                                                                                                                                  | 118                                                                                                                                                                                                                                                                                  | 274                                                                                                                                                                                                                                                                                  | 274                                                                                                                                                                                                                                                                                  | 463                                                                                                                                                                                                                                                                                  | 463                                                                                                                                                                                                                                                                                  |
| IA2                                                                                                                                                                                                                                                                                  | Nominalp HR bound                                                                                                                                                                                                                                                                    | 0.0052 0.6243                                                                                                                                                                                                                                                                        | 0.0108 0.6550                                                                                                                                                                                                                                                                        | 0.0053 0.7343                                                                                                                                                                                                                                                                        | 0.0109 0.7578                                                                                                                                                                                                                                                                        | 0.0053 0.7886                                                                                                                                                                                                                                                                        | 0.0109 0.8079                                                                                                                                                                                                                                                                        |
| IA2                                                                                                                                                                                                                                                                                  | Power                                                                                                                                                                                                                                                                                | 0.7612                                                                                                                                                                                                                                                                               | 0.8319                                                                                                                                                                                                                                                                               | 0.6660                                                                                                                                                                                                                                                                               | 0.7537                                                                                                                                                                                                                                                                               | 0.7161                                                                                                                                                                                                                                                                               | 0.7965                                                                                                                                                                                                                                                                               |
| DFSFA (~78months)                                                                                                                                                                                                                                                                    | Events                                                                                                                                                                                                                                                                               | 141                                                                                                                                                                                                                                                                                  | 141                                                                                                                                                                                                                                                                                  | 326                                                                                                                                                                                                                                                                                  | 326                                                                                                                                                                                                                                                                                  | 551                                                                                                                                                                                                                                                                                  | 551                                                                                                                                                                                                                                                                                  |
| DFSFA (~78months)                                                                                                                                                                                                                                                                    | Nominalp                                                                                                                                                                                                                                                                             | 0.0103                                                                                                                                                                                                                                                                               | 0.0212                                                                                                                                                                                                                                                                               | 0.0103                                                                                                                                                                                                                                                                               | 0.0212 0.7985                                                                                                                                                                                                                                                                        | 0.0103                                                                                                                                                                                                                                                                               | 0.0212                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                      | HR bound                                                                                                                                                                                                                                                                             | 0.6770                                                                                                                                                                                                                                                                               | 0.7105                                                                                                                                                                                                                                                                               | 0.7734                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                      | 0.8208                                                                                                                                                                                                                                                                               | 0.8411                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                      | Power                                                                                                                                                                                                                                                                                | 0.8956                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      | 0.9155                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                      | 0.9374                                                                                                                                                                                                                                                                               | 0.8255                                                                                                                                                                                                                                                                               | 0.8885                                                                                                                                                                                                                                                                               | 0.8627                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                      |
| PD-L1+: PD-L1 posilive (TPS_1%); PD-L1++: PD-L1 strong positive (TPS_50%) This table is for illushation pupose.Ifthe actual number of events at the analyses differ from those specified in the table, the efficacy boundaries will be adjustedusingthespendingfiunctionaccordingly. | PD-L1+: PD-L1 posilive (TPS_1%); PD-L1++: PD-L1 strong positive (TPS_50%) This table is for illushation pupose.Ifthe actual number of events at the analyses differ from those specified in the table, the efficacy boundaries will be adjustedusingthespendingfiunctionaccordingly. | PD-L1+: PD-L1 posilive (TPS_1%); PD-L1++: PD-L1 strong positive (TPS_50%) This table is for illushation pupose.Ifthe actual number of events at the analyses differ from those specified in the table, the efficacy boundaries will be adjustedusingthespendingfiunctionaccordingly. | PD-L1+: PD-L1 posilive (TPS_1%); PD-L1++: PD-L1 strong positive (TPS_50%) This table is for illushation pupose.Ifthe actual number of events at the analyses differ from those specified in the table, the efficacy boundaries will be adjustedusingthespendingfiunctionaccordingly. | PD-L1+: PD-L1 posilive (TPS_1%); PD-L1++: PD-L1 strong positive (TPS_50%) This table is for illushation pupose.Ifthe actual number of events at the analyses differ from those specified in the table, the efficacy boundaries will be adjustedusingthespendingfiunctionaccordingly. | PD-L1+: PD-L1 posilive (TPS_1%); PD-L1++: PD-L1 strong positive (TPS_50%) This table is for illushation pupose.Ifthe actual number of events at the analyses differ from those specified in the table, the efficacy boundaries will be adjustedusingthespendingfiunctionaccordingly. | PD-L1+: PD-L1 posilive (TPS_1%); PD-L1++: PD-L1 strong positive (TPS_50%) This table is for illushation pupose.Ifthe actual number of events at the analyses differ from those specified in the table, the efficacy boundaries will be adjustedusingthespendingfiunctionaccordingly. | PD-L1+: PD-L1 posilive (TPS_1%); PD-L1++: PD-L1 strong positive (TPS_50%) This table is for illushation pupose.Ifthe actual number of events at the analyses differ from those specified in the table, the efficacy boundaries will be adjustedusingthespendingfiunctionaccordingly. |

All DFS analyses are DFS event-driven. Beyond the final analysis of DFS, all OS analyses are OS eventdriven.

## Statistical Analysis

<div style=\"page-break-after: always\"></div>

The primary analyses of the primary and secondary efficacy endpoints (DFS, OS and LCSS) were to be performed on all randomized patients according to the intention to treat (ITT) principle.

Estimates of the median DFS, OS and LCSS were obtained by the Kaplan Meier technique. The 95% confidence interval (CI) for the median were calculated using the reflected CI method. Estimates of hazard ratios and their 95% CI were obtained by Cox regression.

For the primary DFS analysis, the date of first documented disease recurrence (if applicable) was used as the date of event. If a randomized participant is not disease free at baseline, the date of randomization was used as the date of event. Participants alive with no evidence of disease recurrence at the time of their last visit are censored at the time of the last disease assessment.

Table 4: Censoring rules for primary and sensitivity analyses of DFS

| Situation                                                                                                                            | PrimaryAnalysis                                          | Sensitivity Analysis 1                                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Recurrence or death documented after ≤ 1 missed disease assessment, and before new anti-cancer therapy, if any                       | Event at earlier date of documented recurrence and death | Event at earlier date of documented recurrence and death                                                                                        |
| Recurrence or death documented immediately after ≥ 2 consecutive missed disease assessments or after new anti-cancer therapy, if any | Event at earlier date of documented recurrence and death | Censored at last disease assessment prior to the earlier date of ≥ 2 consecutive missed disease assessment and new anti- cancer therapy, if any |
| No recurrence and no death; and new anticancer treatment is not initiated                                                            | Censored at last disease assessment                      | Censored at last disease assessment                                                                                                             |
| No recurrence and no death; new anticancer treatment is initiated                                                                    | Censored atlast disease assessment                       | Censored at last disease assessment before new anticancer treatment                                                                             |

Abbreviations:DFS=disease-free survival.

<div style=\"page-break-after: always\"></div>

Table 5: Analysis strategy for key efficacy endpoints

| Endpoint/Variable                                                                                                                                                                                                                                                                                                                                                                                                  | Statistical Method                                                                                                                                                                                                                                                                                                                                                                                                 | Analysis Population                                                                                                                                                                                                                                                                                                                                                                                                | Missing Data Approach                                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary/dual-primary Endpoints                                                                                                                                                                                                                                                                                                                                                                                     | Primary/dual-primary Endpoints                                                                                                                                                                                                                                                                                                                                                                                     | Primary/dual-primary Endpoints                                                                                                                                                                                                                                                                                                                                                                                     | Primary/dual-primary Endpoints                                                                                                                                                                                                                                                                                                                                                                                     |
| DFS                                                                                                                                                                                                                                                                                                                                                                                                                | Test: Permutation test with multivariate Cox regression models with Efron's tie handling method Estimation:multivariate Cox regression models with Efron's tie handlingmethod to assess the magnitude of treatment difference                                                                                                                                                                                      | ITT all participants, PD-LI strong positive PD-L1 positive                                                                                                                                                                                                                                                                                                                                                         | Censored according to rules in [Table 4]                                                                                                                                                                                                                                                                                                                                                                           |
| SecondaryEndpoints                                                                                                                                                                                                                                                                                                                                                                                                 | SecondaryEndpoints                                                                                                                                                                                                                                                                                                                                                                                                 | SecondaryEndpoints                                                                                                                                                                                                                                                                                                                                                                                                 | SecondaryEndpoints                                                                                                                                                                                                                                                                                                                                                                                                 |
| OS                                                                                                                                                                                                                                                                                                                                                                                                                 | Test:Wald test with multivariate Cox regression models with Efron's tie handling method Estimation:multivariate Cox regression modelS with Efron's tie handlingmethod to assess the magnitude of treatment difference                                                                                                                                                                                              | ITT all participants, PD-LI strong positive PD-L1 positive                                                                                                                                                                                                                                                                                                                                                         | Censoredatthedate participant last known to be alive                                                                                                                                                                                                                                                                                                                                                               |
| LCSS                                                                                                                                                                                                                                                                                                                                                                                                               | Test: Non-adjusted log-rank test Estimation:multivariate Cox regression model§ with Efron's tie handlingmethod to assess the magnitude of treatment difference                                                                                                                                                                                                                                                     | ITT all participants,                                                                                                                                                                                                                                                                                                                                                                                              | Participants are still alive:censoredatthe date last known to be alive Participants die from other causes: censored at the time of death                                                                                                                                                                                                                                                                           |
| Statistical models are described in further detail below: S Adjusted by Stage (IB versus II versus IIIA), PD-L1 IHC expression (0 versus 1-49% versus ≥ 50%), Adjuvant Chemo (No chemotherapy vs. adjuvant platinum-based chemotherapy), Histology (squamous vs. non-squamous), smoking status (smokers vs. non-smokers), and regions (Western Europe versus Eastern Europe versus Rest of the world versus Asia). | Statistical models are described in further detail below: S Adjusted by Stage (IB versus II versus IIIA), PD-L1 IHC expression (0 versus 1-49% versus ≥ 50%), Adjuvant Chemo (No chemotherapy vs. adjuvant platinum-based chemotherapy), Histology (squamous vs. non-squamous), smoking status (smokers vs. non-smokers), and regions (Western Europe versus Eastern Europe versus Rest of the world versus Asia). | Statistical models are described in further detail below: S Adjusted by Stage (IB versus II versus IIIA), PD-L1 IHC expression (0 versus 1-49% versus ≥ 50%), Adjuvant Chemo (No chemotherapy vs. adjuvant platinum-based chemotherapy), Histology (squamous vs. non-squamous), smoking status (smokers vs. non-smokers), and regions (Western Europe versus Eastern Europe versus Rest of the world versus Asia). | Statistical models are described in further detail below: S Adjusted by Stage (IB versus II versus IIIA), PD-L1 IHC expression (0 versus 1-49% versus ≥ 50%), Adjuvant Chemo (No chemotherapy vs. adjuvant platinum-based chemotherapy), Histology (squamous vs. non-squamous), smoking status (smokers vs. non-smokers), and regions (Western Europe versus Eastern Europe versus Rest of the world versus Asia). |

<div style=\"page-break-after: always\"></div>

Table 6: Analysis strategy for key efficacy variables

<!-- image -->

| Endpoint/Variable (Description, Time Point)   | Primary vs. Supportive Approacht   | Statistical Methodt                                                      | Analysis Population                                    | Missing Data Approach         |
|-----------------------------------------------|------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------|-------------------------------|
| Primary/dual-primaryEndpoints                 | Primary/dual-primaryEndpoints      | Primary/dual-primaryEndpoints                                            | Primary/dual-primaryEndpoints                          | Primary/dual-primaryEndpoints |
| DFS                                           | P                                  | Permutationtest withmultivariate Cox regression models                   | ITT all patients, PD-L1 strong positive PD-L1 positive | Model-based                   |
|                                               | S                                  | Wald test in multivariate Cox regression model Non-adjusted logrank test | LII all patients, PD-L1 strong positive PD-L1 positive | Model-based                   |
| SecondaryEndpoints                            | SecondaryEndpoints                 | SecondaryEndpoints                                                       | SecondaryEndpoints                                     | SecondaryEndpoints            |
| OS                                            | P                                  | Wald test in Multivariate Cox regression model                           | 11I all patients, PD-L1 strong positive PD-L1 positive | Model-based                   |
| LCSS                                          | P                                  | Non-adjusted 1ogrank test                                                | 11I all patients,                                      | Model-based                   |

- P=Primary approach; S=Secondary approach.
- Statistical models are described in fiuther detail below:

Adjusted by Stage (IB versus II versus IIIA), PD-L1 IHC expression (0 versus 1-49% versus ≥50%), Adjuvant Chemo (No chemotherapy vs. adjuvant platinum-based chemotherapy), Histology (squamous vs. non-squamous), smoking status (smokers vs.non-smokers), and regions (Westem Europe versus Eastem Europe versus Rest of the world versus Asia).

## Subgroup analyses

Subgroup analyses are planned to compare DFS and OS by treatment arm in the stratification factors. In addition, subgroup analyses by histology, smoking status, sex, age, baseline ECOG performance status, race, geographic region, and EGFR mutation status were also planned.

## Exploratory analyses

The key exploratory endpoint is Health-Related Quality of Life (HRQoL). The global health/QoL scale was be used as primary outcome of interest for this study. A difference of 10 points on the 100-point QLQ-C30 scale either within a patient or between the two arms was considered as clinically relevant. The standard deviation of this scale is approximately 20 points. With the 2-sided alpha set at 5% and a power of 80% to detect a difference of 10 points (effect size of 0.5), a minimum of 128 patients (64 per treatment arm) is required. For an effect size of 0.75 (difference of 15 points), 56 patients (28 per treatment arm) are required.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

<!-- image -->

CONSORT diagram (Database Cut-off Date: 20SEP2021) . Please note that consort diagram is related to IA2. IA3 diagram should be added.

Abbreviations: ITT=intention-to-treat.

a Reasons for not randomized (ie, screen failure)

b One participant who did not consent to the main study was randomized due to an administrative error; this participant was not included in the ITT population

Table 7: Disposition of participants not randomized

|                                                              | n (%)                        |
|--------------------------------------------------------------|------------------------------|
| NotRandomized                                                | 777                          |
| Central Confirmation Of Pd-L1 ExpressionWas Non-Eligible     | 7 (0.9)                      |
| Patient Could NotBeRandomized WithinTheProtocol Timelines    | 74 (9.5)                     |
| Patient DoesNot Meet Criteria For -NoEvidence Of Disease     | 137 (17.6)                   |
| Patient Does Not Meet Ecog Performance Criteria              | 11 (1.4)                     |
| Patient Does Not Meet The Protocol Defined Surgical Criteria | 97 (12.5)                    |
| Patient Was Ineligible For Another Reason                    | 131 (16.9)                   |
| Patient'sRefusal                                             | 320 (41.2)                   |
| DatabaseCutoffDate:20SEP2021                                 | DatabaseCutoffDate:20SEP2021 |

Details of the exact reason for 'patient's refusal' and 'other reasons' were not collected for most participants. Most common reasons collected for 'patient's refusal' were logistic/travel, did not want to receive placebo or AE's following adjuvant chemotherapy, while for 'other reasons' were AEs following surgery, lab values and treatment with exclusionary concomitant medications. Overall, no concern is raised over the representativeness of the randomized population.

<div style=\"page-break-after: always\"></div>

Table 8: dispositions of participants (IA3)

|                                                    | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   |
|----------------------------------------------------|-----------------|-----------------|-----------|-----------|
|                                                    | n               | (%)             | n         | (%)       |
| Participants in population                         | 590             |                 | 587       |           |
| Status for Study Medication of Treatment Phase     |                 |                 |           |           |
| Started                                            | 580 300         |                 | 581       |           |
| Completed                                          |                 | (51.7)          | 381       | (65.6)    |
| Discontinued                                       | 280             | (48.3)          | 200       | (34.4)    |
| Administrative Reasons                             | 1               | (0.2)           | 1         | (0.2)     |
| Associated with COVID-19                           | 0               | (0.0)           | 1         | (0.2)     |
| Adverse Event Not Related To Study Medication      | 16              | (2.8)           | 6         | (1.0)     |
| Ineligible                                         | 1               | (0.2)           | 0         | (0.0)     |
| Investigator's Decision                            | 19              | (3.3)           | 13        | (2.2)     |
| Associated with COVID-19                           | 1               | (0.2)           | 1         | (0.2)     |
| Lost To Follow-Up                                  | 3               | (0.5)           | 0         | (0.0)     |
| Other Malignancy                                   | 5               | (0.9)           | 8         | (1.4)     |
| Patient's Decision Not Related To Toxicity         | 46              | (7.9)           | 21        | (3.6)     |
| Associated with COVID-19                           | 6               | (1.0)           | 6         | (1.0)     |
| Recurrence/Relapse/Death Due To Pd                 | 72              | (12.4)          | 127       | (21.9)    |
| Toxicity Due To Study Medication                   | 114             | (19.7)          | 22        | (3.8)     |
| Other                                              | 3               | (0.5)           | 2         | (0.3)     |
| Status for Trial                                   |                 |                 |           |           |
| Started                                            | 590             |                 | 587       |           |
| Discontinued                                       | 161             | (27.3)          | 172       | (29.3)    |
| Death                                              | 136             | (23.1)          | 154       | (26.2)    |
| Associated with COVID-19                           | 6               | (1.0)           | 1         | (0.2)     |
| Lost to follow-up                                  | 0               | (0.0)           | 2         | (0.3)     |
| Withdrawal of Consent                              | 25              | (4.2)           | 16        | (2.7)     |
| Associated with COVID-19, No further survival info | 2               | (0.3)           | 0         | (0.0)     |
| Participants Ongoing                               | 429             | (72.7)          | 415       | (70.7)    |

(65.6)

(34.4)

(0.2)

(0.2)

(1.0)

(0.0)

(2.2)

(0.2)

(0.0)

(1.4)

(3.6)

(1.0)

(21.9)

(3.8)

(0.3)

(29.3)

(26.2)

(0.2)

(0.3)

(2.7)

(0.0)

(70.7)

If the overall count of participants is calculated and displayed within a section in the first row, then it is used as the denominator for the percentage calculation. Otherwise, participants in population is used as the denominator for the percentage calculation. Database Cutoff Date: 24JAN2023

## Recruitment

First participant first visit was on 10-NOV-2015, last patient was randomized on 06-MAY-2020. Study is ongoing. Patients were screened and enrolled across 206 study sites in 29 countries.

At the data cut-off date of IA2 (20-SEP-2021), all patients had had either completed or discontinued treatment. The minimum follow-up time from the last patient randomized to the data cutoff date of IA2 was 16.5 months. The follow-up time off-treatment (i.e., time from the date of last dose of treatment to the data cutoff date) across the arms had a median of 26.0 months (26.8 vs 25.5 months in the pembrolizumab arm and in the placebo arm, respectively. The median follow-up time was 32.4 months (range: 0.6 - 68).

At the data cut-off date of IA3 (24-JAN-2023), the median follow-up was 46.7 months (range: 0.6 84.2).

<div style=\"page-break-after: always\"></div>

## Conduct of the study

## Protocol amendments

| Protocol ver'sion   | Date of PRC approval/notification   | Amendmentreference   | Amendmentreference   |
|---------------------|-------------------------------------|----------------------|----------------------|
|                     |                                     | No                   | Classification       |
| Outline Amended     | December 02, 2014 April 10, 2015    |                      |                      |
| 1.0                 | April 23, 2015                      |                      |                      |
| 2.0                 | December 2,2016                     | 3                    | Scientific           |
| 3.0                 | August 14, 2018                     | 8                    | Scientific           |
| 4.0                 | June 15, 2020                       | 13                   | Scientific           |

| Merck Amendment No.       | Date of Issue   | Overall Rationale                                                                                                                                                                                                                                                                                                                                          |
|---------------------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MK-3475-091-0315-JUN-2020 |                 | Updated the guidelines for management of toxicity due to irAEs. Updated the SAP including addition ofOS analysis at each interim analysis for DFS, clarification of text describing the relaxed alpha level for the all comer population, clarification of multiplicity strategy language, and adjustments to the triggers for the first interim analysis. |
| MK-3475-091-0214-AUG-2018 |                 | Updated the sample size of the study based on the updates of the prevalence of PD-L1 TPS ≥50% NSCLC.                                                                                                                                                                                                                                                       |
| MK-3475-091-01            | 02-DEC-2016     | Updated surgical inclusion criteria to be more inclusive. Modified the mediastinal lymph node dissection requirements.                                                                                                                                                                                                                                     |
| MK-3475-091-00            | 23-APR-2015     | Original protocol.                                                                                                                                                                                                                                                                                                                                         |

Table 9: Summary of Key Changes in KEYNOTE-091 Protocol Amendments

| KEYNOTE-091Amendment1/02-DEC-2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | KEYNOTE-091Amendment1/02-DEC-2016                                                                                                                                                                                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Rationale                                                                                                                                                                                                                                                                                                                |
| Text describing surgical inclusion criteria was added: should be considered to be the bronchial, venous and arterial stumps, peribronchial soft tissue, any peripheral margin near the tumor or of additionallyresected tissue. ·A systematic nodal dissection is recommended or at least a lobe-specific systematic nodal dissection. However, the intraoperative lymph node evaluation canbe acceptedif nolymph nodes arefound in those area and exploration of the required lymph node areas. At minimum, the pathology and/or operative report should include the examination of at least two different mediastinal nodal (N2) station with one being subcarinal (level 7). No extracapsular nodal extensionof thetumor. The highest mediastinal node removed can be positive.The term“uncertain resection”was proposed for operations in which the highest(furthest from the tumor)mediastinal lymph nodewas not demonstratedfree of metastatic societiesandwas removed. Carcinoma in situ can bepresent at bronchial margin.This doesnot represent a positive resection margin. Only invasive cancer is considered as a positive margin. | ·Many ofthe early participantswere technically ineligiblebecause they did not have the extensive lymph node dissection required by the initial protocol. The eligibility criteria concerning surgery were modified to betterreflectclinicalpractice. The purposeofthelymph node dissectionwas toensure accurate staging. |

<div style=\"page-break-after: always\"></div>

| KEYNOTE-091Amendment2/14-AUG-2018 Overall rationale:Updated the studydesignbased on newexternal datafrom studies in the adjuvant settinginNSCLC and the updated prevalenceof PD-L1 TPS >50% in KEYNOTE-091.                                                                                                                                                                                                                                                                                                                                                                                                                              | KEYNOTE-091Amendment2/14-AUG-2018 Overall rationale:Updated the studydesignbased on newexternal datafrom studies in the adjuvant settinginNSCLC and the updated prevalenceof PD-L1 TPS >50% in KEYNOTE-091.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Rationale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Study design was revisitedwithSAPupdated,including Used a new assumption for median DFS of 42 months in control arm (as The target HR in the overall population was assumed stronger(reduced from 0.78 to 0.75). dual primary endpoints. Updated the DFS interim/final analyses timing Reduced the sample size to1080 Dropped the futility interim analysis for PD-L1 negative subgroup. Made secondary OS endpoints under alpha control. Introduced OS interim analyses along with DFS analyses. Add 3 additional OS analyses after DFS FA ·The notation of primary/co-primary endpoints was replaced by primary/dual primary endpoints | ECOG Study (E1505-adjuvant chemowith Beva inNSCLC) median DFS 42 months [Ref. 5.4: 05P7M4] Stronger confidence of the role in immune checkpoint inhibitors in early-stage diseasebased on external data: PACIFIC study (durvalumab in locally advanced stage II): greater than anticipated intervention benefit (HR = 0.52, median PFS 5.6 to 16.8 months regardless of the PD-L1 status) [Ref. 5.4: 059GPT] EORTC 1325-MG/KEYNOTE-054 adjuvant study in Melanoma: Pembro is positive regardless of PD-L1 status (HR = 0.57) [Ref. 5.4: 04WXLF] previous assumed 15%)based on the pre-planned standard review of blinded study data Based on rationale stated above Futility analysis timing close to enrolment completion due to shortened enrolment duration based on reduced sample size.Deemed unnecessary. Details in [Company Response 5]. Strengthens conclusions regarding OS. OfferedchancetowinOSearlyiftreatmenteffectispronounced. Clarify the study will be positive if either of the endpoint is positive objectives need tobe reached to conclude that the study ispositive |

## KEYNOTE-091 Amendment 03/15-JUN-2020

| Overall rationale:Updated the guidelinesformanagement oftoxicity due toirAEs.Clarified text describing therelaxed alphalevelfor the all-comer    | Overall rationale:Updated the guidelinesformanagement oftoxicity due toirAEs.Clarified text describing therelaxed alphalevelfor the all-comer                                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Key Changes                                                                                                                                      | Rationale                                                                                                                                                                                                                                                                                                                                            |
| Update of the approximate number of randomized patients (ie., 1180 patients instead of 1080 patients)throughout the document.                    | ·The increase in the number of participants was intended toreflect the study over enrolment.Though every effort is made to approximate enrolment was unexpectedly rapid during the final months of the trial. Though the MAH set an end to screening well before reaching the accrual goal, the increase in sample size allowed for participants who |
| Section5.6 updates on withdrawal criteria and follow-up afterwithdrawal of study treatment, Section 6.4/6.8.2:DFS replaced by disease recurrence | met (sample size: 1180).                                                                                                                                                                                                                                                                                                                             |
| standardgraphical approachwithout considering thecorrelationbetween the populations.                                                             | An unpublished novel approach that extended the method of Spiessens and Debois (2010) to the group sequential design was employedin amendment 2torelaxtheefficacyboundary of the overall studypopulation,by considering the correlation between the                                                                                                  |
| Clarified OS analysis timing                                                                                                                     | testing method based on the graphical approach of Maurer andBretz (2013). Clarified OSIAs afterDFSFA areevent driven.Clarified the OSFA timing if the targeted OS event numbers cannot be reached.                                                                                                                                                   |

## Protocol deviations

Protocol deviations were classified as per the ICH E3 classification of protocol deviations as important (those that may significantly impact the quality or integrity of key study data or that may significantly affect a participant's rights, safety, or well-being) or not important. Important protocol deviations were further classified as either clinically important (deviations that may compromise critical data analyses pertaining to primary efficacy and/or safety endpoints or the participant's safety) or not clinically important.

Important protocol deviations were reported for 175 participants overall (see table below):

<div style=\"page-break-after: always\"></div>

Table 10: Summary of important protocol deviation (in the ITT population)

|                                                                                                                                                      | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   |
|------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|-----------|-----------|
|                                                                                                                                                      | n               | (%)             |           | (%)       |
| Participants in population with one or more important protocol deviations                                                                            | 590 122         |                 | 587       |           |
|                                                                                                                                                      |                 | (20.7)          | 53        | (9.0)     |
| with no important protocol deviations                                                                                                                | 468             | (79.3)          | 534       | (91.0)    |
| Discontinuationcriteria                                                                                                                              | 1               | (0.2)           | 1         | (0.2)     |
| Inadherence to Appendix G                                                                                                                            | 1               | (0.2)           | 0         | (0.0)     |
| Participants who develop trial specific discontinuationcriteria asperAppendixGbut werenot discontinuedfromthetrial.                                  | 0               | (0.0)           | 1         | (0.2)     |
| Inclusion/Exclusioncriteria                                                                                                                          | 1               | (0.2)           | 0         | (0.0)     |
| History of a hematologicorprimarysolidtumor malignancy, unless in remission for at least 5 years                                                     |                 | (0.2)           | 0         | (0.0)     |
| Prohibitedmedications                                                                                                                                | 1               | (0.2)           | 2         | (0.3)     |
| Participantreceivedstudyprohibitedconcomitant medications as per Section 5.8.1                                                                       |                 | (0.2)           | 2         | (0.3)     |
| Safety reporting                                                                                                                                     | 117             | (19.8)          | 47        | (8.0)     |
| Participants with reportable Safety Events and/or follow upSafety Event informationthat were not reported per the timelines outlined in the protocol | 117             | (19.8)          | 47        | (8.0)     |
| StudyIntervention                                                                                                                                    | 4               | (0.7)           | 3         | (0.5)     |
| Participant was administered improperly stored studyinterventionthatwasdeemed unacceptablefor use.                                                   | 4               | (0.7)           | 1         | (0.2)     |
| Participant was dispensed study intervention otherthanwhatwasassignedinthe allocation schedule,cross-treatment                                       | 0               | (0.0)           |           | (0.2)     |

Part of this study was conducted during the COVID-19 pandemic. Important and not important protocol deviations associated with the pandemic were reported for 225 participants overall, similarly in both treatment arms (18.8% vs 19.4% of patients in the pembrolizumab and placebo arm, respectively). None of the important protocol deviations associated with the pandemic were considered to be clinically important.

No participant's data were excluded from analyses due to an important protocol deviation. No important protocol deviations were classified as a serious GCP compliance issue.

## Baseline data

Table 11: Participant Characteristics (ITT Population)

|                                  | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   | Total    | Total   |
|----------------------------------|-----------------|-----------------|-----------|-----------|----------|---------|
|                                  | n               | (%)             | n         | (%)       | n        | (%)     |
| Participants in population       | 590             |                 | 587       |           | 1,177    |         |
| Sex                              |                 |                 |           |           |          |         |
| Male                             | 401             | (68.0)          | 403       | (68.7)    | 804      | (68.3)  |
| Female                           | 189             | (32.0)          | 184       | (31.3)    | 373      | (31.7)  |
| Age (Years)                      |                 |                 |           |           |          |         |
| < 65                             | 285             | (48.3)          | 273       | (46.5)    | 558      | (47.4)  |
| >= 65                            | 305             | (51.7)          | 314       | (53.5)    | 619      | (52.6)  |
| Mean                             | 64.1            |                 | 64.5      |           | 64.3     |         |
| SD                               | 8.5             |                 | 8.4       |           | 8.4      |         |
| Median                           | 65.0            |                 | 65.0      |           | 65.0     |         |
| Range                            | 31 to 87        |                 | 37 to 85  |           | 31 to 87 |         |
| Race                             |                 |                 |           |           |          |         |
| American Indian Or Alaska Native | 1               | (0.2)           | 0         | (0.0)     | 1        | (0.1)   |

804

(68.3)

373

(31.7)

558

(47.4)

619

(52.6)

64.3

8.4

65.0

1

(0.1)

<div style=\"page-break-after: always\"></div>

214

(18.2)

3

(0.3)

5

(0.4)

1

(0.1)

1

(0.1)

1

(0.1)

2

(0.2)

8

(0.7)

905

(76.9)

41

(3.5)

836

(71.0)

341

(29.0)

558

(47.4)

498

(42.3)

116

5

(0.4)

604

(51.3)

229

(19.5)

133

(11.3)

211

(17.9)

788

(66.9)

389

(33.1)

211

(17.9)

966

(82.1)

169

(14.4)

667

(56.7)

339

(28.8)

2

(0.2)

167

(14.2)

(85.8)

465

(39.5)

379

(32.2)

333

(28.3)

153

(13.0)

859

(73.0)

165

(14.0)

723

(61.4)

454

(38.6)

416

(35.3)

761

(64.7)

| Asian                                  | 107   | (18.1)   | 107   | (18.2)   | 214   | (18.2)   |
|----------------------------------------|-------|----------|-------|----------|-------|----------|
| Black Or African American              | 0     | (0.0)    | 3     | (0.5)    | 3     | (0.3)    |
| Multiple                               | 4     | (0.7)    | 1     | (0.2)    | 5     | (0.4)    |
| American Indian Or Alaska Native White | 1     | (0.2)    | 0     | (0.0)    | 1     | (0.1)    |
| Mestiza                                | 1     | (0.2)    | 0     | (0.0)    | 1     | (0.1)    |
| Mixed Race                             | 1     | (0.2)    | 0     | (0.0)    | 1     | (0.1)    |
| White Black Or African American        | 1     | (0.2)    | 1     | (0.2)    | 2     | (0.2)    |
| Other                                  | 6     | (1.0)    | 2     | (0.3)    | 8     | (0.7)    |
| White                                  | 450   | (76.3)   | 455   | (77.5)   | 905   | (76.9)   |
| Missing                                | 22    | (3.7)    | 19    | (3.2)    | 41    | (3.5)    |
| Age (Years)                            |       |          |       |          |       |          |
| < 70                                   | 420   | (71.2)   | 416   | (70.9)   | 836   | (71.0)   |
| >= 70                                  | 170   | (28.8)   | 171   | (29.1)   | 341   | (29.0)   |
| Age (Years)                            |       |          |       |          |       |          |
| < 65                                   | 285   | (48.3)   | 273   | (46.5)   | 558   | (47.4)   |
| 65 - 74                                | 250   | (42.4)   | 248   | (42.2)   | 498   | (42.3)   |
| 75 - 84                                | 52    | (8.8)    | 64    | (10.9)   | 116   | (9.9)    |
| 85+                                    | 3     | (0.5)    | 2     | (0.3)    | 5     | (0.4)    |
| Geographic Region                      |       |          |       |          |       |          |
| Western Europe                         | 303   | (51.4)   | 301   | (51.3)   | 604   | (51.3)   |
| Eastern Europe                         | 116   | (19.7)   | 113   | (19.3)   | 229   | (19.5)   |
| Rest of World                          | 65    | (11.0)   | 68    | (11.6)   | 133   | (11.3)   |
| Asia                                   | 106   | (18.0)   | 105   | (17.9)   | 211   | (17.9)   |
| Region                                 |       |          |       |          |       |          |
| EU                                     | 396   | (67.1)   | 392   | (66.8)   | 788   | (66.9)   |
| Non-EU                                 | 194   | (32.9)   | 195   | (33.2)   | 389   | (33.1)   |
| Region                                 |       |          |       |          |       |          |
| East Asia                              | 106   | (18.0)   | 105   | (17.9)   | 211   | (17.9)   |
| Non-East Asia                          | 484   | (82.0)   | 482   | (82.1)   | 966   | (82.1)   |
| Stage at Baseline per AJCC V7          |       |          |       |          |       |          |
| IB                                     | 84    | (14.2)   | 85    | (14.5)   | 169   | (14.4)   |
| II                                     | 329   | (55.8)   | 338   | (57.6)   | 667   | (56.7)   |
| IIIA                                   | 177   | (30.0)   | 162   | (27.6)   | 339   | (28.8)   |
| IV                                     | 0     | (0.0)    | 2     | (0.3)    | 2     | (0.2)    |
| Adjuvant Chemotherapy                  |       |          |       |          |       |          |
| No                                     | 84    | (14.2)   | 83    | (14.1)   | 167   | (14.2)   |
| Yes                                    | 506   | (85.8)   | 504   | (85.9)   | 1,010 | (85.8)   |
| PD-L1 Status (Stratification)          |       |          |       |          |       |          |
| <1%                                    | 233   | (39.5)   | 232   | (39.5)   | 465   | (39.5)   |
| 1-49%                                  | 189   | (32.0)   | 190   | (32.4)   | 379   | (32.2)   |
| >=50%                                  | 168   | (28.5)   | 165   | (28.1)   | 333   | (28.3)   |
| Smoking Status                         |       |          |       |          |       |          |
| Never Smoker                           | 87    | (14.7)   | 66    | (11.2)   | 153   | (13.0)   |
| Former Smoker                          | 428   | (72.5)   | 431   | (73.4)   | 859   | (73.0)   |
| Current Smoker                         | 75    | (12.7)   | 90    | (15.3)   | 165   | (14.0)   |
| Baseline ECOG                          |       |          |       |          |       |          |
| 0                                      | 380   | (64.4)   | 343   | (58.4)   | 723   | (61.4)   |
| 1                                      | 210   | (35.6)   | 244   | (41.6)   | 454   | (38.6)   |
| Histology                              |       |          |       |          |       |          |
| Squamous                               | 192   | (32.5)   | 224   | (38.2)   | 416   | (35.3)   |
| Non-squamous                           | 398   | (67.5)   | 363   | (61.8)   | 761   | (64.7)   |
| EGFR Mutation Status                   |       |          |       |          |       |          |

<div style=\"page-break-after: always\"></div>

434

(36.9)

73

(6.2)

670

(56.9)

416

(35.3)

14

(1.2)

747

(63.5)

| N                               | 218                             | (36.9)                          | 216                             | (36.8)                          | 434                             | (36.9)                          |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Y                               | 39                              | (6.6)                           | 34                              | (5.8)                           | 73                              | (6.2)                           |
| Unknown                         | 333                             | (56.4)                          | 337                             | (57.4)                          | 670                             | (56.9)                          |
| ALK Mutation Status             |                                 |                                 |                                 |                                 |                                 |                                 |
| N                               | 226                             | (38.3)                          | 190                             | (32.4)                          | 416                             | (35.3)                          |
| Y                               | 7                               | (1.2)                           | 7                               | (1.2)                           | 14                              | (1.2)                           |
| Unknown                         | 357                             | (60.5)                          | 390                             | (66.4)                          | 747                             | (63.5)                          |
| Database Cutoff Date: 20SEP2021 | Database Cutoff Date: 20SEP2021 | Database Cutoff Date: 20SEP2021 | Database Cutoff Date: 20SEP2021 | Database Cutoff Date: 20SEP2021 | Database Cutoff Date: 20SEP2021 | Database Cutoff Date: 20SEP2021 |

Table 12: Participant Characteristics (PD-L1 &gt;= 50%)

|                                  | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   | Total   | Total   |
|----------------------------------|-----------------|-----------------|-----------|-----------|---------|---------|
|                                  | 1               | (%)             | n         | (%)       | n       | (%)     |
| Participants in population       | 168             |                 | 165       |           | 333     |         |
| Sex                              |                 |                 |           |           |         |         |
| Male                             | 121             | (72.0)          | 116       | (70.3)    | 237     | (71.2)  |
| Female                           | 47              | (28.0)          | 49        | (29.7)    | 96      | (28.8)  |
| Age (Years)                      |                 |                 |           |           |         |         |
| $9>                              | 84              | (50.0)          | 82        | (49.7)    | 166     | (49.8)  |
| >65                              | 84              | (50.0)          | 83        | (50.3)    | 167     | (50.2)  |
| Mean                             | 64.0            |                 | 64.3      |           | 64.2    |         |
| SD                               | 7.9             |                 | 8.8       |           | 8.4     |         |
| Median                           | 64.5            |                 | 65.0      |           | 65.0    |         |
| Range                            | 38 to 82        |                 | 37 to 85  |           | 37to 85 |         |
| Race                             |                 |                 |           |           |         |         |
| American Indian Or Alaska Native | 1               | (0.6)           | 0         | (0.0)     | 1       | (0.3)   |
| Asian                            | 29              | (17.3)          | 29        | (17.6)    | 58      | (17.4)  |
| Multiple                         | 0               | (0.0)           | 1         | (0.6)     | 1       | (0.3)   |
| White Black Or African American  | 0               | (0.0)           | 1         | (0.6)     | 1       | (0.3)   |
| Other                            | 3               | (1.8)           | 1         | (0.6)     | 4       | (1.2)   |
| White                            | 128             | (76.2)          | 127       | (77.0)    | 255     | (76.6)  |
| Missing                          | 7               | (4.2)           | 7         | (4.2)     | 14      | (4.2)   |
| Age (Years)                      |                 |                 |           |           |         |         |
| <70                              | 126             | (75.0)          | 114       | (69.1)    | 240     | (72.1)  |
| >= 70                            | 42              | (25.0)          | 51        | (30.9)    | 93      | (27.9)  |
| Age (Years)                      |                 |                 |           |           |         |         |
| $9>                              | 84              | (50.0)          | 82        | (49.7)    | 166     | (49.8)  |
| 65 - 74                          | 72              | (42.9)          | t9        | (38.8)    | 136     | (40.8)  |
| 75 -84                           | 12              | (7.1)           | 17        | (10.3)    | 29      | (8.7)   |
| 85+                              | 0               | (0.0)           | 2         | (1.2)     | 2       | (0.6)   |
| Geographic Region                |                 |                 |           |           |         |         |
| Western Europe                   | 90              | (53.6)          | 89        | (53.9)    | 179     | (53.8)  |
| Eastern Europe                   | 31              | (18.5)          | 30        | (18.2)    | 61      | (18.3)  |
| Rest of World                    | 18              | (10.7)          | 17        | (10.3)    | 35      | (10.5)  |

<div style=\"page-break-after: always\"></div>

| Asia                          | 29   | (17.3)   | 29   | (17.6)   | 58   | (17.4)   |
|-------------------------------|------|----------|------|----------|------|----------|
| Region                        |      |          |      |          |      |          |
| EU                            | 115  | (68.5)   | 112  | (67.9)   | 227  | (68.2)   |
| Non-EU                        | 53   | (31.5)   | 53   | (32.1)   | 106  | (31.8)   |
| Region                        |      |          |      |          |      |          |
| East Asia                     | 29   | (17.3)   | 29   | (17.6)   | 58   | (17.4)   |
| Non-East Asia                 | 139  | (82.7)   | 136  | (82.4)   | 275  | (82.6)   |
| Stage at Baseline per AJCC V7 |      |          |      |          |      |          |
| IB                            | 21   | (12.5)   | 22   | (13.3)   | 43   | (12.9)   |
| II                            | 95   | (56.5)   | 93   | (56.4)   | 188  | (56.5)   |
| IIIA                          | 52   | (31.0)   | 50   | (30.3)   | 102  | (30.6)   |
| Adjuvant Chemotherapy         |      |          |      |          |      |          |
| No                            | 25   | (14.9)   | 24   | (14.5)   | 49   | (14.7)   |
| Yes                           | 143  | (85.1)   | 141  | (85.5)   | 284  | (85.3)   |
| Smoking Status                |      |          |      |          |      |          |
| Never Smoker                  | 14   | (8.3)    | 13   | (7.9)    | 27   | (8.1)    |
| Former Smoker                 | 130  | (77.4)   | 123  | (74.5)   | 253  | (76.0)   |
| Current Smoker                | 24   | (14.3)   | 29   | (17.6)   | 53   | (15.9)   |
| BaselineECOG                  |      |          |      |          |      |          |
| 0                             | 116  | (69.0)   | 101  | (61.2)   | 217  | (65.2)   |
| 1                             | 52   | (31.0)   | 64   | (38.8)   | 116  | (34.8)   |
| Histology                     |      |          |      |          |      |          |
| Squamous                      | 65   | (38.7)   | 60   | (36.4)   | 125  | (37.5)   |
| Non-squamous                  | 103  | (61.3)   | 105  | (63.6)   | 208  | (62.5)   |
| EGFRMutationStatus            |      |          |      |          |      |          |
| N                             | 57   | (33.9)   | 67   | (40.6)   | 124  | (37.2)   |
| Y                             | 6    | (3.6)    | 5    | (3.0)    | 11   | (3.3)    |
| Unknown                       | 105  | (62.5)   | 93   | (56.4)   | 198  | (59.5)   |
| ALK MutationStatus            |      |          |      |          |      |          |
| N                             | 55   | (32.7)   | 58   | (35.2)   | 113  | (33.9)   |
| Y                             | 3    | (1.8)    | 0    | (0.0)    | 3    | (0.9)    |
| Unknown                       | 110  | (65.5)   | 107  | (64.8)   | 217  | (65.2)   |

Table 13: EGFR Status by Histology (ITT Population)

|                      | Squamous              | Squamous             | Squamous             | Non-squamous          | Non-squamous         | Non-squamous         |
|----------------------|-----------------------|----------------------|----------------------|-----------------------|----------------------|----------------------|
|                      | Pembrolizumab (n=192) | Placebo (n=224)      | Total (n=416)        | Pembrolizumab (n=398) | Placebo (n=363)      | Total (n=761)        |
| EGFR Mutation Status | EGFR Mutation Status  | EGFR Mutation Status | EGFR Mutation Status | EGFR Mutation Status  | EGFR Mutation Status | EGFR Mutation Status |
| N                    | 39 (20.3%)            | 56 (25.0%)           | 95 (22.8%)           | 179 (45.0%)           | 160 (44.1%)          | 339 (44.5%)          |
| Y                    | 2 (1.0%)              | 5 (2.2%)             | 7 (1.7%)             | 37 (9.3%)             | 29 (8.0%)            | 66 (8.7%)            |
| Unknown              | 151 (78.6%)           | 163 (72.8%)          | 314 (75.5%)          | 182 (45.7%)           | 174 (47.9%)          | 356 (46.8%)          |

Table 14: EGFR positivity by PD-L1 expression

| EGFR (known) positive TOTAL   |   39 |   34 |
|-------------------------------|------|------|
| EGFR positive PD-L1<1%        |   18 |   15 |
| EGFR positive PD-L1 1-49%     |   15 |   14 |
| EGFR positive PD- L1 ≥50%     |    6 |    5 |

<div style=\"page-break-after: always\"></div>

No additional assessment of EGFR status was planned in KEYNOTE-091 study.

## Prior adjuvant chemotherapy

Approximately 86% of participants in both arms received adjuvant chemotherapy. Of the 14% who did not receive adjuvant chemotherapy 32.3% were Stage IB, 54.5% were Stage II, and 13.2% were Stage IIIA. A higher proportion of participants who did not receive adjuvant chemotherapy were ≥ 65 years old (74.9% vs. 48.9%; median age 64 vs 71 without and with chemo, respectively), had Stage IB disease (32.3% vs. 11.4%), and had squamous cell histology (44.9% vs. 33.8%) compared with those who received adjuvant chemotherapy.

Table 15: Exposure to prior adjuvant chemotherapy

|                              | Pembrolizumab (N=506)        | Placebo (N=504)              |
|------------------------------|------------------------------|------------------------------|
| Duration on Therapy (days)   |                              |                              |
| Mean                         | 71.2                         | 72.5                         |
| Median                       | 71.0                         | 72.0                         |
| SD                           | 19.67                        | 19.47                        |
| Range                        | 1.0 to 124.0                 | 1.0 to 133.0                 |
| Number of Cycles             |                              |                              |
| Mean                         | 3.7                          | 3.7                          |
| Median                       | 4.0                          | 4.0                          |
| SD                           | 0.68                         | 0.62                         |
| Range                        | 1.0 to 5.0                   | 1.0 to 4.0                   |
| DatabaseCutoffDate:20SEP2021 | DatabaseCutoffDate:20SEP2021 | DatabaseCutoffDate:20SEP2021 |

Table 16: Type of prior adjuvant chemotherapy

|                                              | Pembrolizumab                           | Pembrolizumab                           | Placebo                                 | Placebo                                 |
|----------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                              |                                         | (%)                                     | n                                       | (%)                                     |
| Participants in population                   | 590                                     |                                         | 587                                     |                                         |
| with one or more prior adjuvant chemotherapy | 506                                     | (85.8)                                  | 504                                     | (85.9)                                  |
| with no prior adjuvant chemotherapy          | 84                                      | (14.2)                                  | 83                                      | (14.1)                                  |
| ANTINEOPLASTICANDIMMUNOMODULATINGAGENTS      | ANTINEOPLASTICANDIMMUNOMODULATINGAGENTS | ANTINEOPLASTICANDIMMUNOMODULATINGAGENTS | ANTINEOPLASTICANDIMMUNOMODULATINGAGENTS | ANTINEOPLASTICANDIMMUNOMODULATINGAGENTS |
| ANTINEOPLASTICAGENTS                         | 506                                     | (85.8)                                  | 504                                     | (85.9)                                  |
| ANTINEOPLASTIC AGENTS                        | 24                                      | (4.1)                                   | 30                                      | (5.1)                                   |
| CARBOPLATIN;DOCETAXEL                        | 2                                       | (0.3)                                   | 0                                       | (0.0)                                   |
| CARBOPLATIN;ETOPOSIDE                        | 5                                       | (0.8)                                   | 3                                       | (0.5)                                   |
| CARBOPLATIN;GEMCITABINE                      | 17                                      | (2.9)                                   | 14                                      | (2.4)                                   |
| CARBOPLATIN;PACLITAXEL                       | 60                                      | (10.2)                                  | 75                                      | (12.8)                                  |
| CARBOPLATIN:PEMETREXED                       | 18                                      | (3.1)                                   | 9                                       | (1.5)                                   |
| CARBOPLATIN;VINORELBINE                      | 81                                      | (13.7)                                  | 70                                      | (11.9)                                  |
| CISPLATIN;DOCETAXEL                          | 1                                       | (0.2)                                   | 3                                       | (0.5)                                   |
| CISPLATIN;ETOPOSIDE                          | 0                                       | (0.0)                                   | 3                                       | (0.5)                                   |
| CISPLATIN;GEMCITABINE                        | 27                                      | (4.6)                                   | 30                                      | (5.1)                                   |
| CISPLATIN;IRINOTECAN                         | 0                                       | (0.0)                                   | 1                                       | (0.2)                                   |
| CISPLATIN;PACLITAXEL                         | 2                                       | (0.3)                                   | 1                                       | (0.2)                                   |
| CISPLATIN;PEMETREXED                         | 28                                      | (4.7)                                   | 15                                      | (2.6)                                   |
| CISPLATIN;VINORELBINE                        | 241                                     | (40.8)                                  | 250                                     | (42.6)                                  |

Everyparticipant is counted a singletimefor each applicablespecificprior adjuvant chemotherapy.Aparticipant with multiple prior adjuvant chemotherapy within a medication category is counted a single time for that category. Eachspecific prior adjuvant chemotherapyis listedunder allrelevantmedication classes based on themedication's generic name, regardless of route of administration or reason for use.

A medication class or specific medication appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

DatabaseCutoffDate:20SEP2021

<div style=\"page-break-after: always\"></div>

Table 17: Summary of duration between surgery and adjuvant chemotherapy, adjuvant chemotherapy and study treatment, and between surgery and study treatment

| Event                                                                                                            | Days           | Pembrolizumab   | Placebo      |
|------------------------------------------------------------------------------------------------------------------|----------------|-----------------|--------------|
| Surgery to 1st dose a of adjuvant                                                                                |                | N=504           | N=502        |
| chemotherapy (ITT- participants with adjuvant chemotherapy)                                                      | median (range) | 46 (16-91)      | 44 (17-121)  |
| chemotherapy (ITT- participants with adjuvant chemotherapy)                                                      | IQR            | 18              | 20           |
| Last dose of adjuvant chemotherapy to 1st dose of study treatment (APaT-participants with adjuvant chemotherapy) |                | N=496           | N=499        |
|                                                                                                                  | median (range) | 43 (16-98)      | 43 (9-87)    |
|                                                                                                                  | IQR            | 19              | 19           |
| Surgery to 1st dose of study treatment (APaT-participants with adjuvant chemotherapy)                            |                | N=496           | N=499        |
| Surgery to 1st dose of study treatment (APaT-participants with adjuvant chemotherapy)                            | median (range) | 161 (71-244)    | 158 (80-254) |
| Surgery to 1st dose of study treatment (APaT-participants with adjuvant chemotherapy)                            | IQR            | 36              | 36           |
| Surgery to 1st dose of study treatment (APaT-participants without adjuvant chemotherapy)                         |                | N=84            | N=82         |
| Surgery to 1st dose of study treatment (APaT-participants without adjuvant chemotherapy)                         | median (range) | 57 (28 - 87)    | 57 (40 - 85) |
| Surgery to 1st dose of study treatment (APaT-participants without adjuvant chemotherapy)                         | IQR            | 16.5            | 20           |
| Surgery to 1st dose of study treatment (APaT population)                                                         |                | N=580           | N=581        |
| Surgery to 1st dose of study treatment (APaT population)                                                         | median (range) | 156 (28-244)    | 154 (40-254) |
| Surgery to 1st dose of study treatment (APaT population)                                                         | IQR            | 44.5            | 47           |

a  2 participants in pembrolizumab arm and 2 participants in placebo arm received adjuvant chemotherapy without the 1st dose date of adjuvant chemotherapy reported in the database.  These 4 participants are not included in the analysis.

<div style=\"page-break-after: always\"></div>

Table 18: Characteristics of Participants with Adjuvant Chemotherapy (ITT Population)

|                                    | Pembrolizumab    | Pembrolizumab    | Placebo          | Placebo          | Total            | Total            |
|------------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|
|                                    | n                | (%)              | n                | (%)              |                  | (%)              |
| Participants in population         | 506              |                  | 504              |                  | 1,010            |                  |
| Sex                                |                  |                  |                  |                  |                  |                  |
| Male                               | 339              | (67.0)           | 347              | (68.8)           | 686              | (67.9)           |
| Female                             | 167              | (33.0)           | 157              | (31.2)           | 324              | (32.1)           |
| Age (Years)                        |                  |                  |                  |                  |                  |                  |
| S9 >                               | 264              | (52.2)           | 252              | (50.0)           | 516              | (51.1)           |
| >=65                               | 242              | (47.8)           | 252              | (50.0)           | 494              | (48.9)           |
| Mean                               | 63.3             |                  | 63.6             |                  | 63.4             |                  |
| SD                                 | 8.1              |                  | 7.9              |                  | 8.0              |                  |
| Median                             | 64.0             |                  | 64.5             |                  | 64.0             |                  |
| Range                              | 35 to 80         |                  | 37 to 84         |                  | 35 to 84         |                  |
| Race                               |                  |                  |                  |                  |                  |                  |
| Asian                              | 88               | (17.4)           | 89               | (17.7)           | 177              | (17.5)           |
| BlackOrAfricanAmerican             | 0                | (0.0)            | 3                | (0.6)            | 3                | (0.3)            |
| Multiple                           | 4                | (0.8)            | 1                | (0.2)            | 5                | (0.5)            |
| AmericanIndian OrAlaskaNativeWhite | 1                | (0.2)            | 0                | (0.0)            | 1                | (0.1)            |
| Mestiza                            | 1                | (0.2)            | 0                | (0.0)            | 1                | (0.1)            |
| Mixed Race                         | 1                | (0.2)            | 0                | (0.0)            | 1                | (0.1)            |
| White Black Or African American    | 1                | (0.2)            | 1                | (0.2)            | 2                | (0.2)            |
| Other                              | 6                | (1.2)            | 1                | (0.2)            | 7                | (0.7)            |
| White                              | 387              | (76.5)           | 392              | (77.8)           | 779              | (77.1)           |
| Missing                            | 21               | (4.2)            | 18               | (3.6)            | 39               | (3.9)            |
| Age (Years)                        |                  |                  |                  |                  |                  |                  |
| <70                                | 384              | (75.9)           | 382              | (75.8)           | 766              | (75.8)           |
| >=70                               | 122              | (24.1)           | 122              | (24.2)           | 244              | (24.2)           |
| Age (Years)                        |                  |                  |                  |                  |                  |                  |
| <65                                | 264              | (52.2)           | 252              | (50.0)           | 516              | (51.1)           |
| 65-74                              | 211              | (41.7)           | 222              | (44.0)           | 433              | (42.9)           |
| 75 - 84                            | 31               | (6.1)            | 30               | (6.0)            | 61               | (6.0)            |
| GeographicRegion                   | GeographicRegion | GeographicRegion | GeographicRegion | GeographicRegion | GeographicRegion | GeographicRegion |

<div style=\"page-break-after: always\"></div>

| Westem Europe                | 261   | (51.6)   | 266   | (52.8)   | 527   | (52.2)   |
|------------------------------|-------|----------|-------|----------|-------|----------|
| Eastern Europe               | 105   | (20.8)   | 96    | (19.0)   | 201   | (19.9)   |
| Rest of World                | 53    | (10.5)   | 55    | (10.9)   | 108   | (10.7)   |
| Asia                         | 87    | (17.2)   | 87    | (17.3)   | 174   | (17.2)   |
| Region                       |       |          |       |          |       |          |
| EU                           | 343   | (67.8)   | 342   | (67.9)   | 685   | (67.8)   |
| Non-EU                       | 163   | (32.2)   | 162   | (32.1)   | 325   | (32.2)   |
| Region                       |       |          |       |          |       |          |
| East Asia                    | 87    | (17.2)   | 87    | (17.3)   | 174   | (17.2)   |
| Non-East Asia                | 419   | (82.8)   | 417   | (82.7)   | 836   | (82.8)   |
| StageatBaselineperAJCCV7     |       |          |       |          |       |          |
| IB                           | 60    | (11.9)   | 55    | (10.9)   | 115   | (11.4)   |
| IⅡI                          | 281   | (55.5)   | 295   | (58.5)   | 576   | (57.0)   |
| VIII                         | 165   | (32.6)   | 152   | (30.2)   | 317   | (31.4)   |
| IV                           | 0     | (0.0)    | 2     | (0.4)    | 2     | (0.2)    |
| PD-L1Status (Stratification) |       |          |       |          |       |          |
| <1%                          | 198   | (39.1)   | 198   | (39.3)   | 396   | (39.2)   |
| 1-49%                        | 165   | (32.6)   | 165   | (32.7)   | 330   | (32.7)   |
| %0S=<                        | 143   | (28.3)   | 141   | (28.0)   | 284   | (28.1)   |
| Smoking Status               |       |          |       |          |       |          |
| Never Smoker                 | 80    | (15.8)   | 57    | (11.3)   | 137   | (13.6)   |
| FormerSmoker                 | 362   | (71.5)   | 375   | (74.4)   | 737   | (73.0)   |
| CurrentSmoker                | 64    | (12.6)   | 72    | (14.3)   | 136   | (13.5)   |
| BaselineECOG                 |       |          |       |          |       |          |
| 0                            | 326   | (64.4)   | 292   | (57.9)   | 618   | (61.2)   |
| 1                            | 180   | (35.6)   | 212   | (42.1)   | 392   | (38.8)   |
| Histology                    |       |          |       |          |       |          |
| Squamous                     | 157   | (31.0)   | 184   | (36.5)   | 341   | (33.8)   |
| snowenbs-uoN                 | 349   | (69.0)   | 320   | (63.5)   | 669   | (66.2)   |
| EGFRMutationStatus           |       |          |       |          |       |          |
| N                            | 190   | (37.5)   | 192   | (38.1)   | 382   | (37.8)   |
| Y                            | 36    | (7.1)    | 30    | (6.0)    | 66    | (6.5)    |
| Unknown                      | 280   | (55.3)   | 282   | (56.0)   | 562   | (55.6)   |
| ALKMutationStatus            |       |          |       |          |       |          |
| N                            | 196   | (38.7)   | 166   | (32.9)   | 362   | (35.8)   |
| Y                            | 6     | (1.2)    | 6     | (1.2)    | 12    | (1.2)    |
| Unknown                      | 304   | (60.1)   | 332   | (65.9)   | 636   | (63.0)   |
| DatabaseCutoffDate:20SEP2021 |       |          |       |          |       |          |

## Subsequent antineoplastic therapies

Fewer participants initiated subsequent antineoplastic therapies in the pembrolizumab group than the placebo group (14.6% vs 21.0%). Similarly, fewer participants initiated subsequent immunotherapies in the pembrolizumab group than the placebo group (2.5% vs 10.4%). The most commonly prescribed (&gt;2%) subsequent antineoplastic agents in pembrolizumab arm were carboplatin/pemetrexed (3.2%) and carboplatin/paclitaxel (2.4%). In placebo-treated participants, the most commonly prescribed subsequent antineoplastic agents were pembrolizumab (5.3%), pemetrexed (2.6%), and atezolizumab (2.6%) (data related to IA2).

Table 19: participants with subsequent antineoplastic therapy

|                                                      | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   |
|------------------------------------------------------|-----------------|-----------------|-----------|-----------|
|                                                      |                 | (%)             |           | (%)       |
| Participants in population                           | 590             |                 | 587       |           |
| with one or more subscquent antineoplastic therapies | 86              | (14.6)          | 123       | (21.0)    |
| with no subsequent antineoplastic therapies          | 504             | (85.4)          | 464       | (79.0)    |

<div style=\"page-break-after: always\"></div>

Table 20: participants with subsequent immunotherapies

|                                             | Pembrolizumab                           | Pembrolizumab                           | Placebo                                 | Placebo                                 |
|---------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                             | 1                                       | (%)                                     | 1                                       | (%)                                     |
| Participantsinpopulation                    | 590                                     |                                         | 587                                     |                                         |
| with one or more subsequent immunotherapies | 15                                      | (2.5)                                   | 61                                      | (10.4)                                  |
| with no subsequent immunotherapies          | 575                                     | (97.5)                                  | 526                                     | (89.6)                                  |
| ANTINEOPLASTICANDIMMUNOMODULATINGAGENTS     | ANTINEOPLASTICANDIMMUNOMODULATINGAGENTS | ANTINEOPLASTICANDIMMUNOMODULATINGAGENTS | ANTINEOPLASTICANDIMMUNOMODULATINGAGENTS | ANTINEOPLASTICANDIMMUNOMODULATINGAGENTS |
| ANTINEOPLASTICAGENTS                        | 15                                      | (2.5)                                   | 61                                      | (10.4)                                  |
| ATEZOLIZUMAB                                | 2                                       | (0.3)                                   | 15                                      | (2.6)                                   |
| CARBOPLATIN:PACLITAXEL:PEMBROLIZU MAB       | 1                                       | (0.2)                                   | 1                                       | (0.2)                                   |
| CARBOPLATIN;PEMBROLIZUMAB;PEMETRE XED       | 0                                       | (0.0)                                   | 1                                       | (0.2)                                   |
| DURVALUMAB                                  | 4                                       | (0.7)                                   | 5                                       | (0.9)                                   |
| IPILIMUMAB:NIVOLUMAB                        | 1                                       | (0.2)                                   | 0                                       | (0.0)                                   |
| NIVOLUMAB                                   | 1                                       | (0.2)                                   | 10                                      | (1.7)                                   |
| PEMBROLIZUMAB                               | 8                                       | (1.4)                                   | 31                                      | (5.3)                                   |
| IMMUNOSTIMULANTS                            | 0                                       | (0.0)                                   | 2                                       | (0.3)                                   |
| EFTILAGIMOD ALFA                            | 0                                       | (0.0)                                   | 1                                       | (0.2)                                   |
| INTERLEUKIN-2                               | 0                                       | (0.0)                                   | 1                                       | (0.2)                                   |

Every participant is counted a single time for each applicable specific subsequent immunotherapies. A participant with multiple subsequent immunotherapies within a medication category is counted a single time for that category. Eachspecificsubsequent immunotherapies is listed under all relevant medication classes based on themedication's generic name,regardless of route of administration or reason for use.

A medication class or specific medication appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Database Cutoff Date: 20SEP2021

## Numbers analysed

1955 patients were screened, and a total of 1177 participants were randomized in KEYNOTE-091 and included in the ITT population (590 in the pembrolizumab group, 587 in the placebo group). 333 patients presented with PDL1 expression ≥50%, of which 168 randomized to pembrolizumab and 165 to placebo. 712 patients had PDL1≥1 %, 357 in pembrolizumab and 355 in placebo arm. 1161 patients were included in the PRO FAS population.

## Outcomes and estimation

Efficacy results from prespecified IA2 of KEYNOTE-091 are presented below, followed by efficacy results from the IA3 (data cut-off 24-JAN-2023).

Table 21: Summary of Outcomes for Primary and Key Secondary Endpoints at IA2

| Endpoints     | Endpoints                                                                                           | Outcome                                                                                                                                                                                          |
|---------------|-----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary       | DFS in the overall study population DFS in TPS≥50% subgroup                                         | Positive Not positive: To be tested again at next IA                                                                                                                                             |
| Key Secondary | DFS in TPS≥1% subgroup OS in TPS≥50% subgroup OS in the overall study population OSinTPS≥1%subgroup | Not tested; To be tested once positive DFS in TPS>50% Not positive; To be tested again at next IA Not positive; To be tested again at next IA Not tested; Tobe tested once positive OSin TPS≥50% |

<div style=\"page-break-after: always\"></div>

Table 22: Summary of efficacy at IA2

| Endpoint                  | Overall StudyPopulation   | Overall StudyPopulation   | TPS ≥50%          | TPS ≥50%          | TPS>=1%           | TPS>=1%           |
|---------------------------|---------------------------|---------------------------|-------------------|-------------------|-------------------|-------------------|
|                           | Pembro N=590              | Placebo N=587             | Pembro N=168      | Placebo N=165     | Pembro N=357      | Placebo N=355     |
| DFS                       |                           |                           |                   |                   |                   |                   |
| Median in months (95% CI) | 53.6 (39.2, NR)           | 42.0 (31.3, NR)           | NR (44.3, NR)     | NR (35.8, NR)     | 53.6 (44.2, NR)   | 42.0 (31.3, NR)   |
| Hazard ratio (95% CI)b    | 0.76 (0.63, 0.91)         | 0.76 (0.63, 0.91)         | 0.82 (0.57, 1.18) | 0.82 (0.57, 1.18) | 0.73 (0.57, 0.92) | 0.73 (0.57, 0.92) |
| p-Valuec                  | 0.00143                   | 0.00143                   | 0.13639           | 0.13639           | Not Tested        | Not Tested        |
| Osd                       |                           |                           |                   |                   |                   |                   |
| Hazard ratio (95% CI)b    | 0.87 (0.67,1.15)          | 0.87 (0.67,1.15)          | 0.92 (0.52,1.62)  | 0.92 (0.52,1.62)  | 0.76 (0.52, 1.09) | 0.76 (0.52, 1.09) |
| p-Valuee                  | 0.16811                   | 0.16811                   | 0.38517           | 0.38517           | Not Tested        | Not Tested        |

## -DFS in ITT population (primary endpoint)

Table 23: Analysis of Disease-Free Survival (Primary Censoring Rule) Primary Analysis with Permutation Test (ITT Population)

0.00143

|               |     |                      |                | Event Rate/        | Median DFS a (Months)   | DFS Rate at Month 12 in%   | vs. Placebo               | vs. Placebo   |
|---------------|-----|----------------------|----------------|--------------------|-------------------------|----------------------------|---------------------------|---------------|
| Treatment     | N   | Number of Events (%) | Person- Months | 100 Person- Months | (95% CI)                | a (95% CI)                 | Hazard Ratio b (95% CI) b | p-Value c     |
| Pembrolizumab | 590 | 212 (35.9)           | 13872.6        | 1.5                | 53.6 (39.2, .)          | 78.7 (75.1, 81.9)          | 0.76 (0.63, 0.91)         | 0.00143       |
| Placebo       | 587 | 260 (44.3)           | 13089.8        | 2.0                | 42.0 (31.3, .)          | 71.6 (67.7, 75.1)          | ---                       | ---           |

|                                                                                           | Pembrolizumab (N=590)   | Placebo (N=587)   |
|-------------------------------------------------------------------------------------------|-------------------------|-------------------|
| DFSrateat12Monthsin(95%CI)a                                                               | 78.7 (75.1,81.9)        | 71.6 (67.7,75.1)  |
| DFSrate at18 Months in(95%CI)                                                             | 73.4 (69.6, 76.9)       | 64.3 (60.3, 68.1) |
| DFSrate at 24 Monthsin(95%CI)a                                                            | 67.4 (63.2, 71.2)       | 59.5 (55.2,63.4)  |
| DFSrate at30Monthsin(95%CI)a                                                              | 63.7 (59.3,67.8)        | 55.1 (50.7,59.3)  |
| DFSrate at36Monthsin(95%CI)                                                               | 58.1 (53.1,62.8)        | 50.1 (45.1, 54.8) |
| DFSrateat42Monthsin(95%CI)a                                                               | 54.4 (48.7, 59.8)       | 49.2 (44.1, 54.1) |
| aFrom theproduct-limit(Kaplan-Meier)methodfor censored data. DatabaseCutoffDate:20SEP2021 |                         |                   |

<div style=\"page-break-after: always\"></div>

Figure 5: Kaplan-Meier Estimates of Disease-Free Survival (Primary Censoring Rule) (ITT Population)

<!-- image -->

Database Cutoff Date: 20SEP2021

Table 24: Disease status - DFS events (ITT population)

|                                                                                                  | Pembrolizumab                                                                                    | Pembrolizumab                                                                                    | Placebo                                                                                          | Placebo                                                                                          |
|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
|                                                                                                  | n                                                                                                | (%)                                                                                              | n                                                                                                | (%)                                                                                              |
| Participants in population                                                                       | 590                                                                                              |                                                                                                  | 587                                                                                              |                                                                                                  |
| Type of First Event in DFS Analysis                                                              | Type of First Event in DFS Analysis                                                              | Type of First Event in DFS Analysis                                                              | Type of First Event in DFS Analysis                                                              | Type of First Event in DFS Analysis                                                              |
| No event                                                                                         | 378                                                                                              | (64.1)                                                                                           | 327                                                                                              | (55.7)                                                                                           |
| Event                                                                                            | 212                                                                                              | (35.9)                                                                                           | 260                                                                                              | (44.3)                                                                                           |
| Not disease-free at baseline                                                                     | 7                                                                                                | (1.2)                                                                                            | 4                                                                                                | (0.7)                                                                                            |
| Recurrence                                                                                       | 157                                                                                              | (26.6)                                                                                           | 212                                                                                              | (36.1)                                                                                           |
| Local and/orregional recurrence                                                                  | 56                                                                                               | (9.5)                                                                                            | 70                                                                                               | (11.9)                                                                                           |
| Distant metastasis                                                                               | 68                                                                                               | (11.5)                                                                                           | 101                                                                                              | (17.2)                                                                                           |
| Both                                                                                             | 33                                                                                               | (5.6)                                                                                            | 41                                                                                               | (7.0)                                                                                            |
| New malignancy                                                                                   | 21                                                                                               | (3.6)                                                                                            | 32                                                                                               | (5.5)                                                                                            |
| Death                                                                                            | 27                                                                                               | (4.6)                                                                                            | 12                                                                                               | (2.0)                                                                                            |
| New malignancy includes the second primary and second malignancies. DatabaseCutoffDate:20SEP2021 | New malignancy includes the second primary and second malignancies. DatabaseCutoffDate:20SEP2021 | New malignancy includes the second primary and second malignancies. DatabaseCutoffDate:20SEP2021 | New malignancy includes the second primary and second malignancies. DatabaseCutoffDate:20SEP2021 | New malignancy includes the second primary and second malignancies. DatabaseCutoffDate:20SEP2021 |

<div style=\"page-break-after: always\"></div>

## -DFS in PD-L1 TPS ≥ 50% population (primary endpoint)

Table 25: Analysis of Disease-Free Survival (Primary Censoring Rule) Primary Analysis with Permutation Test with TPS ≥ 50% (ITT Population)

0.82 (0.57, 1.18)

0.13639

---

|               |     |                      |                | Event Rate/ 100 Person-   | Median DFS a (Months)   | DFS Rate at Month 12 in%   | vs. Placebo               | vs. Placebo   |
|---------------|-----|----------------------|----------------|---------------------------|-------------------------|----------------------------|---------------------------|---------------|
| Treatment     | N   | Number of Events (%) | Person- Months | Months                    | (95% CI)                | a (95% CI)                 | Hazard Ratio b (95% CI) b | p-Value c     |
| Pembrolizumab | 168 | 54 (32.1)            | 3948.7         | 1.4                       | Not Reached (44.3,)     | 79.5 (72.4, 85.0)          | 0.82 (0.57, 1.18)         | 0.13639       |
| Placebo       | 165 | 63 (38.2)            | 3976.8         | 1.6                       | Not Reached (35.8,)     | 74.5 (67.1, 80.5)          | ---                       | ---           |

Figure 6: Kaplan-Meier Estimates of Disease-Free Survival (Primary Censoring Rule) with TPS &gt;= 50% (ITT Population)

<!-- image -->

Database Cutoff Date: 20SEP2021

## -OS in the ITT (secondary endpoint)

## · OS in the ITT

For OS in the ITT population, the observed p-value did not cross the multiplicity-adjusted, one-sided pvalue boundary at IA2.

<div style=\"page-break-after: always\"></div>

Table 26: Analysis of Overall Survival (Primary Analysis) (ITT Population)

|               |     |                      |                | Event Rate/ 100 Person-   | Median OS a (Months)   | OS Rate at Month 12 in%   | vs. Placebo               | vs. Placebo   |
|---------------|-----|----------------------|----------------|---------------------------|------------------------|---------------------------|---------------------------|---------------|
| Treatment     | N   | Number of Events (%) | Person- Months | Months                    | (95% CI)               | a (95% CI)                | Hazard Ratio b (95% CI) b | p-Value c     |
| Pembrolizumab | 590 | 98 (16.6)            | 19215.5        | 0.5                       | Not Reached (., )      | 95.2 (93.1, 96.7)         | 0.87 (0.67, 1.15)         | 0.16811       |
| Placebo       | 587 | 111 (18.9)           | 19071.7        | 0.6                       | Not Reached (., .)     | 95.2 (93.1, 96.7)         | ---                       | ---           |

Database Cutoff Date: 20SEP2021

Figure 7: Kaplan-Meier Estimates of Overall Survival (Primary analysis) (ITT Population)

<!-- image -->

Database Cutoff Date: 20SEP2021

## Ancillary analyses

Subgroup analyses

0.16811

---

---

<div style=\"page-break-after: always\"></div>

Figure 8: Forest Plot of DFS Hazard Ratio by Subgroup Factors (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

1. For overall population, analysis is based on multivariate Cox regression model with treatment adjusted by the following covariates: stage (IB vs. II vs. IIIA), PD-L1 status (&gt;=50% vs. 1-49% vs. &lt;1%), adjuvant chemotherapy (yes vs. no), region (Western Europe vs. Eastern Europe vs. Rest of World vs. Asia), histology (squamous vs. non-squamous), and smoking status (never vs. former/current). For subgroups, analysis is based on Cox regression model with treatment as a covariate. 2. If a subgroup variable has two levels and one level of the subgroup meets any criteria below, then this subgroup variable will not be displayed: (1) if the number of participants in a category of a subgroup variable is less than 50, (2) the number of events in a category of a subgroup variable is zero in one treatment arm, (3) the number of events in a category of a subgroup variable is less than 5 in the pooled arms. Database Cutoff Date: 20SEP2021

## Results by PD-L1 status:

Figure 9: Forest Plot of DFS Hazard Ratio by PD-L1 Expression (ITT Population)

<!-- image -->

For overall population and the PD-L1 subgroup, analysis is based on multivariate Cox regression model with treatment adjusted by the following covariates: stage (IB vs. II vs. IIIA), PD-L1 status (&gt;=50% vs. 1-49% vs. &lt;1%), adjuvant chemotherapy (yes vs. no), region (Western Europe vs. Eastern Europe vs. Rest of World vs. Asia), histology (squamous vs. non-squamous), and smoking status (never vs. former/current). Database Cutoff Date: 20SEP2021

Figure 10: Kaplan-Meier Estimates of Disease-Free Survival (Primary Censoring Rule) by PD-L1 Expression (ITT population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Sensitivity analyses

Several prespecified sensitivity analyses for DFS were conducted in the overall study population and in the PD L1 TPS ≥ 50% and TPS ≥ 1% subgroups. Results in each sensitivity analysis were consistent with the primary analysis.

## Restricted Mean Survival Times (RMST) of DFS

Table 27: Analysis of restricted mean survival times (RMST) of disease-free survival (ITT population)

|                                                               | Pembrolizumab (N=590)                                         | Pembrolizumab (N=590)                                         | Placebo (N=587)                                               | Placebo (N=587)                                               | Difference(95%CI) Pembrolizumab vs Placebo                    |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                               | Numberof Events                                               | RMST                                                          | NumberofEvents                                                | RMST                                                          |                                                               |
| RMSTbasedon6monthsoffollowup                                  | 67                                                            | 5.67                                                          | 89                                                            | 5.66                                                          | 0.02 (-0.10,0.14)                                             |
| RMSTbasedon12months offollowup                                | 120                                                           | 10.70                                                         | 165                                                           | 10.39                                                         | 0.31(-0.04 ,0.66)                                             |
| RMSTbasedon18monthsoffollowup                                 | 148                                                           | 15.27                                                         | 205                                                           | 14.47                                                         | 0.80(0.18,1.42)                                               |
| RMSTbasedon24monthsoffollow up                                | 176                                                           | 19.49                                                         | 228                                                           | 18.20                                                         | 1.29 (0.38,2.20)                                              |
| RMSTbasedon30monthsoffollowup                                 | 189                                                           | 23.46                                                         | 244                                                           | 21.64                                                         | 1.81 (0.61,3.02)                                              |
| RMST:Restrictedmeansurvivaltime. DatabaseCutoffDate:20SEP2021 | RMST:Restrictedmeansurvivaltime. DatabaseCutoffDate:20SEP2021 | RMST:Restrictedmeansurvivaltime. DatabaseCutoffDate:20SEP2021 | RMST:Restrictedmeansurvivaltime. DatabaseCutoffDate:20SEP2021 | RMST:Restrictedmeansurvivaltime. DatabaseCutoffDate:20SEP2021 | RMST:Restrictedmeansurvivaltime. DatabaseCutoffDate:20SEP2021 |

## Patient-Reported Outcomes (exploratory endpoint)

Based on the early results, global health status/quality of life scores were stable over time in both the pembrolizumab and placebo groups.

Table 28: Summary and Analysis of Overall Improvement / Stability Rate for EORTC QLQ-C30 Global Health Status/QoL (PRO FAS Population)

|                         | Pembrolizumab(N=580)           | Pembrolizumab(N=580)           | Pembrolizumab(N=580)           | Placebo (N=581)                | Placebo (N=581)                | Placebo (N=581)                |
|-------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Summary                 |                                | %                              | 95% CIa                        |                                | %                              | 95% CI                         |
| Improved                | 145                            | 25.0                           | (21.5,28.7)                    | 200                            | 34.4                           | (30.6, 38.4)                   |
| Stable                  | 268                            | 46.2                           | (42.1, 50.4)                   | 271                            | 46.6                           | (42.5, 50.8)                   |
| Improved+Stable         | 413                            | 71.2                           | (67.3,74.9)                    | 471                            | 81.1                           | (77.6, 84.2)                   |
| Deteriorated            | 110                            | 19.0                           | (15.9, 22.4)                   | 83                             | 14.3                           | (11.5, 17.4)                   |
| Unconfirmed             | 23                             | 4.0                            | (2.5, 5.9)                     | 20                             | 3.4                            | (2.1, 5.3)                     |
| NoAssessment            | 34                             | 5.9                            | (4.1, 8.1)                     | 7                              | 1.2                            | (0.5, 2.5)                     |
|                         | Difference in % Improved       | Difference in % Improved       | Difference in % Improved       | Difference in % Improved       | Difference in % Improved       | Difference in % Improved       |
| Analysis                | Estimate (95% CI)b             | Estimate (95% CI)b             | Estimate (95% CI)b             | p-Valueb                       | p-Valueb                       | p-Valueb                       |
| Pembrolizumabvs.Placebo | -9.4 (-14.6, -4.2)             | -9.4 (-14.6, -4.2)             | -9.4 (-14.6, -4.2)             | 0.0004c                        | 0.0004c                        | 0.0004c                        |
|                         | Difference in %Improved+Stable | Difference in %Improved+Stable | Difference in %Improved+Stable | Difference in %Improved+Stable | Difference in %Improved+Stable | Difference in %Improved+Stable |
| Analysis                | Estimate (95% CI)b             | Estimate (95% CI)b             | Estimate (95% CI)b             | p-Valueb                       | p-Valueb                       | p-Valueb                       |
| Pembrolizumabvs.Placebo | -9.9 (-14.7, -5.0)             | -9.9 (-14.7, -5.0)             | -9.9 (-14.7, -5.0)             | <.0001c                        | <.0001c                        | <.0001c                        |

No assessment is defined as participants who do not have baseline or post-baseline assessments available.

Database Cutoff Date: 20SEP2021

<div style=\"page-break-after: always\"></div>

Figure 11: Empirical Mean Change from Baseline and 95% CI for the EORTC QLQ-C30 Global Health Status/QoL Over Time by Treatment Group (Observed Data Only) (PRO FAS Population)

<!-- image -->

## RESULTS AT INTERIM ANALYSIS 3

Results from the 3 rd  efficacy interim analysis with a data cutoff date of 24-Jan-2023, which is the final DFS analysis per protocol, are presented below. DFS in the overall study population was not tested since the study already met the success criterion at IA2. At IA3, neither DFS in participants with TPS ≥ 50% nor OS were statistically significant. OS will continue to be tested at the next analysis (IA4).

Table 29: IA3 (Final DFS Analysis) Topline Summary of Results for Primary and Key Secondary Endpoints

| Endpoints (pembrolizumab vs. placebo)   | Endpoints (pembrolizumab vs. placebo)   | No. events (IF e )   | HR (95% CI)       | Median (Months)   | P-value a boundary   |   Observed P-value a | Outcome                                              |
|-----------------------------------------|-----------------------------------------|----------------------|-------------------|-------------------|----------------------|----------------------|------------------------------------------------------|
| Primary                                 | b DFS in the overall population         | 561 (102%)           | 0.81 (0.68, 0.96) | 53.8 vs. 43.0     | -                    |              0.00812 | Not tested (success criterion met at IA2)            |
| Primary                                 | b DFS in TPS≥50%                        | 140 (99%)            | 0.83 (0.59, 1.16) | 67.0 vs. 47.6     | 0.01038              |              0.13499 | Not positive d                                       |
|                                         | b DFS in TPS≥1%                         | 331 (102%)           | 0.78 (0.62, 0.97) | 58.7 vs. 42.8     | -                    |              0.01327 | Not tested d                                         |
|                                         | c OS in the overall population          | 290                  | 0.87 (0.69, 1.10) | NR vs NR          |                      |              0.11792 | Not positive; To be tested again at next IA          |
|                                         | c OS in TPS≥50%                         | 67                   | 0.93 (0.57, 1.50) | NR vs NR          |                      |              0.3778  | Not positive; To be tested again at next IA          |
|                                         | c OS in TPS≥1%                          | 165                  | 0.83 (0.61, 1.13) | NR vs NR          | -                    |              0.1239  | Not tested; To be tested once OS positive in TPS≥50% |

NR= Not Reached

a  One-sided P-value

b  P-values for DFS endpoints are based on the permutation test with the multivariate Cox regression model

c  P-values for OS endpoints are based on the Wald test in the multivariate Cox regression model

d  Although the DFS hypothesis in TPS ≥50% can be re -tested at the full alpha level (0.025) after all the OS hypotheses are all rejected, the observed p-value is already above the largest possible p-value boundary and therefore not possible to be statistically significant. As a result, DFS in TPS ≥1% cannot be tested at future analyses given DFS in TPS ≥50% is not positive regardless of OS outcomes.

e  IF: Information Fraction, the percentage of observed events at the time of analysis divided by protocol specified targeted events at Final Analysis

<div style=\"page-break-after: always\"></div>

Table 30: Summary of Efficacy Results From KEYNOTE-091 - IA2 and IA3

| Endpoint                 | DFS                      | DFS                      | OS                       | OS                       |
|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Analysis                 | IA2                      | IA3 (Final DFS)          | IA2                      | IA3                      |
| Overall Study Population | Overall Study Population | Overall Study Population | Overall Study Population | Overall Study Population |
| Events ( a IF)           | 472 (86%)                | 561 (102%)               | 209                      | 290                      |
| Number of events (%)     | 35.9% vs 44.3%           | 44.7% vs 50.6%           | 16.6% vs 18.9%           | 23.1% vs 26.6%           |
| b Median (Months)        | 53.6 vs. 42.0            | 53.8 vs. 43.0            | NR vs. NR                | NR vs. NR                |
| c HR (95% CI)            | 0.76 (0.63-0.91)         | 0.81 (0.68-0.96)         | 0.87 (0.67-1.15)         | 0.87 (0.69-1.10)         |
| d P-value                | 0.00143 (stat sign)      | 0.00812                  | 0.16811                  | 0.11792                  |
| TPS ≥50%                 | TPS ≥50%                 | TPS ≥50%                 | TPS ≥50%                 | TPS ≥50%                 |
| Events ( a IF)           | 117 (83%)                | 140 (99%)                | 49                       | 67                       |
| Number of events (%)     | 32.1% vs 38.2%           | 38.7% vs 45.5%           | 14.3% vs 15.2%           | 19.6% vs 20.6%           |
| b Median (Months)        | NR vs. NR                | 67.0 vs 47.6             | NR vs. NR                | NR vs. NR                |
| c HR (95% CI)            | 0.82 (0.57-1.18)         | 0.83 (0.59-1.16)         | 0.92 (0.52-1.62)         | 0.93 (0.57-1.50)         |
| d P-value                | 0.13639                  | 0.13499                  | 0.38517                  | 0.3778                   |
| TPS ≥1%                  | TPS ≥1%                  | TPS ≥1%                  | TPS ≥1%                  | TPS ≥1%                  |
| Events ( a IF)           | 277 (85%)                | 331 (102%)               | 119                      | 165                      |
| Number of events (%)     | 34.5% vs 43.4%           | 42.6% vs 50.4%           | 14.6% vs 18.9%           | 21.3% vs 25.1%           |
| b Median (Months)        | 53.6 vs. 42.0            | 58.7 vs. 42.8            | NR vs. NR.               | NR vs. NR                |
| c HR (95% CI)            | 0.73 (0.57-0.92)         | 0.78 (0.62-0.97)         | 0.76 (0.52-1.09)         | 0.83 (0.61-1.13)         |
| d P-value                | Not Tested               | Not Tested               | Not Tested               | Not Tested               |

a  Information Fraction, the percentage of observed events at the time of analysis divided by protocol specified targeted events at Final Analysis b  From product-limit (Kaplan-Meier) method for censored data (pembrolizumab vs. placebo).

c  Based on the multivariate Cox regression model with treatment adjusted by the following covariates: stage (IB vs. II vs. IIIA), PDL1 status (≥50% vs. 1 -49% vs. &lt;1%), adjuvant chemotherapy (yes vs. no), region (Western Europe vs. Eastern Europe vs. Rest of World vs. Asia), histology (squamous vs. non-squamous), and smoking status (never vs. former/current).

d  One-sided p-value. For DFS, this is based on the permutation test with multivariate Cox regression model; for OS, this is based on the Wald test with multivariate Cox regression model.

<div style=\"page-break-after: always\"></div>

Figure 12: Kaplan-Meier Estimates of Disease-Free Survival (Primary Censoring Rule) (ITT Population) IA3

## Overall population

<!-- image -->

Database Cutoff Date: 24JAN2023

## TPS &gt;= 50%

<!-- image -->

Database Cutoff Date: 24JAN2023

<div style=\"page-break-after: always\"></div>

TPS &gt;= 1%

<!-- image -->

Database Cutoff Date: 24JAN2023

<div style=\"page-break-after: always\"></div>

Figure 13: Kaplan-Meier Estimates of Overall Survival (Primary Analysis) (ITT Population) - IA3

## Overall population

<!-- image -->

Database Cutoff Date: 24JAN2023

TPS &gt;= 50%

<!-- image -->

Database Cutoff Date: 24JAN2023

<div style=\"page-break-after: always\"></div>

TPS &gt;= 1%

<!-- image -->

Database Cutoff Date: 24JAN2023

Figure 14: Forest Plot of DFS Hazard Ratio by Subgroup Factors (ITT Population) - IA3

<!-- image -->

|                               | N/#Event                      | HR   | 95% CI       | Estimated Hazard Ratio (HR)   |
|-------------------------------|-------------------------------|------|--------------|-------------------------------|
| Overall1177/561               | Overall1177/561               | 0.81 | (0.68, 0.96) |                               |
| Age                           | Age                           |      |              |                               |
| <65 years                     | 558/253                       | 0.76 | (0.59, 0.98) |                               |
| >= 65 years                   | 619/308                       | 0.91 | (0.73, 1.14) |                               |
| Gender                        | Gender                        |      |              |                               |
| Female                        | 373/186                       | 0.81 | (0.61, 1.08) |                               |
| Male                          | 804/375                       | 0.85 | (0.70, 1.05) |                               |
| Race                          | Race                          |      |              |                               |
| White                         | 905/416                       | 0.88 | (0.73, 1.07) |                               |
| All Others                    | 231/126                       | 0.76 | (0.54, 1.09) |                               |
| Region: EU vs Non-EU          | Region: EU vs Non-EU          |      |              |                               |
| EU                            | 788/375                       | 0.84 | (0.68,1.02)  |                               |
| Non-EU                        | 389/186                       | 0.85 | (0.64, 1.14) |                               |
| GeographicRegion              | GeographicRegion              |      |              |                               |
| Western Europe                | 604/294                       | 0.81 | (0.65, 1.02) |                               |
| Eastern Europe                | 229/103                       | 0.99 | (0.67, 1.45) | TT                            |
| Asia                          | 211/112                       | 0.80 | (0.55, 1.16) |                               |
| RestofWorld                   | 133/52                        | 0.81 | (0.47, 1.41) |                               |
| Stage at Baseline per AJCC V7 | Stage at Baseline per AJCC V7 |      |              |                               |
|                               |                               |      |              | 0.1 1                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

1 For overall population, analysis is based on multivariate Cox regression model with treatment adjusted by the following covariates: stage (IB vs. II vs. IIIA), PD-L1 status (&gt;=50% vs. 1-49% vs. &lt;1%), adjuvant chemotherapy (yes vs. no), region (Western Europe vs. Eastern Europe vs. Rest of World vs. Asia), histology (squamous vs. non-squamous), and smoking status (never vs. former/current). For subgroups, analysis is based on Cox regression model with treatment as a covariate.

2 If a subgroup variable has two levels and one level of the subgroup meets any criteria below, then this subgroup variable will not be displayed: (1) if the number of participants in a category of a subgroup variable is less than 50, (2) the number of events in a category of a subgroup variable is zero in one treatment arm, (3) the number of events in a category of a subgroup variable is less than 5 in the pooled arms.

Database Cutoff Date: 24JAN2023

<div style=\"page-break-after: always\"></div>

Figure 15: Forest Plot of DFS Hazard Ratio by PD-L1 Expression (ITT Population) - IA3

<!-- image -->

|                                  | N/#Event                         | HR                               | 95% CI                           | Estimated Hazard Ratio (HR)      |
|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                  | Overall1177/561                  | 0.81                             | (0.68, 0.96)                     |                                  |
| PD-L1 expression by TPS 1%and50% | PD-L1 expression by TPS 1%and50% | PD-L1 expression by TPS 1%and50% | PD-L1 expression by TPS 1%and50% | PD-L1 expression by TPS 1%and50% |
| <1%                              | 465/230                          | 0.84                             | (0.64,1.09)                      |                                  |
| 1-49%                            | 379/191                          | 0.74                             | (0.55, 0.98)                     |                                  |
| >=50%                            | 333/140                          | 0.83                             | (0.59, 1.16)                     |                                  |
| PD-L1 expression by TPS 1%       | PD-L1 expression by TPS 1%       | PD-L1 expression by TPS 1%       | PD-L1 expression by TPS 1%       | PD-L1 expression by TPS 1%       |
| <1%                              | 465/230                          | 0.84                             | (0.64, 1.09)                     |                                  |
| >=1%                             | 712/331                          | 0.78                             | (0.62, 0.97)                     |                                  |
| PD-L1 expression by TPS 50%      | PD-L1 expression by TPS 50%      | PD-L1 expression by TPS 50%      | PD-L1 expression by TPS 50%      | PD-L1 expression by TPS 50%      |
| <50%                             | 844/421                          | 0.79                             | (0.65, 0.96)                     |                                  |
| >=50%                            | 333/140                          | 0.83                             | (0.59, 1.16)                     |                                  |
|                                  |                                  |                                  |                                  | 1 10                             |
|                                  |                                  |                                  |                                  | Pembrolizumab←Favor →Placebo     |

For overall population and the PD-L1 subgroup, analysis is based on multivariate Cox regression model with treatment adjusted by the following covariates: stage (IB vs. II vs. IIIA), PD-L1 status (&gt;=50% vs. 1-49% vs. &lt;1%), adjuvant chemotherapy (yes vs. no), region (Western Europe vs. Eastern Europe vs. Rest of World vs. Asia), histology (squamous vs. non-squamous), and smoking status (never vs. former/current). Database Cutoff Date: 24JAN2023

## RESULTS IN THE POPULATION WITH ADJUVANT CHEMOTHERAPY

By inclusion criteria, adjuvant chemotherapy was not mandatory but considered for patients with stage IB (T ≥ 4 cm) and strongly recommended for stage II and IIIA, and was administered according to national and local guidelines. Adjuvant chemotherapy yes/no was a stratification factor. Overall, 86% of patients received adjuvant chemotherapy before pembrolizumab/placebo, this percentage was overall similar across subgroup by PD-L1 expression, and balanced between treatment arms.

All results below are based on the IA3.

Table 31: IA3 Analysis of Disease-Free Survival (Primary Censoring Rule) - Multivariate Analysis - ITT population - with adjuvant chemotherapy

---

---

| Treatment     | N   | Number of Events   | Person- Months   | Event Rate/100 Person-   | Median DFS a (Months) (95% CI)   | DFS Rate at Month 12 in% a   | vs. Placebo               | vs. Placebo   |
|---------------|-----|--------------------|------------------|--------------------------|----------------------------------|------------------------------|---------------------------|---------------|
|               |     | (%)                |                  | Months                   |                                  | (95% CI)                     | Hazard Ratio b (95% CI) b | p-Value c     |
| Pembrolizumab | 506 | 225 (44.5)         | 15754.5          | 1.4                      | 53.8 (46.2, 70.4)                | 78.7 (74.8, 82.1)            | 0.76 (0.64, 0.91)         | 0.00150       |
| Placebo       | 504 | 262 (52.0)         | 14614.8          | 1.8                      | 40.5 (32.9, 47.4)                | 71.0 (66.8, 74.7)            | ---                       | ---           |

Database Cutoff Date: 24JAN2023

<div style=\"page-break-after: always\"></div>

Figure 16: IA3 Kaplan-Meier Estimates of Disease-Free Survival (Primary Censoring Rule) (ITT population - with adjuvant chemotherapy)

<!-- image -->

Database Cutoff Date: 24JAN2023

Results of DFS based on the univariate Cox model were similar (HR 0.80; 95%CI 0.67, 0.96).

Table 32: IA3 Analysis of Overall Survival - Multivariate Analysis - (ITT Population - with adjuvant chemotherapy)

0.03224

| Treatment     | N   | Number of Events (%)   | Person- Months   | Event Rate/100 Person- Months   | Median OS a (Months) (95% CI)   | OS Rate at Month 12 in% a   | vs. Placebo               | vs. Placebo   |
|---------------|-----|------------------------|------------------|---------------------------------|---------------------------------|-----------------------------|---------------------------|---------------|
|               |     |                        |                  |                                 |                                 | (95% CI)                    | Hazard Ratio b (95% CI) b | p-Value c     |
| Pembrolizumab | 506 | 113 (22.3)             | 22810.0          | 0.5                             | Not Reached (., .)              | 95.6 (93.4, 97.1)           | 0.79 (0.62, 1.01)         | 0.03224       |
| Placebo       | 504 | 138 (27.4)             | 22313.1          | 0.6                             | Not Reached (., .)              | 95.0 (92.7, 96.6)           | ---                       | ---           |

Database Cutoff Date: 24JAN2023

<div style=\"page-break-after: always\"></div>

Figure 17: IA3 Kaplan-Meier Estimates of Overall Survival (ITT population - with adjuvant chemotherapy)

<!-- image -->

Database Cutoff Date: 24JAN2023

<div style=\"page-break-after: always\"></div>

Table 33: Subgroup Analysis of Disease-free Survival - Multivariate Analysis (ITT Population with adjuvant chemotherapy)

504

252

252

222

382

474

347

157

392

0.75 (0.55, 1.04)

0.75 (0.58, 0.96)

0.84 (0.56, 1.26)

23

57

295

0.82 (0.61,1.09)

57

375

184

0.85 (0.60, 1.20)

320

0.72 (0.59, 0.89)

0.76 (0.61, 0.96)

0.77 (0.57,1.03)

192

30

282

198

0.70 (0.51, 0.96)

141

0.75 (0.56, 0.99)

306

0.76 (0.60, 0.96)

363

0.83 (0.57, 1.19)

|                               | Pembrolizumab                 | Pembrolizumab                | Pembrolizumab                | Placebo                     | Placebo                      | Placebo                      | Pembrolizumab vs. Placebo              |
|-------------------------------|-------------------------------|------------------------------|------------------------------|-----------------------------|------------------------------|------------------------------|----------------------------------------|
|                               | N                             | (N=506) Number (%) of Events | (N=506) Number (%) of Events | N                           | (N=504) Number (%) of Events | (N=504) Number (%) of Events | a                                      |
| Overall                       | 506                           | 225                          | (44.5)                       | 504                         | 262                          | (52.0)                       | Hazard Ratio (95% CI) 0.76 (0.64,0.91) |
| Age Category                  |                               |                              |                              |                             |                              |                              |                                        |
| < 65 years                    | 264                           | 113                          | (42.8)                       | 252                         | 129                          | (51.2)                       | 0.75 (0.58, 0.97)                      |
| >= 65 years                   | 242                           | 112                          | (46.3)                       | 252                         | 133                          | (52.8)                       | 0.75 (0.58, 0.98)                      |
| Age Category                  |                               |                              |                              |                             |                              |                              |                                        |
| < 65 years                    | 264                           | 113                          | (42.8)                       | 252                         | 129                          | (51.2)                       | 0.75 (0.58, 0.97)                      |
| 65 - 74 years                 | 211                           | 95                           | (45.0)                       | 222                         | 113                          | (50.9)                       | 0.77 (0.58, 1.02)                      |
| 75 - 84 years                 | 31                            | 17                           | (54.8)                       | 30                          | 20                           | (66.7)                       | 0.70 (0.35, 1.39)                      |
| Age Category                  |                               |                              |                              |                             |                              |                              |                                        |
| < 70 years                    | 384                           | 166                          | (43.2)                       | 382                         | 195                          | (51.0)                       | 0.76 (0.62, 0.94)                      |
| >= 70 years                   | 122                           | 59                           | (48.4)                       | 122                         | 67                           | (54.9)                       | 0.73 (0.51, 1.06)                      |
| Age Category                  |                               |                              |                              |                             |                              |                              |                                        |
| < 75 years                    | 475                           | 208                          | (43.8)                       | 474                         | 242                          | (51.1)                       | 0.77 (0.63, 0.92)                      |
| >= 75 years                   | 31                            | 17                           | (54.8)                       | 30                          | 20                           | (66.7)                       | 0.70 (0.35, 1.39)                      |
| Gender                        |                               |                              |                              |                             |                              |                              |                                        |
| M                             | 339                           | 149                          | (44.0)                       | 347                         | 175                          | (50.4)                       | 0.81 (0.65, 1.02)                      |
| F                             | 167                           | 76                           | (45.5)                       | 157                         | 87                           | (55.4)                       | 0.70 (0.51, 0.96)                      |
| Race                          |                               |                              |                              |                             |                              |                              |                                        |
| White                         | 387                           | 167                          | (43.2)                       | 392                         | 194                          | (49.5)                       | 0.80 (0.65, 0.98)                      |
| All Others                    | 98                            | 49                           | (50.0)                       | 94                          | 58                           | (61.7)                       | 0.67 (0.45, 1.01)                      |
| Region: EU vs non-EU          |                               |                              |                              |                             |                              |                              |                                        |
| EU                            | 343                           | 153                          | (44.6)                       | 342                         | 178                          | (52.0)                       | 0.76 (0.61, 0.95)                      |
| Non-EU                        | 163                           | 72                           | (44.2)                       | 162                         | 84                           | (51.9)                       | 0.75 (0.55, 1.04)                      |
| Geographic Region             |                               |                              |                              |                             |                              |                              |                                        |
| Western Europe                | 261                           | 117                          | (44.8)                       | 266                         | 141                          | (53.0)                       | 0.75 (0.58, 0.96)                      |
| Eastern Europe                | 105                           | 49                           | (46.7)                       | 96                          | 46                           | (47.9)                       | 0.84 (0.56, 1.26)                      |
| Rest of World                 | 53                            | 17                           | (32.1)                       | 55                          | 23                           | (41.8)                       | 0.75 (0.38, 1.44)                      |
| Asia                          | 87                            | 42                           | (48.3)                       | 87                          | 52                           | (59.8)                       | 0.71 (0.47, 1.08)                      |
| Stage at Baseline per AJCC V7 | Stage at Baseline per AJCC V7 |                              |                              |                             |                              |                              |                                        |
| IB                            | 60                            | 19                           | (31.7)                       | 57                          | 21                           | (36.8)                       | 0.66 (0.33, 1.33)                      |
| II                            | 283                           | 114                          | (40.3)                       | 295                         | 143                          | (48.5)                       | 0.73 (0.57,0.94)                       |
| IIIA                          | 163                           | 92                           | (56.4)                       | 150                         | 96                           | (64.0)                       | 0.82 (0.61,1.09)                       |
| Smoking status                |                               |                              |                              |                             |                              |                              |                                        |
| Never Smoker                  | 80                            | 46                           | (57.5)                       | 57                          | 38                           | (66.7)                       | 0.72 (0.46, 1.14)                      |
| Former Smoker                 | 362                           | 157                          | (43.4)                       | 375                         | 187                          | (49.9)                       | 0.81 (0.65, 1.00)                      |
| Current Smoker                | 64                            | 22                           | (34.4)                       | 72                          | 37                           | (51.4)                       | 0.45 (0.25, 0.79)                      |
| Histology                     |                               |                              |                              |                             |                              |                              |                                        |
| Squamous                      | 157                           | 57                           | (36.3)                       | 184                         | 75                           | (40.8)                       | 0.85 (0.60, 1.20)                      |
| Non-squamous                  | 349                           | 168                          | (48.1)                       | 320                         | 187                          | (58.4)                       | 0.72 (0.59, 0.89)                      |
| ECOG                          |                               |                              |                              |                             |                              |                              |                                        |
| 0                             | 326                           | 145                          | (44.5)                       | 292                         | 148                          | (50.7)                       | 0.76 (0.61, 0.96)                      |
| 1                             | 180                           | 80                           | (44.4)                       | 212                         | 114                          | (53.8)                       | 0.77 (0.57,1.03)                       |
| EGFR mutation status          |                               |                              |                              |                             |                              |                              |                                        |
| N                             | 190                           | 90                           | (47.4)                       | 192                         | 109                          | (56.8)                       | 0.75 (0.56, 1.00)                      |
| Y                             | 36                            | 20                           | (55.6)                       | 30                          | 24                           | (80.0)                       | 0.44 (0.22, 0.87)                      |
| Unknown                       | 280                           | 115                          | (41.1)                       | 282                         | 129                          | (45.7)                       | 0.80 (0.62, 1.04)                      |
| PD-L1 expression              |                               |                              |                              |                             |                              |                              |                                        |
| <1%                           | 198                           | 92                           | (46.5)                       | 198                         | 108                          | (54.5)                       | 0.75 (0.56, 0.99)                      |
| 1-49%                         | 165                           | 76                           | (46.1)                       | 165                         | 91                           | (55.2)                       | 0.70 (0.51, 0.96)                      |
| >=50%                         | 143                           | 57                           | (39.9)                       | 141                         | 63                           | (44.7)                       | 0.83 (0.57, 1.19)                      |
| PD-L1 expression by TPS 1%    | PD-L1 expression by TPS 1%    |                              |                              |                             |                              |                              |                                        |
| TPS <1%                       | 198                           | 92                           | (46.5)                       | 198                         | 108                          | (54.5)                       | 0.75 (0.56, 0.99)                      |
| TPS >=1%                      | 308                           | 133                          | (43.2)                       | 306                         | 154                          | (50.3)                       | 0.76 (0.60, 0.96)                      |
| PD-L1 expression by TPS 50%   | PD-L1 expression by TPS 50%   | PD-L1 expression by TPS 50%  | PD-L1 expression by TPS 50%  | PD-L1 expression by TPS 50% | PD-L1 expression by TPS 50%  |                              |                                        |
| TPS <50%                      | 363                           | 168                          | (46.3)                       | 363                         | 199                          | (54.8)                       | 0.72 (0.59, 0.89)                      |
| TPS >=50%                     | 143                           | 57                           | (39.9)                       | 141                         | 63                           | (44.7)                       | 0.83 (0.57, 1.19)                      |

<div style=\"page-break-after: always\"></div>

Table 34: IA3 Subgroup Analysis of Overall Survival - Multivariate Analysis (ITT Population with adjuvant chemotherapy)

252

0.70 (0.50, 0.99)

252

222

0.61 (0.41, 0.90)

1.23 (0.55, 2.72)

382

0.70 (0.44, 1.11)

474

1.23 (0.55, 2.72)

347

0.88 (0.65, 1.18)

157

392

0.77 (0.58, 1.03)

0.80 (0.43, 1.51)

0.82 (0.61, 1.11)

0.52 (0.22, 1.23)

1.01 (0.51, 1.99)

0.60 (0.24, 1.55)

0.81 (0.58, 1.14)

0.85 (0.64,1.14)

0.61 (0.29,1.31)

0.76 (0.49, 1.19)

0.79 (0.57, 1.10)

|                               | Pembrolizumab                 | Pembrolizumab               | Pembrolizumab               | Placebo                     | Placebo                     | Placebo                     | Pembrolizumab vs. Placebo               |
|-------------------------------|-------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------------------|
|                               | N                             | (N=506) Number of Events    | (%)                         | N                           | (N=504) Number of Events    | (%)                         | a                                       |
| Overall                       | 506                           | 113                         | (22.3)                      | 504                         | 138                         | (27.4)                      | Hazard Ratio (95% CI) 0.79 (0.62, 1.01) |
| Age Category                  |                               |                             |                             |                             |                             |                             |                                         |
| < 65 years                    | 264                           | 55                          | (20.8)                      | 252                         | 58                          | (23.0)                      | 0.90 (0.62, 1.30)                       |
| >= 65 years                   | 242                           | 58                          | (24.0)                      | 252                         | 80                          | (31.7)                      | 0.70 (0.50, 0.99)                       |
| Age Category                  |                               |                             |                             |                             |                             |                             |                                         |
| < 65 years                    | 264                           | 55                          | (20.8)                      | 252                         | 58                          | (23.0)                      | 0.90 (0.62, 1.30)                       |
| 65 - 74 years                 | 211                           | 43                          | (20.4)                      | 222                         | 68                          | (30.6)                      | 0.61 (0.41, 0.90)                       |
| 75 - 84 years                 | 31                            | 15                          | (48.4)                      | 30                          | 12                          | (40.0)                      | 1.23 (0.55, 2.72)                       |
| Age Category                  |                               |                             |                             |                             |                             |                             |                                         |
| < 70 years                    | 384                           | 77                          | (20.1)                      | 382                         | 94                          | (24.6)                      | 0.80 (0.59, 1.09)                       |
| >= 70 years                   | 122                           | 36                          | (29.5)                      | 122                         | 44                          | (36.1)                      | 0.70 (0.44, 1.11)                       |
| Age Category                  |                               |                             |                             |                             |                             |                             |                                         |
| < 75 years                    | 475                           | 98                          | (20.6)                      | 474                         | 126                         | (26.6)                      | 0.75 (0.58, 0.98)                       |
| >= 75 years                   | 31                            | 15                          | (48.4)                      | 30                          | 12                          | (40.0)                      | 1.23 (0.55, 2.72)                       |
| Gender                        |                               |                             |                             |                             |                             |                             |                                         |
| M                             | 339                           | 82                          | (24.2)                      | 347                         | 94                          | (27.1)                      | 0.88 (0.65, 1.18)                       |
| F                             | 167                           | 31                          | (18.6)                      | 157                         | 44                          | (28.0)                      | 0.65 (0.40,1.03)                        |
| Race                          |                               |                             |                             |                             |                             |                             |                                         |
| White                         | 387                           | 87                          | (22.5)                      | 392                         | 111                         | (28.3)                      | 0.77 (0.58, 1.03)                       |
| All Others                    | 98                            | 21                          | (21.4)                      | 94                          | 23                          | (24.5)                      | 0.80 (0.43, 1.51)                       |
| Region: EU vs non-EU          |                               |                             |                             |                             |                             |                             |                                         |
| EU                            | 343                           | 82                          | (23.9)                      | 342                         | 97                          | (28.4)                      | 0.82 (0.61, 1.11)                       |
| Non-EU                        | 163                           | 31                          | (19.0)                      | 162                         | 41                          | (25.3)                      | 0.69 (0.43, 1.11)                       |
| Geographic Region             |                               |                             |                             |                             |                             |                             |                                         |
| Western Europe                | 261                           | 57                          | (21.8)                      | 266                         | 71                          | (26.7)                      | 0.81 (0.57, 1.14)                       |
| Eastern Europe                | 105                           | 31                          | (29.5)                      | 96                          | 34                          | (35.4)                      | 0.81 (0.50, 1.32)                       |
| Rest of World                 | 53                            | 8                           | (15.1)                      | 55                          | 16                          | (29.1)                      | 0.52 (0.22, 1.23)                       |
| Asia                          | 87                            | 17                          | (19.5)                      | 87                          | 17                          | (19.5)                      | 1.01 (0.51, 1.99)                       |
| Stage at Baseline per AJCC V7 | Stage at Baseline per AJCC V7 |                             |                             |                             |                             |                             |                                         |
| IB                            | 60                            | 9                           | (15.0)                      | 57                          | 12                          | (21.1)                      | 0.60 (0.24, 1.55)                       |
| II                            | 283                           | 60                          | (21.2)                      | 295                         | 76                          | (25.8)                      | 0.81 (0.58, 1.14)                       |
| IIIA                          | 163                           | 44                          | (27.0)                      | 150                         | 49                          | (32.7)                      | 0.78 (0.51, 1.18)                       |
| Smoking status                |                               |                             |                             |                             |                             |                             |                                         |
| Never Smoker                  | 80                            | 18                          | (22.5)                      | 57                          | 18                          | (31.6)                      | 0.70 (0.35, 1.37)                       |
| Former Smoker                 | 362                           | 84                          | (23.2)                      | 375                         | 100                         | (26.7)                      | 0.85 (0.64,1.14)                        |
| Current Smoker                | 64                            | 11                          | (17.2)                      | 72                          | 20                          | (27.8)                      | 0.61 (0.29,1.31)                        |
| Histology                     |                               |                             |                             |                             |                             |                             |                                         |
| Squamous                      | 157                           | 34                          | (21.7)                      | 184                         | 48                          | (26.1)                      | 0.76 (0.49, 1.19)                       |
| Non-squamous                  | 349                           | 79                          | (22.6)                      | 320                         | 90                          | (28.1)                      | 0.79 (0.59, 1.07)                       |
| ECOG                          |                               |                             |                             |                             |                             |                             |                                         |
| 0                             | 326                           | 70                          | (21.5)                      | 292                         | 70                          | (24.0)                      | 0.86 (0.62, 1.20)                       |
| 1                             | 180                           | 43                          | (23.9)                      | 212                         | 68                          | (32.1)                      | 0.72 (0.49, 1.06)                       |
| EGFR mutation status          |                               |                             |                             |                             |                             |                             |                                         |
| N                             | 190                           | 46                          | (24.2)                      | 192                         | 51                          | (26.6)                      | 0.91 (0.60, 1.36)                       |
| Y                             | 36                            | 6                           | (16.7)                      | 30                          | 12                          | (40.0)                      | 0.35 (0.13, 0.98)                       |
| Unknown                       | 280                           | 61                          | (21.8)                      | 282                         | 75                          | (26.6)                      | 0.78 (0.56, 1.10)                       |
| PD-L1 expression              |                               |                             |                             |                             |                             |                             |                                         |
| <1%                           | 198                           | 48                          | (24.2)                      | 198                         | 62                          | (31.3)                      | 0.78 (0.53, 1.14)                       |
| 1-49%                         | 165                           | 36                          | (21.8)                      | 165                         | 48                          | (29.1)                      | 0.69 (0.45, 1.08)                       |
| >=50%                         | 143                           | 29                          | (20.3)                      | 141                         | 28                          | (19.9)                      | 0.93 (0.55, 1.57)                       |
| PD-L1 expression by TPS 1%    | PD-L1 expression by TPS 1%    |                             |                             |                             |                             |                             |                                         |
| TPS <1%                       | 198                           | 48                          | (24.2)                      | 198                         | 62                          | (31.3)                      | 0.78 (0.53, 1.14)                       |
| TPS >=1%                      | 308                           | 65                          | (21.1)                      | 306                         | 76                          | (24.8)                      | 0.79 (0.57, 1.10)                       |
| PD-L1 expression by TPS 50%   | PD-L1 expression by TPS 50%   | PD-L1 expression by TPS 50% | PD-L1 expression by TPS 50% | PD-L1 expression by TPS 50% | PD-L1 expression by TPS 50% | PD-L1 expression by TPS 50% |                                         |
| TPS <50%                      | 363                           | 84                          | (23.1)                      | 363                         | 110                         | (30.3)                      | 0.74 (0.55, 0.98)                       |
| TPS >=50%                     | 143                           | 29                          | (20.3)                      | 141                         | 28                          | (19.9)                      | 0.93 (0.55, 1.57)                       |

a  For overall population and all subgroups, analysis is based on multivariate Cox regression model with treatment adjusted by the following covariates: stage (IB vs. II vs. IIIA), PDL1 status (≥50% vs. 1 -49% vs. &lt;1%), region (Western Europe vs. Eastern Europe vs. Rest of World vs. Asia), histology (squamous vs. non-squamous), and smoking status (never vs. former/current).

If the number of participants in a category of a subgroup variable is less than 50 (except EGFR mutation status), or the number of events in a category of a subgroup variable is zero in one treatment arm, or the number of events in a category of a subgroup variable is less than 5 in the pooled arms, the subgroup analysis will not be performed for this category of the subgroup variable.

<div style=\"page-break-after: always\"></div>

Figure 18: IA3 Kaplan-Meier Estimates by PD-L1 - ITT population - with adjuvant chemotherapy

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 19: IA3 Kaplan-Meier Estimates by histology - ITT population - with adjuvant chemotherapy

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Summary of main study

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 35 : S ummary of Efficacy for trial KEYNOTE-091

| Title: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)   | Title: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)   | Title: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)   | Title: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                        | P091V01MK3475 (IND: 116,833, EudraCT: 2015-000575-27, NCT: 02504372, Intergroup Study: EORTC-1416-LCG, ETOP Trial Number: ETOP-8-15)                                                                                    | P091V01MK3475 (IND: 116,833, EudraCT: 2015-000575-27, NCT: 02504372, Intergroup Study: EORTC-1416-LCG, ETOP Trial Number: ETOP-8-15)                                                                                    | P091V01MK3475 (IND: 116,833, EudraCT: 2015-000575-27, NCT: 02504372, Intergroup Study: EORTC-1416-LCG, ETOP Trial Number: ETOP-8-15)                                                                                                                                                                                                                                   |
| Design                                                                                                                                                                                                                  | Phase 3, two-arm, multicentre, triple-blinded, randomized, placebo-controlled study                                                                                                                                     | Phase 3, two-arm, multicentre, triple-blinded, randomized, placebo-controlled study                                                                                                                                     | Phase 3, two-arm, multicentre, triple-blinded, randomized, placebo-controlled study                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                  | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                          | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                          | The first patient first visit was 10-NOV- 2015; the study is ongoing. not applicable not applicable                                                                                                                                                                                                                                                                    |
| Hypothesis                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                             | Superiority                                                                                                                                                                                                             | Superiority                                                                                                                                                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                       | Pembrolizumab                                                                                                                                                                                                           | Pembrolizumab                                                                                                                                                                                                           | 200 mg IV infusion Q3W for up to 18 cycles (approximately 1 year), 590 participants were randomized.                                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                                                                       | Placebo                                                                                                                                                                                                                 | Placebo                                                                                                                                                                                                                 | Normal saline solution dosed and administered in the same manner as the investigational product, 587 participants were randomized.                                                                                                                                                                                                                                     |
| Endpoints and definitions                                                                                                                                                                                               | Dual Primary endpoint                                                                                                                                                                                                   | Disease-free survival (DFS), overall study population                                                                                                                                                                   | DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event. |
| Endpoints and definitions                                                                                                                                                                                               | Dual Primary endpoint                                                                                                                                                                                                   | DFS, PD-L1 TPS ≥ 50%                                                                                                                                                                                                    | DFS                                                                                                                                                                                                                                                                                                                                                                    |
| Endpoints and definitions                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                      | DFS, PD-L1 TPS ≥ 1%                                                                                                                                                                                                     | DFS                                                                                                                                                                                                                                                                                                                                                                    |
| Endpoints and definitions                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                      | overall survival (OS), overall study population                                                                                                                                                                         | OS was defined as the time from randomization to the date of death (whatever the cause).                                                                                                                                                                                                                                                                               |
| Endpoints and definitions                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                      | OS, PD-L1 TPS ≥ 50%                                                                                                                                                                                                     | OS                                                                                                                                                                                                                                                                                                                                                                     |
| Endpoints and definitions                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                      | OS, PD-L1 TPS ≥ 1%                                                                                                                                                                                                      | OS                                                                                                                                                                                                                                                                                                                                                                     |
| Database lock                                                                                                                                                                                                           | The last patient last visit was 20-SEP-2021, which was the data cutoff                                                                                                                                                  | The last patient last visit was 20-SEP-2021, which was the data cutoff                                                                                                                                                  | The last patient last visit was 20-SEP-2021, which was the data cutoff                                                                                                                                                                                                                                                                                                 |
| Results and Analysis                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                   |
| Analysis description                                                                                                                                                                                                    | Primary Analysis - DFS, overall study population DFS in the overall study population was prespecified and formally tested with the multiplicity-                                                                        | Primary Analysis - DFS, overall study population DFS in the overall study population was prespecified and formally tested with the multiplicity-                                                                        | Primary Analysis - DFS, overall study population DFS in the overall study population was prespecified and formally tested with the multiplicity-                                                                                                                                                                                                                       |
| Analysis population and time point description                                                                                                                                                                          | Intent-to-treat (ITT) population (overall study population) Interim Analysis 2 (IA2; data cut-off 20-SEP-2021)                                                                                                          | Intent-to-treat (ITT) population (overall study population) Interim Analysis 2 (IA2; data cut-off 20-SEP-2021)                                                                                                          | Intent-to-treat (ITT) population (overall study population) Interim Analysis 2 (IA2; data cut-off 20-SEP-2021)                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability   | Treatment group                                                                                                                                                                                                                                                                              | Pembrolizumab                                                                                                                                                                                                                                                                                | Placebo                                                                                                                                                                                                                                                                                      |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability   | Number of subjects                                                                                                                                                                                                                                                                           | 590                                                                                                                                                                                                                                                                                          | 587                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability   | DFS, overall study population                                                                                                                                                                                                                                                                | 53.6 months                                                                                                                                                                                                                                                                                  | 42.0 months                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability   | (median)                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability   | 95% confidence interval (CI)                                                                                                                                                                                                                                                                 | 39.2, not reached (NR)                                                                                                                                                                                                                                                                       | 31.3, NR                                                                                                                                                                                                                                                                                     |
| Effect estimate per comparison                    | Dual Primary endpoint                                                                                                                                                                                                                                                                        | Comparison groups                                                                                                                                                                                                                                                                            | Pembrolizumab Placebo                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                    | Dual Primary endpoint                                                                                                                                                                                                                                                                        | Hazard ratio (HR)                                                                                                                                                                                                                                                                            | 0.76                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                    | Dual Primary endpoint                                                                                                                                                                                                                                                                        | 95% CI                                                                                                                                                                                                                                                                                       | 0.63, 0.91                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                    | Dual Primary endpoint                                                                                                                                                                                                                                                                        | P-value                                                                                                                                                                                                                                                                                      | 0.00143                                                                                                                                                                                                                                                                                      |
| Notes                                             | At IA2, the success criterion was met for one of the dual primary endpoints of DFS in the overall study population. The result was statistically significant compared with the prespecified p-value boundary.                                                                                | At IA2, the success criterion was met for one of the dual primary endpoints of DFS in the overall study population. The result was statistically significant compared with the prespecified p-value boundary.                                                                                | At IA2, the success criterion was met for one of the dual primary endpoints of DFS in the overall study population. The result was statistically significant compared with the prespecified p-value boundary.                                                                                |
| Notes                                             | The dual primary endpoint DFS in PD- L1 ≥50% population was tested at IA2 but was not statistically significant, thus was retested at IA3 (see below).                                                                                                                                       | The dual primary endpoint DFS in PD- L1 ≥50% population was tested at IA2 but was not statistically significant, thus was retested at IA3 (see below).                                                                                                                                       | The dual primary endpoint DFS in PD- L1 ≥50% population was tested at IA2 but was not statistically significant, thus was retested at IA3 (see below).                                                                                                                                       |
| Analysis description                              | Dual Primary Analysis - DFS, PD-L1 TPS ≥ 50% DFS in the TPS ≥ 50% subgroup was prespecified and formally retested at IA3 with the                                                                                                                                                            | Dual Primary Analysis - DFS, PD-L1 TPS ≥ 50% DFS in the TPS ≥ 50% subgroup was prespecified and formally retested at IA3 with the                                                                                                                                                            | Dual Primary Analysis - DFS, PD-L1 TPS ≥ 50% DFS in the TPS ≥ 50% subgroup was prespecified and formally retested at IA3 with the                                                                                                                                                            |
| Analysis description                              | multiplicity-adjusted, one-sided p-value boundary of 0.01038.                                                                                                                                                                                                                                | multiplicity-adjusted, one-sided p-value boundary of 0.01038.                                                                                                                                                                                                                                | multiplicity-adjusted, one-sided p-value boundary of 0.01038.                                                                                                                                                                                                                                |
| Analysis population and time point description    | ITT population (PD-L1 TPS ≥ 50%) Interim Analysis 3 (IA3; data cut-off 24-JAN-2023) (FA for DFS)                                                                                                                                                                                             | ITT population (PD-L1 TPS ≥ 50%) Interim Analysis 3 (IA3; data cut-off 24-JAN-2023) (FA for DFS)                                                                                                                                                                                             | ITT population (PD-L1 TPS ≥ 50%) Interim Analysis 3 (IA3; data cut-off 24-JAN-2023) (FA for DFS)                                                                                                                                                                                             |
| Descriptive statistics and estimate variability   | Treatment group                                                                                                                                                                                                                                                                              | Pembrolizumab                                                                                                                                                                                                                                                                                | Placebo                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability   | Number of subjects                                                                                                                                                                                                                                                                           | 168                                                                                                                                                                                                                                                                                          | 165                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability   | DFS, PD-L1 TPS ≥ 50%) (median)                                                                                                                                                                                                                                                               | 67                                                                                                                                                                                                                                                                                           | 47.6                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                    | Dual Primary endpoint                                                                                                                                                                                                                                                                        | Comparison groups                                                                                                                                                                                                                                                                            | Pembrolizumab Placebo                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                    | Dual Primary endpoint                                                                                                                                                                                                                                                                        | HR                                                                                                                                                                                                                                                                                           | 0.83                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                    | Dual Primary endpoint                                                                                                                                                                                                                                                                        | 95%                                                                                                                                                                                                                                                                                          | 0.59,                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                    | Dual Primary endpoint                                                                                                                                                                                                                                                                        | CI                                                                                                                                                                                                                                                                                           | 1.16                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                    | Dual Primary endpoint                                                                                                                                                                                                                                                                        | P-value                                                                                                                                                                                                                                                                                      | 0.13499                                                                                                                                                                                                                                                                                      |
| Notes                                             | At IA3, the DFS in the TPS ≥ 50% subgroup was not statistically significant.                                                                                                                                                                                                                 | At IA3, the DFS in the TPS ≥ 50% subgroup was not statistically significant.                                                                                                                                                                                                                 | At IA3, the DFS in the TPS ≥ 50% subgroup was not statistically significant.                                                                                                                                                                                                                 |
| Analysis description                              | Secondary analysis - DFS, PD-L1 TPS ≥ 1% DFS in the TPS ≥ 1% subgroup was prespecified but could not be formally tested because the protocol multiplicity strategy requires a statistically significant DFS in the TPS ≥ 50% subgroup to be demonstrated first, which was not showed at IA2. | Secondary analysis - DFS, PD-L1 TPS ≥ 1% DFS in the TPS ≥ 1% subgroup was prespecified but could not be formally tested because the protocol multiplicity strategy requires a statistically significant DFS in the TPS ≥ 50% subgroup to be demonstrated first, which was not showed at IA2. | Secondary analysis - DFS, PD-L1 TPS ≥ 1% DFS in the TPS ≥ 1% subgroup was prespecified but could not be formally tested because the protocol multiplicity strategy requires a statistically significant DFS in the TPS ≥ 50% subgroup to be demonstrated first, which was not showed at IA2. |
| Analysis description                              | Secondary analysis - OS, overall study population The OS in the overall study population was prespecified; given DFS was statistically significant in the overall study population, OS in the overall study population was formally tested with the multiplicity-adjusted p-value.           | Secondary analysis - OS, overall study population The OS in the overall study population was prespecified; given DFS was statistically significant in the overall study population, OS in the overall study population was formally tested with the multiplicity-adjusted p-value.           | Secondary analysis - OS, overall study population The OS in the overall study population was prespecified; given DFS was statistically significant in the overall study population, OS in the overall study population was formally tested with the multiplicity-adjusted p-value.           |
| Analysis population and time point description    | ITT population (overall study population) IA3 (data cutoff 24-JAN-2023)                                                                                                                                                                                                                      | ITT population (overall study population) IA3 (data cutoff 24-JAN-2023)                                                                                                                                                                                                                      | ITT population (overall study population) IA3 (data cutoff 24-JAN-2023)                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability   | Treatment group                                                                                                                                                                                                                                                                              | Pembrolizumab                                                                                                                                                                                                                                                                                | Placebo                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability   | Number of subjects                                                                                                                                                                                                                                                                           | 590                                                                                                                                                                                                                                                                                          | 587                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability   | OS, overall study population (median)                                                                                                                                                                                                                                                        | NR                                                                                                                                                                                                                                                                                           | NR                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                      | Pembrolizumab Placebo                                                                                                                                                                                                                  |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                     | HR                                                                                                                                                                                                                                     | 0.87                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                                                 | 0.69, 1.10                                                                                                                                                                                                                             |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                | 0.11792                                                                                                                                                                                                                                |
| Notes                                           | The observed p-value did not cross the prespecified p-value boundary at IA2 and also at IA3 and will continue to be tested at the next analysis.                                                                                       | The observed p-value did not cross the prespecified p-value boundary at IA2 and also at IA3 and will continue to be tested at the next analysis.                                                                                       | The observed p-value did not cross the prespecified p-value boundary at IA2 and also at IA3 and will continue to be tested at the next analysis.                                                                                       |
| Analysis description                            | Secondary analysis - OS, PD-L1 TPS ≥ 50% The OS in the TPS ≥ 50% subgroup was prespecified; given DFS was statistically significant in the overall study population, OS in participants with PD L1 TPS ≥ 50% NSCLC was formally tested | Secondary analysis - OS, PD-L1 TPS ≥ 50% The OS in the TPS ≥ 50% subgroup was prespecified; given DFS was statistically significant in the overall study population, OS in participants with PD L1 TPS ≥ 50% NSCLC was formally tested | Secondary analysis - OS, PD-L1 TPS ≥ 50% The OS in the TPS ≥ 50% subgroup was prespecified; given DFS was statistically significant in the overall study population, OS in participants with PD L1 TPS ≥ 50% NSCLC was formally tested |
| Analysis population and time point description  | ITT population (PD-L1 TPS ≥ 50%) IA3 (data cutoff 24-JAN-2023)                                                                                                                                                                         | ITT population (PD-L1 TPS ≥ 50%) IA3 (data cutoff 24-JAN-2023)                                                                                                                                                                         | ITT population (PD-L1 TPS ≥ 50%) IA3 (data cutoff 24-JAN-2023)                                                                                                                                                                         |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                        | Pembrolizumab                                                                                                                                                                                                                          | Placebo                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                     | 168                                                                                                                                                                                                                                    | 165                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | OS, PD-L1 TPS ≥ 50% (median)                                                                                                                                                                                                           | NR                                                                                                                                                                                                                                     | NR                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                 | NR, NR                                                                                                                                                                                                                                 | NR, NR                                                                                                                                                                                                                                 |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                      | Pembrolizumab Placebo                                                                                                                                                                                                                  |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                     | HR                                                                                                                                                                                                                                     | 0.93                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                                                 | 0.57, 1.50                                                                                                                                                                                                                             |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                | 0.3778                                                                                                                                                                                                                                 |
| Notes                                           | The observed p-value did not cross the prespecified p-value boundary at IA2 and at IA3 and will continue to be tested at the next analysis.                                                                                            | The observed p-value did not cross the prespecified p-value boundary at IA2 and at IA3 and will continue to be tested at the next analysis.                                                                                            | The observed p-value did not cross the prespecified p-value boundary at IA2 and at IA3 and will continue to be tested at the next analysis.                                                                                            |
| Analysis description                            | Secondary analysis - OS, PD-L1 TPS ≥ 1% The OS in the TPS ≥ 1% subgroup was prespecified but was not formally tested at IA2 given that a statistically significant OS in participants with TPS ≥ 50% was not demonstrated.             | Secondary analysis - OS, PD-L1 TPS ≥ 1% The OS in the TPS ≥ 1% subgroup was prespecified but was not formally tested at IA2 given that a statistically significant OS in participants with TPS ≥ 50% was not demonstrated.             | Secondary analysis - OS, PD-L1 TPS ≥ 1% The OS in the TPS ≥ 1% subgroup was prespecified but was not formally tested at IA2 given that a statistically significant OS in participants with TPS ≥ 50% was not demonstrated.             |

## Analysis performed across trials (pooled analyses and meta-analysis)

Not performed

## Clinical studies in special populations

See subgroup analyses according to age groups (tables 56 and 57).

## 2.4.3. Discussion on clinical efficacy

The MAH for Keytruda initially sought the following extension of indication: 'KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with Stage IB (T2a ≥ 4 cm), II or IIIA non-small cell lung carcinoma who have undergone complete resection.' During the procedure, the MAH updated the requested indication to 'KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy (for selection criteria, see section 5.1)'.

<div style=\"page-break-after: always\"></div>

## Design and conduct of clinical studies

The pivotal study is KEYNOTE-091/PEARLS study (EORTC-1416/ETOP-8-15), a randomized, phase 3 trial testing adjuvant pembrolizumab after primary surgical resection (R0) of NSCLC, and adjuvant chemotherapy if indicated. Patients were eligible regardless of the mutational profile of the tumour or histology, as well as regardless of PD-L1 status, which was assessed centrally as TPS score with IHC 22C3 antibody (IUO). Tumou rs were to be stage IB with T≥4 cm, II -IIIA NSCLC according to AJCC staging 7 th  in place at the time of study start (2015). Adjuvant chemotherapy was not mandatory but recommended according to guidelines. Overall, the inclusion/exclusion criteria are detailed and well define the population under study.

Patients received 18 cycles every 3 weeks of pembrolizumab/placebo (i.e. one year of treatment). Baseline imaging was performed to confirm no evidence of disease, and imaging assessment was continued initially every 12 weeks during treatment. This is considered acceptable.

Dual primary endpoints were DFS in the ITT and in the strongly PD-L1 positive (TPS ≥ 50%) populations, as assessed by investigator.

Sample size calculation and power for DFS and OS endpoints was correctly conducted. Randomization was well conducted and stratified by stage, adjuvant chemotherapy, PD-L1 status and regions, which are considered appropriate, although it is unclear why histology (squamous vs non-squamous) was not used as stratification factor. The study was conducted in triple blind, with the exception of the pharmacist, which is considered acceptable. The statistical methods were generally adequate and well described.

Overall, the study appears well conducted. Collaterally, a problem in data transfer from EORTC to sponsor due to the incompatible date formatting were found, although related only to the protocol deviations' data listing and it's reassuring that the MAH confirmed that this problem did not affect any other dataset, with no impact on any analysis results.

## Efficacy data and additional analyses

The MAH initially submitted the results of the interim analysis 2 (data cut-off 20 Sept 2021). A total of 1177 patients were randomized (590 in the pembrolizumab group and 587 in the placebo group).

It should be noted that less patients in the pembrolizumab group were able to complete the treatment as planned as compared to placebo (51.7% vs 65.6%), with higher rate of treatment discontinuation, the main reason being progressive disease in the placebo arm (12.4% vs 21.9%), and study drug toxicity in the pembrolizumab arm (19.8% vs 3.8%). Regarding the latter, the AEs leading to pembrolizumab discontinuation were however in line with pembrolizumab's known safety profile, and the incidence of discontinuations due to drug-related AEs was similar in the KEYNOTE-091 safety dataset and the reference dataset for pembrolizumab in an adjuvant setting (see also Clinical safety section), as well as also with other anti-PD(L)1 agents in the same adjuvant NSCLC setting (IMpower010 ~18% 20 ).

At the IA2, median FU was 32.4 months (range 0.6, 68). All patients had either completed 1 year of treatment or discontinued treatment. The minimum follow-up time of the last patient randomized to the data cut-off date of IA2 was 16.5 months (at least 6 months after completion of 1 year of treatment), which is of importance in an adjuvant setting.

In the ITT and in the PDL1 TPS≥50% population s (including approximately 30% of patients), baseline characteristics are consistent, and balanced between treatment arms. A slight difference is however

20  EMA/667840/2022 EPAR CHMP Assessment Report Tecentriq EMEA/H/C/004143/II/0064

<div style=\"page-break-after: always\"></div>

noted in histology distribution in the ITT (squamous histology 32.5 vs 38.2%), more marked in some PD-L1 subgroup. It would have been preferred if  KEYNOTE-091 was stratified by histology. In addition, due to the unknown EGFR mutational status in 57% of the enrolled population, any analysis on EGFR mutated NSCLC is speculative at present. The MAH confirmed that no further biomarker analysis of EGFR status is planned in this study. In line with the SA, the CHMP considered the patient population to be heterogeneous, and noted that the impact on the final indication of any potential contrasting results will be a matter of assessment at time of evaluation.

At the interim analysis 2, statistical significance was reached for DFS in the overall population. With 36% and 44% of DFS event in pembrolizumab and placebo arm, respectively, DFS HR was 0.76, 95% CI: 0.63, 0.91; p=0.00143, median DFS 53.6 vs 42 months, DFS rate at month 12 78.7% vs 71.6%. With the results of IA2, the CHMP concluded that it was not yet possible to assess the cure rate (if any in NSCLC) in the context of an adjuvant setting (see also EMA anticancer guideline 21 ). The tendence of DFS KM curves to converge was considered not particularly reassuring, although curves were hardly interpretable after month 16 due to high rate of censoring, thus not able to support the assumption of an increased cure rate for pembrolizumab. It might be expected that generally most of the recurrence will occur within 5 years after NSCLC resection. It was acknowledged that the largest difference of events rates between both treatment arms was due to a lower event rate of distant metastasis in the pembrolizumab arm (11.5% vs 17.2%). However, a higher rate of death as first DFS event was observed in the pembrolizumab arm (27 vs 12). Of those, 11 vs 5 were deaths related to treatment emergent AEs, and 4 vs 0 was due to treatment-related AEs. The MAH's explanation that participants receiving placebo have more chances of disease recurrence or new malignancy as the first event can be followed. The possibility for fatal treatment-related events with pembrolizumab, also in an adjuvant setting, can occur and should be considered. It is reassuring that the overall total number of deaths in the pembrolizumab group was however lower than that observed in the placebo group (98 [16.6%] vs 111 [18.9%]).

Contrary to ITT, DFS in the subgroup with higher PD-L1 expression TPS ≥ 50% (dual primary endpoint) was not statistically significant at IA2 (HR 0.82, 95% CI: 0.57, 1.18; p=0.13639). The lack of statistical success in the PDL1 TPS ≥50% subpopulation, with better results in lower PD -L1 expressors 1-49% (DFS HR 0.67, 95%CI 0.48, 0.92) were unexpected, as of limited biological plausibility and inconsistent with respect to accumulating evidence for immunotherapy. It cannot be excluded that imbalances in histology distribution in the ITT (squamous histology 32.5 vs 38.2%), more marked in some PD-L1 subgroup, had a role in the unexpected results of this study. No convincing explanation to this observation was provided. This was noted.

OS was also not considered very helpful in taking any decision based on IA2: OS HR was 0.87 (95%CI 0.67, 1.15) in the ITT population, and 0.92 (95%CI 0.52, 1.62) in the high PD-L1 expressor subgroup, with overlapping KM curves in both populations, yet of difficult interpretation due to low number of events and high censoring from month 18 onwards. No further support can be expected from other intermediate endpoints (e.g. DMFS or DFS2), as the MAH confirmed that those data have not been collected.

In order to clarify the unexpected results in the PD-L1 subgroups, the MAH was requested to discuss also the PD-L1 assay: based on the information provided, no concern was raised about PD-L1 determination.

Based on the IA2 results, the CHMP concluded that biological plausibility and external validity of the DFS data according to PD-L1 expression were put into question and uncertainties on KEYNOTE-091 results prevented to grant an unrestricted indication. Further, although in the overall population OS HR point estimate was &lt;1 with KM curves almost overlapping, OS data was considered immature to draw

21  EMA/CHMP/205/95 Rev.6 Guideline on the clinical evaluation of anticancer medicinal products.

<div style=\"page-break-after: always\"></div>

any conclusions. As such, it was decided to wait for more mature data of IA3 (i.e. final DFS analysis and more mature OS) for any regulatory decision, to alleviate those uncertainties and to allow more confidence on the ITT results as well as possibly on subgroups, especially given the adjuvant setting.

Patients reported outcomes were assessed as an exploratory endpoint. The global health status/quality of life score of the EORTC QLQ-30 did not show meaningful change with pembrolizumab as compared to placebo.

The CHMP raised concern over the results in the population having squamous histology (35%), as no benefit from the use of pembrolizumab over placebo was suggested in DFS (HR 1.08, 95%CI 0.77, 1.50) or in OS (HR 1.09, 95%CI 0.70, 1.71), while benefit of adjuvant pembrolizumab seemed driven by non-squamous histology. The lack of stratification by histology was considered an issue: baseline characteristics by histology showed some differences as compared to the ITT population, such as more males, fewer never smokers and fewer EGFR mutated (all expected) and less PD-L1 negative, as well as some differences within the squamous histology between treatment arms such as age and ECOG performance status (in favour of the pembrolizumab arm) and disease stage. According to the MAH, DFS result in the squamous histology was driven by the TPS ≥50% population (HR 1.86, 95% CI: 0.92, 3.77), which was not expected and may be due, in part, to the better-than-expected DFS in participants receiving placebo in this population.

At IA2, subgroup analysis by EGFR status showed in the ITT population benefit of pembrolizumab over placebo regardless of EGFR expression but higher in known EGFR mutated tumours. Although treatment arms were overall balanced in EGFR mutated patients, data were of difficult interpretation as EGFR mutational status was unknown for about 60% of study participants. Data in ALK positive disease were far more limited, with only 14 participants with ALK rearrangement (7 in each arm), as ALK mutation status was unknown in 64% of participants. To conclude, overall data may suggest an activity of pembrolizumab in the adjuvant setting regardless of EGFR mutation. For ALK positive disease, no conclusion can be drawn.

To date, targeted therapy is approved and indicated in EGFR mutated NSCLC tumours in the adjuvant setting, although this was not the case when the study started. The clinical relevance of adjuvant pembrolizumab in mutated tumours is unclear, especially when the changed treatment landscape is considered. It would have been preferred if further biomarker analysis of EGFR status in KEYNOTE-091 was planned by the MAH. The IA3 data confirmed however a numerically favourable trend in DFS (HR 0.44, 95%CI 0.22, 0.87) and OS (HR 0.35, 95%CI 0.13, 0.98) in patients with EGFR positive NSCLC, acknowledging the large confidence intervals due to the small sample size. Therefore, no reason is found to explicitly exclude EGFR mutated tumours from the adjuvant indication. The information that testing for genomic tumour aberrations/oncogenic drivers was not mandatory for enrolment, as well as the number of patients with EGFR positive/negative/undetermined status have been included in the SmPC section 5.1.

Patients who did not receive prior adjuvant chemotherapy did not show apparent benefit for adjuvant treatment with pembrolizumab as compared to placebo. Acknowledging that this subgroup was a minority (84 vs 83, approximately 15% of the ITT population), adjuvant chemotherapy was a stratification factor, thus strengthening the data. No imbalances are observed with regard to prior adjuvant chemotherapy among study arms, received by approximately 86% of participants in both treatment arms. The most common agents used were cisplatin/vinorelbine, carboplatin/vinorelbine, and carboplatin/paclitaxel. The median duration of exposure to prior adjuvant chemotherapy and median number of cycles (4) was similar in both treatment groups. Patients who did not receive adjuvant chemotherapy were older (although ECOG was similar), slightly more Asian, with lower disease stage, and more squamous histology. Overall, about 14% of patients with stage II disease and approximately 6% of patients with stage IIIA did not receive adjuvant chemotherapy. It might be

<div style=\"page-break-after: always\"></div>

reasonable to assume that the investigator's choice of avoiding adjuvant chemotherapy had been based on differences in baseline characteristics that are likely not fully reportable.

In the population of participants who did not receive adjuvant chemotherapy, at IA2 DFS HR was 1.21 (95% CI: 0.73, 2.03), contrary to patients who received adjuvant chemotherapy (HR 0.73, 95%CI 0.60, 0.89). When broken down by PD-L1 subgroups, results in patients not receiving prior adjuvant chemotherapy should be interpreted with caution due to small numbers. The MAH did not elaborate on any possible explanation for the observed lack of effect in patients who did not receive adjuvant treatment, and it was unclear how to interpret such data, acknowledging the limited number of patients who did not receive adjuvant treatment.

Stage (according to AJCC 7th ed) was a stratification factor. Overall, a trend toward more limited benefit in the higher stage (IIIA) was observed, which seems counterintuitive. However, maturity progresses differently across prognostic subgroups, and there are still fewer events in the IB stage for a conclusive assessment.

The assessment of IA2 results did not allow the CHMP to conclude a positive benefit/risk of one year of adjuvant pembrolizumab vs placebo in a broad population, or to restrict the indication to best performing subgroup(s) with reasonable degree of confidence. As a result, more mature results were requested, corresponding to the pre-planned IA3 data (i.e. final analysis for DFS).

The IA3 results (data cut-off date 24-Jan-2023) provided by the MAH, included patients with a median FU of 46.7 months, approximately 13 months longer compared with IA2; the minimum follow-up of the last patient randomized was 32 months i.e. about 1.7 year after the end of 1-year adjuvant treatment.

DFS in the overall population was updated (but not statistically tested, as already significant at IA2) (HR 0.81; 95%CI 0.68-0.96; 45% vs 51% of DFS events). Although HR point estimate was slightly worse than IA2 (from 0.76 to 0.81), confidence interval was still below the unity. DFS in TPS≥50% was tested at IA3 but again did not reach statistical significance (HR 0.83; 95%CI 0.59-1.16), as well as OS in the overall population (HR 0.87; 95%CI 0.69-1.10; p=0.118; 23% vs 27% of OS events) and in the TPS≥50% (HR 0.93; 95%CI 0.57 -1.50 p=0.38). It can be concluded that results are overall consistent with IA2 data.

Also, the results of the DFS subgroup analyses at IA3 are consistent with IA2, with no subgroup driving the results. Most of the subgroups have confidence interval crossing 1, with HR point estimate &gt;1 in squamous disease, no prior adjuvant chemotherapy, and stage IB.

With the submission of IA3 data, the MAH decided to seek a more limited indication by excluding patients who have not received previous adjuvant chemotherapy treatment. The MAH has justified the new proposal as IA2 and IA3 data were consistent, because limiting the population to those patients receiving adjuvant chemotherapy, the DFS HR point estimates for all subgroups were &lt;1. Baseline characteristics of the newly proposed population treated with adjuvant chemotherapy (85% of the overall population) are balanced between treatment arms, being 'adjuvant chemotherapy yes/no' a stratification factor. At IA3, the results in the population with adjuvant chemotherapy are numerically more favourable as compared to the ITT:

- DFS HR 0.76 (95%CI 0.64, 0.91), 44% vs 52 % events, medians 54 vs 40 months, DFS rate at 24 months 67% vs 59%. KM curves open after month 6 and remain separated with apparently constant distance.

- OS HR 0.79 (95%CI 0.62, 1.01), 22% vs 27% events, medians NR in either arm, pembrolizumab curve is marginally higher than placebo after 12 months but uninterpretable after month 36.

<div style=\"page-break-after: always\"></div>

In the population treated with adjuvant chemotherapy, DFS HR point estimates for subgroups are all &lt;1, although the same trend seen in the ITT is generally observed, e.g. worse outcome in PDL1≥50% than in PD-L1&lt;50%, and worse estimates in squamous histology rather than in the non-squamous. Regarding subgroups analysis for OS, HR point estimates for subgroups are all &lt;1, with the exception of patients over 75 years. No subgroups appear to drive the results.

While it is agreed that the subgroup of patients who did not receive adjuvant chemotherapy showed negative DFS trend (HR 1.16; 95%CI 0.73, 1.84), biological plausibility of the choice of this patient population is not discussed and not clear. External evidence may however support the proposed population, as adjuvant Tecentriq in NSCLC was approved after adjuvant chemotherapy only, although the replication of findings is not fully evaluable as study IMpower010 enrolled only patients who have received prior adjuvant chemotherapy, differently from KEYNOTE-091. From a statistical perspective, however, adjuvant chemotherapy yes/no was a stratification factor, and pre-specified subgroup analyses, which strengthened the result.

Uncertainty remains in terms of OS maturity. The MAH will submit updated OS data as part of the imposed PAES (see Annex II). In addition, the MAH will submit data on treatment post-progression, and particularly on the uptake and activity of anti-PD(L)1 in patients previously treated with adjuvant pembrolizumab.

## 2.4.4. Conclusions on the clinical efficacy

KEYNOTE-091 study showed, at the IA2, statistically significant improvement in DFS for pembrolizumab over placebo when used for one year duration as adjuvant treatment after complete NSCLC resection in the ITT population. The results of the more mature IA3 confirmed IA2 data, providing reassurance that the benefit of adjuvant pembrolizumab can be maintained with longer follow-up.

The indication was restricted to patients who have been treated with prior adjuvant chemotherapy excluding a (small) subgroup of patients not receiving prior adjuvant chemotherapy in whom DFS detriment cannot be excluded. The overall results in the population after adjuvant chemotherapy suggest a relevant DFS benefit and positive OS trend for pembrolizumab vs placebo. In addition, this population will be aligned with indications of other medicines from the same class approved in the adjuvant NSCLC setting.

Uncertainty remains in terms of OS maturity. The MAH will submit updated OS data as part of the imposed PAES (see Annex II). In addition, the MAH will submit data on treatment post-progression, and particularly on the uptake and activity of anti-PD(L)1 in patients previously treated with adjuvant pembrolizumab.

The following measure is considered necessary to address issues related to clinical efficacy:

Post-authorisation efficacy study (PAES): in order to further characterise the efficacy of Keytruda for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence, the MAH should submit the results of the final OS analysis of study KEYNOTE-091. The MAH should submit updated data on treatment post-progression, and particularly on the uptake and activity of anti-PD(L)1 in patients previously treated with adjuvant pembrolizumab.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

## General safety profile

Pembrolizumab is most commonly associated with immune related adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of pembrolizumab.

When used as monotherapy , the most frequent adverse reactions with pembrolizumab were fatigue (30%) and diarrhoea (22%). The majority of adverse reactions reported for monotherapy were of Grades 1 or 2 severity. The most serious adverse reactions were immune-related adverse reactions and severe infusion-related reactions. The incidences of immune-related adverse reactions were 36.9% all Grades and 8.7% for Grades 3-5 for monotherapy in the adjuvant setting and 24.5% all Grades and 6.3% for Grades 3-5 in the metastatic setting.

## Safety Datasets used in the present submission

Safety results for pembrolizumab are presented for the following 4 datasets:

- -KEYNOTE-091 Pembrolizumab Dataset (N=580): Stage IB (T2a ≥ 4 cm), Stage II, or Stage IIIA NSCLC who participated in KEYNOTE-091 treated with adjuvant pembrolizumab monotherapy.
- -KEYNOTE-091 Placebo Dataset (N=581): Stage IB (T2a ≥ 4 cm), Stage II, or Stage IIIA NSCLC who participated in KEYNOTE-091 treated with placebo.
- -Pembrolizumab Monotherapy RSD [EU] (N=6185): The 6185 pembrolizumab-treated participants from the RSD consists of 2076 participants with advanced melanoma and 2022 participants with NSCLC (with pembrolizumab used as first-line treatment). In addition, this dataset includes participants with cHL, urothelial cancer, CRC, HNSCC. This dataset represents the established safety profile for pembrolizumab monotherapy.
- -Cumulative Reference Safety Dataset (N=10,997): Participants from the Safety Dataset, the RSD, and participants treated with pembrolizumab in the studies listed in the footnotes of the data tables in this document and the ISS comprise the Cumulative Running Safety Dataset.

NOTE: safety data of KEYNOTE-091 are presented at IA2 (data cutoff 20-SEP-2021), unless noted otherwise.

## Patient exposure

KEYNOTE-091 is an ongoing study. As of the data cutoff on 20-SEP-2021, n=1161 participants had received at least one dose of study treatment, including 580 in the pembrolizumab group and 581 in the placebo group. No participants were still receiving treatment. Thus, drug exposure was not changed at IA3 (data cut-off 24-Jan-2023). Pembrolizumab/placebo was given for up to 1 year.

The following table shows a summary on drug exposure.

<div style=\"page-break-after: always\"></div>

Table 36 : summary of drug exposure (APaT population)

<!-- image -->

|                              | KN091 Data for Pembrolizumab (N=580)   | KN091 Data for Placebo (N=581)   | Reference Safety Dataset for Pembrolizumabi (N=6185)   | Cumulative Running Safety Dataset for Pembrolizumabi (N=10997)   |
|------------------------------|----------------------------------------|----------------------------------|--------------------------------------------------------|------------------------------------------------------------------|
| Duration On Therapy (months) |                                        |                                  |                                                        |                                                                  |
| Mean Median SD Range         | 8.7 11.7 4.50 0.03 to 18.86            | 10.0 11.8 3.59 0.03 to 18.10     | 7.5 4.9 7.03 0.03 to 30.62                             | 7.5 5.1 6.92 0.03 to 40.05                                       |
| Number of Administrations    |                                        |                                  |                                                        |                                                                  |
| Mean Median SD Range         | 12.8 17.0 6.22 1.00 to 18.00           | 14.9 18.0 4.97 1.00 to 19.00     | 12.0 8.0 10.43 1.00 to 59.00                           | 11.7 8.0 10.08 1.00 to 59.00                                     |

<!-- image -->

The following table shows the distribution of patients by drug exposure duration categories:

<div style=\"page-break-after: always\"></div>

Table 37: drug exposure by duration (APaT population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Adverse events

## Baseline characteristics

## Table 38: participant characteristics (APaT population)

|                                                                | KN091DataforPembrolizumab   | KN091DataforPembrolizumab   | KN091 DataforPlacebo   | KN091 DataforPlacebo       | ReferenceSafetyDataset for Pembrolizumabi   | ReferenceSafetyDataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   |
|----------------------------------------------------------------|-----------------------------|-----------------------------|------------------------|----------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                                | n                           | (%)                         | n                      | (%)                        | n                                           | (%)                                         | n                                                      | (%)                                                    |
| Age Class (Years)                                              |                             |                             |                        |                            |                                             |                                             |                                                        |                                                        |
| <65 65-74 75-84 >=85                                           | 281 245 51 3                | (48.4) (42.2) (8.8) (0.5)   | 272 243 64 2           | (46.8) (41.8) (11.0) (0.3) | 3,587 1,797 694 107                         | (58.0) (29.1) (11.2) (1.7)                  | 6,233 3,333 1,253 178                                  | (56.7) (30.3) (11.4) (1.6)                             |
| ECOGPerformance Status                                         |                             |                             |                        |                            |                                             |                                             |                                                        |                                                        |
| [0] Normal Activity [1] Symptoms, but ambulatory Other/Missing | 375 205 0                   | (64.7) (35.3) (0.0)         | 339 242 0              | (58.3) (41.7) (0.0)        | 2,942 3,069 174                             | (47.6) (49.6) (2.8)                         | 5,570 5,110 317                                        | (50.7) (46.5) (2.9)                                    |
| Geographic Region                                              |                             |                             |                        |                            |                                             |                                             |                                                        |                                                        |
| EU Ex-EU                                                       | 388 192                     | (66.9) (33.1)               | 387 194                | (66.6) (33.4)              | 2,217 3,968                                 | (35.8) (64.2)                               | 4,209 6,788                                            | (38.3) (61.7)                                          |
| Geographic Region 2                                            |                             |                             |                        |                            |                                             |                                             |                                                        |                                                        |
| East Asia                                                      | 106                         | (18.3)                      | 105                    | (18.1)                     | 595                                         | (9.6)                                       | 1,441                                                  | (13.1)                                                 |
|                                                                |                             |                             |                        |                            |                                             | (90.4)                                      |                                                        | (86.9)                                                 |

## Ex-East Asia

474

(81.7)

476

(81.9)

5,590

9,556

Includes allparticipants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase),KN006, KN010, KN012 cohorts B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177 and KN204.

Includes all participants who received atleast one dose of pembrolizumab in KN001 Part B1, B2,B3, D,C,F1, F2,F3,KN002 (original phase), KN006,KN010,KN012 cohorts B ,B2,C and D, KN013 cohorts 3 and 4A, P017, KN024, KN028 cohorts B4, C1 and A4, KN040, KN042,KN045,KN048, KN052, KN054,KN055, KN057, KN059 cohorts 1 and 3,KN061, KN062, KN087,

KN091, KN158 cohorts E, G, TMB-H and K, KN164 cohorts A and B, KN170, KN177, KN180, KN181, KN204, KN224, KN361, KN427, KN564, KN629 and KN716.

PembrolizumabDatabase cutoff date forMelanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015,KN054:03APR2020,KN716:21JUN2021)

Pembrolizumab Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016,KN040:15MAY2017,KN048: 25FEB2019,KN055: 22APR2016)

Pembrolizumab Database cutoff date forGastric (KN012-Gastric:26APR2016,KN059-Cohorts 1 and 3:08AUG2018,KN061:26OCT2017,KN062:26MAR2019)

PembrolizumabDatabase cutoff date forcHL(KN013-Cohort3:28SEP2018,KN087:15MAR2021,KN204:16JAN2020)

Pembrolizumab Database cutoff date forBladder (KN012-Urothelial: 01SEP2015,KN045:26OCT2017,KN052: 26SEP2018,KN057: 24MAY2019,KN361: 29APR2020)

Pembrolizumab Database cutoff date for Colorectal(KN164-Cohorts A and B:09SEP2019,KN177:19FEB2020)

Pembrolizumab Database cutoff date for PMBCL (KN013-Cohort 4A:04AUG2017.KN170: 07MAY2020)

PembrolizumabDatabase cutoff date for Cervical(KN028-Cohort B4:20FEB2017,KN158-Cohort E:27JUN2019)

Pembrolizumab Database cutoff date for HCC (KN224: 05JUN2019)

PembrolizumabDatabase cutoff date forMCC (P017:06FEB2018)

PembrolizumabDatabase cutoff date forEsophageal(KN028:31JAN2018,KN180:30JUL2018,KN181: 15OCT2018)

PembrolizumabDatabase cutoff date forRenal Cell Carcinoma (KN427CohortA:07SEP2018,KN564:14JUN2021)

PembrolizumabDatabase cutoff date forSCLC(KN028-Cohort C1: 31JUL2018,KN158-Cohort G:27JUN2019)

Pembrolizumab Database cutoff date for TMB-H (KN158: 27JUN2019)

PembrolizumabDatabase cutoff date forMSI-H(KN158:05OCT2020)

PembrolizumabDatabase cutoff dateforCSCC (KN629:29JUL2020)

<div style=\"page-break-after: always\"></div>

AEs

|                                                               | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   | KN091 Data for Placebo   | KN091 Data for Placebo   | Reference SafetyDataset for Pembrolizumabi   | Reference SafetyDataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   |
|---------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                               | n                              | (%)                            | n                        | (%)                      | n                                            | (%)                                          | n                                                      | (%)                                                    |
| Participants in population                                    | 580                            |                                | 581                      |                          | 6,185                                        |                                              | 10,997                                                 |                                                        |
| with one or more adverse events                               | 556                            | (95.9)                         | 529                      | (91.0)                   | 5,989                                        | (96.8)                                       | 10,597                                                 | (96.4)                                                 |
| with no adverse event                                         | 24                             | (4.1)                          | 52                       | (9.0)                    | 196                                          | (3.2)                                        | 400                                                    | (3.6)                                                  |
| with drug-related adverse events                              | 436                            | (75.2)                         | 305                      | (52.5)                   | 4,366                                        | (70.6)                                       | 7,689                                                  | (69.9)                                                 |
| with toxicity grade 3-5 adverse events                        | 198                            | (34.1)                         | 150                      | (25.8)                   | 2,984                                        | (48.2)                                       | 5,178                                                  | (47.1)                                                 |
| with toxicity grade 3-5 drug-related adverse events           | 88                             | (15.2)                         | 25                       | (4.3)                    | 975                                          | (15.8)                                       | 1,761                                                  | (16.0)                                                 |
| with serious adverse events                                   | 142                            | (24.5)                         | 90                       | (15.5)                   | 2,371                                        | (38.3)                                       | 3,984                                                  | (36.2)                                                 |
| with serious drug-related adverse events                      | 68                             | (11.7)                         | 13                       | (2.2)                    | 701                                          | (11.3)                                       | 1,227                                                  | (11.2)                                                 |
| who died                                                      |                                | (1.9)                          | 6                        | (1.0)                    | 321                                          | (5.2)                                        | 542                                                    | (4.9)                                                  |
| who died due to a drug-related adverse event                  | 4                              | (0.7)                          | 0                        | (0.0)                    | 39                                           | (0.6)                                        | 74                                                     | (0.7)                                                  |
| discontinued drug due to an adverse event                     | 115                            | (19.8)                         | 34                       | (5.9)                    | 832                                          | (13.5)                                       | 1,508                                                  | (13.7)                                                 |
| discontinueddrugdueto adrug-related adverse event             | 98                             | (16.9)                         | 20                       | (3.4)                    | 444                                          | (7.2)                                        | 907                                                    | (8.2)                                                  |
| discontinued drug due to a serious adverse event              | 49                             | (8.4)                          | 14                       | (2.4)                    | 598                                          | (9.7)                                        | 1,007                                                  | (9.2)                                                  |
| discontinued drug due to a serious drug-related adverse event | 34                             | (5.9)                          | 4                        | (0.7)                    | 265                                          | (4.3)                                        | 488                                                    | (4.4)                                                  |

Table 39: Adverse event summary (APaT population)

<!-- image -->

Source:[ISS: adam-adsl; adae]

## Table 40: Exposure-adjusted adverse event summary (including multiple occurrences of events) APaT population)

|                                                               | Event Count and Rate(Events/100person-months)a   | Event Count and Rate(Events/100person-months)a   | Event Count and Rate(Events/100person-months)a   | Event Count and Rate(Events/100person-months)a   |
|---------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                                                               | KN091 Data for Pembrolizumab                     | KN091DataforPlacebo                              | ReferenceSafetyDatasetfor Pembrolizumabi         | CumulativeRunningSafety DatasetforPembrolizumabi |
| Number of subjects exposed                                    | 580                                              | 581                                              | 6185                                             | 10997                                            |
| Total exposurebin person-months                               | 5596.37                                          | 6400.56                                          | 52032.15                                         | 92405.52                                         |
| Total events (rate)                                           |                                                  |                                                  |                                                  |                                                  |
| adverse events                                                | 4151 (74.17) 1533 (27.39)                        | 3633 (56.76) 915 (14.30)                         | 64171 (123.33) 20041 (38.52)                     | 106365 (115.11) 32767 (35.46)                    |
| drug-relatedadverse events                                    |                                                  |                                                  |                                                  |                                                  |
| toxicitygrade 3-5 adverse events                              | 312(5.58)                                        | 229 (3.58)                                       | 6478 (12.45)                                     | 11285 (12.21)                                    |
| toxicitygrade3-5drug-related adverse events                   | 113 (2.02)                                       | 35 (0.55)                                        | 1467 (2.82)                                      | 2627 (2.84)                                      |
| serious adverse events                                        | 217 (3.88)                                       | 130 (2.03)                                       | 4264 (8.19)                                      | 6986 (7.56)                                      |
| serious drug-related adverse events                           | 81 (1.45)                                        | 16 (0.25)                                        | 971 (1.87)                                       | 1633 (1.77)                                      |
| adverseeventsleadingtodeath                                   | 13 (0.23)                                        | 6 (0.09)                                         | 328 (0.63)                                       | 553 (0.60)                                       |
| drug-related adverse events leading todeath                   | 6 (0.11)                                         | 0 (0.00)                                         | 39 (0.07)                                        | 76 (0.08)                                        |
| adverseeventsresultingin drugdiscontinuation                  | 130 (2.32)                                       | 42 (0.66)                                        | 904 (1.74)                                       | 1635 (1.77)                                      |
| drug-related adverse events resulting in drug discontinuation | 108 (1.93)                                       | 26 (0.41)                                        | 481 (0.92)                                       | 987 (1.07)                                       |
| seriousadverseeventsresultingindrugdiscontinuation            | 57 (1.02)                                        | 15 (0.23)                                        | 635 (1.22)                                       | 1058 (1.14)                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source:[ISS:adam-adsl; adae]

The most frequently reported (incidence &gt;15%) AEs were weight increased, pruritus, hypothyroidism, arthralgia, diarrhoea, and fatigue (as shown in the table below).

<div style=\"page-break-after: always\"></div>

Table 41 : Participants with adverse events by decreasing incidence of preferred term (incidence ≥10% in one or more treatment groups) (APaT population)

|                            |   KN091Datafor Pembrolizumab | KN091Datafor Pembrolizumab   |   KN091 Data for Placebo | KN091 Data for Placebo   | Reference Safety Dataset for Pembrolizumabi   | Reference Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   |
|----------------------------|------------------------------|------------------------------|--------------------------|--------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                            |                            1 | (%)                          |                        1 | (%)                      | 11                                            | (%)                                           | n                                                      | (%)                                                    |
| Participants in population |                          580 |                              |                      581 |                          | 6,185                                         |                                               | 10,997                                                 |                                                        |
| withoneormoreadverseevents |                          556 | (95.9)                       |                      529 | (91.0)                   | 5,989                                         | (96.8)                                        | 10,597                                                 | (96.4)                                                 |
| withnoadverseevents        |                           24 | (4.1)                        |                       52 | (9.0)                    | 196                                           | (3.2)                                         | 400                                                    | (3.6)                                                  |
| Weight increased           |                          133 | (22.9)                       |                      168 | (28.9)                   | 209                                           | (3.4)                                         | 417                                                    | (3.8)                                                  |
| Pruritus                   |                          125 | (21.6)                       |                       74 | (12.7)                   | 1,111                                         | (18.0)                                        | 1,992                                                  | (18.1)                                                 |
| Hypothyroidism             |                          120 | (20.7)                       |                       27 | (4.6)                    | 699                                           | (11.3)                                        | 1,316                                                  | (12.0)                                                 |
| Arthralgia                 |                          108 | (18.6)                       |                       75 | (12.9)                   | 1,148                                         | (18.6)                                        | 1,924                                                  | (17.5)                                                 |
| Diarrhoca                  |                          106 | (18.3)                       |                       83 | (14.3)                   | 1,295                                         | (20.9)                                        | 2,279                                                  | (20.7)                                                 |
| Fatigue                    |                           96 | (16.6)                       |                       89 | (15.3)                   | 1,967                                         | (31.8)                                        | 3,205                                                  | (29.1)                                                 |
| Cough                      |                           87 | (15.0)                       |                       98 | (16.9)                   | 1,200                                         | (19.4)                                        | 1,861                                                  | (16.9)                                                 |
| Hypertension               |                           67 | (11.6)                       |                       74 | (12.7)                   | 318                                           | (5.1)                                         | 585                                                    | (5.3)                                                  |
| Dyspnoca                   |                           66 | (11.4)                       |                       72 | (12.4)                   | 1,020                                         | (16.5)                                        | 1,496                                                  | (13.6)                                                 |
| Hyperthyroidism            |                           62 | (10.7)                       |                       17 | (2.9)                    | 261                                           | (4.2)                                         | 583                                                    | (5.3)                                                  |
| Nausea                     |                           52 | (9.0)                        |                       37 | (6.4)                    | 1,282                                         | (20.7)                                        | 2,114                                                  | (19.2)                                                 |
| Rash                       |                           49 | (8.4)                        |                       29 | (5.0)                    | 936                                           | (15.1)                                        | 1,515                                                  | (13.8)                                                 |
| Back pain                  |                           45 | (7.8)                        |                       46 | (7.9)                    | 709                                           | (11.5)                                        | 1,205                                                  | (11.0)                                                 |
| Headache                   |                           45 | (7.8)                        |                       46 | (7.9)                    | 747                                           | (12.1)                                        | 1,175                                                  | (10.7)                                                 |
| Asthenia                   |                           44 | (7.6)                        |                       32 | (5.5)                    | 692                                           | (11.2)                                        | 1,262                                                  | (11.5)                                                 |
| Decreased appetite         |                           41 | (7.1)                        |                       27 | (4.6)                    | 1,181                                         | (19.1)                                        | 1,951                                                  | (17.7)                                                 |
| Constipation               |                           35 | (6.0)                        |                       41 | (7.1)                    | 1,032                                         | (16.7)                                        | 1,729                                                  | (15.7)                                                 |
| Pyrexia                    |                           32 | (5.5)                        |                       34 | (5.9)                    | 802                                           | (13.0)                                        | 1,300                                                  | (11.8)                                                 |
| Vomiting                   |                           28 | (4.8)                        |                       21 | (3.6)                    | 784                                           | (12.7)                                        | 1,338                                                  | (12.2)                                                 |
| Anaemia                    |                           25 | (4.3)                        |                       18 | (3.1)                    | 872                                           | (14.1)                                        | 1,526                                                  | (13.9)                                                 |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in thereport title,afierrounding.

the drug are excluded.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

For KN091, Adverse Events of Special Interest (AEOSl) up to 90 days of last dose are included.

Includes all participants who received atleast one dose of pembrolizumab in KN001 Part B1,B2, B3,D, C, F1,F2,F3,KN002 (original phase), KN006, KN010, KN012 cohorts B and B2,KN013 cohort 3,KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055,KN087,KN177 and KN204.

jIncludes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2,F3, KN002

(originalphase),KN006,KN010,KN012cohorts B,B2,C andD,KN013cohorts3 and 4A,P017,KN024,KN028cohorts B4,

C1 and A4,KN040,KN042,KN045,KN048,KN052,KN054,KN055,KN057,KN059 cohorts 1 and3,KN061,KN062,

KN087, KN091, KN158 cohorts E, G, TMB-H and K, KN164 cohorts A and B, KN170, KN177, KN180, KN181, KN204,

KN224,KN361,KN427,KN564,KN629 andKN716.

PembrolizumabDatabasecutoff dateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015. KN054:03APR2020,KN716:21JUN2021)

Pembrolizumab Database cutoff date for Lung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEPT2018,KN091:20SEP2021)

PembrolizumabDatabase cutoff date forHNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019, KN055:22APR2016)

PembrolizumabDatabase cutoff date for Gastric(KN012-Gastric:26APR2016,KN059-Cohorts1 and3:08AUG2018,KN061: 26OCT2017,KN062:26MAR2019)

Pembrolizumab Database cutoff date for cHL (KN013-Cohort 3:28SEP2018,KN087:15MAR2021,KN204:16JAN2020)

PembrolizumabDatabasc cutoff dateforBladder(KN012-Urothelial:01SEP2015,KN045:26OCT2017,KN052:26SEP2018,

KN057:24MAY2019,KN361:29APR2020)

Pembrolizumab Database cutoff date for Colorectal(KN164-Cohorts A and B:09SEP2019,KN177:19FEB2020)

Pembrolizumab Databasc cutoff datc for PMBCL (KN013-Cohort 4A:04AUG2017.KN170:07MAY2020)

PembrolizumabDatabasecutoff datefor Cervical(KN028-CohortB4:20FEB2017,KN158-Cohort E:27JUN2019)

Pembrolizumab Database cutoff date for HCC (KN224:05JUN2019)

PembrolizumabDatabase cutoff date for MCC (P017:06FEB2018)

Pembrolizumab Database cutoff date for Esophageal (KN028: 31JAN2018, KN180: 30JUL2018,KN181: 15OCT2018)

PembrolizumabDatabase cutoff date for Renal Cell Carcinoma (KN427Cohort A:07SEP2018,KN564:14JUN2021)

PembrolizumabDatabase cutoff date forSCLC (KN028-Cohort Cl: 31JUL2018,KN158-Cohort G:27JUN2019)

PembrolizumabDatabase cutoffdateforTMB-H (KN158:27JUN2019)

PembrolizumabDatabasecutoff datefor MSI-H(KN158:05OCT2020)

PembrolizumabDatabasecutoff dateforCSCC(KN629:29JUL2020)

The following table shows data about drug-related AEs.

<div style=\"page-break-after: always\"></div>

Table 42: Participants with drug-related adverse events by decreasing incidence of preferred term (incidence ≥5% in one or more treatment groups) (APaT population)

|                                    | KN091Data for Pembrolizumab   | KN091Data for Pembrolizumab   | KN091 Data for Placcbo   | KN091 Data for Placcbo   | Reference Safety Dataset for Pembrolizumab'   | Reference Safety Dataset for Pembrolizumab'   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   |
|------------------------------------|-------------------------------|-------------------------------|--------------------------|--------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                    |                               | (%)                           |                          | (%)                      |                                               | (%)                                           |                                                        | (%)                                                    |
| Participants in population         | 580                           |                               | 581                      |                          | 6,185                                         |                                               | 10,997                                                 |                                                        |
| withoneormoreadverseevents         | 436                           | (75.2)                        | 305                      | (52.5)                   | 4,366                                         | (70.6)                                        | 7,689                                                  | (69.9)                                                 |
| with no advcisecvents              | 144                           | (24.8)                        | 276                      | (47.5)                   | 1,819                                         | (29.4)                                        | 3,308                                                  | (30.1)                                                 |
| Hypothyroidism                     | 114                           | (19.7)                        | 19                       | (3.3)                    | 605                                           | (9.8)                                         | 1,153                                                  | (10.5)                                                 |
| Pruritus                           | 104                           | (17.9)                        | 60                       | (10.3)                   | 871                                           | (14.1)                                        | 1,559                                                  | (14.2)                                                 |
| Diarrhoea                          | 74                            | (12.8)                        | 47                       | (8.1)                    | 681                                           | (11.0)                                        | 1,200                                                  | (10.9)                                                 |
| Fatigue                            | 61                            | (10.5)                        | 53                       | (9.1)                    | 1,216                                         | (19.7)                                        | 1,952                                                  | (17.8)                                                 |
| Hyperthyroidism                    | 54                            | (9.3)                         | 15                       | (2.6)                    | 231                                           | (3.7)                                         | 515                                                    | (4.7)                                                  |
| Arthralgia                         | 52                            | (9.0)                         | 29                       | (5.0)                    | 488                                           | (7.9)                                         | 855                                                    | (7.8)                                                  |
| Rash maculo-papular                | 38                            | (6.6)                         | 13                       | (2.2)                    | 166                                           | (2.7)                                         | 346                                                    | (3.1)                                                  |
| Rash                               | 35                            | (6.0)                         | 17                       | (2.9)                    | 702                                           | (11.4)                                        | 1,135                                                  | (10.3)                                                 |
| Alanine aminotransferase incrcased | 33                            | (5.7)                         | 24                       | (4.1)                    | 254                                           | (4.1)                                         | 476                                                    | (4.3)                                                  |
| Pneumonitis                        | 33                            | (5.7)                         | 12                       | (2.1)                    | 242                                           | (3.9)                                         | 374                                                    | (3.4)                                                  |
| Nausea                             | 29                            | (5.0)                         | 14                       | (2.4)                    | 561                                           | (9.1)                                         | 864                                                    | (7.9)                                                  |
| Asthenia                           | 26                            | (4.5)                         | 18                       | (3.1)                    | 376                                           | (6.1)                                         | 670                                                    | (6.1)                                                  |
| Decreased appetite                 | 22                            | (3.8)                         | 10                       | (1.7)                    | 479                                           | (7.7)                                         | 732                                                    | (6.7)                                                  |

Every participant is counted a single time for cach applicable row and column.

Aspecific adverse event appears on thisreport onlyifitsincidenceinone or more ofthe columnsmeets theincidence criterionin the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

For KN091,Adverse Events of Special Interest (AEOSI) up to 90 days of last dose are included.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2,B3, D, C, F1, F2,F3,KN002 (original phasc),KN006,KN010,KN012 cohorts B and B2,KN013 cohort 3,KN024,KN040,KN042,KN045,KN048,KN052, KN054, KN055,KN087, KN177 and KN204.

jIncludes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohorts B ,B2, C and D, KN013 cohorts 3 and 4A, P017, KN024, KN028 cohorts B4, C1 and A4,KN040,KN042,KN045,KN048,KN052,KN054,KN055,KN057,KN059 cohorts 1 and3,KN061,KN062, KN087, KN091,KN158 cohorts E,G, TMB-H and K,KN164 cohorts A and B,KN170, KN177, KN180,KN181,KN204,

- PembrolizumabDatabasccutoffdateforMelanoma(KN001-Mclanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015, KN054: 03APR2020,KN716: 21JUN2021)
- Pembrolizumab Databasc cutoff date for Lung(KN001-NSCLC:23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042: 04SEPT2018,KN091:20SEP2021)

Pembrolizumab Database cutoff date for HNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019, KN055:22APR2016)

- PembrolizumabDatabasecutoffdateforGastric(KN012-Gastric:26APR2016,KN059-Cohorts1and3:08AUG2018,KN06l: 26OCT2017,KN062:26MAR2019)

Pembrolizumab Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 15MAR2021, KN204: 16JAN2020)

Pembrolizumab Database cutoff date for Bladder(KN012-Urothelial:01SEP2015,KN045:26OCT2017,KN052:26SEP2018,

KN057: 24MAY2019,KN361: 29APR2020)

PembrolizumabDatabase cutoff datefor Colorectal(KN164-CohortsAandB:09SEP2019,KN177:19FEB2020)

Pembrolizumab Databasc cutoff date for PMBCL (KN013-Cohort 4A:04AUG2017.KN170:07MAY2020)

PembrolizumabDatabasecutoff dateforCervical(KN028-CohortB4:20FEB2017,KN158-CohortE:27JUN2019)

Pembrolizumab Database cutoff date for HCC (KN224:05JUN2019)

PembrolizumabDatabasecutoffdateforMCC(P017:06FEB20l8)

Pembrolizumab Database cutoff date for Esophageal (KN028: 31JAN2018, KN180: 30JUL2018, KN181: 15OCT2018)

PembrolizumabDatabasecutoff datefor Renal Cel1Carcinoma (KN427Cohort A:07SEP2018,KN564:14JUN2021)

Pembrolizumab Databasc cutoff date for SCLC (KN028-Cohort C1: 31JUL2018, KN158-Cohort G: 27JUN2019)

PembrolizumabDatabase cutoff date forTMB-H (KN158:27JUN2019)

PembrolizumabDatabasecutoffdateforMSI-H(KN158:05OCT2020)

PembrolizumabDatabasecutoffdateforCSCC(KN629:29JUL2020)

The following table shows the proportion of patients with grade 3-5 AEs by decreasing incidence.

<div style=\"page-break-after: always\"></div>

Table 43: Participants with Grade 3-5 adverse events by decreasing incidence of preferred term (incidence ≥1% in one or more treatment groups) (APaT population)

|                                     | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   | KN091Data for Placcbo   | KN091Data for Placcbo   | Reference Safety Dataset for Pembrolizumabi   | Reference Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   |
|-------------------------------------|--------------------------------|--------------------------------|-------------------------|-------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                     |                                | (%)                            |                         | (%)                     |                                               | (%)                                           |                                                        | (%)                                                    |
| Participantsinpopulation            | 580                            |                                | 581                     |                         | 6,185                                         |                                               | 10,997                                                 |                                                        |
| with one ormore adverseevents       | 198                            | (34.1)                         | 150                     | (25.8)                  | 2,984                                         | (48.2)                                        | 5,178                                                  | (47.1)                                                 |
| with noadverse cvents               | 382                            | (65.9)                         | 431                     | (74.2)                  | 3,201                                         | (51.8)                                        | 5,819                                                  | (52.9)                                                 |
| Hypertension                        | 35                             | (6.0)                          | 32                      | (5.5)                   | 113                                           | (1.8)                                         | 210                                                    | (1.9)                                                  |
| Pneumonia                           | 12                             | (2.1)                          | 7                       | (1.2)                   | 255                                           | (4.1)                                         | 379                                                    | (3.4)                                                  |
| Dyspnoea                            | 8                              | (1.4)                          | 7                       | (1.2)                   | 133                                           | (2.2)                                         | 201                                                    | (1.8)                                                  |
| Hyponatraemia                       | 8                              | (1.4)                          | 6                       | (1.0)                   | 161                                           | (2.6)                                         | 255                                                    | (2.3)                                                  |
| Diarrhoea                           | 7                              | (1.2)                          | 2                       | (0.3)                   | 91                                            | (1.5)                                         | 160                                                    | (1.5)                                                  |
| Pneumonitis                         | 7                              | (1.2)                          | 4                       | (0.7)                   | 89                                            | (1.4)                                         | 125                                                    | (1.1)                                                  |
| Weightincreased                     | 6                              | (1.0)                          | 9                       | (1.5)                   | 11                                            | (0.2)                                         | 26                                                     | (0.2)                                                  |
| Alanine aminotransferaseincreased   | 4                              | (0.7)                          | 3                       | (0.5)                   | 67                                            | (1.1)                                         | 143                                                    | (1.3)                                                  |
| Arthralgia                          | 4                              | (0.7)                          | 1                       | (0.2)                   | 59                                            | (1.0)                                         | 87                                                     | (0.8)                                                  |
| Colitis                             | 4                              | (0.7)                          | 1                       | (0.2)                   | 64                                            | (1.0)                                         | 106                                                    | (1.0)                                                  |
| Hypokalaemia                        | 4                              | (0.7)                          | 0                       | (0.0)                   | 62                                            | (1.0)                                         | 107                                                    | (1.0)                                                  |
| Urinary tract infection             | 4                              | (0.7)                          | 3                       | (0.5)                   | 74                                            | (1.2)                                         | 142                                                    | (1.3)                                                  |
| Anacmia                             | 3                              | (0.5)                          | 3                       | (0.5)                   | 247                                           | (4.0)                                         | 485                                                    | (4.4)                                                  |
| Asthenia                            | 3                              | (0.5)                          | 3                       | (0.5)                   | 61                                            | (1.0)                                         | 125                                                    | (1.1)                                                  |
| Pulmonary cmbolism                  | 3                              | (0.5)                          | 4                       | (0.7)                   | 94                                            | (1.5)                                         | 142                                                    | (1.3)                                                  |
| Acutekidneyinjury                   | 2                              | (0.3)                          | 0                       | (0.0)                   | 56                                            | (0.9)                                         | 105                                                    | (1.0)                                                  |
| Aspartate aminotransferaseincreased | 2                              | (0.3)                          | 4                       | (0.7)                   | 70                                            | (1.1)                                         | 158                                                    | (1.4)                                                  |
| Hyperglycaemia                      | 2                              | (0.3)                          | 2                       | (0.3)                   | 67                                            | (1.1)                                         | 128                                                    | (1.2)                                                  |
| Back pain                           | 1                              | (0.2)                          | 0                       | (0.0)                   | 66                                            | (1.1)                                         | 108                                                    | (1.0)                                                  |
| Blood alkalinephosphataseincreased  | 1                              | (0.2)                          | 0                       | (0.0)                   | 52                                            | (0.8)                                         | 110                                                    | (1.0)                                                  |
| Decreased appetite                  | 1                              | (0.2)                          | 1                       | (0.2)                   | 74                                            | (1.2)                                         | 130                                                    | (1.2)                                                  |
| Fatigue                             | 1                              | (0.2)                          | 3                       | (0.5)                   | 150                                           | (2.4)                                         | 241                                                    | (2.2)                                                  |
| Abdominal pain                      | 0                              | (0.0)                          | 1                       | (0.2)                   | 51                                            | (0.8)                                         | 116                                                    | (1.1)                                                  |
| Dchydration                         | 0                              | (0.0)                          | 0                       | (0.0)                   | 64                                            | (1.0)                                         | 106                                                    | (1.0)                                                  |

Pleural effusion

0

(0.0)

Every participant is counted a single time for each applicable row and column.

Aspecificadverseeventappearsonthisreport only ifitsincidenceinone ormore ofthecolumnsmeets theincidencecriterion in the report title, after rounding.

the drug are excluded.

Non-serious adverse cventsup to 30 days of last dose and serious adverse evcnts up to 9o days oflast dose are included.

For KN091, Adverse Events of Special Interest (AEOSD) up to 90 days of last dose are included.

- Includes all participants who received at least one dose of pembrolizumab in KN001Part B1, B2, B3, D, C, F1,F2, F3,KN002 (originalphase),KN006,KN010,KN012cohortsB andB2,KN013 cohort3,KN024,KN040,KN042,KN045,KN048,KN052. KN054, KN055,KN087,KN177 and KN204.

j Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, Fl, F2, F3, KN002

C1andA4,KN040,KN042,KN045,KN048,KN052,KN054,KN055,KN057,KN059cohorts1and3,KN061,KN062,

(original phasc),KN006,KN010,KN012 cohorts B ,B2,C and D, KN013 cohorts 3 and 4A,P017,KN024, KN028 cohorts B4,

KN087,KN091,KN158 cohorts E,G,TMB-H and K,KN164 cohorts A and B,KN170, KN177,KN180,KN181,KN204,

KN224, KN361,KN427, KN564, KN629 and KN716.

- PembrolizumabDatabasecutoffdateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015. KN054:03APR2020, KN716: 21JUN2021)
- PembrolizumabDatabase cutoff dateforLung(KN001-NSCLC:23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042: 04SEPT2018,KN091:20SEP2021)
- Pembrolizumab Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016,KN040: 15MAY2017, KN048: 25FEB2019, KN055:22APR2016)
- PembrolizumabDatabasecutoffdateforGastric(KN012-Gastric:26APR2016,KN059-Cohorts1and3:08AUG2018,KN061: 26OCT2017,KN062:26MAR2019)

PembrolizumabDatabasecutoffdateforcHL(KN013-Cohort3:28SEP2018,KN087:15MAR2021,KN204:16JAN2020)

PembrolizumabDatabasecutoffdateforBladder(KN012-Urothelial:01SEP2015,KN045:26OCT2017,KN052:26SEP2018,

KN057:24MAY2019,KN361:29APR2020)

PembrolizumabDatabasecutoff dateforColorectal(KN164-CohortsAandB:09SEP2019,KN177:19FEB2020)

PembrolizumabDatabasecutoffdateforPMBCL(KN013-Cohort4A:04AUG2017.KN170:07MAY2020)

PembrolizumabDatabasecutoff datefor Cervical(KN028-Cohort B4:20FEB2017,KN158-Cohort E:27JUN2019)

PembrolizumabDatabasecutoffdateforHCC(KN224:05JUN2019)

PembrolizumabDatabasecutoffdateforMCC(P017:06FEB2018)

PembrolizumabDatabase cutoff date forEsophageal(KN028:31JAN2018,KN180:30JUL2018,KN181:15OCT2018)

PembrolizumabDatabasecutoffdateforRenalCellCarcinoma(KN427CohortA:07SEP2018,KN564:14JUN2021)

PembrolizumabDatabasccutoff datefor SCLC(KN028-Cohort C1:31JUL2018,KN158-Cohort G:27JUN2019)

PembrolizumabDatabasecutoffdateforTMB-H(KN158:27JUN2019)

PembrolizumabDatabasc cutoff date for MSI-H (KN158: 05OCT2020)

PembrolizumabDatabasecutoffdateforCSCC(KN629:29JUL2020)

The  most  frequently  reported  (incidence ≥ 1%) Grade 3 to  5  drug-related  AEs  in  the  KEYNOTE-091 Pembrolizumab Dataset were pneumonitis and diarrhea. There were no Grade 3 to 5 drug-related AEs reported more frequently in the KEYNOTE-091 Pembrolizumab Dataset than in the RSD.

(0.2)

69

(1.1)

105

(1.0)

<div style=\"page-break-after: always\"></div>

Table 44: Participants with Grade 3-5 drug-related adverse events by decreasing incidence of preferred term (incidence ≥1% in one or more treatment groups) (APaT population)

|                                 | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   |   KN091 Data for Placebo | KN091 Data for Placebo   | Reference Safety Dataset for Pembrolizumabi   | Reference Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   |
|---------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                 | n1                             | (%)                            |                        1 | (%)                      | 11                                            | (%)                                           | 1                                                      | (%)                                                    |
| Participants in population      | 580                            |                                |                      581 |                          | 6,185                                         |                                               | 10,997                                                 |                                                        |
| with one or more adverse events | 88                             | (15.2)                         |                       25 | (4.3)                    | 975                                           | (15.8)                                        | 1,761                                                  | (16.0)                                                 |
| with no adverse events          | 492                            | (84.8)                         |                      556 | (95.7)                   | 5,210                                         | (84.2)                                        | 9,236                                                  | (84.0)                                                 |
| Pneumonitis                     | 7                              | (1.2)                          |                        3 | (0.5)                    | 84                                            | (1.4)                                         | 118                                                    | (1.1)                                                  |
| Diarrhoea                       | 6                              | (1.0)                          |                        1 | (0.2)                    | 60                                            | (1.0)                                         | 103                                                    | (0.9)                                                  |
| Fatigue                         | 1                              | (0.2)                          |                        3 | (0.5)                    | 66                                            | (1.1)                                         | 108                                                    | (1.0)                                                  |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

For KN091, Adverse Events of Special Interest (AEOSl) up to 90 days of last dose are included.

- ' Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, Fl, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohorts B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177 and KN204.
- Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohorts B ,B2, C and D, KN013 cohorts 3 and 4A, P017, KN024, KN028 cohorts B4, C1 and A4, KN040,KN042,KN045, KN048,KN052,KN054,KN055,KN057, KN059 cohorts 1 and3,KN061,KN062, KN087, KN091, KN158 cohorts E, G, TMB-H and K,KN164 cohorts A and B, KN170, KN177, KN180, KN181, KN204, KN224,KN361,KN427,KN564,KN629 and KN716.
- PembrolizumabDatabase cutoff datefor Melanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015, KN054:03APR2020,KN716:21JUN2021)
- Pembrolizumab Database cutoff date forLung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEPT2018,KN091: 20SEP2021)
- PembrolizumabDatabase cutoff date for HNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019, KN055: 22APR2016)
- Pembrolizumab Database cutoff date for Gastric (KN012-Gastric: 26APR2016, KN059-Cohorts 1 and 3: 08AUG2018, KN061: 260CT2017, KN062:26MAR2019)
- Pembrolizumab Database cutoff date for cHL (KN013-Cohort 3:28SEP2018,KN087:15MAR2021,KN204: 16JAN2020) PembrolizumabDatabase cutoffdateforBladder(KN012-Urothelial:01SEP2015,KN045:26OCT2017,KN052:26SEP2018, KN057: 24MAY2019,KN361:29APR2020)

Pembrolizumab Database cutoff date for Colorectal (KN164-Cohorts A and B: 09SEP2019, KN177: 19FEB2020)

PembrolizumabDatabase cutoff dateforPMBCL (KN013-Cohort 4A:04AUG2017.KN170:07MAY2020)

Pembrolizumab Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158-Cohort E: 27JUN2019)

Pembrolizumab Database cutoff date for HCC (KN224: 05JUN2019)

Pembrolizumab Database cutoff date for MCC (P017: 06FEB2018)

Pembrolizumab Database cutoff date for Esophageal (KN028: 31JAN2018, KN180: 30JUL2018, KN181: 15OCT2018)

Pembrolizumab Database cutoff date for Renal Cell Carcinoma (KN427 Cohort A: 07SEP2018, KN564: 14JUN2021)

Pembrolizumab Database cutoff date for SCLC (KN028-Cohort C1: 31JUL2018, KN158-Cohort G: 27JUN2019)

Pembrolizumab Database cutoff date for TMB-H (KN158: 27JUN2019)

PembrolizumabDatabasecutoff datefor MSI-H (KN158:05OCT2020)

Pembrolizumab Database cutoff date for CSCC (KN629: 29JUL2020)

Source: [ISS: adam-adsl; adae]

The most frequently reported (incidence ≥ 1%) Grade 3 to 5 drug-related AEs in the KEYNOTE-091 Pembrolizumab Dataset were pneumonitis and diarrhea as shown in the table below. There were no Grade 3 to 5 drug-related AEs reported more frequently in the KEYNOTE-091 Pembrolizumab Dataset than in the RSD.

AEOSIs are immune-related events and infusion-related reactions associated with pembrolizumab (showed in the next two tables).

<div style=\"page-break-after: always\"></div>

Table 45: Adverse event summary for AEOSI (APaT population)

|                                                       | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   |   KN091 Data for Placebo | KN091 Data for Placebo   | Reference Safety Dataset for Pembrolizumab'   | Reference Safety Dataset for Pembrolizumab'   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   |
|-------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                       | n                              | (%)                            |                        1 | (%)                      | 1                                             | (%)                                           |                                                        | (%)                                                    |
| Participants in population                            | 580                            |                                |                      581 |                          | 6,185                                         |                                               | 10,997                                                 |                                                        |
| with one or more adverse events                       | 226                            | (39.0)                         |                       75 | (12.9)                   | 1,577                                         | (25.5)                                        | 2,874                                                  | (26.1)                                                 |
| with no adverse event                                 | 354                            | (61.0)                         |                      506 | (87.1)                   | 4,608                                         | (74.5)                                        | 8,123                                                  | (73.9)                                                 |
| with drug-related adverse events                      | 214                            | (36.9)                         |                       53 | (9.1)                    | 1,367                                         | (22.1)                                        | 2,538                                                  | (23.1)                                                 |
| with toxicity grade 3-5 adverse events                | 46                             | (7.9)                          |                       11 | (1.9)                    | 405                                           | (6.5)                                         | 738                                                    | (6.7)                                                  |
| with toxicity grade 3-5 drug-related adverse events   | 45                             | (7.8)                          |                        9 | (1.5)                    | 351                                           | (5.7)                                         | 656                                                    | (6.0)                                                  |
| with serious adverse events                           | 47                             | (8.1)                          |                        9 | (1.5)                    | 405                                           | (6.5)                                         | 698                                                    | (6.3)                                                  |
| with serious drug-related adverse events              | 46                             | (7.9)                          |                        7 | (1.2)                    | 359                                           | (5.8)                                         | 629                                                    | (5.7)                                                  |
| who died                                              | 2                              | (0.3)                          |                        0 | (0.0)                    | 11                                            | (0.2)                                         | 24                                                     | (0.2)                                                  |
| who died due to a drug-related adverse event          | 2                              | (0.3)                          |                        0 | (0.0)                    | 11                                            | (0.2)                                         | 24                                                     | (0.2)                                                  |
| discontinued drug due to an adverse event             | 59                             | (10.2)                         |                        9 | (1.5)                    | 256                                           | (4.1)                                         | 502                                                    | (4.6)                                                  |
| discontinued drug due to a drug-related adverse event | 59                             | (10.2)                         |                        9 | (1.5)                    | 252                                           | (4.1)                                         | 497                                                    | (4.5)                                                  |
| discontinued drugduetoaserious adverseevent           | 23                             | (4.0)                          |                        3 | (0.5)                    | 172                                           | (2.8)                                         | 302                                                    | (2.7)                                                  |

discontinued drug due to a serious drug-related adverse event

* Determined by the investigator to be related to the drug.

For KN091, Adverse Events of Special Interest (AEOSl) up to 90 days of last dose are included. For allother studies, non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Includes all participants who received at least one dose of pembrolizumab in KN001Part B1, B2,B3,D,C,F1, F2,F3,KN002 (original phase),KN006,KN010, KN012 cohorts B and B2,KN013 cohort 3,KN024, KN040, KN042, KN045, KN048, KN052,KN054,KN055, KN087,KN177 and KN204.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C,F1, F2,F3, KN002 (original phase), KN006, KN010, KN012 cohorts B ,B2, C and D, KN013 cohorts 3 and 4A, P017, KN024, KN028 cohorts B4, C1 and A4, KN040, KN042, KN045, KN048,KN052,KN054,KN055, KN057, KN059 cohorts 1 and3, KN061, KN062, KN087,

KN091, KN158 cohorts E, G, TMB-H and K, KN164 cohorts A and B, KN170,KN177,KN180, KN181, KN204, KN224, KN361,KN427, KN564, KN629 and KN716.

Pembrolizumab Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015,KN054:03APR2020,KN716:21JUN2021)

Pembrolizumab Database cutoff date forLung (KN001-NSCLC: 23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:04SEPT2018,KN091: 20SEP2021)

Pembrolizumab Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016,KN040: 15MAY2017,KN048: 25FEB2019,KN055:22APR2016)

Pembrolizumab Database cutoff date for Gastric(KN012-Gastric: 26APR2016,KN059-Cohorts 1 and 3:08AUG2018,KN061: 26OCT2017,KN062:26MAR2019)

PembrolizumabDatabase cutoff datefor cHL(KN013-Cohort 3:28SEP2018,KN087: 15MAR2021,KN204:16JAN2020)

PembrolizumabDatabase cutoff dateforBladder(KN012-Urothelial:01SEP2015,KN045:26OCT2017,KN052:26SEP2018,KN057:24MAY2019,KN361:29APR2020)

Pembrolizumab Database cutoff date for Colorectal(KN164-Cohorts A and B:09SEP2019,KN177:19FEB2020)

Pembrolizumab Database cutoff date for PMBCL (KN013-Cohort 4A: 04AUG2017.KN170:07MAY2020)

PembrolizumabDatabasecutoff dateforCervical(KN028-CohortB4:20FEB2017,KN158-Cohort E:27JUN2019)

PembrolizumabDatabase cutoff datefor HCC (KN224:05JUN2019)

PembrolizumabDatabase cutoff date for MCC(P017:06FEB2018)

PembrolizumabDatabase cutoff dateforRenal Cell Carcinoma(KN427Cohort A:07SEP2018,KN564:14JUN2021)

PembrolizumabDatabase cutoff date forSCLC (KN028-Cohort C1: 31JUL2018,KN158-CohortG:27JUN2019)

Pembrolizumab Database cutoff date for TMB-H (KN158: 27JUN2019)

PembrolizumabDatabasecutoff dateforMSI-H (KN158:05OCT2020)

PembrolizumabDatabase cutoff datefor CSCC(KN629:29JUL2020)

Source:[ISS: adam-adsl; adae]

(0.5)

(2.7)

(2.7)

<div style=\"page-break-after: always\"></div>

Table 46: Exposure-adjusted adverse event of special interest summary (including multiple occurrences of events) (APaT population)

|                                                                       | Event Count and Rate (Events/100 person-months)a   | Event Count and Rate (Events/100 person-months)a   | Event Count and Rate (Events/100 person-months)a   | Event Count and Rate (Events/100 person-months)a    |
|-----------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-----------------------------------------------------|
|                                                                       | KN091 Data for Pembrolizumab                       | KN091 Data for Placebo                             | Reference Safety Dataset for Pembrolizumabi        | Cumulative Running Safety Dataset forPembrolizumabi |
| Number of subjects exposed                                            | 580                                                | 581                                                | 6185                                               | 10997                                               |
| Total exposure in person-months                                       | 5596.37                                            | 6400.56                                            | 52032.15                                           | 92405.52                                            |
| Total events (rate)                                                   |                                                    |                                                    |                                                    |                                                     |
| adverse events                                                        | 320 (5.72)                                         | 85 (1.33)                                          | 2268 (4.36)                                        | 4121 (4.46)                                         |
| drug-related adverse events                                           | 296 (5.29)                                         | 61 (0.95)                                          | 1950 (3.75)                                        | 3591 (3.89)                                         |
| toxicitygrade3-5adverse events                                        | 51 (0.91)                                          | 11 (0.17)                                          | 482 (0.93)                                         | 858 (0.93)                                          |
| toxicity grade 3-5 drug-related adverse events                        | 49 (0.88)                                          | 9 (0.14)                                           | 418 (0.80)                                         | 759 (0.82)                                          |
| serious adverse events                                                | 52 (0.93)                                          | 10 (0.16)                                          | 478 (0.92)                                         | 803 (0.87)                                          |
| serious drug-related adverse events                                   | 50 (0.89)                                          | 8 (0.12)                                           | 426 (0.82)                                         | 723 (0.78)                                          |
| adverse eventsleading to death                                        | 2 (0.04)                                           | 0 (0.00)                                           | 11 (0.02)                                          | 24 (0.03)                                           |
| drug-related adverse events leading to death                          | 2 (0.04)                                           | 0 (0.00)                                           | 11 (0.02)                                          | 24 (0.03)                                           |
| adverse eventsresulting in drug discontinuation                       | 62 (1.11)                                          | 9 (0.14)                                           | 262 (0.50)                                         | 515 (0.56)                                          |
| drug-related adverse events resulting in drug discontinuation         | 62 (1.11)                                          | 9 (0.14)                                           | 258 (0.50)                                         | 510 (0.55)                                          |
| serious adverse events resulting in drug discontinuation              | 26 (0.46)                                          | 3 (0.05)                                           | 177 (0.34)                                         | 312 (0.34)                                          |
| serious drug-related adverse events resulting in drug discontinuation | 26 (0.46)                                          | 3 (0.05)                                           | 175 (0.34)                                         | 310 (0.34)                                          |

Source: [ISS: adam-adsl; adae]

<!-- image -->

The next table shows the number of patients with AEOSI by Category and Preferred Term.

<div style=\"page-break-after: always\"></div>

Table 47: Participants with adverse events of special interest by AEOSI category and preferred term (Incidence &gt;0% in one or more treatment groups) (APaT population)

|                                                                      | KN091 Data for    | KN091 Data for    | KN091Data forPlacebo   | KN091Data forPlacebo   | Reference Safety Dataset for   | Reference Safety Dataset for   | Cumulative Running Safety Dataset forPembrolizumabi   | Cumulative Running Safety Dataset forPembrolizumabi   |
|----------------------------------------------------------------------|-------------------|-------------------|------------------------|------------------------|--------------------------------|--------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                                      | Pembrolizumab (%) | Pembrolizumab (%) |                        |                        | Pembrolizumabi n (%)           | Pembrolizumabi n (%)           | (%)                                                   | (%)                                                   |
|                                                                      | n                 |                   | n                      | (%)                    |                                |                                |                                                       |                                                       |
| Participants in population with one or more adverse events           | 580 226           | (39.0)            | 581 75                 | (12.9)                 | 6,185 1,577                    | (25.5)                         | 10,997 2,874                                          | (26.1)                                                |
| with no adverse events                                               | 354               | (61.0)            | 506                    | (87.1)                 | 4,608                          | (74.5)                         | 8,123                                                 | (73.9)                                                |
| Adrenal Insufficiency                                                | 10                | (1.7)             | 0                      | (0.0)                  | 52                             | (0.8)                          | 106                                                   | (1.0)                                                 |
| Adrenal insufficiency                                                | 10                | (1.7)             | 0                      | (0.0)                  | 47                             | (0.8)                          | 94                                                    | (0.9)                                                 |
| Addison's disease                                                    | 0                 | (0.0)             | 0                      | (0.0)                  | 2                              | (0.0)                          | 4                                                     | (0.0)                                                 |
| Adrenocortical insufficiency acute                                   | 0                 | (0.0)             | 0                      | (0.0)                  | 2                              | (0.0)                          | 2                                                     | (0.0)                                                 |
| Primary adrenal insufficiency Secondary adrenocortical insufficiency | 0 0               | (0.0) (0.0)       | 0 0                    | (0.0) (0.0)            | 0 2                            | (0.0) (0.0)                    | 2 5                                                   | (0.0) (0.0)                                           |
| Colitis                                                              | 14                | (2.4)             | 5                      | (0.9)                  | 122                            | (2.0)                          | 226                                                   | (2.1)                                                 |
| Colitis                                                              | 14                | (2.4)             | 5                      | (0.9)                  | 104                            | (1.7)                          | 192                                                   | (1.7)                                                 |
| Immune-mediated enterocolitis                                        | 1                 | (0.2)             | 0                      | (0.0)                  | 4                              | (0.1)                          | 7                                                     | (0.1)                                                 |
| Autoimmune colitis                                                   | 0                 | (0.0)             | 0                      | (0.0)                  | 4                              | (0.1)                          | 8                                                     | (0.1)                                                 |
| Colitis microscopic                                                  | 0                 | (0.0)             | 0                      | (0.0)                  | 4                              | (0.1)                          | 4                                                     | (0.0)                                                 |
| Enterocolitis                                                        | 0                 | (0.0)             | 0                      | (0.0)                  | 8                              | (0.1)                          | 17                                                    | (0.2)                                                 |
| Enterocolitis haemorrhagic                                           | 0                 | (0.0)             |                        | (0.0)                  | 0                              | (0.0)                          | 1                                                     | (0.0)                                                 |
| Encephalitis                                                         | 0                 | (0.0)             | 0 0                    | (0.0)                  | 4                              | (0.1)                          | 8                                                     | (0.1)                                                 |
| Encephalitis                                                         | 0                 | (0.0)             | 0                      | (0.0)                  | 3                              | (0.0)                          | 6                                                     | (0.1)                                                 |
| Encephalitis autoimmune                                              | 0                 | (0.0)             | 0                      | (0.0)                  | 1                              | (0.0)                          | 2                                                     | (0.0)                                                 |
| Guillain-BarreSyndrome                                               |                   |                   |                        | (0.0)                  | 4                              |                                | 8                                                     | (0.1)                                                 |
|                                                                      | 0 0               | (0.0) (0.0)       | 0 0                    | (0.0)                  | 1                              | (0.1)                          | 1                                                     | (0.0)                                                 |
| Axonal neuropathy                                                    | 0                 | (0.0)             | 0                      |                        |                                | (0.0)                          | 1                                                     |                                                       |
| Demyelinating polyneuropathy Guillain-Barre syndrome                 | 0                 | (0.0)             | 0                      | (0.0) (0.0)            | 1 2                            | (0.0) (0.0)                    | 6                                                     | (0.0) (0.1)                                           |
| Hepatitis                                                            | 10                | (1.7)             | +                      | (0.7)                  | 60                             | (1.0)                          | 121                                                   | (1.1)                                                 |
| Immune-mediated hepatitis                                            | 4                 | (0.7)             | 乙                      | (0.3)                  | 2                              | (0.0)                          | 9                                                     | (0.1)                                                 |
| Hepatitis                                                            | 3                 | (0.5)             | 1                      | (0.2)                  | 25                             | (0.4) (0.4)                    | 49                                                    | (0.4)                                                 |
| Autoimmune hepatitis                                                 | 2                 | (0.3)             | 0                      | (0.0)                  | 26                             | (0.1)                          | 52                                                    | (0.5)                                                 |
| Drug-induced liver injury                                            | 2                 | (0.3)             | 1                      | (0.2)                  | 7                              |                                | 12                                                    | (0.1)                                                 |
| Hepatitis acute                                                      | 0                 | (0.0)             | 0                      | (0.0)                  | 1                              | (0.0)                          | 1                                                     | (0.0)                                                 |
| Hyperthyroidism                                                      | 62                | (10.7)            | 17                     | (2.9)                  | 261                            | (4.2)                          | 583                                                   | (5.3)                                                 |
| Hyperthyroidism                                                      | 62                | (10.7)            | 17                     | (2.9)                  | 261                            | (4.2)                          | 583                                                   | (5.3)                                                 |
| Hypophysitis                                                         | 7                 | (1.2)             | 0                      | (0.0)                  | 38                             | (0.0)                          | 73                                                    | (0.7)                                                 |
| Hypophysitis                                                         | 6                 | (1.0)             | 0                      | (0.0)                  | 23                             | (0.4)                          | 46                                                    | (0.4)                                                 |
| Hypopituitarism                                                      |                   |                   |                        |                        |                                |                                | 25                                                    | (0.2)                                                 |
| Lymphocytic hypophysitis                                             | 1 0               | (0.2) (0.0)       | 0 0                    | (0.0) (0.0)            | 14 1                           | (0.2) (0.0)                    | 3                                                     | (0.0)                                                 |
| Hypothyroidism                                                       | 120               | (20.7)            | 27                     | (4.0)                  | 700                            | (11.3)                         | 1,321                                                 | (12.0)                                                |
| Hypothyroidism                                                       | 120 0             | (20.7)            | 27                     | (4.6)                  | 699                            | (11.3) (0.0)                   | 1,316 3                                               | (12.0) (0.0)                                          |
| Autoimmune hypothyroidism                                            |                   | (0.0)             | 0                      | (0.0)                  | 0                              |                                |                                                       |                                                       |
| Myxoedema                                                            | 0                 | (0.0)             | 0                      | (0.0)                  | 1                              | (0.0)                          | 2                                                     | (0.0)                                                 |
| Primary hypothyroidism                                               | 0                 |                   | 0                      | (0.0)                  |                                |                                |                                                       |                                                       |
|                                                                      |                   | (0.0)             |                        |                        | 1                              | (0.0)                          | 1                                                     | (0.0)                                                 |
| Infusion Reactions                                                   | 5                 | (0.9)             | 4                      | (0.7)                  | 149 63                         | (2.4)                          | 209 103                                               | (1.9) (0.9)                                           |
| Infusion related reaction Hypersensitivity                           | 3 2               | (0.5) (0.3)       | 1 3                    | (0.2) (0.5)            | 47                             | (1.0) (0.8)                    | 59                                                    | (0.5)                                                 |
| Anaphylactic reaction                                                | 0                 | (0.0)             | 0                      | (0.0) (0.0)            | 10                             | (0.2)                          | 12                                                    | (0.1)                                                 |
| Anaphylactoid reaction                                               | 0                 | (0.0)             | 0                      |                        | 1                              | (0.0)                          | 1                                                     | (0.0)                                                 |
| Cytokine release syndrome                                            | 0                 | (0.0)             | 0                      | (0.0)                  | 8                              | (0.1)                          | 9                                                     | (0.1)                                                 |
| Drug hypersensitivity                                                | 0                 | (0.0)             | 0                      | (0.0)                  | 22                             | (0.4)                          | 28                                                    | (0.3)                                                 |
| Myasthenic Syndrome                                                  | 0                 | (0.0)             | 0                      | (0.0)                  | 3                              | (0.0)                          | 9                                                     | (0.1)                                                 |
| Myasthenia gravis                                                    | 0                 | (0.0)             | 0                      | (0.0)                  | 1                              | (0.0)                          | 5                                                     | (0.0)                                                 |
| Myasthenic syndrome                                                  | 0                 | (0.0)             | 0                      | (0.0)                  | 2                              | (0.0)                          | 4                                                     | (0.0)                                                 |
| Myelitis                                                             | 0                 | (0.0)             | 0                      | (0.0)                  | 2                              | (0.0)                          | 3                                                     | (0.0)                                                 |
| Myelitis                                                             | 0                 | (0.0)             | 0                      | (0.0)                  | 1 1                            |                                | 1                                                     | (0.0)                                                 |
| Myelitis transverse                                                  | 0                 | (0.0)             | 0                      | (0.0)                  |                                | (0.0) (0.0)                    | 2                                                     | (0.0)                                                 |
| Myocarditis                                                          | 5                 | (0.9)             | 1                      | (0.2)                  | 7                              | (0.1)                          | 16                                                    | (0.1)                                                 |
| Myocarditis                                                          | 5                 | (0.9)             | 1                      | (0.2)                  |                                | (0.1)                          | 16                                                    |                                                       |
| Myositis                                                             | 1                 | (0.2)             | 0                      | (0.0)                  | 7 21                           | (0.3)                          | 49                                                    | (0.1) (0.4)                                           |
| Myopathy                                                             |                   | (0.2)             | 0                      | (0.0)                  | 4                              | (0.1)                          | 9                                                     |                                                       |
| Myositis                                                             | 1 0               | (0.0)             | 0                      | (0.0)                  | 14                             | (0.2)                          | 34                                                    | (0.1) (0.3)                                           |
| Necrotising myositis                                                 | 0                 | (0.0)             | 0                      | (0.0)                  | 1                              | (0.0)                          | 1                                                     | (0.0)                                                 |
| Polymyositis                                                         | 0                 | (0.0)             | 0                      | (0.0) (0.0)            | 0                              | (0.0)                          | 1                                                     | (0.0)                                                 |
| Rhabdomyolysis                                                       | 0                 |                   | 0                      |                        | 2                              | (0.0)                          |                                                       |                                                       |
|                                                                      |                   | (0.0)             |                        |                        |                                |                                | 5                                                     | (0.0)                                                 |

<div style=\"page-break-after: always\"></div>

|                                                   | KN091 Data for   | KN091 Data for    | KN091 Data for Placebo   | KN091 Data for Placebo   | Reference Safety Dataset for   | Reference Safety Dataset for   | Cumulative RunningSafety Dataset forPembrolizumabi   | Cumulative RunningSafety Dataset forPembrolizumabi   |
|---------------------------------------------------|------------------|-------------------|--------------------------|--------------------------|--------------------------------|--------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                   | n                | Pembrolizumab (%) | n                        | (%)                      | n                              | Pembrolizumabi (%)             | n                                                    | (%)                                                  |
| Nephritis                                         | 4                | (0.7)             | 0                        | (0.0)                    | 25                             | (0.4)                          | 55                                                   | (0.5)                                                |
| Nephritis                                         | 4                | (0.7)             | 0                        | (0.0)                    | 4                              | (0.1)                          | 21                                                   | (0.2)                                                |
| Acute kidney injury                               | 0                | (0.0)             | 0                        | (0.0)                    | 2                              | (0.0)                          | 2                                                    | (0.0)                                                |
| Autoimmune nephritis                              | 0                | (0.0)             | 0                        | (0.0)                    | 3                              | (0.0)                          | 8                                                    | (0.1)                                                |
| Glomerulonephritis                                | 0                | (0.0)             | 0                        | (0.0)                    | 1                              | (0.0)                          | 1                                                    | (0.0)                                                |
| Glomerulonephritis acute                          | 0                | (0.0)             | 0                        | (0.0)                    | 0                              | (0.0)                          | 1                                                    | (0.0)                                                |
| Glomerulonephritis membranous                     | 0                | (0.0)             | 0                        | (0.0)                    | 1                              | (0.0)                          | 1                                                    | (0.0)                                                |
| Nephrotic syndrome                                | 0                | (0.0)             | 0                        | (0.0)                    | 1                              | (0.0)                          | 2                                                    | (0.0)                                                |
| Renal failure                                     | 0                | (0.0)             | 0                        | (0.0)                    | 2                              | (0.0)                          | 2                                                    | (0.0)                                                |
| Tubulointerstitial nephritis                      | 0                | (0.0)             | 0                        | (0.0)                    | II                             | (0.2)                          | 17                                                   | (0.2)                                                |
| Pancreatitis                                      | 2                | (0.3)             | 2                        | (0.3)                    | 21                             | (0.3)                          | 41                                                   | (0.4)                                                |
| Pancreatitis                                      | 2                | (0.3)             | 2                        | (0.3)                    | 17                             | (0.3)                          | 36                                                   | (0.3)                                                |
| Autoimmune pancreatitis                           | 0                | (0.0)             | 0                        | (0.0)                    | 1                              | (0.0)                          | 1                                                    | (0.0)                                                |
| Pancreatitis acute                                | 0                | (0.0)             | 0                        | (0.0)                    | 4                              | (0.1)                          | 5                                                    | (0.0)                                                |
| Pneumonitis                                       | 40               | (6.9)             | 17                       | (2.9)                    | 288                            | (4.7)                          | 455                                                  | (4.1)                                                |
| Pneumonitis                                       | 34               | (5.9)             | 16                       | (2.8)                    | 263                            | (4.3)                          | 402                                                  | (3.7)                                                |
| Interstitial lung disease                         | 5                | (0.9)             | 1                        | (0.2)                    | 25                             | (0.4)                          | 48                                                   | (0.4)                                                |
| Immune-mediated lung disease                      | 1                | (0.2)             | 0                        | (0.0)                    | 0                              | (0.0)                          | 5                                                    | (0.0)                                                |
| Organising pneumonia                              | 0                | (0.0)             | 0                        | (0.0)                    | 3                              | (0.0)                          | 3                                                    | (0.0)                                                |
| Sarcoidosis                                       | 1                | (0.2)             | 0                        | (0.0)                    | 10                             | (0.2)                          | 22                                                   | (0.2)                                                |
| Sarcoidosis                                       | 1                | (0.2)             | 0                        | (0.0)                    | 10                             | (0.2)                          | 20                                                   | (0.2)                                                |
| Cutaneous sarcoidosis                             | 0                | (0.0)             | 0                        | (0.0)                    | 0                              | (0.0)                          | 1                                                    | (0.0)                                                |
| Pulmonary sarcoidosis                             | 0 16             | (0.0) (2.8)       | 0 4                      | (0.0)                    | 0 102                          | (0.0) (1.6)                    | 2 185                                                | (0.0) (1.7)                                          |
| Severe Skin Reactions Rash maculo-papular         | 3                | (0.5)             | 0                        | (0.7) (0.0)              | 17                             | (0.3)                          | 33                                                   | (0.3)                                                |
| Erythema multiforme                               | 2                | (0.3) (0.3)       | 1                        | (0.2)                    | 5 3                            | (0.1) (0.0)                    | 13 9                                                 | (0.1)                                                |
| Pemphigoid                                        | 2                |                   | 0                        | (0.0)                    |                                |                                | 57                                                   | (0.1)                                                |
| Rash                                              | 2                | (0.3)             | 0                        | (0.0)                    | 31                             | (0.5)                          | 4                                                    | (0.5)                                                |
| Dermatitis exfoliative generalised                | 1                | (0.2)             | 0                        | (0.0)                    | 2                              | (0.0)                          | 8                                                    | (0.0) (0.1)                                          |
| Lichen planus Pruritus                            | 1                | (0.2)             | 0                        | (0.0) (0.3)              | 5 12                           | (0.1) (0.2)                    | 20                                                   |                                                      |
| Rash erythematous                                 | 1 1              | (0.2)             | 2                        | (0.0)                    | 1                              | (0.0)                          | 2                                                    | (0.2)                                                |
|                                                   |                  | (0.2)             | 0                        |                          |                                |                                |                                                      | (0.0)                                                |
| Rash pustular                                     | 1                | (0.2)             | 0                        | (0.0)                    | 1                              | (0.0)                          | 4                                                    | (0.0)                                                |
| Stevens-Johnson syndrome                          | 1                | (0.2)             | 0                        | (0.0)                    | 3                              | (0.0)                          | 5                                                    | (0.0)                                                |
| Toxic skin eruption Dermatitis bullous            | 1                | (0.2)             | 0                        | (0.0) (0.2)              | 4 8                            | (0.1) (0.1)                    | 6 10                                                 | (0.1) (0.1)                                          |
| Dermatitis exfoliative                            | 0 0              | (0.0)             | 1                        | (0.0)                    | 5                              | (0.1)                          | 5                                                    | (0.0)                                                |
|                                                   |                  | (0.0)             | 0                        |                          | 2                              | (0.0)                          | 6                                                    | (0.1)                                                |
| Exfoliative rash                                  | 0                | (0.0)             | 0                        | (0.0)                    |                                | (0.0)                          | 2                                                    | (0.0)                                                |
| Oral lichen planus Pemphigus                      | 0 0              | (0.0)             | 0                        | (0.0)                    | 1                              | (0.0)                          | 3                                                    | (0.0)                                                |
| Pruritus genital                                  | 0                | (0.0)             | 0 0                      | (0.0) (0.0)              | 2 2                            | (0.0)                          | 2                                                    | (0.0)                                                |
| Rash pruritic                                     | 0                | (0.0) (0.0)       | 0                        | (0.0)                    | 2                              | (0.0)                          | 5                                                    | (0.0)                                                |
| Skin necrosis                                     |                  |                   |                          |                          | 2                              | (0.0)                          | 2                                                    |                                                      |
|                                                   | 0                | (0.0)             | 0                        | (0.0)                    |                                |                                |                                                      | (0.0)                                                |
| Thyroiditis                                       |                  | (1.0)             |                          |                          |                                |                                |                                                      | (0.9)                                                |
| Thyroiditis Autoimmune thyroiditis                | 6                |                   | 1                        | (0.2)                    | 60                             | (1.0)                          | 99 69                                                | (0.6)                                                |
|                                                   | 5 1              | (0.9) (0.2)       | 1 0                      | (0.2) (0.0)              | 43 16 3                        | (0.7) (0.3) (0.0)              | 27 5                                                 | (0.2) (0.0)                                          |
| Thyroid disorder Immune-mediated thyroiditis      | 1 0              | (0.2) (0.0)       | 0 0                      | (0.0)                    | 0                              |                                | 1                                                    | (0.0)                                                |
|                                                   |                  | (0.2)             |                          | (0.0) (0.0)              | 21                             | (0.0)                          | 46                                                   |                                                      |
| Type 1 Diabetes Mellitus Type 1 diabetes mellitus | 1 1              | (0.2)             | 0 0                      | (0.0)                    | 17                             | (0.3) (0.3)                    | 34                                                   | (0.4) (0.3)                                          |
| Diabetic ketoacidosis                             | 0                | (0.0)             | 0                        | (0.0)                    | 9                              | (0.1)                          | 19                                                   | (0.2)                                                |
|                                                   |                  |                   | 0                        | (0.0)                    |                                | (0.0)                          | 2                                                    | (0.0)                                                |
| Fulminant type 1 diabetes mellitus                | 0                | (0.0)             |                          | (0.0)                    | 0 23                           | (0.4)                          | 30                                                   | (0.3)                                                |
| Uveitis                                           | 0                | (0.0)             | 0                        |                          | 1                              |                                |                                                      |                                                      |
| Choriorctinitis                                   | 0                | (0.0)             | 0                        | (0.0)                    |                                | (0.0)                          | 1                                                    | (0.0)                                                |
| Iridocyclitis                                     | 0                | (0.0)             | 0                        | (0.0)                    | 4                              | (0.1)                          | 5                                                    | (0.0)                                                |
| Iritis                                            | 0                | (0.0)             | 0                        | (0.0)                    | 3                              | (0.0)                          | 5                                                    | (0.0)                                                |
| Uveitis                                           | 0                | (0.0)             | 0                        | (0.0)                    | 15                             | (0.2)                          | 20                                                   | (0.2)                                                |
| Vasculitis                                        | 1                |                   | 0                        |                          |                                | (0.0)                          |                                                      |                                                      |
|                                                   |                  | (0.2)             |                          | (0.0)                    | 2                              |                                | 7                                                    | (0.1)                                                |
| Giant cell arteritis                              | 1                | (0.2)             | 0                        | (0.0)                    | 0                              | (0.0)                          | 3                                                    | (0.0)                                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source:[ISS: adam-adsl; adae]

At the IA3, one additional patient with hepatitis and one additional patient with arthritis classified as AEOSI have been reported.

## Serious adverse event/deaths/other significant events

## SAEs

The most frequently reported SAEs in the KEYNOTE-091 Dataset were pneumonia, pneumonitis, and diarrhoea, as shown in the next table.

<div style=\"page-break-after: always\"></div>

Table 48: Participants with serious adverse events by decreasing incidence of preferred term (incidence ≥1% in one or more treatment groups) (APaT population)

|                                 | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   | KN091 Data for Placebo   | KN091 Data for Placebo   | Reference Safety Dataset for Pembrolizumabi   | Reference Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   |
|---------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                 | 1n                             | (%)                            |                          | (%)                      | n                                             | (%)                                           | n                                                      | (%)                                                    |
| Participants in population      | 580                            |                                | 581                      |                          | 6,185                                         |                                               | 10,997                                                 |                                                        |
| with one or more adverse events | 142                            | (24.5)                         | 90                       | (15.5)                   | 2,371                                         | (38.3)                                        | 3,984                                                  | (36.2)                                                 |
| with no adverse events          | 438                            | (75.5)                         | 491                      | (84.5)                   | 3,814                                         | (61.7)                                        | 7,013                                                  | (63.8)                                                 |
| Pneumonia                       | 13                             | (2.2)                          | 9                        | (1.5)                    | 257                                           | (4.2)                                         | 376                                                    | (3.4)                                                  |
| Pneumonitis                     | 12                             | (2.1)                          | 4                        | (0.7)                    | 126                                           | (2.0)                                         | 180                                                    | (1.6)                                                  |
| Diarrhoea                       | 7                              | (1.2)                          | 1                        | (0.2)                    | 63                                            | (1.0)                                         | 102                                                    | (0.9)                                                  |
| Colitis                         | 4                              | (0.7)                          | 2                        | (0.3)                    | 61                                            | (1.0)                                         | 98                                                     | (0.9)                                                  |
| Dyspnoea                        | 4                              | (0.7)                          | 4                        | (0.7)                    | 82                                            | (1.3)                                         | 109                                                    | (1.0)                                                  |
| Pulmonary embolism              | 3                              | (0.5)                          | 0                        | (0.0)                    | 72                                            | (1.2)                                         | 108                                                    | (1.0)                                                  |
| Urinary tract infection         | 3                              | (0.5)                          | 2                        | (0.3)                    | 59                                            | (1.0)                                         | 110                                                    | (1.0)                                                  |
| Acute kidney injury             | 2                              | (0.3)                          | 0                        | (0.0)                    | 55                                            | (0.9)                                         | 114                                                    | (1.0)                                                  |
| Anaemia                         | 1                              | (0.2)                          | 0                        | (0.0)                    | 61                                            | (1.0)                                         | 112                                                    | (1.0)                                                  |
| Pyrexia                         | 1                              | (0.2)                          | 3                        | (0.5)                    | 75                                            | (1.2)                                         | 108                                                    | (1.0)                                                  |
| Pleural effusion                | 0                              | (0.0)                          | 0                        | (0.0)                    | 83                                            | (1.3)                                         | 118                                                    | (1.1)                                                  |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms \"Neoplasm Progression\",\"Malignant Neoplasm Progression\" and\"Discase Progression\" not related to the drug are excluded.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. For KN091, Adverse Events of Special Interest (AEOSI) up to 90 days of last dose are included.

Includes all participants who received at least one dose ofpembrolizumab in KN001 Part B1, B2,B3,D,C,F1,F2,F3,KN002 (oniginal phase), KN006, KN010, KN012 cohorts B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177 and KN204.

j Includes allparticipants who received at least one dose ofpembrolizumab in KN001 Part B1, B2,B3, D, C,F1, F2,F3,KN002 (oniginal phase), KN006,KN010, KN012 cohorts B ,B2, C and D, KN013 cohorts 3 and 4A, P017, KN024, KN028 cohorts B4, C1andA4,KN040,KN042,KN045,KN048,KN052,KN054,KN055,KN057,KN059cohorts1and3,KN061,KN062, KN087,KN091,KN158cohortsE,G,TMB-HandK,KN164cohortsAandB,KN170,KN177,KN180,KN181,KN204, KN224, KN361, KN427, KN564, KN629 and KN716.

PembrolizumabDatabasecutoffdateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015, KN054:03APR2020,KN716:21JUN2021)

- Pembrolizumab Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEPT2018,KN091:20SEP2021)
- PembrolizumabDatabasecutoff dateforHNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019, KN055: 22APR2016)
- PembrolizumabDatabase cutoff date for Gastric(KN012-Gastric:26APR2016,KN059-Cohorts1and 3:08AUG2018,KN061: 260CT2017,KN062:26MAR2019)

PembrolizumabDatabase cutoff date for cHL (KN013-Cohort 3:28SEP2018,KN087: 15MAR2021,KN204:16JAN2020) PembrolizumabDatabase cutoff date forBladder(KN012-Urothelial:01SEP2015,KN045:26OCT2017,KN052:26SEP2018, KN057:24MAY2019,KN361:29APR2020)

PembrolizumabDatabase cutoff date forColorectal(KN164-Cohorts A and B:09SEP2019,KN177:19FEB2020)

Pembrolizumab Database cutoff date for PMBCL (KN013-Cohort 4A: 04AUG2017. KN170: 07MAY2020)

PembrolizumabDatabase cutoff dateforCervical(KN028-Cohort B4:20FEB2017,KN158-Cohort E:27JUN2019)

Pembrolizumab Database cutoff date for HCC (KN224: 05JUN2019)

PembrolizumabDatabasecutoff dateforMCC(P017:06FEB2018)

Pembrolizumab Database cutoff date for Esophageal (KN028: 31JAN2018,KN180: 30JUL2018,KN181: 15OCT2018)

Pembrolizumab Database cutoff date for Renal Cell Carcinoma (KN427 Cohort A: 07SEP2018, KN564: 14JUN2021)

PembrolizumabDatabase cutoff date for SCLC (KN028-Cohort C1: 31JUL2018,KN158-Cohort G: 27JUN2019)

Pembrolizumab Database cutoff date for TMB-H (KN158: 27JUN2019)

PembrolizumabDatabase cutoff date for MSI-H(KN158:05OCT2020)

PembrolizumabDatabase cutoff date forCSCC (KN629: 29JUL2020)

The most frequent Drug-related SAEs were (pembrolizumab vs placebo) Pneumonitis (2.1% vs 0.5%) and Diarrhoea (1.0% vs 0), in line with the frequency observed in the RDS.

## DEATHS

In the present study 11 patients died in the pembrolizumab (1.9%) vs 6 (1.0%) in placebo (RSD: n=321, 5.2%) arm. In pembrolizumab arm, most of these cases were for cardiac causes (2 Myocarditis, 1 Myocardial infarction, 1 Myocardial ischaemia, and other cardiac generic conditions). Two other patients died by sepsis and other 2 by pulmonary infections.

<div style=\"page-break-after: always\"></div>

The MAH considered 4 participants (in pembrolizumab arm) to have died due to drug-related AEs: myocarditis and cardiogenic shock in 1 participant; myocarditis and septic shock in 1 participant; and pneumonia and sudden death each in 1 participant.

Patient was with a history including (but not limited to) Sleep apnoea syndrome, Chronic obstructive pulmonary disease. From Days 40 to 46 and Days 56 to 63 (after pembrolizumab start), the participant experienced 2 separate events of lower respiratory tract infection (Grade 2), treated with antibiotics and corticosteroids. On Day 68 the participant had dyspnea and orthopnea and was hospitalized with the diagnosis respiratory tract infection (Grade 3) with bilateral interstitial pattern at the x-ray. On Day 74 a fibrobronchoscopy showed acute inflammation and infection by Stenotrophomonas maltophilia.

On Day 83 a CT showed an unspecified infiltrate and the participant was readmitted to the hospital with increased dyspnea and fever. Lab test showed increased WBC and neutrophils. On Day 88 pembrolizumab was discontinued in response to respiratory infection (last dose on Day 64). On Day 91 the participant died due to respiratory tract infection. The investigator considered respiratory tract infection not related to pembrolizumab.

Patient was with a history of atrial fibrillation and hypertension, who developed myocardial ischemia at Day 121 (after pembrolizumab start) after a total of 5 doses of pembrolizumab. The patient also developed pericardial effusion, at the same time, and the microbiological analysis revealed that the fluid was positive for Staphylococcus spp. The participant died due to myocardial ischemia on Day 121. The investigator considered myocardial ischemia not related to pembrolizumab.

Patient , according to the MAH, developed hypothyroidism. The table with his lab tests is shown below. The diagnosis of hypothyroidism was on day 43 and the start of treatment with thyroid hormone was on day 53. The patient died by sudden death after chest pain (no further information available).

Table 49: Participants With Adverse Events Resulting in Death by Decreasing Incidence of Preferred Term (ApaT Population)

10,997

(4.9)

10,455

(0.0)

(0.1)

(0.0)

(0.0)

(0.1)

(0.1)

(0.0)

(0.5)

(0.0)

(0.2)

(0.2)

(0.0)

(0.0)

(0.7)

(0.0)

(0.0)

|                                                                                   | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   | KN091 Data for Placebo   | KN091 Data for Placebo   | Reference Safety Dataset for Pembrolizumab i   | Reference Safety Dataset for Pembrolizumab i   | Cumulative Running Safety Dataset for Pembrolizumab j   | Cumulative Running Safety Dataset for Pembrolizumab j   |
|-----------------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                                                                                   | n                              | (%)                            | n                        | (%)                      | n                                              | (%)                                            | n                                                       | (%)                                                     |
| Participants in population with one or more adverse events with no adverse events | 580 11 569                     | (1.9) (98.1)                   | 581 6 575                | (1.0) (99.0)             | 6,185 321 5,864                                | (5.2) (94.8)                                   | 10,997 542 10,455                                       | (4.9) (95.1)                                            |
| Myocarditis                                                                       | 2                              | (0.3)                          | 0                        | (0.0)                    | 0                                              | (0.0)                                          | 4                                                       | (0.0)                                                   |
| Cardiac arrest                                                                    | 1                              | (0.2)                          | 0                        | (0.0)                    | 9                                              | (0.1)                                          | 15                                                      | (0.1)                                                   |
| Cardiac death                                                                     | 1                              | (0.2)                          | 0                        | (0.0)                    | 0                                              | (0.0)                                          | 1                                                       | (0.0)                                                   |
| Cardiogenic shock                                                                 | 1                              | (0.2)                          | 0                        | (0.0)                    | 0                                              | (0.0)                                          | 1                                                       | (0.0)                                                   |
| Completed suicide                                                                 | 1                              | (0.2)                          | 0                        | (0.0)                    | 3                                              | (0.0)                                          | 7                                                       | (0.1)                                                   |
| Myocardial infarction                                                             | 1                              | (0.2)                          | 1                        | (0.2)                    | 6                                              | (0.1)                                          | 9                                                       | (0.1)                                                   |
| Myocardial ischaemia                                                              | 1                              | (0.2)                          | 0                        | (0.0)                    | 0                                              | (0.0)                                          | 1                                                       | (0.0)                                                   |
| Pneumonia                                                                         | 1                              | (0.2)                          | 1                        | (0.2)                    | 37                                             | (0.6)                                          | 58                                                      | (0.5)                                                   |
| Respiratory tract infection                                                       | 1                              | (0.2)                          | 0                        | (0.0)                    | 0                                              | (0.0)                                          | 3                                                       | (0.0)                                                   |
| Sepsis                                                                            | 1                              | (0.2)                          | 0                        | (0.0)                    | 9                                              | (0.1)                                          | 19                                                      | (0.2)                                                   |
| Septic shock                                                                      | 1                              | (0.2)                          | 0                        | (0.0)                    | 10                                             | (0.2)                                          | 17                                                      | (0.2)                                                   |
| Sudden death                                                                      | 1                              | (0.2)                          | 0                        | (0.0)                    | 2                                              | (0.0)                                          | 3                                                       | (0.0)                                                   |
| Aortic aneurysm rupture                                                           | 0                              | (0.0)                          | 1                        | (0.2)                    | 0                                              | (0.0)                                          | 0                                                       | (0.0)                                                   |
| Death                                                                             | 0                              | (0.0)                          | 1                        | (0.2)                    | 44                                             | (0.7)                                          | 73                                                      | (0.7)                                                   |
| Pneumonia bacterial                                                               | 0                              | (0.0)                          | 1                        | (0.2)                    | 0                                              | (0.0)                                          | 0                                                       | (0.0)                                                   |
| Post procedural pneumonia                                                         | 0                              | (0.0)                          | 1                        | (0.2)                    | 0                                              | (0.0)                                          | 0                                                       | (0.0)                                                   |

Table 50: Participants With Drug-Related Adverse Events Resulting in Death by Decreasing Incidence of Preferred Term (APaT Population)

| KN091 Data for Pembrolizumab   | KN091 Data for Placebo   | Reference Safety Dataset for   | Cumulative Running Safety   |
|--------------------------------|--------------------------|--------------------------------|-----------------------------|

<div style=\"page-break-after: always\"></div>

10,997

(0.7)

10,923

(0.0)

(0.0)

(0.1)

(0.0)

(0.0)

|                                 |     |        |     |         | Pembrolizumab i   | Pembrolizumab i   | Dataset for Pembrolizumab j   | Dataset for Pembrolizumab j   |
|---------------------------------|-----|--------|-----|---------|-------------------|-------------------|-------------------------------|-------------------------------|
|                                 | n   | (%)    | n   | (%)     | n                 | (%)               | n                             | (%)                           |
| Participants in population      | 580 |        | 581 |         | 6,185             |                   | 10,997                        |                               |
| with one or more adverse events | 4   | (0.7)  | 0   | (0.0)   | 39                | (0.6)             | 74                            | (0.7)                         |
| with no adverse events          | 576 | (99.3) | 581 | (100.0) | 6,146             | (99.4)            | 10,923                        | (99.3)                        |
| Myocarditis                     | 2   | (0.3)  | 0   | (0.0)   | 0                 | (0.0)             | 4                             | (0.0)                         |
| Cardiogenic shock               | 1   | (0.2)  | 0   | (0.0)   | 0                 | (0.0)             | 1                             | (0.0)                         |
| Pneumonia                       | 1   | (0.2)  | 0   | (0.0)   | 3                 | (0.0)             | 7                             | (0.1)                         |
| Septic shock                    | 1   | (0.2)  | 0   | (0.0)   | 0                 | (0.0)             | 1                             | (0.0)                         |
| Sudden death                    | 1   | (0.2)  | 0   | (0.0)   | 2                 | (0.0)             | 3                             | (0.0)                         |

The AEs compared to other adjuvant setting are reported below.

Table 51: Adverse event summary (APaT population)

|                                                           | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   | KN091 Data for Placebo   | KN091 Data for Placebo   | Current Safety Dataset for Pembrolizumab in Adjuvant Setting'   | Current Safety Dataset for Pembrolizumab in Adjuvant Setting'   | Reference SafetyDataset for Pembrolizumabi   | Reference SafetyDataset for Pembrolizumabi   |
|-----------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                                           | n                              | (%)                            | n                        | (%)                      | n                                                               | (%)                                                             | n                                            | (%)                                          |
| Participants in population                                | 580                            |                                | 581                      |                          | 1,480                                                           |                                                                 | 7,631                                        |                                              |
| with one or more adverse events                           | 556                            | (95.9)                         | 529                      | (91.0)                   | 1,411                                                           | (95.3)                                                          | 7,375                                        | (96.6)                                       |
| with no adverse event                                     | 24                             | (4.1)                          | 52                       | (9.0)                    | 69                                                              | (4.7)                                                           | 256                                          | (3.4)                                        |
| with drug-related adverse events                          | 436                            | (75.2)                         | 305                      | (52.5)                   | 1,184                                                           | (80.0)                                                          | 5,462                                        | (71.6)                                       |
| with toxicity grade 3-5 adverse events                    | 198                            | (34.1)                         | 150                      | (25.8)                   | 455                                                             | (30.7)                                                          | 3,514                                        | (46.0)                                       |
| with toxicity grade 3-5 drug-related adverse events       | 88                             | (15.2)                         | 25                       | (4.3)                    | 247                                                             | (16.7)                                                          | 1,208                                        | (15.8)                                       |
| with serious adverse events                               | 142                            | (24.5)                         | 90                       | (15.5)                   | 329                                                             | (22.2)                                                          | 2,742                                        | (35.9)                                       |
| with serious drug-related adverse events                  | 68                             | (11.7)                         | 13                       | (2.2)                    | 167                                                             | (11.3)                                                          | 840                                          | (11.0)                                       |
| who died                                                  | 11                             | (1.9)                          | 6                        | (1.0)                    | 4                                                               | (0.3)                                                           | 346                                          | (4.5)                                        |
| who died due to a drug-related adverse event              | 4                              | (0.7)                          | 0                        | (0.0)                    | 0                                                               | (0.0)                                                           | 42                                           | (0.6)                                        |
| discontinued drug due to an adverse event                 | 115                            | (19.8)                         | 34                       | (5.9)                    | 258                                                             | (17.4)                                                          | 1,066                                        | (14.0)                                       |
| discontinued drug due to a drug-related adverse event     | 98                             | (16.9)                         | 20                       | (3.4)                    | 230                                                             | (15.5)                                                          | 639                                          | (8.4)                                        |
| discontinued drug due to a serious adverse event          | 49                             | (8.4)                          | 14                       | (2.4)                    | 115                                                             | (7.8)                                                           | 714                                          | (9.4)                                        |
| discontinueddrugdue to aseriousdrug-related adverse event | 34                             | (5.9)                          | 4                        | (0.7)                    | 92                                                              | (6.2)                                                           | 347                                          | (4.5)                                        |

a Determined by the investigator to be related to the drug.

MedDRA preferred terms \"Neoplasm Progression\",\"Malignant Neoplasm Progression\" and \"Disease Progression\" not rclated to the drug are excluded.

Non-serious adverse events up to30 days of last dose and serious adverse events up to90 days of last dose are included.

For KN091, Adverse Events of Special Interest(AEOSI) up to 90 days of last dose are included.

Includes all participants who received at least one dose of pembrolizumab in KN054,KN716,KN564.

jIncludes allparticipants who received atleast one dose of Pembrolizumab in KN001 Part B1, B2,B3, D, C,F1, F2,F3, KN002 (original phase), KN006,KN010,KN012 cohortB and B2,KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158, KN164, KN177, KN204, KN564 and KN716.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015,KN054: 03APR2020, KN716: 21JUN2021)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015, KN024:10JUL2017, KN042: 04SEP2018,KN091: 20SEP2021)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016,KN040: 15MAY2017,KN048: 25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3:28SEP2018,KN087: 21MAR2019,KN204:16JAN2020)

Database cutoff date for Colorectal (KN164:09SEP2019,KN177:19FEB2021, KN564:14JUN2021)

Databasecutoff date forMSI-H (KN158:05OCT2020)

## Laboratory findings

|                                                                     | KN091 Data for Pembrolizumab (N=580) n                              | KN091 Data for Pembrolizumab (N=580) n                              | KN091 Data for Placebo (N=581)                                      | KN091 Data for Placebo (N=581)                                      | ReferenceSafetyDatasetfor Pembrolizumabi (N=6185) n                 | ReferenceSafetyDatasetfor Pembrolizumabi (N=6185) n                 | CumulativeRunningSafety DatasetforPembrolizumab (N=10997)           | CumulativeRunningSafety DatasetforPembrolizumab (N=10997)           |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| LaboratoryTest                                                      |                                                                     | (%)                                                                 |                                                                     | (%)                                                                 |                                                                     | (%)                                                                 |                                                                     | (%)                                                                 |
| AlanineAminotransferaseIncreased(Alanine aminotransferaseincreased) | AlanineAminotransferaseIncreased(Alanine aminotransferaseincreased) | AlanineAminotransferaseIncreased(Alanine aminotransferaseincreased) | AlanineAminotransferaseIncreased(Alanine aminotransferaseincreased) | AlanineAminotransferaseIncreased(Alanine aminotransferaseincreased) | AlanineAminotransferaseIncreased(Alanine aminotransferaseincreased) | AlanineAminotransferaseIncreased(Alanine aminotransferaseincreased) | AlanineAminotransferaseIncreased(Alanine aminotransferaseincreased) | AlanineAminotransferaseIncreased(Alanine aminotransferaseincreased) |
| Participants with baseline and post-baseline measurements           | 578                                                                 |                                                                     | 579                                                                 |                                                                     | 5786                                                                |                                                                     | 10258                                                               |                                                                     |
| Grade 1                                                             | 133                                                                 | (23.0)                                                              | 109                                                                 | (18.8)                                                              | 1196                                                                | (20.7)                                                              | 2052                                                                | (20.0)                                                              |
| Grade 2                                                             | 20                                                                  | (3.5)                                                               | 10                                                                  | (1.7)                                                               | 156                                                                 | (2.7)                                                               | 302                                                                 | (2.9)                                                               |
| Grade 3                                                             | 15                                                                  | (2.6)                                                               | 3                                                                   | (0.5)                                                               | 148                                                                 | (2.6)                                                               | 320                                                                 | (3.1)                                                               |
| Grade 4                                                             | 4                                                                   | (0.7)                                                               | 0                                                                   | (0.0)                                                               | 24                                                                  | (0.4)                                                               | 45                                                                  | (0.4)                                                               |
| Grade 3-4                                                           | 19                                                                  | (3.3)                                                               | 3                                                                   | (0.5)                                                               | 172                                                                 | (3.0)                                                               | 365                                                                 | (3.6)                                                               |
| All Grades                                                          | 172                                                                 | (29.8)                                                              | 122                                                                 | (21.1)                                                              | 1524                                                                | (26.3)                                                              | 2719                                                                | (26.5)                                                              |
| AlbuminDecreased(Hypoalbuminemia)                                   |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |                                                                     |
| Participants with baseline and post-baseline measurements           | 575                                                                 |                                                                     | 572                                                                 |                                                                     | 5698                                                                |                                                                     | 9822                                                                |                                                                     |
| Grade 1                                                             | 100                                                                 | (17.4)                                                              | 54                                                                  | (9.4)                                                               | 1113                                                                | (19.5)                                                              | 1758                                                                | (17.9)                                                              |
| Grade 2                                                             | 15                                                                  | (2.6)                                                               | 8                                                                   | (1.4)                                                               | 787                                                                 | (13.8)                                                              | 1247                                                                | (12.7)                                                              |
| Grade 3                                                             | 2                                                                   | (0.3)                                                               | 0                                                                   | (0.0)                                                               | 86                                                                  | (1.5)                                                               | 169                                                                 | (1.7)                                                               |
| Grade 4                                                             | 0                                                                   | (0.0)                                                               | 0                                                                   | (0.0)                                                               | 0                                                                   | (0.0)                                                               | 0                                                                   | (0.0)                                                               |
| Grade 3-4                                                           | 2                                                                   | (0.3)                                                               | 0                                                                   | (0.0)                                                               | 86                                                                  | (1.5)                                                               | 169                                                                 | (1.7)                                                               |
| All Grades                                                          | 117                                                                 | (20.3)                                                              | 62                                                                  | (10.8)                                                              | 1986                                                                | (34.9)                                                              | 3174                                                                | (32.3)                                                              |
| AllkalinePhosphataseIncreased(Alkaline phosphatase increased)       | AllkalinePhosphataseIncreased(Alkaline phosphatase increased)       | AllkalinePhosphataseIncreased(Alkaline phosphatase increased)       | AllkalinePhosphataseIncreased(Alkaline phosphatase increased)       | AllkalinePhosphataseIncreased(Alkaline phosphatase increased)       | AllkalinePhosphataseIncreased(Alkaline phosphatase increased)       | AllkalinePhosphataseIncreased(Alkaline phosphatase increased)       | AllkalinePhosphataseIncreased(Alkaline phosphatase increased)       | AllkalinePhosphataseIncreased(Alkaline phosphatase increased)       |
| Participants with bascline and post-bascline measurements           | 578                                                                 |                                                                     | 579                                                                 |                                                                     | 5770                                                                |                                                                     | 10233                                                               |                                                                     |
| Grade 1                                                             | 85                                                                  | (14.7)                                                              | 86                                                                  | (14.9)                                                              | 1091                                                                | (18.9)                                                              | 1821                                                                | (17.8)                                                              |
| Grade 2                                                             | 10                                                                  | (1.7)                                                               | 4                                                                   | (0.7)                                                               | 292                                                                 | (5.1)                                                               | 531                                                                 | (5.2)                                                               |

<div style=\"page-break-after: always\"></div>

Grade 3

Grade 3-4

Grade 4

All Grades

5

0

5

100

Aspartate Aminotransferase Increased (Aspartate aminotransferase inereased)

Participants with baseline and post-baseline measurements

Grade 2

Grade 1

Grade 3

Grade 4

Grade 3-4

All Grades

Bilirubin Inereased (Blood bilirubin inereased)

Participants with baseline and post-baseline measurements

Grade 2

Grade 1

Grade 3

Grade 3-4

Grade 4

All Grades

Calcium Deereased (Hypocalcemia)

Participants with baseline and post-bascline mcasurements

Grade 2

Grade 1

Grade3

Grade 4

Grade 3-4

All Grades

Calcium Inereased (Hypercalcemia)

Participants with baseline and post-baseline measurements

Grade 2

Grade 1

Grade 3

Grade 4

Grade 3-4

All Grades

CreatinineInereased (Creatinine increased)

Participants with baseline and post-bascline measurements

Grade 2

Grade 1

Grade 3

Grade 3-4

Grade 4

All Grades

Glucose Decreased (Hypoglycemia)

Participants with baseline and post-baseline measurements

Grade 2

Grade 1

Grade 3

Grade 4

Grade 3-4

All Grades

Glucose Inereased (Hyperglycemia)

Participants with bascline and post-bascline measurements

Grade 2

(0.0)

(0.0)

(0.0)

(15.5)

(18.1)

(0.9)

(1.0)

(0.0)

(0.9)

(20.0)

(6.2)

(0.0)

(0.7)

(0.0)

(0.0)

(6.9)

(10.6)

(0.2)

(1.0)

(0.0)

(0.2)

(611)

(11.2)

(0.2)

(0.2)

(0.2)

(0.3)

(11.7)

(22.6)

(0.2)

(4.3)

(0.0)

(0.2)

(27.1)

(8.5)

(0.0)

(0.5)

(0.0)

(0.0)

(9.0)

(0.0)

(2.5)

(2.5)

(0.1)

(26.5)

(22.4)

(2.4)

(3.6)

(0.6)

(3.0)

(29.0)

(6.2)

(1.3)

(3.1)

(0.3)

(1.7)

(10.9)

(17.5)

(0.6)

(4.4)

(0.9)

(1.5)

(23.4)

(8.6)

(0.7)

(1.2)

(1.3)

(2.0)

(11.8)

(13.2)

(1.0)

(4.8)

(0.4)

(1.4)

(19.4)

(8.2)

(0.3)

(1.3)

(0.3)

(0.6)

(10.2)

(32.8)

319

6

325

2677

10248

393

2184

328

59

387

2964

10220

606

171

324

56

227

1157

10183

467

1701

61

137

76

2305

10163

110

894

61

171

110

1175

10253

569

1521

113

45

158

2248

9552

178

891

40

34

74

1143

9024

1174

2795

(3.1)

(0.1)

(3.2)

(26.2)

(21.3)

(3.2)

(3.8)

(0.6)

(3.8)

(28.9)

(5.9)

(1.7)

(3.2)

(0.5)

(2.2)

(11.3)

(16.7)

(0.6)

(4.6)

(0.7)

(1.3)

(22.6)

(8.8)

(0.6)

(1.1)

(1.1)

(1.7)

(11.6)

(14.8)

(1.1)

(5.5)

(0.4)

(1.5)

(21.9)

(9.3)

(0.4)

(1.9)

(0.4)

(0.8)

(12.0)

(31.0)

Grade 1

(0.0)

(0.9)

(0.9)

(17.3)

(23.7)

(1.7)

(2.8)

(1.0)

(2.8)

(29.3)

(5.2)

(0.3)

(2.1)

(0.7)

(1.0)

(8.3)

(12.8)

(1.4)

(0.2)

(0.0)

(0.2)

(14.4)

(12.8)

(0.2)

(0.7)

(0.0)

(0.2)

(13.7)

(23.4)

(4.3)

(0.5)

(0.5)

(0.0)

(28.2)

(8.3)

(0.0)

(0.7)

(0.2)

(0.2)

(9.2)

(0.0)

577

16

137

10

6

16

169

578

12

30

2

4

6

48

570

73

8

0

1

1

82

570

4

73

1

0

1

78

578

25

135

3

0

3

163

564

47

4

0

1

1

52

0

0

0

(0.0)

0

0

0

06

579

105

6

5

0

5

116

579

36

4

0

0

0

40

573

61

6

1

0

1

68

573

64

1

1

1

2

67

579

25

131

1

0

1

157

556

47

3

0

0

0

50

0

0

0

(0.0)

3

144

147

1530

5782

208

1295

139

33

172

1675

5761

177

356

77

19

96

629

5766

253

1009

34

54

88

1350

5760

68

496

41

113

72

677

5792

280

762

59

83

24

1125

5175

69

424

15

33

18

526

5193

654

(12.6)

(13.0)

|                                                           | KN091 Data for Pembrolizumab (N=580)   | KN091 Data for Pembrolizumab (N=580)   | KN091 Data for Placebo (N=581)   | KN091 Data for Placebo (N=581)   | Reference Safety Dataset for Pembrolizumabi (N=6185)   | Reference Safety Dataset for Pembrolizumabi (N=6185)   | Cumulative Running Safety DatasetforPembrolizumabi (N=10997) 1n   | Cumulative Running Safety DatasetforPembrolizumabi (N=10997) 1n   |
|-----------------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------------------------|--------------------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
| Laboratory Test                                           | n (%)                                  | n (%)                                  | (%)                              | (%)                              | n (%)                                                  | n (%)                                                  | (%)                                                               | (%)                                                               |
| Glucose Increased (Hyperglycemia)                         |                                        |                                        |                                  |                                  |                                                        |                                                        |                                                                   |                                                                   |
| Grade 3                                                   | 0                                      | (0.0)                                  | 0                                | (0.0)                            | 230                                                    | (4.4)                                                  | 407                                                               | (4.5)                                                             |
| Grade 4                                                   | 0                                      | (0.0)                                  | 0                                | (0.0)                            | 37                                                     | (0.7)                                                  | 81                                                                | (0.9)                                                             |
| Grade3-4                                                  | 0                                      | (0.0)                                  | 0                                | (0.0)                            | 267                                                    | (5.1)                                                  | 488                                                               | (5.4)                                                             |
| All Grades                                                | 0                                      | (0.0)                                  | 0                                | (0.0)                            | 2626                                                   | (50.6)                                                 | 4457                                                              | (49.4)                                                            |
| Hemoglobin Decreased (Anemia)                             |                                        |                                        |                                  |                                  |                                                        |                                                        |                                                                   |                                                                   |
| Participants with baseline and post-baseline measurements | 578                                    |                                        | 579                              |                                  | 5349                                                   |                                                        | 9899                                                              |                                                                   |
| Grade 1                                                   | 54                                     | (9.3)                                  | 40                               | (6.9)                            | 1135                                                   | (21.2)                                                 | 1919                                                              | (19.4)                                                            |
| Grade 2                                                   | 21                                     | (3.6)                                  | 16                               | (2.8)                            | 865                                                    | (16.2)                                                 | 1441                                                              | (14.6)                                                            |
| Grade 3                                                   | 5                                      | (0.9)                                  | 3                                | (0.5)                            | 333                                                    | (6.2)                                                  | 652                                                               | (6.6)                                                             |
| Grade 4                                                   | 0                                      | (0.0)                                  | 0                                | (0.0)                            | 9                                                      | (0.2)                                                  | 10                                                                | (0.1)                                                             |
| Grade 3-4                                                 | 5                                      | (0.9)                                  | 3                                | (0.5)                            | 342                                                    | (6.4)                                                  | 662                                                               | (6.7)                                                             |
| All Grades                                                | 80                                     | (13.8)                                 | 59                               | (10.2)                           | 2342                                                   | (43.8)                                                 | 4022                                                              | (40.6)                                                            |
| Leukocytes Decreased (White blood cell decreased)         |                                        |                                        |                                  |                                  |                                                        |                                                        |                                                                   |                                                                   |
| Participants with baseline and post-baseline measurements | 578                                    |                                        | 579                              |                                  | 5809                                                   |                                                        | 10326                                                             |                                                                   |
| Grade 1                                                   | 38                                     | (6.6)                                  | 35                               | (6.0)                            | 526                                                    | (9.1)                                                  | 900                                                               | (8.7)                                                             |
| Grade 2                                                   | 7                                      | (1.2)                                  | 6                                | (1.0)                            | 172                                                    | (3.0)                                                  | 304                                                               | (2.9)                                                             |
| Grade 3                                                   | 0                                      | (0.0)                                  | 2                                | (0.3)                            | 19                                                     | (0.3)                                                  | 43                                                                | (0.4)                                                             |
| Grade 4                                                   | 0                                      | (0.0)                                  | 0                                | (0.0)                            | 26                                                     | (0.4)                                                  | 43                                                                | (0.4)                                                             |
| Grade 3-4                                                 | 0                                      | (0.0)                                  | 2                                | (0.3)                            | 45                                                     | (0.8)                                                  | 86                                                                | (0.8)                                                             |

1705

<div style=\"page-break-after: always\"></div>

| All Grades                                                | 45   | (7.8)       | 43   | (7.4)       | 743    | (12.8)      | 1290    | (12.5)      |
|-----------------------------------------------------------|------|-------------|------|-------------|--------|-------------|---------|-------------|
| Lymphocytes Decreased (Lymphoeyte count decreased)        |      |             |      |             |        |             |         |             |
| Participants with baseline and post-baseline measurements | 577  |             | 577  |             | 5469   |             | 9895    |             |
| Grade 1                                                   | 73   | (12.7)      | 36   | (6.2)       | 645    | (11.8)      | 1141    | (11.5)      |
| Grade 2                                                   | 45   | (7.8)       | 33   | (5.7)       | 835    | (15.3)      | 1406    | (14.2)      |
| Grade 3                                                   | 12   | (2.1)       | 9    | (1.6)       | 462    | (8.4)       | 763     | (7.7)       |
| Grade 4                                                   | 0    | (0.0)       | 0    | (0.0)       | 95     | (1.7)       | 163     | (1.6)       |
| Grade 3-4                                                 | 12   | (2.1)       | 9    | (1.6)       | 557    | (10.2)      | 926     | (9.4)       |
| All Grades                                                | 130  | (22.5)      | 78   | (13.5)      | 2037   | (37.2)      | 3473    | (35.1)      |
| PlateletsDecreased(Platelet count decreased)              |      |             |      |             |        |             |         |             |
| Participants with baseline and post-baseline measurements | 578  |             | 579  |             | 5817   |             | 10314   |             |
| Grade 1                                                   | 57   | (9.9)       | 62   | (10.7)      | 588    | (10.1)      | 997     | (9.7)       |
| Grade 2                                                   | 1    | (0.2)       | 0    | (0.0)       | 56     | (1.0)       | 104     | (1.0)       |
| Grade 3                                                   | 0    | (0.0)       | 0    | (0.0)       | 33     | (0.6)       | 61      | (0.6)       |
| Grade 4                                                   | 0    | (0.0)       | 0    | (0.0)       | 72     | (1.2)       | 106     | (1.0)       |
| Grade 3-4                                                 | 0    | (0.0)       | 0    | (0.0)       | 105    | (1.8)       | 167     | (1.6)       |
| All Grades                                                | 58   | (10.0)      | 62   | (10.7)      | 749    | (12.9)      | 1268    | (12.3)      |
| PotassiumDecreased(Hypokalemia)                           |      |             |      |             |        |             |         |             |
| Participants with baseline and post-baseline measurements | 577  |             | 578  |             | 5772   |             | 10223   |             |
| Grade 1                                                   | 46   | (8.0)       | 41   | (7.1)       | 636    | (11.0)      | 1101    | (10.8)      |
| Grade 2                                                   | 0    | (0.0)       | 0    | (0.0)       | 0      | (0.0)       | 20      | (0.2)       |
| Grade 3                                                   | 10   | (1.7)       | 2    | (0.3)       | 108    | (1.9)       | 191     | (1.9)       |
| Grade 4                                                   | 1    | (0.2)       | 0    | (0.0)       | 29     | (0.5)       | 67      | (0.7)       |
| Grade 3-4                                                 |      | (1.9)       | 2    | (0.3)       | 137    | (2.4)       | 258     | (2.5)       |
| Potassium Increased (Hyperkalemia)                        |      |             |      |             |        |             |         |             |
| Participants with baseline and post-baseline measurements | 577  |             | 578  |             | 5772   |             | 10217   |             |
| Grade 1                                                   | 118  | (20.5)      | 113  | (9:61)      | 745    | (12.9)      | 1351    | (13.2)      |
| Grade 2                                                   | 40   | (6.9)       | 40   | (6.9)       | 243    | (4.2)       | 435     | (4.3)       |
| Grade 3                                                   | 7    | (1.2)       | 11   | (1.9)       | 70     | (1.2)       | 137     | (1.3)       |
| Grade 4                                                   | 1    | (0.2)       | 0    | (0.0)       | 42     | (0.7)       | 87      | (0.9)       |
| Grade 3-4                                                 | 8    | (1.4)       |      | (1.9)       | 112    | (1.9)       | 224     | (2.2)       |
| SodiumDecreased (Hyponatremia)                            |      |             |      |             |        |             |         |             |
| Participants with baseline and post-baseline measurements | 578  |             | 579  |             | 5807   |             | 10267   |             |
| Grade 1                                                   | 101  | (17.5)      | 101  | (17.4)      | 1603   | (27.6)      | 2542    | (24.8)      |
| Grade 2                                                   | 0    | (0.0)       | 0    | (0.0)       | 0      | (0.0)       | 1       | (0.0)       |
| Grade 3                                                   | 18   | (3.1)       | 9    | (1.6)       | 397    | (6.8)       | 670     | (6.5)       |
| Grade 4 Grade 3-4                                         | 3 21 | (0.5) (3.6) | 3 12 | (0.5) (2.1) | 88 485 | (1.5) (8.4) | 153 823 | (1.5) (8.0) |

| Laboratory Test                 | KN091 Data for Pembrolizumab (N=580) n (%)   | KN091 Data for Placebo (N=581) n (%)   | Reference Safety Dataset for Pembrolizumabi (N=6185) 1 (%)   | Cumulative Running Safety Dataset forPembrolizumabi (N=10997) (%)   |
|---------------------------------|----------------------------------------------|----------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------------|
| Sodium Decreased (Hyponatremia) |                                              |                                        |                                                              |                                                                     |
| All Grades                      | 122 (21.1)                                   | 113 (19.5)                             | 2088 (36.0)                                                  | 3366 (32.8)                                                         |

Source: [ISS: adam-adsl; adbgrd]

<!-- image -->

## Immunogenicity

The immunogenicity incidence rate of treatment emergent positive participants for pembrolizumab monotherapy as adjuvant treatment in participants with completely resected lymph node-positive stage III melanoma (KEYNOTE-054 / EORTC-1325-MG) or completely resected stages IB, II, or IIIA

<div style=\"page-break-after: always\"></div>

NSCLC (KEYNOTE-091 / EORTC-1416-LCG) is 2.8% (30 out of 1053 evaluable participants). The historical incidence rate reported after pembrolizumab monotherapy is 2.1% (27 out of 1289 evaluable participants) (see next table). Overall, treatment-emergent ADA status in KEYNOTE-091 and KEYNOTE-054 is not found to affect pembrolizumab exposures. Without any impact on exposures, ADA status is not expected to impact on safety and efficacy.

Table 52: Summary of subject immunogenicity results after pembrolizumab adjuvant treatment (200 mg pembrolizumab Q3W), in participants with completely resected lymph node-positive Stage III melanoma (KEYNOTE-054/EORTC-1325-MG) or completely resected early stage NSCLC (KEYNOTE091/EORTC-1416-LCG)

| PembrolizumabTherapy             | PembrolizumabTherapy   | PembrolizumabTherapy                | PembrolizumabTherapy              |
|----------------------------------|------------------------|-------------------------------------|-----------------------------------|
| Immunogenicitystatus             | Total                  | Melanoma KEYNOTE-054/ EORTC-1325-MG | NSCLC KEYNOTE-091/ EORTC-1416-LCG |
| Assessable participantsa         | 1057                   | 496                                 | 561                               |
| Inconclusive participantsb       | 4                      | 1                                   | 3                                 |
| Evaluable participantsc          | 1053                   | 495                                 | 558                               |
| Negatived                        | 1011 (96.0%)           | 473 (95.6%)                         | 538 (96.4%)                       |
| Non-Treatment emergent positived | 12 (1.1%)              | 5 (1.0%)                            | 7 (1.3%)                          |
| Neutralizing negative            | 9 (0.8%)               | 5 (1.0%)                            | 4 (0.7%)                          |
| Neutralizing positive            | 3 (0.3%)               | 0                                   | 3 (0.5%)                          |
| Treatment emergent positived     | 30 (2.8%)              | 17 (3.4%)                           | 13 (2.3%)                         |
| Neutralizing negative            | 30 (2.8%)              | 17 (3.4%)                           | 13 (2.3%)                         |
| Neutralizing positive            | 0                      | 0                                   | 0                                 |

a: Included are participants with at least one ADA sample available after treatment with pembrolizumab

b: Inconclusive participants are the number of participants with no positive ADA samples present and the drug concentration in the last sample above the drug tolerance level.

- c:Evaluable participants are the total number of negative and positive participants(non-treatment emergentandtreatmentemergent.

d: Denominator was total number of evaluable participants.

## Safety in special populations

## Age

The AE profile based on age (with a cutoff at 65 years) in the KEYNOTE-091 Pembrolizumab Dataset is shown in the table below.

Table 53: Adverse event summary by age category (&lt;65 , ≥65 years) (APaT population)

|                                                    | KN091DataforPembrolizumab   | KN091DataforPembrolizumab   | KN091DataforPembrolizumab   | KN091DataforPembrolizumab   | KN091Data forPlacebo   | KN091Data forPlacebo   | KN091Data forPlacebo   | KN091Data forPlacebo   | ReferenceSafetyDatasetfor Pembrolizumab'   | ReferenceSafetyDatasetfor Pembrolizumab'   | ReferenceSafetyDatasetfor Pembrolizumab'   | ReferenceSafetyDatasetfor Pembrolizumab'   | CumulativeRunningSafetyDataset forPembrolizumabi   | CumulativeRunningSafetyDataset forPembrolizumabi   | CumulativeRunningSafetyDataset forPembrolizumabi   | CumulativeRunningSafetyDataset forPembrolizumabi   |
|----------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|------------------------|------------------------|------------------------|------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                                                    | <65                         | <65                         | >=65                        | >=65                        | <65                    | <65                    |                        |                        | $9>                                        | $9>                                        | >=65                                       | >=65                                       | <65                                                | <65                                                | >=65                                               | >=65                                               |
|                                                    | 1n                          | (%)                         | 1                           | (%)                         | 1                      | (%)                    | 1                      | (%)                    | 11                                         | (%)                                        | 1                                          | (%)                                        |                                                    | (%)                                                |                                                    | (%)                                                |
| Participants in population                         | 281                         |                             | 299                         |                             | 272                    |                        | 309                    |                        | 3,587                                      |                                            | 2,598                                      |                                            | 6,233                                              |                                                    | 4,764                                              |                                                    |
| with one ormore adverse events                     | 267                         | (95.0)                      | 289                         | (96.7)                      | 250                    | (91.9)                 | 279                    | (90.3)                 | 3,469                                      | (96.7)                                     | 2,520                                      | (97.0)                                     | 5,998                                              | (96.2)                                             | 4,599                                              | (96.5)                                             |
| with no adverse event                              | 14                          | (5.0)                       | 10                          | (3.3)                       | 22                     | (8.1)                  | 30                     | (9.7)                  | 118                                        | (3.3)                                      | 78                                         | (3.0)                                      | 235                                                | (3.8)                                              | 165                                                | (3.5)                                              |
| with drug-relatedadverse events                    | 210                         | (74.7)                      | 226                         | (75.6)                      | 147                    | (54.0)                 | 158                    | (51.1)                 | 2,521                                      | (70.3)                                     | 1,845                                      | (71.0)                                     | 4,316                                              | (69.2)                                             | 3,373                                              | (70.8)                                             |
| withtoxicitygrade3-5adverseevents                  | 92                          | (32.7)                      | 106                         | (35.5)                      | 71                     | (26.1)                 | 79                     | (25.6)                 | 1,596                                      | (44.5)                                     | 1,388                                      | (53.4)                                     | 2,759                                              | (44.3)                                             | 2,419                                              | (50.8)                                             |
| with toxicitygrade 3-5drug-related adverse events  | 43                          | (15.3)                      | 45                          | (15.1)                      | 11                     | (4.0)                  | 14                     | (4.5)                  | 495                                        | (13.8)                                     | 480                                        | (18.5)                                     | 886                                                | (14.2)                                             | 875                                                | (18.4)                                             |
| withserious adverse events                         | 62                          | (22.1)                      | 80                          | (26.8)                      | 44                     | (16.2)                 | 46                     | (14.9)                 | 1,236                                      | (34.5)                                     | 1,135                                      | (43.7)                                     | 2,059                                              | (33.0)                                             | 1,925                                              | (40.4)                                             |
| withserious drug-related adverseevents             | 29                          | (10.3)                      | 39                          | (13.0)                      | 6                      | (2.2)                  | 7                      | (2.3)                  | 371                                        | (10.3)                                     | 330                                        | (12.7)                                     | 623                                                | (10.0)                                             | 604                                                | (12.7)                                             |
| who died                                           | 5                           | (1.8)                       | 6                           | (2.0)                       | 1                      | (0.4)                  | 5                      | (1.6)                  | 148                                        | (4.1)                                      | 173                                        | (6.7)                                      | 233                                                | (3.7)                                              | 309                                                | (6.5)                                              |
| whodiedduetoadrug-related adverse event            | 3                           | (1.1)                       | 1                           | (0.3)                       | 0                      | (0.0)                  | 0                      | (0.0)                  | 21                                         | (0.6)                                      | 18                                         | (0.7)                                      | 32                                                 | (0.5)                                              | 42                                                 | (0.9)                                              |
| discontinueddrug dueto an adverseevent             | 50                          | (17.8)                      | 65                          | (21.7)                      | 11                     | (4.0)                  | 23                     | (7.4)                  | 423                                        | (11.8)                                     | 409                                        | (15.7)                                     | 737                                                | (11.8)                                             | 771                                                | (16.2)                                             |
| discontinueddrug dueto a drug-related adverseevent | 43                          | (15.3)                      | 55                          | (18.4)                      | 6                      | (2.2)                  | 14                     | (4.5)                  | 228                                        | (6.4)                                      | 216                                        | (8.3)                                      | 440                                                | (7.1)                                              | 467                                                | (9.8)                                              |
| discontinueddrug dueto a serious adverse event     | 22                          | (7.8)                       | 27                          | (9.0)                       | 8                      | (2.9)                  | 6                      | (1.9)                  | 301                                        | (8.4)                                      | 297                                        | (11.4)                                     | 491                                                | (7.9)                                              | 516                                                | (10.8)                                             |

The following table shows the data about AEs in pembrolizumab and placebo arms with subcategories for patients &gt;65 years (table truncated for brevity).

<div style=\"page-break-after: always\"></div>

Table 54: Adverse event summary by age category (&lt;65, 65-74, 7584, ≥85 years) (APaT population)

|                                                       | KN091 DataforPembrolizumab   | KN091 DataforPembrolizumab   | KN091 DataforPembrolizumab   | KN091 DataforPembrolizumab   | KN091 DataforPembrolizumab   | KN091 DataforPembrolizumab   | KN091 DataforPembrolizumab   | KN091 DataforPembrolizumab   | KN091 Data forPlacebo   | KN091 Data forPlacebo   | KN091 Data forPlacebo   | KN091 Data forPlacebo   | KN091 Data forPlacebo   | KN091 Data forPlacebo   | KN091 Data forPlacebo   |
|-------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                                       | <65                          | <65                          | 65-74                        | 65-74                        | 75-84                        | 75-84                        | >=85                         | >=85                         | <65                     | <65                     | 65-74                   | 65-74                   | 75-84                   | >=85                    |                         |
|                                                       | n                            | (%)                          |                              | (%)                          | n                            | (%)                          | n                            | (%)                          | n                       | (%)                     | n                       | (%)                     | (%)                     | n (%)                   |                         |
| Participants in population                            | 281                          |                              | 245                          |                              | 51                           |                              | 3                            |                              | 272                     |                         | 243                     |                         | 64                      | 2                       |                         |
| with one or more adverse events                       | 267                          | (95.0)                       | 236                          | (96.3)                       | 50                           | (98.0)                       | 3                            | (100.0)                      | 250                     | (91.9)                  | 220                     | (90.5) 57               | (89.1)                  | 2 (100.0)               |                         |
| with no adverse event                                 | 14                           | (5.0)                        | 9                            | (3.7)                        | 1                            | (2.0)                        | 0                            | (0.0)                        | 22                      | (8.1)                   | 23                      | (9.5)                   | 7 (10.9)                | 0 (0.0)                 |                         |
| with drug-relateda adverse events                     | 210                          | (74.7)                       | 187                          | (76.3)                       | 36                           | (70.6)                       | 3                            | (100.0)                      | 147                     | (54.0)                  | 132                     | (54.3) 26               | (40.6)                  | 0 (0.0)                 |                         |
| with toxicity grade 3-5 adverse events                | 92                           | (32.7)                       | 87                           | (35.5)                       | 18                           | (35.3)                       | 1                            | (33.3)                       | 71                      | (26.1)                  | 58                      | (23.9) 20               | (31.3)                  | 1 (50.0)                |                         |
| with toxicity grade 3-5 drug-related adverse events   | 43                           | (15.3)                       | 36                           | (14.7)                       | 9                            | (17.6)                       | 0                            | (0.0)                        | 11                      | (4.0)                   | 10                      | (4.1)                   | 4 (6.3)                 | 0 (0.0)                 |                         |
| with serious adverse events                           | 62                           | (22.1)                       | 65                           | (26.5)                       | 14                           | (27.5)                       | 1                            | (33.3)                       | 44                      | (16.2)                  | 33                      | (13.6) 12               | (18.8)                  | 1 (50.0)                |                         |
| with serious drug-related adverse events              | 29                           | (10.3)                       | 33                           | (13.5)                       | 6                            | (11.8)                       | 0                            | (0.0)                        | 6                       | (2.2)                   | 6                       | (2.5)                   | 1 (1.6)                 | 0 (0.0)                 |                         |
| who died                                              | 5                            | (1.8)                        | 5                            | (2.0)                        | 1                            | (2.0)                        | 0                            | (0.0)                        | 1                       | (0.4)                   | 4                       | (1.6)                   | 1 (1.6)                 | 0 (0.0)                 |                         |
| who died dueto a drug-related adverse event           | 3                            | (1.1)                        | 1                            | (0.4)                        | 0                            | (0.0)                        | 0                            | (0.0)                        | 0                       | (0.0)                   | 0                       | (0.0)                   | 0 (0.0)                 | 0 (0.0)                 |                         |
| discontinued drug due toan adverse event              | 50                           | (17.8)                       | 48                           | (19.6)                       | 17                           | (33.3)                       | 0                            | (0.0)                        | 11                      | (4.0)                   | 17                      | 6                       | (9.4)                   | 0 (0.0)                 |                         |
| discontinued drug due to a drug-related adverse event | 43                           | (15.3)                       | 42                           | (17.1)                       | 13                           | (25.5)                       | 0                            | (0.0)                        | 6                       | (2.2)                   | 11                      | (7.0) (4.5)             | 3 (4.7)                 | 0 (0.0)                 |                         |
| discontinued drugdue toa serious adverse event        | 22                           | (7.8)                        | 22                           | (9.0)                        | 5                            | (9.8)                        | 0                            | (0.0)                        | 8                       | (2.9)                   | 5                       | (2.1) 1                 | (1.6)                   | 0 (0.0)                 |                         |

|                                                       | ReferenceSafety Dataset forPembrolizumabi   | ReferenceSafety Dataset forPembrolizumabi   | ReferenceSafety Dataset forPembrolizumabi   | ReferenceSafety Dataset forPembrolizumabi   | ReferenceSafety Dataset forPembrolizumabi   | ReferenceSafety Dataset forPembrolizumabi   | ReferenceSafety Dataset forPembrolizumabi   | ReferenceSafety Dataset forPembrolizumabi   | Cumulative Running Safety Dataset forPembrolizumabi   | Cumulative Running Safety Dataset forPembrolizumabi   | Cumulative Running Safety Dataset forPembrolizumabi   | Cumulative Running Safety Dataset forPembrolizumabi   | Cumulative Running Safety Dataset forPembrolizumabi   | Cumulative Running Safety Dataset forPembrolizumabi   | Cumulative Running Safety Dataset forPembrolizumabi   | Cumulative Running Safety Dataset forPembrolizumabi   |
|-------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                       | <65                                         | <65                                         | 65-74                                       | 65-74                                       | 75-84                                       | 75-84                                       | >=85                                        | >=85                                        | <65                                                   | <65                                                   | 65-74                                                 | 65-74                                                 | 75-84                                                 | 75-84                                                 | >=85                                                  | >=85                                                  |
|                                                       | n                                           | (%)                                         | n                                           | (%)                                         | n                                           | (%)                                         | n                                           | (%)                                         | 1n                                                    | (%)                                                   | n                                                     | (%)                                                   | n                                                     | (%)                                                   | n                                                     | (%)                                                   |
| Participants in population                            | 3,587                                       |                                             | 1,797                                       |                                             | 694                                         |                                             | 107                                         |                                             | 6,233                                                 |                                                       | 3,333                                                 |                                                       | 1,253                                                 |                                                       | 178                                                   |                                                       |
| with one or more adverse events                       | 3,469                                       | (96.7)                                      | 1,737                                       | (96.7)                                      | 677                                         | (97.6)                                      | 106                                         | (99.1)                                      | 5,998                                                 | (96.2)                                                | 3,203                                                 | (96.1)                                                | 1,221                                                 | (97.4)                                                | 175                                                   | (98.3)                                                |
| with no adverse event                                 | 118                                         | (3.3)                                       | 60                                          | (3.3)                                       | 17                                          | (2.4)                                       | 1                                           | (0.9)                                       | 235                                                   | (3.8)                                                 | 130                                                   | (3.9)                                                 | 32                                                    | (2.6)                                                 | 3                                                     | (1.7)                                                 |
| with drug-related adverse events                      | 2,521                                       | (70.3)                                      | 1,272                                       | (70.8)                                      | 491                                         | (70.7)                                      | 82                                          | (76.6)                                      | 4,316                                                 | (69.2)                                                | 2.360                                                 | (70.8)                                                | 884                                                   | (70.6)                                                | 129                                                   | (72.5)                                                |
| with toxicity grade 3-5 adverse events                | 1,596                                       | (44.5)                                      | 928                                         | (51.6)                                      | 392                                         | (56.5)                                      | 68                                          | (63.6)                                      | 2,759                                                 | (44.3)                                                | 1,629                                                 | (48.9)                                                | 688                                                   | (54.9)                                                | 102                                                   | (57.3)                                                |
| with toxicity grade 3-5 drug-related adverse events   | 495                                         | (13.8)                                      | 321                                         | (17.9)                                      | 135                                         | (19.5)                                      | 24                                          | (22.4)                                      | 886                                                   | (14.2)                                                | 596                                                   | (17.9)                                                | 241                                                   | (19.2)                                                | 38                                                    | (21.3)                                                |
| with serious adverse events                           | 1,236                                       | (34.5)                                      | 749                                         | (41.7)                                      | 329                                         | (47.4)                                      | 57                                          | (53.3)                                      | 2,059                                                 | (33.0)                                                | 1,263                                                 | (37.9)                                                | 577                                                   | (46.0)                                                | 85                                                    | (47.8)                                                |
| with serious drug-related adverse events              | 371                                         | (10.3)                                      | 223                                         | (12.4)                                      | 90                                          | (13.0)                                      | 17                                          | (15.9)                                      | 623                                                   | (10.0)                                                | 419                                                   | (12.6)                                                | 160                                                   | (12.8)                                                | 25                                                    | (14.0)                                                |
| who died                                              | 148                                         | (4.1)                                       | 106                                         | (5.9)                                       | 55                                          | (7.9)                                       | 12                                          | (11.2)                                      | 233                                                   | (3.7)                                                 | 184                                                   | (5.5)                                                 | 105                                                   | (8.4)                                                 | 20                                                    | (11.2)                                                |
| who died due to a drug-related adverse event          | 21                                          | (0.6)                                       | 12                                          | (0.7)                                       | 5                                           | (0.7)                                       | 1                                           | (0.9)                                       | 32                                                    | (0.5)                                                 | 26                                                    | (0.8)                                                 | 14                                                    | (1.1)                                                 | 2                                                     | (1.1)                                                 |
| discontinued drug due to an adverse event             | 423                                         | (11.8)                                      | 255                                         | (14.2)                                      | 138                                         | (19.9)                                      | 16                                          | (15.0)                                      | 737                                                   | (11.8)                                                | 488                                                   | (14.6)                                                | 252                                                   | (20.1)                                                | 31                                                    | (17.4)                                                |
| discontinued drug due to a drug-related adverse event | 228                                         | (6.4)                                       | 142                                         | (7.9)                                       | 67                                          | (9.7)                                       | 7                                           | (6.5)                                       | 440                                                   | (7.1)                                                 | 310                                                   | (9.3)                                                 | 142                                                   | (11.3)                                                | 15                                                    | (8.4)                                                 |
| discontinued drug due to a serious adverse event      | 301                                         | (8.4)                                       | 181                                         | (10.1)                                      | 103                                         | (14.8)                                      | 13                                          | (12.1)                                      | 491                                                   | (7.9)                                                 | 319                                                   | (9.6)                                                 | 173                                                   | (13.8)                                                | 24                                                    | (13.5)                                                |

<!-- image -->

## Gender

The next table shows the overall summary of AEs by gender in the different datasets.

Source:[ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

|                                                                | KN091 DataforPembrolizumab   | KN091 DataforPembrolizumab   | KN091 DataforPembrolizumab   | KN091 DataforPembrolizumab   | KN091 Data for Placebo   | KN091 Data for Placebo   | KN091 Data for Placebo   | KN091 Data for Placebo   | ReferenceSafetyDataset for Pembrolizumab'   | ReferenceSafetyDataset for Pembrolizumab'   | ReferenceSafetyDataset for Pembrolizumab'   | ReferenceSafetyDataset for Pembrolizumab'   | Cumulative RunningSafetyDataset for Pembrolizumab'   | Cumulative RunningSafetyDataset for Pembrolizumab'   | Cumulative RunningSafetyDataset for Pembrolizumab'   | Cumulative RunningSafetyDataset for Pembrolizumab'   |
|----------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                                | M                            | M                            | F                            | F                            | M                        | M                        |                          |                          | M                                           | M                                           |                                             |                                             | M                                                    | M                                                    |                                                      |                                                      |
|                                                                | 1                            | (%)                          | 1n                           | (%)                          | n                        | (%)                      | 1                        | (%)                      |                                             | (%)                                         | n                                           | (%)                                         | n                                                    | (%)                                                  | n                                                    | (%)                                                  |
| Participants in population                                     | 394                          |                              | 186                          |                              | 397                      |                          | 184                      |                          | 4,039                                       |                                             | 2,146                                       |                                             | 7,259                                                |                                                      | 3,738                                                |                                                      |
| with one or more adverse events                                | 374                          | (94.9)                       | 182                          | (97.8)                       | 358                      | (90.2)                   | 171                      | (92.9)                   | 3,908                                       | (96.8)                                      | 2,081                                       | (97.0)                                      | 6,964                                                | (95.9)                                               | 3,633                                                | (97.2)                                               |
| with no adverse event                                          | 20                           | (5.1)                        | 4                            | (2.2)                        | 39                       | (9.8)                    | 13                       | (7.1)                    | 131                                         | (3.2)                                       | 65                                          | (3.0)                                       | 295                                                  | (4.1)                                                | 105                                                  | (2.8)                                                |
| with drug-related adverse events                               | 295                          | (74.9)                       | 141                          | (75.8)                       | 195                      | (49.1)                   | 110                      | (59.8)                   | 2,826                                       | (70.0)                                      | 1,540                                       | (71.8)                                      | 5,008                                                | (69.0)                                               | 2,681                                                | (71.7)                                               |
| with toxicity grade 3-5 adverse events                         | 143                          | (36.3)                       | 55                           | (29.6)                       | 100                      | (25.2)                   | 50                       | (27.2)                   | 1,965                                       | (48.7)                                      | 610'1                                       | (47.5)                                      | 3,445                                                | (47.5)                                               | 1,733                                                | (46.4)                                               |
| with toxicity grade 3-5 drug-related adverse events            | 56                           | (14.2)                       | 32                           | (17.2)                       | 13                       | (3.3)                    | 12                       | (6.5)                    | 662                                         | (16.4)                                      | 313                                         | (14.6)                                      | 1,205                                                | (16.6)                                               | 556                                                  | (14.9)                                               |
| with serious adverse events                                    | 103                          | (26.1)                       | 39                           | (21.0)                       | 65                       | (16.4)                   | 25                       | (13.6)                   | 1,580                                       | (39.1)                                      | 791                                         | (36.9)                                      | 2,680                                                | (36.9)                                               | 1,304                                                | (34.9)                                               |
| with serious drug-related adverse events                       | 46                           | (11.7)                       | 22                           | (11.8)                       | 7                        | (1.8)                    | 6                        | (3.3)                    | 473                                         | (11.7)                                      | 228                                         | (10.6)                                      | 844                                                  | (11.6)                                               | 383                                                  | (10.2)                                               |
| who died                                                       | 10                           | (2.5)                        | 1                            | (0.5)                        | 5                        | (1.3)                    | 1                        | (0.5)                    | 224                                         | (5.5)                                       | 97                                          | (4.5)                                       | 395                                                  | (5.4)                                                | 147                                                  | (3.9)                                                |
| who died due to a drug-related adverse event                   | 3                            | (0.8)                        | 1                            | (0.5)                        | 0                        | (0.0)                    | 0                        | (0.0)                    | 24                                          | (0.6)                                       | 15                                          | (0.7)                                       | 50                                                   | (0.7)                                                | 24                                                   | (0.6)                                                |
| discontinued drug due to an adverse event                      | 81                           | (20.6)                       | 34                           | (18.3)                       | 22                       | (5.5)                    | 12                       | (6.5)                    | 544                                         | (13.5)                                      | 288                                         | (13.4)                                      | 110'1                                                | (13.9)                                               | 497                                                  | (13.3)                                               |
| discontinued drug due to a drug-related adverse event          | 65                           | (16.5)                       | 33                           | (17.7)                       | 12                       | (3.0)                    | 8                        | (4.3)                    | 292                                         | (7.2)                                       | 152                                         | (7.1)                                       | 601                                                  | (8.3)                                                | 306                                                  | (8.2)                                                |
| discontinued drug due to a serious adverse event               | 35                           | (8.9)                        | 14                           | (7.5)                        | 10                       | (2.5)                    | 4                        | (2.2)                    | 397                                         | (9.8)                                       | 201                                         | (9.4)                                       | 684                                                  | (9.4)                                                | 323                                                  | (8.6)                                                |
| discontinued drug due to a serious drug- related adverse event | 20                           | (5.1)                        | 14                           | (7.5)                        | 2                        | (0.5)                    | 2                        | (1.1)                    | 177                                         | (4.4)                                       | 88                                          | (4.1)                                       | 328                                                  | (4.5)                                                | 160                                                  | (4.3)                                                |

Table 55: Adverse event summary by sex (Male, Female) (APaT population)

<!-- image -->

## Race

The next table shows the overall summary of AEs by race.

<div style=\"page-break-after: always\"></div>

Table 56: Adverse event summary by race (white, other, not applicable) (APaT population)

|                                                               | KNO91 Data for Pembrolizumab   | KNO91 Data for Pembrolizumab   | KNO91 Data for Pembrolizumab   | KNO91 Data for Pembrolizumab   | KNO91 Data for Pembrolizumab   | KNO91 Data for Pembrolizumab   | KN091 Data for Placebo   | KN091 Data for Placebo   | KN091 Data for Placebo   | KN091 Data for Placebo   | KN091 Data for Placebo   | KN091 Data for Placebo   |
|---------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                               | White                          | White                          | Other                          | Other                          | Not Applicable                 | Not Applicable                 | White                    | White                    | Other                    | Other                    | Not Applicable           | Not Applicable           |
|                                                               | n                              | (%)                            | n                              | (%)                            | n                              | (%)                            | n                        | (%)                      | n                        | (%)                      | n                        | (%)                      |
| Participants in population                                    | 442                            |                                | 117                            |                                | 21                             |                                | 450                      |                          | 113                      |                          | 18                       |                          |
| with one or more adverse events                               | 422                            | (95.5)                         | 114                            | (97.4)                         | 20                             | (95.2)                         | 411                      | (91.3)                   | 100                      | (88.5)                   | 18                       | (100.0)                  |
| with no adverse event                                         | 20                             | (4.5)                          | 3                              | (2.6)                          | 1                              | (4.8)                          | 39                       | (8.7)                    | 13                       | (11.5)                   | 0                        | (0.0)                    |
| with drug-related adverse events                              | 334                            | (75.6)                         | 85                             | (72.6)                         | 17                             | (81.0)                         | 238                      | (52.9)                   | 51                       | (45.1)                   | 16                       | (88.9)                   |
| with toxicity grade 3-5 adverse events                        | 164                            | (37.1)                         | 27                             | (23.1)                         | 7                              | (33.3)                         | 131                      | (29.1)                   | 14                       | (12.4)                   | 5                        | (27.8)                   |
| with toxicity grade 3-5 drug-related adverse events           | 71                             | (16.1)                         | 15                             | (12.8)                         | 2                              | (9.5)                          | 20                       | (4.4)                    | 4                        | (3.5)                    | 1                        | (5.6)                    |
| with serious adverse events                                   | 116                            | (26.2)                         | 22                             | (18.8)                         | 4                              | (19.0)                         | 81                       | (18.0)                   | 8                        | (7.1)                    | 1                        | (5.6)                    |
| with serious drug-related adverse events                      | 54                             | (12.2)                         | 12                             | (10.3)                         | 2                              | (9.5)                          | 10                       | (2.2)                    | 3                        | (2.7)                    | 0                        | (0.0)                    |
| who died                                                      | 9                              | (2.0)                          | 2                              | (1.7)                          | 0                              | (0.0)                          | 5                        | (1.1)                    | 0                        | (0.0)                    | 1                        | (5.6)                    |
| who died due to a drug-related adverse event                  | 3                              | (0.7)                          | 1                              | (0.9)                          | 0                              | (0.0)                          | 0                        | (0.0)                    | 0                        | (0.0)                    | 0                        | (0.0)                    |
| discontinued drug due to an adverse event                     | 96                             | (21.7)                         | 14                             | (12.0)                         | 5                              | (23.8)                         | 26                       | (5.8)                    | 8                        | (7.1)                    | 0                        | (0.0)                    |
| discontinued drug dueto a drug-related adverse event          | 80                             | (18.1)                         | 14                             | (12.0)                         | 4                              | (19.0)                         | 14                       | (3.1)                    | 6                        | (5.3)                    | 0                        | (0.0)                    |
| discontinueddrug dueto a serious adverse event                | 40                             | (9.0)                          | 7                              | (6.0)                          | 2                              | (9.5)                          | 13                       | (2.9)                    | 1                        | (0.9)                    | 0                        | (0.0)                    |
| discontinued drug due to a serious drug-related adverse event | 25                             | (5.7)                          | 7                              | (6.0)                          | 2                              | (9.5)                          | 4                        | (0.9)                    | 0                        | (0.0)                    | 0                        | (0.0)                    |

|                                                              | ReferenceSafetyDataset forPembrolizumabi   | ReferenceSafetyDataset forPembrolizumabi   | ReferenceSafetyDataset forPembrolizumabi   | ReferenceSafetyDataset forPembrolizumabi   | ReferenceSafetyDataset forPembrolizumabi   | ReferenceSafetyDataset forPembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   |
|--------------------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                              | White                                      | White                                      | Other                                      | Other                                      | Not Applicable                             | Not Applicable                             | White                                                  | White                                                  | Other                                                  | Other                                                  | Not Applicable                                         | Not Applicable                                         |
|                                                              | n                                          | (%)                                        | n                                          | (%)                                        | n                                          | (%)                                        | n                                                      | (%)                                                    | n                                                      | (%)                                                    | n                                                      | (%)                                                    |
| Participants in population                                   | 4,673                                      |                                            | 921                                        |                                            | 591                                        |                                            | 8,170                                                  |                                                        | 1,996                                                  |                                                        | 831                                                    |                                                        |
| with one or more adverse events                              | 4,545                                      | (97.3)                                     | 886                                        | (96.2)                                     | 558                                        | (94.4)                                     | 7,902                                                  | (96.7)                                                 | 1,908                                                  | (95.6)                                                 | 787                                                    | (94.7)                                                 |
| with no adverse event                                        | 128                                        | (2.7)                                      | 35                                         | (3.8)                                      | 33                                         | (5.6)                                      | 268                                                    | (3.3)                                                  | 88                                                     | (4.4)                                                  | 44                                                     | (5.3)                                                  |
| with drug-related adverse events                             | 3,292                                      | (70.4)                                     | 615                                        | (66.8)                                     | 459                                        | (77.7)                                     | 5,714                                                  | (69.9)                                                 | 1,330                                                  | (66.6)                                                 | 645                                                    | (77.6)                                                 |
| with toxicity grade 3-5 adverse events                       | 2,334                                      | (49.9)                                     | 448                                        | (48.6)                                     | 202                                        | (34.2)                                     | 3,983                                                  | (48.8)                                                 | 902                                                    | (45.2)                                                 | 293                                                    | (35.3)                                                 |
| with toxicity grade 3-5 drug-related adverse events          | 736                                        | (15.8)                                     | 155                                        | (16.8)                                     | 84                                         | (14.2)                                     | 1,313                                                  | (16.1)                                                 | 329                                                    | (16.5)                                                 | 119                                                    | (14.3)                                                 |
| with serious adverse events                                  | 1,852                                      | (39.6)                                     | 361                                        | (39.2)                                     | 158                                        | (26.7)                                     | 3,066                                                  | (37.5)                                                 | 685                                                    | (34.3)                                                 | 233                                                    | (28.0)                                                 |
| with serious drug-related adverse events                     | 495                                        | (10.6)                                     | 134                                        | (14.5)                                     | 72                                         | (12.2)                                     | 860                                                    | (10.5)                                                 | 265                                                    | (13.3)                                                 | 102                                                    | (12.3)                                                 |
| who died                                                     | 255                                        | (5.5)                                      | 63                                         | (6.8)                                      | 3                                          | (0.5)                                      | 426                                                    | (5.2)                                                  | 104                                                    | (5.2)                                                  | 12                                                     | (1.4)                                                  |
| whodied due to a drug-related adverse event                  | 29                                         | (0.6)                                      | 10                                         | (1.1)                                      | 0                                          | (0.0)                                      | 49                                                     | (0.6)                                                  | 22                                                     | (1.1)                                                  | 3                                                      | (0.4)                                                  |
| discontinued drug due to an adverse event                    | 625                                        | (13.4)                                     | 129                                        | (14.0)                                     | 78                                         | (13.2)                                     | 1,136                                                  | (13.9)                                                 | 251                                                    | (12.6)                                                 | 121                                                    | (14.6)                                                 |
| discontinued drug due to a drug-related adverse event        | 306                                        | (6.5)                                      | 71                                         | (7.7)                                      | 67                                         | (11.3)                                     | 641                                                    | (7.8)                                                  | 162                                                    | (8.1)                                                  | 104                                                    | (12.5)                                                 |
| discontinued drug due to a serious adverse event             | 464                                        | (9.9)                                      | 101                                        | (0'11)                                     | 33                                         | (5.6)                                      | 763                                                    | (9.3)                                                  | 184                                                    | (9.2)                                                  | 60                                                     | (7.2)                                                  |
| discontinued drug due toa serious drug-related adverse event | 191                                        | (4.1)                                      | 50                                         | (5.4)                                      | 24                                         | (4.1)                                      | 336                                                    | (4.1)                                                  | 106                                                    | (5.3)                                                  | 46                                                     | (5.5)                                                  |

Source:[ISS: adam-adsl; adae]

<!-- image -->

## Pregnancy and lactation

There were no reports of pregnancy in KEYNOTE-091.

Pembrolizumab should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. It is not known whether pembrolizumab is secreted in human milk. Because many drugs and IgG antibodies are secreted in human milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

<div style=\"page-break-after: always\"></div>

## ECOG status

The following table shows a summary of the AEs by ECOG status.

Table 57: Adverse event summary by ECOG status category (0, 1) (APaT population)

|                                                                | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   | KN091 Data for Placebo   | KN091 Data for Placebo   | KN091 Data for Placebo       | KN091 Data for Placebo       | Reference Safety Dataset for Pembrolizumabi   | Reference Safety Dataset for Pembrolizumabi   | Reference Safety Dataset for Pembrolizumabi   | Reference Safety Dataset for Pembrolizumabi   | CumulativeRunningSafetyDataset for Pembrolizumabi   | CumulativeRunningSafetyDataset for Pembrolizumabi   | CumulativeRunningSafetyDataset for Pembrolizumabi   | CumulativeRunningSafetyDataset for Pembrolizumabi   |
|----------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|------------------------------|------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                                | [0] Normal Activity            | [0] Normal Activity            | [1] Symptoms, but ambulatory   | [1] Symptoms, but ambulatory   | [0] Normal Activity      | [0] Normal Activity      | [1] Symptoms, but ambulatory | [1] Symptoms, but ambulatory | [0] Normal Activity                           | [0] Normal Activity                           | [1] Symptoms, but ambulatory                  | [1] Symptoms, but ambulatory                  | [0] Normal Activity                                 | [0] Normal Activity                                 | [1] Symptoms, but ambulatory                        | [1] Symptoms, but ambulatory                        |
|                                                                | n                              | (%)                            | n                              | (%)                            | n                        | (%)                      | n                            | (%)                          | n                                             | (%)                                           |                                               | (%)                                           |                                                     | (%)                                                 | n                                                   | (%)                                                 |
| Participants in population                                     | 375                            |                                | 205                            |                                | 339                      |                          | 242                          |                              | 2,942                                         |                                               | 3,069                                         |                                               | 5,570                                               |                                                     | 5,110                                               |                                                     |
| with one or more adverse events                                | 358                            | (95.5)                         | 198                            | (96.6)                         | 307                      | (90.6)                   | 222                          | (91.7)                       | 2,852                                         | (96.9)                                        | 2,970                                         | (96.8)                                        | 5,363                                               | (96.3)                                              | 4,929                                               | (96.5)                                              |
| with no adverse event                                          | 17                             | (4.5)                          | 7                              | (3.4)                          | 32                       | (9.4)                    | 20                           | (8.3)                        | 90                                            | (3.1)                                         | 99                                            | (3.2)                                         | 207                                                 | (3.7)                                               | 181                                                 | (3.5)                                               |
| with drug-related adverse events                               | 282                            | (75.2)                         | 154                            | (75.1)                         | 169                      | (49.9)                   | 136                          | (56.2)                       | 2,223                                         | (75.6)                                        | 2,048                                         | (66.7)                                        | 4,148                                               | (74.5)                                              | 3,336                                               | (65.3)                                              |
| with toxicity grade 3-5 adverse events                         | 117                            | (31.2)                         | 81                             | (39.5)                         | 68                       | (20.1)                   | 82                           | (33.9)                       | 1,196                                         | (40.7)                                        | 1,680                                         | (54.7)                                        | 2,182                                               | (39.2)                                              | 2,815                                               | (55.1)                                              |
| with toxicity grade 3-5 drug-related adverse events            | 54                             | (14.4)                         | 34                             | (16.6)                         | 12                       | (3.5)                    | 13                           | (5.4)                        | 446                                           | (15.2)                                        | 499                                           | (16.3)                                        | 860                                                 | (15.4)                                              | 836                                                 | (16.4)                                              |
| with serious adverse events                                    | 86                             | (22.9)                         | 56                             | (27.3)                         | 43                       | (12.7)                   | 47                           | (19.4)                       | 930                                           | (31.6)                                        | 1,347                                         | (43.9)                                        | 1,634                                               | (29.3)                                              | 2,196                                               | (43.0)                                              |
| with serious drug-related adverse events                       | 46                             | (12.3)                         | 22                             | (10.7)                         | 6                        | (1.8)                    | 7                            | (2.9)                        | 336                                           | (11.4)                                        | 348                                           | (11.3)                                        | 613                                                 | (011)                                               | 574                                                 | (11.2)                                              |
| who died                                                       | 5                              | (1.3)                          | 6                              | (2.9)                          | 3                        | (0.9)                    | 3                            | (1.2)                        | 83                                            | (2.8)                                         | 222                                           | (7.2)                                         | 154                                                 | (2.8)                                               | 366                                                 | (7.2)                                               |
| who died due to a drug-related adverse event                   | 3                              | (0.8)                          | 1                              | (0.5)                          | 0                        | (0.0)                    | 0                            | (0.0)                        | 13                                            | (0.4)                                         | 26                                            | (0.8)                                         | 26                                                  | (0.5)                                               | 47                                                  | (0.9)                                               |
| discontinued drug due to an adverse event                      | 71                             | (18.9)                         | 44                             | (21.5)                         | 13                       | (3.8)                    | 21                           | (8.7)                        | 333                                           | (11.3)                                        | 470                                           | (15.3)                                        | 713                                                 | (12.8)                                              | 742                                                 | (14.5)                                              |
| discontinueddrugdue to adrug-related adverse event             | 65                             | (17.3)                         | 33                             | (16.1)                         | 9                        | (2.7)                    | 11                           | (4.5)                        | 217                                           | (7.4)                                         | 214                                           | (7.0)                                         | 519                                                 | (9.3)                                               | 358                                                 | (7.0)                                               |
| discontinued drugdue to aserious adverse event                 | 27                             | (7.2)                          | 22                             | (10.7)                         | 4                        | (1.2)                    | 10                           | (4.1)                        | 214                                           | (7.3)                                         | 363                                           | (11.8)                                        | 408                                                 | (7.3)                                               | 565                                                 | (11.1)                                              |
| discontinued drug due to a serious drug- related adverse event | 21                             | (5.6)                          | 13                             | (6.3)                          | 1                        | (0.3)                    | 3                            | (1.2)                        | 118                                           | (4.0)                                         | 140                                           | (4.6)                                         | 247                                                 | (4.4)                                               | 227                                                 | (4.4)                                               |

a Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

For KN091, Adverse Events of Special Interest(AEOSI) up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Grades are based on NCI CTCAE version 4.03.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2,B3, D, C, F1, F2,F3, KN002 (original phase), KN006, KN010, KN012 cohorts B and B2,KN013 cohort 3,KN024, KN040, KN042, KN045,KN048, KN052,KN054,KN055,KN087,KN177 and KN204.

jIncludes all participants who received at least one dose of pembrolizumab in KN001 Part B1,B2, B3,D, C,F1,F2,F3, KN002 (original phase),KN006, KN010, KN012 cohorts B ,B2, C and D, KN013 cohorts 3 and 4A, P017, KN024, KN028 cohorts B4, C1 and A4, KN040, KN042, KN045, KN048, KN052, KN054,KN055, KN057,KN059 cohorts 1 and 3, KN061, KN062, KN087,

KN091, KN158 cohorts E, G, TMB-H and K, KN164 cohorts A and B, KN170, KN177, KN180, KN181, KN204, KN224, KN361, KN427, KN564, KN629 and KN716.

Pembrolizumab Database cutoff date forMelanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015,KN054:03APR2020,KN716: 21JUN2021)

Pembrolizumab Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016,KN040: 15MAY2017,KN048: 25FEB2019,KN055: 22APR2016)

PembrolizumabDatabase cutoff date forGastric(KN012-Gastric:26APR2016,KN059-Cohorts1and 3:08AUG2018,KN061:26OCT2017,KN062:26MAR2019)

PembrolizumabDatabase cutoff date forcHL(KN013-Cohort 3:28SEP2018,KN087:15MAR2021,KN204:16JAN2020)

Pembrolizumab Database cutoff date for Bladder(KN012-Urothelial:01SEP2015,KN045:26OCT2017,KN052:26SEP2018,KN057: 24MAY2019,KN361: 29APR2020)

PembrolizumabDatabase cutoff date for Colorectal(KN164-CohortsA and B:09SEP2019,KN177:19FEB2020)

PembrolizumabDatabase cutoff date forPMBCL (KN013-Cohort 4A:04AUG2017.KN170:07MAY2020)

Pembrolizumab Database cutoff date for Cervical(KN028-Cohort B4:20FEB2017,KN158-Cohort E:27JUN2019)

PembrolizumabDatabasecutoff date forHCC(KN224:05JUN2019)

PembrolizumabDatabase cutoff date for MCC (P017:06FEB2018)

Pembrolizumab Database cutoff date for Esophageal (KN028: 31JAN2018, KN180: 30JUL2018,KN181: 15OCT2018)

PembrolizumabDatabase cutoff date for RenalCell Carcinoma (KN427Cohort A:07SEP2018,KN564:14JUN2021)

PembrolizumabDatabasecutoff dateforSCLC(KN028-Cohort Cl: 31JUL2018,KN158-Cohort G:27JUN2019)

PembrolizumabDatabasecutoff date for TMB-H(KN158:27JUN2019)

PembrolizumabDatabase cutoff date forMSI-H(KN158:05OCT2020)

PembrolizumabDatabase cutoff dateforCSCC(KN629:29JUL2020)

Source:[ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Geographical region

The following table shows the summary of AEs by geographical region.

Table 58: Adverse event summary by region (EU, ex-EU) (APaT population)

|                                                               | KN091Data forPembrolizumab   | KN091Data forPembrolizumab   | KN091Data forPembrolizumab   | KN091Data forPembrolizumab   | KN091 Data forPlacebo   | KN091 Data forPlacebo   | KN091 Data forPlacebo   | KN091 Data forPlacebo   | ReferenceSafetyDataset for Pembrolizumabi   | ReferenceSafetyDataset for Pembrolizumabi   | ReferenceSafetyDataset for Pembrolizumabi   | ReferenceSafetyDataset for Pembrolizumabi   | Cumulative RunningSafetyDataset forPembrolizumabi   | Cumulative RunningSafetyDataset forPembrolizumabi   | Cumulative RunningSafetyDataset forPembrolizumabi   | Cumulative RunningSafetyDataset forPembrolizumabi   |
|---------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                               |                              |                              | EU                           | EU                           | EU                      | EU                      |                         |                         | EU                                          | EU                                          | Ex-EU                                       | Ex-EU                                       | EU                                                  | EU                                                  | Ex-EU                                               | Ex-EU                                               |
|                                                               | n                            | (%)                          | n                            | (%)                          | n                       | (%)                     | n                       | (%)                     | n                                           | (%)                                         | n                                           | (%)                                         | n                                                   | (%)                                                 | n                                                   | (%)                                                 |
| Participants in population                                    | 388                          |                              | 192                          |                              | 387                     |                         | 194                     |                         | 2,217                                       |                                             | 3,968                                       |                                             | 4,209                                               |                                                     | 6,788                                               |                                                     |
| with one or more adverse events                               | 373                          | (96.1)                       | 183                          | (95.3)                       | 353                     | (91.2)                  | 176                     | (90.7)                  | 2,135                                       | (96.3)                                      | 3,854                                       | (97.1)                                      | 4,042                                               | (96.0)                                              | 6,555                                               | (96.6)                                              |
| with no adverse event                                         | 15                           | (3.9)                        | 9                            | (4.7)                        | 34                      | (8.8)                   | 18                      | (9.3)                   | 82                                          | (3.7)                                       | 114                                         | (2.9)                                       | 167                                                 | (4.0)                                               | 233                                                 | (3.4)                                               |
| with drug-related adverse events                              | 293                          | (75.5)                       | 143                          | (74.5)                       | 215                     | (55.6)                  | 90                      | (46.4)                  | 1,526                                       | (68.8)                                      | 2,840                                       | (71.6)                                      | 2,920                                               | (69.4)                                              | 4,769                                               | (70.3)                                              |
| with toxicitygrade3-5adverse events                           | 147                          | (37.9)                       | 51                           | (26.6)                       | 118                     | (30.5)                  | 32                      | (16.5)                  | 1,022                                       | (46.1)                                      | 1,962                                       | (49.4)                                      | 1,931                                               | (45.9)                                              | 3,247                                               | (47.8)                                              |
| with toxicity grade 3-5 drug-related adverse events           | 65                           | (16.8)                       | 23                           | (12.0)                       | 19                      | (4.9)                   | 6                       | (3.1)                   | 341                                         | (15.4)                                      | 634                                         | (16.0)                                      | 668                                                 | (15.9)                                              | 1,093                                               | (16.1)                                              |
| with serious adverse events                                   | 104                          | (26.8)                       | 38                           | (19.8)                       | 71                      | (18.3)                  | 19                      | (9.8)                   | 846                                         | (38.2)                                      | 1,525                                       | (38.4)                                      | 1,550                                               | (36.8)                                              | 2,434                                               | (35.9)                                              |
| with serious drug-related adverse events                      | 53                           | (13.7)                       | 15                           | (7.8)                        | 9                       | (2.3)                   | 4                       | (2.1)                   | 260                                         | (11.7)                                      | 441                                         | (11.1)                                      | 490                                                 | (11.6)                                              | 737                                                 | (10.9)                                              |
| who died                                                      | 7                            | (1.8)                        | 4                            | (2.1)                        | 4                       | (1.0)                   | 2                       | (1.0)                   | 113                                         | (5.1)                                       | 208                                         | (5.2)                                       | 208                                                 | (4.9)                                               | 334                                                 | (4.9)                                               |
| who died due to a drug-related adverse event                  | 3                            | (0.8)                        | 1                            | (0.5)                        | 0                       | (0.0)                   | 0                       | (0.0)                   | 11                                          | (0.5)                                       | 28                                          | (0.7)                                       | 26                                                  | (0.6)                                               | 48                                                  | (0.7)                                               |
| discontinued drug due to an adverse event                     | 92                           | (23.7)                       | 23                           | (12.0)                       | 21                      | (5.4)                   | 13                      | (6.7)                   | 287                                         | (12.9)                                      | 545                                         | (13.7)                                      | 626                                                 | (14.9)                                              | 882                                                 | (13.0)                                              |
| discontinued drug due to a drug-related adverse event         | 77                           | (19.8)                       | 21                           | (10.9)                       | 12                      | (3.1)                   | 8                       | (4.1)                   | 166                                         | (7.5)                                       | 278                                         | (7.0)                                       | 400                                                 | (9.5)                                               | 507                                                 | (7.5)                                               |
| discontinued drug due to a serious adverse event              | 38                           | (9.8)                        |                              | (5.7)                        |                         | (2.8)                   | 3                       | (1.5)                   | 205                                         | (9.2)                                       | 393                                         | (9.9)                                       | 401                                                 | (9.5)                                               | 606                                                 | (8.9)                                               |
| discontinued drug due to aserious drug- related adverse event | 25                           | (6.4)                        | 9                            | (4.7)                        | 4                       | (1.0)                   | 0                       | (0.0)                   | 98                                          | (4.4)                                       | 167                                         | (4.2)                                       | 202                                                 | (4.8)                                               | 286                                                 | (4.2)                                               |

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

For KN091, Adverse Events of Special Interest (AEOSI) up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\",\"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Grades are based on NCI CTCAE version 4.03.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3,D, C, F1,F2, F3, KN002 (original phase), KN006, KN010,KN012 cohorts B and B2, KN013 cohort 3,KN024,KN040, KN042, KN045, KN048, KN052, KN054, KN055,KN087,KN177 and KN204.

jIncludes all participants who received at least one dose of pembrolizumab in KN001 Part B1,B2,B3,D,C,F1,F2,F3,KN002 (original phase),KN006,KN010,KN012 cohorts B ,B2,C and D,

KN013 cohorts 3 and 4A, P017, KN024,KN028 cohorts B4, C1 and A4, KN040, KN042,KN045,KN048,KN052, KN054, KN055, KN057,KN059 cohorts 1 and 3,KN061, KN062, KN087,

KN091, KN158 cohorts E, G, TMB-H and K, KN164 cohorts A and B, KN170, KN177, KN180, KN181, KN204, KN224, KN361, KN427, KN564, KN629 and KN716.

PembrolizumabDatabase cutoff date forMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:03APR2020,KN716:21JUN2021)

Pembrolizumab Database cutoff date forLung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024:10JUL2017,KN042:04SEPT2018,KN091: 20SEP2021)

PembrolizumabDatabase cutoff date for HNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Pembrolizumab Database cutoff date for Gastric (KN012-Gastric: 26APR2016,KN059-Cohorts 1 and 3:08AUG2018,KN061: 26OCT2017,KN062: 26MAR2019)

PembrolizumabDatabasecutoffdate for cHL(KN013-Cohort 3:28SEP2018,KN087:15MAR2021,KN204:16JAN2020)

Pembrolizumab Database cutoff date forBladder(KN012-Urothelial:01SEP2015,KN045:26OCT2017,KN052:26SEP2018,KN057:24MAY2019,KN361:29APR2020)

Pembrolizumab Database cutoff date for Colorectal (KN164-Cohorts A and B:09SEP2019,KN177:19FEB2020)

Pembrolizumab Database cutoff date for PMBCL (KN013-Cohort 4A: 04AUG2017.KN170:07MAY2020)

PembrolizumabDatabase cutoff date for Cervical(KN028-Cohort B4:20FEB2017,KN158-Cohort E:27JUN2019)

PembrolizumabDatabase cutoff date for HCC(KN224:05JUN2019)

PembrolizumabDatabase cutoff date for MCC(P017:06FEB2018)

Pembrolizumab Database cutoff date for Esophageal (KN028: 31JAN2018,KN180: 30JUL2018, KN181: 15OCT2018)

PembrolizumabDatabase cutoff date forRenal Cell Carcinoma(KN427Cohort A:07SEP2018,KN564:14JUN2021)

PembrolizumabDatabase cutoff date forSCLC (KN028-Cohort C1: 31JUL2018,KN158-Cohort G:27JUN2019)

PembrolizumabDatabase cutoff date for TMB-H (KN158: 27JUN2019)

PembrolizumabDatabasecutoffdate forMSI-H(KN158:05OCT2020)

PembrolizumabDatabasecutoffdateforCSCC(KN629:29JUL2020)

Source:[ISS: adam-adsl; adae]

## Safety related to drug-drug interactions and other interactions

As pembrolizumab is an IgG antibody that is administered parenterally and cleared by catabolism, food and DDI are not anticipated to influence exposure. Drugs that affect the cytochrome P450 enzymes, and other metabolizing enzymes, are not expected to interfere with the metabolism of an IgG antibody. The IgG antibodies, in general, do not directly regulate the expression of cytochrome P450 enzymes, other enzymes, or transporters involved in drug elimination. Therefore, no dedicated DDI studies have been performed. No preclinical pharmacokinetic studies were conducted to assess the propensity of pembrolizumab to be a victim or perpetrator of pharmacokinetic DDIs.

Studies evaluating pharmacodynamic drug interactions with pembrolizumab have not been conducted. However, as systemic corticosteroids may be used in combination with pembrolizumab to ameliorate potential side effects, the potential for a pharmacokinetic DDI with pembrolizumab as a victim was assessed as part of the population pharmacokinetic analysis. No relationship was observed between prolonged use of systemic corticosteroids and pembrolizumab exposure. Nevertheless, given the study design, exclusion criteria, and immunomodulatory mechanism of action, the use of systemic

<div style=\"page-break-after: always\"></div>

corticosteroids (at doses greater than physiologic replacement), or other immunosuppressants before the start of pembrolizumab treatment, is not recommended. However, systemic corticosteroids, or other immunosuppressants, can be used during pembrolizumab treatment to treat immune-related adverse reactions.

## Discontinuation due to adverse events

The proportions of participants who discontinued study medication due to a drug-related AE were higher in the KEYNOTE-091 Pembrolizumab Dataset than in the RSD. The higher incidence of discontinuation of study medication due to drug-related AEs may be explained by the approximately 2fold longer duration of exposure in the KEYNOTE-091 Pembrolizumab Dataset compared with the RSD.

The number of patients who discontinued the drug due to AEs was higher in pembrolizumab than placebo (19.8% vs 5.9%) and also compared to the RSD (13.5%). Most, in both arms pembrolizumab and placebo, discontinued due to a drug-related AE (16.9% vs 3.4%). Those who discontinued due to a SAE were more frequent in pembrolizumab (8.4% vs 2.4%).

The most frequently reported AEs (incidence ≥ 5 participants) leading to treatment discontinuation in the KEYNOTE-091 Pembrolizumab Dataset were pneumonitis, diarrhoea, colitis, and hypothyroidism. Pneumonitis was reported in 3.6% of participants in the KEYNOTE-091 Pembrolizumab Dataset compared with 1.7% in the RSD. Diarrhoea was observed in 1.2% of participants in the KEYNOTE-091 Pembrolizumab Dataset compared with 0.2% in the RSD. Colitis was observed with a similar frequency in the KEYNOTE-091 Pembrolizumab Dataset and RSD.

The following table shows the most frequent causes of discontinuation (the table is truncated for brevity).

<div style=\"page-break-after: always\"></div>

Table 59: Participants with adverse events resulting in treatment discontinuation by decreasing incidence of preferred term (incidence &gt;0% in one or more treatment groups) (APaT population)

|                                      | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   | KN091 Data for Placebo   | KN091 Data for Placebo   | Reference Safety Dataset for Pembrolizumab'   | Reference Safety Dataset for Pembrolizumab'   | Cumulative Running Safety Dataset for Pembrolizumabi   | Cumulative Running Safety Dataset for Pembrolizumabi   |
|--------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                      | n                              | (%)                            | n                        | (%)                      | n                                             | (%)                                           | n                                                      | (%)                                                    |
| Participants in population           | 580                            |                                | 581                      |                          | 6,185                                         |                                               | 10,997                                                 |                                                        |
| withoneormore adverseevents          | 115                            | (19.8)                         | 34                       | (5.9)                    | 832                                           | (13.5)                                        | 1,508                                                  | (13.7)                                                 |
| with noadverse events                | 465                            | (80.2)                         | 547                      | (94.1)                   | 5,353                                         | (86.5)                                        | 9,489                                                  | (86.3)                                                 |
| Pneumonitis                          | 21                             | (3.6)                          | 4                        | (0.7)                    | 107                                           | (1.7)                                         | 159                                                    | (1.4)                                                  |
| Diarrhoea                            | 7                              | (1.2)                          | 2                        | (0.3)                    | 13                                            | (0.2)                                         | 33                                                     | (0.3)                                                  |
| Colitis                              | S                              | (0.9)                          | 1                        | (0.2)                    | 29                                            | (0.5)                                         | 55                                                     | (0.5)                                                  |
| Hypothyroidism                       | 5                              | (0.9)                          | 0                        | (0.0)                    | 2                                             | (0.0)                                         | 12                                                     | (0.1)                                                  |
| Hypophysitis                         | 4                              | (0.7)                          | 0                        | (0.0)                    | 5                                             | (0.1)                                         | 12                                                     | (0.1)                                                  |
| Interstitiallung disease             | 4                              | (0.7)                          | 1                        | (0.2)                    | 10                                            | (0.2)                                         | 22                                                     | (0.2)                                                  |
| Hepatitis                            | 3                              | (0.5)                          | 0                        | (0.0)                    | 9                                             | (0.1)                                         | 23                                                     | (0.2)                                                  |
| Immune-mediated hepatitis            | 3                              | (0.5)                          | 0                        | (0.0)                    | 2                                             | (0.0)                                         | 6                                                      | (0.1)                                                  |
| Myocarditis                          | 3                              | (0.5)                          | 1                        | (0.2)                    | 4                                             | (0.1)                                         | 10                                                     | (0.1)                                                  |
| Psoriasis                            | 3                              | (0.5)                          | 0                        | (0.0)                    | 3                                             | (0.0)                                         | 7                                                      | (0.1)                                                  |
| Adrenalinsufficiency                 | 2                              | (0.3)                          | 0                        | (0.0)                    | 4                                             | (0.1)                                         | 18                                                     | (0.2)                                                  |
| Alanine aminotransferase increased   | 2                              | (0.3)                          | 4                        | (0.7)                    | 21                                            | (0.3)                                         | 44                                                     | (0.4)                                                  |
| Anaemia                              | 2                              | (0.3)                          | 0                        | (0.0)                    | 3                                             | (0.0)                                         | 5                                                      | (0.0)                                                  |
| Aspartate aminotransferase increased | 2                              | (0.3)                          | 4                        | (0.7)                    | 20                                            | (0.3)                                         | 36                                                     | (0.3)                                                  |
| Autoimmune hepatitis                 | 2                              | (0.3)                          | 0                        | (0.0)                    | 12                                            | (0.2)                                         | 31                                                     | (0.3)                                                  |
| Dyspnoea                             | 乙                              | (0.3)                          | 1                        | (0.2)                    | 16                                            | (0.3)                                         | 20                                                     | (0.2)                                                  |
| Fatigue                              | 2                              | (0.3)                          | 2                        | (0.3)                    | 17                                            | (0.3)                                         | 22                                                     | (0.2)                                                  |
| General physicalhealthdeterioration  | 2                              | (0.3)                          | 0                        | (0.0)                    | 10                                            | (0.2)                                         | 16                                                     | (0.1)                                                  |
| Peripheral sensory neuropathy        | 2                              | (0.3)                          | 1                        | (0.2)                    | 2                                             | (0.0)                                         | 4                                                      | (0.0)                                                  |
| Polymyalgia rheumatica               | 2                              | (0.3)                          | 0                        | (0.0)                    | 1                                             | (0.0)                                         | 3                                                      | (0.0)                                                  |
| Sepsis                               | 2                              | (0.3)                          | 0                        | (0.0)                    | 8                                             | (0.1)                                         | 14                                                     | (0.1)                                                  |
| Acute kidney injury                  | 1                              | (0.2)                          | 0                        | (0.0)                    | 8                                             | (0.1)                                         | 20                                                     | (0.2)                                                  |
| Adenocarcinoma gastric               |                                | (0.2)                          | 0                        | (0.0)                    |                                               | (0.0)                                         | 2                                                      | (0.0)                                                  |
| Alopecia                             |                                | (0.2)                          | 0                        | (0.0)                    | 0                                             | (0.0)                                         | 1                                                      | (0.0)                                                  |
| Arthritis                            |                                | (0.2)                          | 0                        | (0.0)                    | 2                                             | (0.0)                                         | 9                                                      | (0.1)                                                  |
| Atypical pneumonia                   |                                | (0.2)                          | 0                        | (0.0)                    | 1                                             | (0.0)                                         | 2                                                      | (0.0)                                                  |
| Azotaemia                            |                                | (0.2)                          | 0                        | (0.0)                    | 0                                             | (0.0)                                         |                                                        | (0.0)                                                  |
| Balanoposthitis                      |                                | (0.2)                          | 0                        | (0.0)                    | 0                                             | (0.0)                                         | 1                                                      | (0.0)                                                  |
| Blood creatinine increased           |                                | (0.2)                          | 1                        | (0.2)                    | 1                                             | (0.0)                                         | 12                                                     | (0.1)                                                  |
| Cardiacfailure congestive            |                                | (0.2)                          | 0                        | (0.0)                    | 1                                             | (0.0)                                         | 2                                                      | (0.0)                                                  |
| Decreased appetite                   |                                | (0.2)                          | 0                        | (0.0)                    | 2                                             | (0.0)                                         | 5                                                      | (0.0)                                                  |
|                                      |                                |                                |                          | (0.0)                    |                                               |                                               | 4                                                      |                                                        |
| Drug-induced liver injury            |                                | (0.2)                          | 0 0                      | (0.0)                    | 0                                             | (0.0) (0.0)                                   | 1                                                      | (0.0)                                                  |
| Erysipelas Gastric cancer            | 1                              | (0.2) (0.2)                    | 0                        | (0.0)                    | 2                                             | (0.0)                                         | 3                                                      | (0.0) (0.0)                                            |
| Gastroenteritis                      |                                | (0.2)                          | 0                        | (0.0)                    | 0                                             | (0.0)                                         | 1                                                      | (0.0)                                                  |
| Giant cell arteritis                 |                                | (0.2)                          | 0                        | (0.0)                    | 0                                             | (0.0)                                         |                                                        | (0.0)                                                  |

The following table shows the AEs resulting in treatment interruption by frequency (the table is truncated for brevity).

<div style=\"page-break-after: always\"></div>

Table 60: Participants with adverse events resulting in treatment interruption by decreasing incidence of preferred term (incidence &gt;0% in one or more treatment groups) (APaT population)

|                                       | KN091 Data for Pembrolizumab   | KN091 Data for Pembrolizumab   | KN091 Data for Placebo   | KN091 Data for Placebo   | Reference Safety Dataset for Pembrolizimabi   | Reference Safety Dataset for Pembrolizimabi   | Cumulative Running Safety Dataset for Pembrolizumab'   | Cumulative Running Safety Dataset for Pembrolizumab'   |
|---------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                       | n                              | (%)                            | n                        | (%)                      | n                                             | (%)                                           | n                                                      | (%)                                                    |
| Participants in population            | 580                            |                                | 581                      |                          | 6,185                                         |                                               | 10,997                                                 |                                                        |
| with one ormore adverse events        | 221                            | (38.1)                         | 145                      | (25.0)                   | 1,596                                         | (25.8)                                        | 2,972                                                  | (27.0)                                                 |
| with no adverse events                | 359                            | (61.9)                         | 436                      | (75.0)                   | 4,589                                         | (74.2)                                        | 8,025                                                  | (73.0)                                                 |
| Hypothyroidism                        | 20                             | (3.4)                          | 1                        | (0.2)                    | 36                                            | (0.0)                                         | 81                                                     | (0.7)                                                  |
| Diarhoea                              | 19                             | (3.3)                          | 6                        | (1.0)                    | 127                                           | (2.1)                                         | 225                                                    | (2.0)                                                  |
| Pneumonitis                           | 18                             | (3.1)                          | 5                        | (0.9)                    | 91                                            | (1.5)                                         | 144                                                    | (1.3)                                                  |
| Arthralgia                            | 16                             | (2.8)                          | 3                        | (0.5)                    | 43                                            | (0.7)                                         | 98                                                     | (0.9)                                                  |
| Bronchitis                            | 10                             | (1.7)                          | 7                        | (1.2)                    | 25                                            | (0.4)                                         | 46                                                     | (0.4)                                                  |
| Upper respiratory tract infection     | 10                             | (1.7)                          | 8                        | (1.4)                    | 46                                            | (0.7)                                         | 68                                                     | (0.6)                                                  |
| Dyspnoea                              | 9                              | (1.6)                          | 6                        | (1.0)                    | 49                                            | (0.8)                                         | 84                                                     | (0.8)                                                  |
| Colitis                               | 8                              | (1.4)                          | 0                        | (0.0)                    | 37                                            | (0.0)                                         | 69                                                     | (0.6)                                                  |
| Fatigue                               | 8                              | (1.4)                          | 6                        | (1.0)                    | 58                                            | (0.9)                                         | 101                                                    | (0.9)                                                  |
| Alanine aminotransferase increased    | 7                              | (1.2)                          | 4                        | (0.7)                    | 82                                            | (1.3)                                         | 148                                                    | (1.3)                                                  |
| Aspartate aminotransferaseincreased   | 7                              | (1.2)                          | 4                        | (0.7)                    | 72                                            | (1.2)                                         | 144                                                    | (1.3)                                                  |
| Hyperthyroidism                       | 7                              | (1.2)                          | 0                        | (0.0)                    | 15                                            | (0.2)                                         | 44                                                     | (0.4)                                                  |
| Pneumonia                             | 7                              | (1.2)                          | 9                        | (1.5)                    | 101                                           | (1.0)                                         | 154                                                    | (1.4)                                                  |
| Rash                                  | 7                              | (1.2)                          | 0                        | (0.0)                    | 49                                            | (0.8)                                         | 83                                                     | (0.8)                                                  |
| Rash maculo-papular                   | 7                              | (1.2)                          | 0                        | (0.0)                    | 22                                            | (0.4)                                         | 49                                                     | (0.4)                                                  |
| Arthritis                             | 6                              | (1.0)                          | 2                        | (0.3)                    | 11                                            | (0.2)                                         | 21                                                     | (0.2)                                                  |
| Blood creatinine increased            | 6                              | (1.0)                          | 7                        | (1.2)                    | 17                                            | (0.3)                                         | 53                                                     | (0.5)                                                  |
| Influenza like illness                | 6                              | (1.0)                          | 8                        | (1.4)                    | 12                                            | (0.2)                                         | 33                                                     | (0.3)                                                  |
| Lower respiratory tract infection     | 5                              | (0.9)                          | 3                        | (0.5)                    | 9                                             | (0.1)                                         | 21                                                     | (0.2)                                                  |
| Myalgia                               | 5                              | (0.9)                          | 0                        | (0.0)                    | 13                                            | (0.2)                                         | 29                                                     | (0.3)                                                  |
| Pyrexia                               | 5                              | (0.9)                          | 6                        | (1.0)                    | 36                                            | (0.0)                                         | 71                                                     | (0.6)                                                  |
| Urinary tract infection               | 5                              | (0.9)                          | 5                        | (0.9)                    | 23                                            | (0.4)                                         | 60                                                     | (0.5)                                                  |
| Vomiting                              | 5                              | (0.9)                          | 3                        | (0.5)                    | 23                                            | (0.4)                                         | 46                                                     | (0.4)                                                  |
| Gamma-glutamyltransferaseincreased    | 4                              | (0.7)                          | 2                        | (0.3)                    | 15                                            | (0.2)                                         | 31                                                     | (0.3)                                                  |
| Interstitial lung disease             | 4                              | (0.7)                          | 0                        | (0.0)                    | 9                                             | (0.1)                                         | 17                                                     | (0.2)                                                  |
| Nausea                                | 4                              | (0.7)                          | 2                        | (0.3)                    | 25                                            | (0.4)                                         | 44                                                     | (0.4)                                                  |
| Adrenal insufficiency                 | 3                              | (0.5)                          | 0                        | (0.0)                    | 19                                            | (0.3)                                         | 31                                                     | (0.3)                                                  |
| Anaemia                               | 3                              | (0.5)                          | 0                        | (0.0)                    | 52                                            | (0.8)                                         | 104                                                    | (0.9)                                                  |
| Back pain                             | 3                              | (0.5)                          | 0                        | (0.0)                    | 15                                            | (0.2)                                         | 27                                                     | (0.2)                                                  |
| Chronic obstructive pulmonary disease | 3                              | (0.5)                          | 一                        | (0.2)                    | 14                                            | (0.2)                                         | 21                                                     | (0.2)                                                  |
| Cough                                 | 3                              | (0.5)                          | 7                        | (1.2)                    | 27                                            | (0.4)                                         | 56                                                     | (0.5)                                                  |
| Herpes zoster                         | 3                              | (0.5)                          | 4                        | (0.7)                    | 12                                            | (0.2)                                         | 25                                                     | (0.2)                                                  |
| Nasopharyngitis                       | 3                              | (0.5)                          | 5                        | (0.9)                    | 13                                            | (0.2)                                         | 24                                                     | (0.2)                                                  |
| Non-cardiac chest pain                | 3                              | (0.5)                          | 2                        | (0.3)                    | 0                                             | (0.0)                                         | 3                                                      | (0.0)                                                  |
| Blood bilirubin increased             | 2                              | (0.3)                          | 0                        | (0.0)                    | 22                                            | (0.4)                                         | 44                                                     | (0.4)                                                  |
| Cataract                              | 2                              | (0.3)                          | 0                        | (0.0)                    | 1                                             | (0.0)                                         | 4                                                      | (0.0)                                                  |

## Post marketing experience

The safety profile of pembrolizumab was summarized in the Periodic Safety Update Report covering the period  04-Sep-2020  through  03-Sep-2021,  specifically  Appendix  20.3  (Numbers  of  Adverse  Drug Reactions by Preferred Term from Postauthorization Sources).

There are no records of any pembrolizumab registration being revoked or withdrawn for safety reasons in any country.

## 2.5.1. Discussion on clinical safety

The known  safety  profile of  pembrolizumab  is  mainly  characterised  by  immune-related  adverse reactions, most of which resolved after appropriate medical therapy or withdrawal of pembrolizumab. When used as monotherapy, the most frequent known ADRs with pembrolizumab were fatigue (30%) and diarrhoea (22%). The majority of ADRs reported were of Grades 1 or 2 severity. The most serious

<div style=\"page-break-after: always\"></div>

adverse reactions were immune-related ADRs and severe infusion-related reactions. The incidences of immune-related  ADRs  were 36.9%  for  all  Grades  and 8.7%  for  Grades 3-5  for  monotherapy  in  the adjuvant setting, and 24.5% for all Grades and 6.3% for Grades 3-5 in the metastatic setting.

The data analysed in the present procedure come mainly from the study KEYNOTE-091 on patients affected by Stage IB (T2a ≥ 4 cm), Stage II, or Stage IIIA NSCLC, randomised to one of the two arms: 1) pembrolizumab (n=580, treated with adjuvant pembrolizumab monotherapy); 2) placebo (n=581). For comparison with the currently known safety profile, data from the pembrolizumab monotherapy RSD (n=6185, mainly patients with advanced melanoma or with NSCLC in first-line setting). A comparison versus the pooled pembrolizumab arms from other adjuvant settings has also been performed.

For the present study, the median of exposure to pembrolizumab was similar to placebo (11.7 vs 11.8 months), whereas the mean was markedly lower for pembrolizumab than placebo (8.7 vs 10.0 months). Also, the patients with exposure &gt;6 months and &gt;9 months were lower in pembrolizumab than in placebo (68.4% vs 81.2% and 60.9% vs 74.2%, respectively). All these data are consistent with higher discontinuation rate in pembrolizumab compared to placebo.

At baseline , more patients in the pembrolizumab arm had an ECOG status of 0 compared to placebo (64.7% vs 58.3%). In the RDS the number of patients with ECOG 0 was lower (47.6%).

## Adverse events

Overall distribution : out of 580 patients in each arm, those with at least one AE were (pembrolizumab vs placebo) 95.9% vs 91.0%. More AEs were adjudicated as drug-related in pembrolizumab compared to placebo (75.2% vs 52.5%) but in line with RSD (70.6%). Many more grade 3-5 AEs were considered as drug-related in pembrolizumab compared to placebo (15.2% vs 4.3%), again in line with RSD. A similar trend was observed with serious drug-related AEs. More patients discontinued the drug in pembrolizumab than in placebo (19.8% vs 5.9%) or in RSD (13.5%): the figure compared to RSD could be explained by a better clinical/general condition of patients enrolled in the present study compared to the average RSD patient and, thus, to a higher probability that every deviation from this wellness condition is attributed to the drug (instead that to the disease). Patients who discontinued the treatment due to drug-related AEs were many more in pembrolizumab than in placebo (16.9% vs 3.4%) or in RSD (7.2%).

The most frequently reported AEs (incidence &gt;15%) were weight increased, pruritus, hypothyroidism, arthralgia, diarrhoea, and fatigue (but weight increased was lower compared to placebo). Pruritus was more common in pembrolizumab (21.6% vs 12.7%) but in line with RSD (18.0%). Hypothyroidism was much more frequent in pembrolizumab than in placebo (20.7% vs 4.6%) and RSD (11.3%); a similar pattern was observed for Hyperthyroidism: more frequent in pembrolizumab than placebo (10.7% vs 2.9%) or RSD (4.2). The higher frequency compared to RSD is probably due to the lower exposure occurred in this latter dataset. Arthralgia was slightly more frequent with pembrolizumab but in line with RSD. Overall, the AEs were similar to what observed for the adjuvant-setting database (with the notable exception of deaths, see below).

Drug-related AEs : Hypothyroidism was the most frequent drug-related AE (pembrolizumab vs placebo: 19.7% vs 3.3%; RSD: 9.8%). A similar pattern was observed for drug-related hyperthyroidism (9.3% vs 3.7%). Pruritus was considered related to treatment more often in pembrolizumab than placebo (17.9% vs 10.3%) but with a similar proportion compared to RSD. A similar pattern was observed for diarrhoea. Rush was also more frequently related to treatment in pembrolizumab vs placebo (manually calculated adding related PTs: 12.6% vs 5.1%). Pneumonitis related to drug in pembrolizumab were more than twice as many as in placebo (5.7% vs 2.1%).

<div style=\"page-break-after: always\"></div>

Grade 3-5 AEs : the number of subjects experiencing at least one grade 3-5 AE was higher with pembrolizumab compared to placebo (34.1% vs 25.8%) but lower compared to RSD (48.2%), as somewhat expected because of the more severe clinical conditions of patients in the latter dataset. The AEs which showed the biggest differences of prevalence between pembrolizumab and placebo were pneumonia/pneumonitis (3.3% vs 1.9%; RSD: 5.5%) and diarrhoea (1.2% vs 0.3%). It is noteworthy that hypothyroidism and hyperthyroidism, which were two frequent AEs, are not listed among the most frequent grade 3-5 AEs (just 1 case for each AE is reported). However, grade 3-5 hypocortisolism (that can be a life-threatening endocrine condition) was observed only in pembrolizumab (n=5, 0.9% vs n=0).

AEOSIs (immune-related events and infusion-related reactions): the number of patients with at least one AEOSI was higher in pembrolizumab than placebo (39.0% vs 12.9%) or RSD (25.5%). A similar pattern is observed for drug-related AEOSI (36.9% vs 9.1%; RSD: 22.1%). Also, when adjusted for the exposure, the incidence of AEOSI was higher in pembrolizumab compared to the RSD, probably because many of these events require some time to develop fully and to become clinically evident: thus, the shorter exposure of the RSD could have been insufficient for many of these events to emerge, resulting in a lower incidence in the RSD.

Hypothyroidism was much more frequent in pembrolizumab than in placebo (20.7% vs 4.6%) or in RSD (11.3%). Hyperthyroidism, too, was much more frequent with pembrolizumab than placebo (10.7% vs 2.9%) or RSD (4.2%). Adrenal insufficiency was observed only in pembrolizumab (n=10, 1.7%): it has been reassigned a frequency of 'Common' at the 4.8 section of the SmPC; the frequency in the RSD was 0.8%. Hypophysitis was only observed in patients in pembrolizumab (n=7, 1.2%) and no cases were registered with placebo; the frequency in the RSD was 0.6%.

Hepatitis was more common in pembrolizumab than placebo (n=10, 1.7% vs n=4, 0.7%) and than RSD (1.0%). Myocarditis was more frequent in pembrolizumab compared to placebo (n=5, 0.9% vs n=1, 0.2%) and to RSD (n=7, 0.1%). Whilst the lower incidence of many immune-mediated AEs in the RSD can be attributed to a lower exposure in that dataset, the difference observed for myocarditis in pembrolizumab vs RSD (0.9% vs 0.1%) seems higher compared to other immune-related AEs (such as hepatitis). Immune-mediated myocarditis is a known AE associated to anti-PD-L1 therapies. It is difficult to assess the relationship between the cases of myocarditis observed in the study and the treatment because of the concomitant complications observed in some patients (such as sepsis). However, since the known causal relationship, it is not possible to exclude pembrolizumab as causal factor of these cases.

The most frequent SAEs (pembrolizumab vs placebo) were: pneumonia (2.2% vs 1.5%), pneumonitis (2.1% vs 0.7%), diarrhoea (1.2% vs 0.2%); the prevalence of these three AEs was not higher than what observed in the RSD. Pulmonary embolism was observed only in the pembrolizumab group (n=3, 0.5%) and none in the placebo (but the prevalence in the RSD was higher: 1.2%); however, only 3 subjects were involved, and therefore it is not possible to establish firmly whether embolism was related to the IMP or it was by chance. In general, SAEs were in line to what already known from the RSD, and the frequency was similar or lower in the current pembrolizumab arm compared to RSD.

Patients who died for AEs were almost double with pembrolizumab compared to placebo (1.9% vs 1.0%) but less than RSD (5.2%). Moreover, it must be kept in mind that the current setting is adjuvant therapy and, therefore, patients had ECOG status 0 or 1 (i.e. they were in relatively good general clinical conditions as compared to the metastatic setting). Compared to other approved adjuvant settings, there were more patients with fatal AEs in the current pembrolizumab arm than in the pooled pembrolizumab arms of the other adjuvant settings, n=11 (1.9%) vs n=4 (0.3%), and the cases considered drug-related were 4 (0.7%) vs 0. Therefore, at first glance a higher number of patients died in the pembrolizumab arm of the current trial compared to the other studies in the

<div style=\"page-break-after: always\"></div>

adjuvant setting. However, when all the deaths in the current trial are considered (both those due to AEs and those counted as outcome events for efficacy evaluation) the number of patients who died in the pembrolizumab arm is lower compared to placebo (98, 16.6% vs 111, 18.9%). Therefore, an overall lower mortality has been registered in the pembrolizumab arm of the current study.

One patient with hyperthyroidism (high FT4, low TSH) was erroneously treated with thyroid hormone therapy. The patient died by sudden death, after chest pain, the day after the finding of a FT4 value more than 3 times higher than the upper normal value. The cause of death could be related to myocardial ischemia, for which a condition of hyperthyroidism is a known risk factor. However, from the data available it has not been possible to gather more information.

Regarding the laboratory findings , a grade 3-4 ALT increase was observed in more patients in pembrolizumab than placebo (3.3% vs 0.5%) but in line with RSD. Similar findings were seen for AST and bilirubin. Grade 3-4 Hypokalaemia was more frequent in pembrolizumab than placebo (1.9% vs 0.3%) but less than RSD. The other main laboratory findings were overall similar between the two arms and to the RSD.

Discontinuation of the IMP was higher with pembrolizumab compared to placebo and to the RSD. The latter finding can be due to the shorter exposure in the RSD. The most frequent cause of discontinuation was Pneumonitis: (pembrolizumab vs placebo) n=21 (3.6%) vs n=4 (0.7); pneumonitis is a well-known ADR to pembrolizumab. This cause was also more frequent in the pembrolizumab arm of the current study compared to the RSD (1.7%). Other AEs which caused discontinuation were Diarrhoea (1.2% vs 0.3%), Colitis (0.9% vs 0.2%), Hypothyroidism (0.9% vs 0). Autoimmune hepatitis was also more frequent in pembrolizumab than placebo (n=5, 0.9% vs n=0).

The most frequent cause of treatment interruption was Hypothyroidism which was more frequent in pembrolizumab than in placebo (3.4% vs 0.2%) and RSD. Again, the difference with the RSD could be due to a shorter exposure in the latter dataset. Other AEs leading to interruption were Diarrhoea (3.3% vs 1.0%) and pneumonitis (3.1% vs 1.5%). Other AEs with a high difference in frequency between the two arms were Arthralgia (2.8% vs 0.5%), Colitis (1.4% vs 0), Hyperthyroidism (1.2% vs 0), Rash (1.2% vs 0), Adrenal insufficiency (n=3, 0.5% vs 0): the latter event is not frequent but, since it is a possible life-threatening condition, deserves particular attention.

The MAH position that food and DDI are not anticipated to influence exposure to pembrolizumab, since it is an IgG antibody, is shared. In the same way, drugs that affect the cytochrome P450 enzymes, and other metabolizing enzymes, are not expected to interfere with the metabolism of pembrolizumab.

The ADA incidence rate in the present study was lower or comparable to what observed in a similar setting (adjuvant treatment of melanoma): 2.3% vs 3.4% respectively. The historical incidence rate of treatment emergent positive subjects reported for monotherapy is 2.1%, that is similar to what observed in the present study.

Relevant figures in section 4.8 of the SmPC were updated to incorporate safety data from this submission. More specifically, the incidences of immune-mediated adverse reactions for pembrolizumab as monotherapy was updated to 37% all Grades and 9% for Grades 3-5 for pembrolizumab monotherapy in the adjuvant setting and 25% all Grades and 6% for Grades 3-5 in the metastatic setting; In patients with NSCLC, pneumonitis occurred in 206 (6.1%), including Grade 2, 3, 4 or 5 cases in 92 (2.7%), 56 (1.7%), 16 (0.5%) and 9 (0.3%), respectively; In patients with melanoma, NSCLC and RCC treated with pembrolizumab monotherapy in the adjuvant setting (n=2,060), the incidence of hyperthyroidism was updated to 11.0%, the majority of which were Grade 1 or 2. In patients with melanoma, NSCLC and RCC treated with pembrolizumab monotherapy in the adjuvant setting (n=2,060), the incidence of hypothyroidism was updated to 18.5%, the majority of which were Grade 1 or 2.

<div style=\"page-break-after: always\"></div>

## Effects of intrinsic and extrinsic factors on safety

Regarding the age , on average, the number of AEs, drug-related AEs and grade 3-5 AEs in the pembrolizumab arm in patients &gt;65 years was similar to that of patient &lt;65 years, except for SAEs and discontinuation which were slightly more frequent in the category &gt;65 years. This pattern seems slightly different than that observed in the RSD where also the overall number of AEs, drug-related AEs and grade 3-5 AEs was higher in the &gt;65 years. The frequency of AEs seems to increase with age in patients &gt;65 years, but the number of patients &gt;85 years is very limited, and no conclusions can be gathered on this age group. In the range 75-84 years (about 50-60 patients in each arm in the current study) in the pembrolizumab arm, the number of AEs was not higher compared to the corresponding RSD age category, except for discontinuations due to AEs that were more frequent in the current pembrolizumab arm (but the small number of subjects prevents any further evaluation).

When analysed by gender , the overall number of patients with at least one AE in pembrolizumab arm was similar between male and female. However, more male patients had grade 3-5 AEs compared to female (36.3% vs 29.6%); but when only drug-related AEs are considered, these were similar between the two categories. A similar pattern can also be observed for SAEs. AEs with fatal outcome were more frequent in male vs female (n=10, 2.5% vs n=1, 0.5%) but the same happened in the placebo group (1.3% vs 0.5%), whereas in the RSD dataset this difference is much lower (5.5% vs 4.5%). However, it seems that male participants had more baseline risk factors than female participants (such as age, smoking history and pre-existing medical conditions) potentially leading to a worse outcome.

There are some differences observed in the frequency of AEs according to the race (divided into white , other and not applicable ). For instance, patients who discontinued the drug due to AEs were more frequent in the white group than in the other group (21.7% vs 12.0%); however, the groups were unbalanced as to numerosity (442 vs 117 subjects enrolled, in pembrolizumab arm, in each category respectively) and in the RSD the differences were much less noticeable.

When patients with AEs were analysed by geographical regions , the number of patients in pembrolizumab arm with grade 3-5 AEs was higher in EU than in non-EU (37.9% vs 26.6%); a similar pattern is observed in the placebo arm but not in RSD where the distribution was similar. Drug-related grade 3-5 AEs, SAEs and discontinuation due to AEs were all more frequent in EU compared to non-EU, in both arms (pembrolizumab and placebo), whereas they had similar frequency in the RSD. It should be noted that the two groups (i.e. EU and non-EU) of the current study were of different size (388 vs 192 respectively). The EU patients seemed to have more risk factors at baseline compared to non-EU (slightly higher age, more smokers). This could have given EU patients a worse outcome.

When analysed by ECOG status there were no relevant differences between patients with ECOG status 0 and 1 in the pembrolizumab arm: the differences, if any, were small, in the expected direction (possible slightly higher frequency of AEs in ECOG 1), and in line with what observed in the placebo arm and in the RSD.

## 2.5.2. Conclusions on clinical safety

The safety profile of pembrolizumab is mainly characterised by immune-related adverse reactions. In the current study, overall, the number of AEs was higher in pembrolizumab compared to placebo but in line with the RSD. However, discontinuations due to AEs and the frequency of AEOSI (such as hypothyroidism and hyperthyroidism) were higher in pembrolizumab than RSD (but exposure was longer in the present study). The AEs most frequently reported were pruritus, hypothyroidism, arthralgia, diarrhoea, and fatigue. Death due to AEs was more commonly observed in pembrolizumab than placebo, and was slightly higher when compared to the pooled pembrolizumab arms from other adjuvant settings. Overall, no new particular safety concerns have arisen from the data submitted in

<div style=\"page-break-after: always\"></div>

the current procedure, and the safety profile could be acceptable. However, considering the adjuvant setting and, thus, the relatively good clinical general condition of these patients, the observed higher mortality compared to placebo, and the higher discontinuation and higher AEOSI rate compared to RSD, will have to be taken into account in the definition of the B/R ratio (see 3.7.2).

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 39.2 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 39.2 with the following content:

## Safety concerns

Table 61: Summary of Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                        |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-mediated adverse reactions                                                                                                                                                                                                                                                                                 |
| Important potential risks    | For hematologic malignancies: increased risk of severe complications of allogeneic stem cell transplantation (SCT) in patients who have previously received pembrolizumab Graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic stem cell transplant (SCT) |
| Missing information          | None                                                                                                                                                                                                                                                                                                              |

## Pharmacovigilance plan

There are no ongoing or planned additional pharmacovigilance studies that are required for pembrolizumab.

## Risk minimisation measures

Table 62: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                               | Risk minimisation Measures                                   | Pharmacovigilance Activities                                 |
|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Important Identified Risks: Immune-Related Adverse Reactions | Important Identified Risks: Immune-Related Adverse Reactions | Important Identified Risks: Immune-Related Adverse Reactions |

<div style=\"page-break-after: always\"></div>

Table 62: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                                                | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-related adverse reactions (including immune- related pneumonitis, colitis, hepatitis, nephritis and endocrinopathies)                  | Routine risk minimisation measures: • The risk of the immune- related adverse reactions (including immune-related pneumonitis colitis, hepatitis, nephritis, and endocrinopathies) associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. | Routine pharmacovigilance activities                                                                                                              |
|                                                                                                                                               | Additional risk minimisation measures: Patient educational material                                                                                                                                                                                                                                                                                    | Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types |
| Important Potential Risks                                                                                                                     | Important Potential Risks                                                                                                                                                                                                                                                                                                                              | Important Potential Risks                                                                                                                         |
| For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab | Routine risk minimisation measures: • For Hematologic malignancies: the increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab is described in the SmPC, Section 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk.                                          | Routine pharmacovigilance activities                                                                                                              |

<div style=\"page-break-after: always\"></div>

Table 62: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                       | Risk minimisation Measures No additional risk minimisation measures warranted                                                                                                                                                                                                                  | Pharmacovigilance Activities Additional pharmacovigilance including: • Safety monitoring in the ongoing HL trials (KN204).                                                             |
|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| GVHD after pembrolizumab administration in patients with a history of allogeneic SCT | Routine risk minimisation measures: • GVHD after pembrolizumab administration in patients with a history of allogeneic SCT is described in the SmPC, Section 4.4 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC as well as annex II.D have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons: There are two limited modifications and no other proposed changes to the content of the package leaflet; in particular the key messages for the safe use of the medicinal product are not impacted. Furthermore, the design, layout and format of the package leaflet will not be affected by the proposed revisions.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The final indication is 'KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy (for selection criteria, see section 5.1)'.

## 3.1.2. Available therapies and unmet medical need

Platinum-based doublets is the mainstay of the systemic adjuvant treatment for resected NSCLC. Standard combinations are cisplatin and vinorelbine, but other combinations are commonly used in the clinical practice (etoposide, gemcitabine, pemetrexed, taxane) 22,23 . Regarding immunotherapy, atezolizumab was approved for the adjuvant treatment of NSCLC after resection and platinum-based chemotherapy at high risk of recurrence and PD-L1 expression on tumour cells (TC) ≥ 50% and who do not have EGFR mutant or ALK -positive NSCLC 24 . In mutated NSCLC, osimertinib was approved for the adjuvant treatment of stage IB-IIIA NSCLC limited to tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations 25 .

## 3.1.3. Main clinical studies

KEYNOTE-091 (PEARLS study/EORTC-1416/ETOP-8-15) is a randomized Phase 3 trial with pembrolizumab versus placebo for patients with early-stage non-small cell lung cancer (NSCLC) Stage IB (T2a ≥ 4 cm), II or IIIA (AJCC 7th ed) after complete resection and completion of standard adjuvant chemotherapy (administered when recommended). The trial randomized 1170 patients 1:1 to receive pembrolizumab or placebo (triple blinded). Dual primary endpoints of the study were DFS in the ITT and in the PD-L1 TPS ≥ 50% subgroup. The MAH submitted the IA2 analysis (data cutoff of 20SEP-2021), at a median follow-up of duration for participants of 33.3 months for the pembrolizumab group and 31.9 months for the placebo group. All patients have either discontinued or completed 1 year of adjuvant treatment. Results of the pre-specified IA3 analysis (data cut-off 24 Jan 2023) were also submitted during the procedure. At IA3, median follow-up was 46.7 months (approximately 13 months longer as compared to IA2).

## 3.2. Favourable effects

- In KEYNOTE-091 study, most of the population (86%, 506 vs 504 patients) received prior adjuvant chemotherapy which was a stratification factor and was balanced between treatment arms. At IA3, the results in the population with adjuvant chemotherapy are numerically more favourable as compared to the ITT, showing relevant DFS benefit maintained with longer follow up [DFS HR 0.76 (95%CI 0.64, 0.91), 44% vs 52 % events, medians 54 vs 40 months, DFS rate at 24 months 67%

22  Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl\\_4):iv1-iv21.

23  National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer; version 8.2020.

24  EMA/667840/2022, EPAR Tecentriq CHMP Assessment report

25  EMA/280219/2021, EPAR Tagrisso CHMP Assessment report

<div style=\"page-break-after: always\"></div>

vs 59%], and numerical positive OS trend [OS HR 0.79 (95%CI 0.62, 1.01), 22% vs 27% events, medians NR in either arm]. In this population, DFS HR point estimates for subgroups are all &lt;1, as well as for OS (with the exception of patients over 75 years). No subgroups appear to drive the results.

- IA3 data confirmed numerically favourable trends in DFS (HR 0.44, 95%CI 0.22, 0.87) and OS (HR 0.35, 95%CI 0.13, 0.98) in patients with EGFR positive NSCLC, acknowledging the large confidence intervals due to the small sample size. Therefore, patients with EGFR mutated tumours are not explicitly excluded from the adjuvant indication.

## 3.3. Uncertainties and limitations about favourable effects

- OS in the ITT and in the PDL1 TPS ≥50% population did not reach statistical significance neither at IA2 nor at IA3, and could not formally be tested in PD-L1 TPS ≥ 1% (IA3 OS in all patients: HR 0.87, 95%CI 0.69, 1.10, p=0.11792, 23% vs 27% OS event; OS in TPS ≥50%: HR 0.93, 95%CI 0.57, 1.50, p= 0.3778, 20% vs 21% OS events). The MAH will submit the final OS analysis which will further characterise the efficacy of Keytruda in the intended indication (see Annex II).
- Some uncertainty remains in terms of the efficacy in the adjuvant treatment of adults with NSCLC, specifically on data on treatment post-progression, and particularly on the uptake and activity of anti-PD(L)1 in patients previously treated with adjuvant pembrolizumab. The MAH is expected to submit these data as part of a PAES (see Annex II).
- The population was not stratified for EGFR/ALK alterations, and the mutational status is unknown in about 60% of the overall population. The low number of positive patients is described in section 5.1 of the SmPC to highlight the limited data available. No further analysis of EGFR is planned in this study.

## 3.4. Unfavourable effects

- The  most  frequently  reported  AEs  were  weight  increased,  pruritus,  hypothyroidism,  arthralgia, diarrhoea, and fatigue. The number of subjects experiencing at least one grade 3-5 AE was higher with pembrolizumab compared to placebo but lower compared to RSD. The AEs which showed the greatest differences of prevalence between pembrolizumab and placebo were pneumonia/pneumonitis (3.3% vs 1.9%; RSD: 5.5%) and diarrhoea (1.2% vs 0.3%). Grade 3-5 hypocortisolism was observed only in pembrolizumab (5 cases, 0.9%).
- AEs  of  special  interest  were  mainly  immune-related  events  and  infusion-related  reactions:  the number of patients with at least one AEOSI was higher in pembrolizumab than placebo (39.0% vs 12.9%) or RSD (25.5%). A similar pattern is observed for drug-related AEOSI. Even when adjusted for  the  exposure,  the  incidence  of  AEOSI  was  higher  in  pembrolizumab  compared  to  the  RSD. Hypothyroidism and hyperthyroidism were more frequent in pembrolizumab than both placebo and RSD.  Adrenal  insufficiency  was  observed  in  10  patients  with  pembrolizumab  vs  0  in  placebo. Hypophysitis  was  only  observed  in  patients  in  pembrolizumab  (n=7,  1.2%).  Hepatitis  and myocarditis were more common in pembrolizumab than placebo or RSD.
- The  most  frequent  SAEs  (pembrolizumab  vs  placebo)  were:  pneumonia  (2.2%  vs  1.5%), pneumonitis (2.1% vs 0.7%), diarrhoea (1.2% vs 0.2%); the prevalence of these three AEs was similar  (or  lower)  to  what  observed  in  the  RSD.  Pulmonary  embolism  was  observed  only  in  the pembrolizumab group (n=3, 0.5%) vs none in the placebo (but lower frequency compared to RSD).

<div style=\"page-break-after: always\"></div>

In general, SAEs were in line to what already known from the RSD, and the frequency was similar or lower in the current pembrolizumab arm compared to RSD.

- Patients who died were almost double with pembrolizumab compared to placebo (1.9% vs 1.0%) but  less  than  RSD  (5.2%).  However,  it  must  be  taken  into  account  that  RSD  patients  were,  on average, affected by more advanced disease. Fatal AEs considered as related were more frequent in pembrolizumab than placebo but similar to RSD. Also, when compared to pembrolizumab in the other approved adjuvant settings, a higher number of fatal AEs were recorded (n=11, 1.9% vs n=4 0.3%).
- The  safety  profile  was  similar  in  patients  &gt;65  years  and  &lt;65  years,  except  for  SAEs  and discontinuation which were slightly more frequent in &gt;65 years.
- AEs with fatal outcome were more frequent in male vs female (n=10, 2.5% vs n=1, 0.5%) but the same happened in the placebo group (1.3% vs 0.5%). It seems that male patients had more risk factors at baseline (age, smoking).
- The number of patients in pembrolizumab arm with grade 3-5 AEs was higher in EU than in non-EU (37.9% vs 26.6%) and the same was observed in the placebo arm. A similar trend was observed for drug-related grade 3-5 AEs, for SAEs and for discontinuation due to AEs. It seems that EU patients had more risk factors at baseline (age, smoking).

## 3.5. Uncertainties and limitations about unfavourable effects

None

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 63 : Effects Table for Keytruda in adjuvant Stage IB(≥4cm) -IIIA NSCLC after complete resection and adjuvant chemotherapy (IA3, data cut-off: 24 Jan 2023)

| Effects                                          | Short description                                                                                                                                      | Short description                                                                                                                                      | Unit                           | Treatment Pembrolizumab (n=506)                                                     | Treatment Pembrolizumab (n=506)                                                     | Uncertainties / Strength of evidence                                                                                                     | Referen ces                |
|--------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| Favourable Effect                                | Favourable Effect                                                                                                                                      | Favourable Effect                                                                                                                                      | Favourable Effect              | Favourable Effect                                                                   | Favourable Effect                                                                   | Favourable Effect                                                                                                                        | Favourable Effect          |
| DFS in patients with prior adjuvant chemotherapy | DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. | DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. | Events% Median Months (95% CI) | 44.5% vs 52% 53.8 (46.2, 70.4) vs 40.5 (32.9, 47.4) HR 0.76 (0.64, 0.91), p=0.00143 | 44.5% vs 52% 53.8 (46.2, 70.4) vs 40.5 (32.9, 47.4) HR 0.76 (0.64, 0.91), p=0.00143 | Relevant DFS benefit confirmed at IA3; prior chemotherapy stratification factor and prespecified subgroup analyses; all subgroups HRs <1 | MAH's response to 2 nd RSI |
| OS in patients with prior adjuvant chemotherapy  | OS was defined as the time from randomization to the date of death (whatever the cause).                                                               | OS was defined as the time from randomization to the date of death (whatever the cause).                                                               | Events% Median Months (95% CI) | 22.3% vs 27.4% NR vs NR HR 0.79 (0.62, 1.01; p=0.03224                              | 22.3% vs 27.4% NR vs NR HR 0.79 (0.62, 1.01; p=0.03224                              | Positive OS trend; prior chemotherapy stratification factor; all subgroups HRs<1 (except >75y) / still interim OS data                   |                            |
| Unfavourable Effects                             | Unfavourable Effects                                                                                                                                   | Unfavourable Effects                                                                                                                                   | Unfavourable Effects           | Unfavourable Effects                                                                | Unfavourable Effects                                                                | Unfavourable Effects                                                                                                                     | Unfavourable Effects       |
|                                                  |                                                                                                                                                        |                                                                                                                                                        |                                | Placebo / RSD                                                                       | Patients in RSD had more severe disease                                             | Patients in RSD had more severe disease                                                                                                  | KEYNOTE 091 CSR            |
| Patients with NO AEs                             | Patients with NO AEs                                                                                                                                   | %                                                                                                                                                      | 4.1                            | 9.0 / 3.2                                                                           |                                                                                     |                                                                                                                                          |                            |
| Patients with drug-related                       | Patients with drug-related                                                                                                                             | %                                                                                                                                                      | 75.2                           | 52.5 / 70.6                                                                         | AEs                                                                                 | AEs                                                                                                                                      |                            |
| Patients with grade 3-5 AEs                      | Patients with grade 3-5 AEs                                                                                                                            | %                                                                                                                                                      | 34.1                           | 25.8 / 48.2                                                                         |                                                                                     |                                                                                                                                          |                            |
| SAEs                                             | SAEs                                                                                                                                                   | %                                                                                                                                                      | 24.5                           | 15.5 / 38.3                                                                         | Patients with                                                                       | Patients with                                                                                                                            |                            |
| Deaths                                           | Deaths                                                                                                                                                 | n (%)                                                                                                                                                  | 11 (1.9)                       | 6 (1) / 321 (5.2)                                                                   |                                                                                     |                                                                                                                                          |                            |
| Deaths due to drug-related                       | Deaths due to drug-related                                                                                                                             | n (%)                                                                                                                                                  | 4 (0.7)                        | 0 / 39 (0.6)                                                                        | AEs                                                                                 | AEs                                                                                                                                      |                            |
|                                                  |                                                                                                                                                        | %                                                                                                                                                      | 20.7                           | 4.6 / 11.3                                                                          | Hypothyroidism                                                                      | Hypothyroidism                                                                                                                           |                            |
| Hyperthyroidism                                  | Hyperthyroidism                                                                                                                                        | %                                                                                                                                                      | 10.7                           | 2.9 / 4.2                                                                           |                                                                                     |                                                                                                                                          |                            |

Abbreviations: DFS=disease free survival; OS=overall survival; CI: confidence interval; IA: interim analysis; NR=not reached;

AE=adverse event; SAE=serious adverse event; RSD=reference safety dataset; CSR=clinical study report.

Notes: One-sided p-value based on the Wald Test in the multivariate Cox regression model.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

KEYNOTE-091 showed at the IA2 a statistically significant improvement in DFS for one year of adjuvant pembrolizumab vs placebo in the overall population of patients with resected Stage IB (T2a ≥ 4cm), II and IIIA (AJCC 7th ed) NSCLC in KEYNOTE-091 study. The results of IA3 (i.e. final DFS analysis) were consistent with IA2, reassuring on the stability of the benefit of pembrolizumab over placebo in the overall population with more mature data and longer follow-up (including relevant observation time after stopping treatment given the adjuvant setting), but showing also unclear less

<div style=\"page-break-after: always\"></div>

favourable trends in some subgroups (for patients with squamous histology, PD-L1 TPS ≥ 50% and patients without prior adjuvant chemotherapy). The indication in patients with NSCLC at high risk of recurrence [Stage IB (T2a ≥ 4 cm), II, or IIIA, as defined by the AJCC 7th edition] following complete resection of the lung tumour AND adjuvant platinum based chemotherapy is based on numerically more favourable results in the population who have received prior adjuvant chemotherapy as compared to the ITT, suggesting relevant DFS benefit and positive OS trend (with no current suggestion of detriment) for pembrolizumab vs placebo. In the population treated with prior adjuvant chemotherapy, DFS HR point estimates for subgroups are all &lt;1, with no subgroups driving the results. Although the retrospective exclusion of patients without adjuvant chemotherapy subgroup can at least not be regarded as optimal as the MAH failed to provide a clear rationale, it is important that adjuvant treatment (received or not) had been a stratification factor and as such the subgroup analysis was pre-specified. The MAH will submit updated OS data as part of the imposed PAES (see Annex II). In addition, the MAH will submit data on treatment post-progression, and particularly on the uptake and activity of anti-PD(L)1 in patients previously treated with adjuvant pembrolizumab.

Overall, the safety profile in the current setting is similar to what is already known for pembrolizumab in general and pembrolizumab as adjuvant treatment. Higher discontinuations and higher AEOSI rate have been observed compared to the RSD; however, the exposure in the current study was longer than that in RSD, potentially explaining this finding. Discontinuations due to AEs was also overall similar to other studies using pembrolizumab or other anti-PD(L)1 agents with an adjuvant aim. While more fatal AEs were observed compared to patients receiving placebo and compared to the pembrolizumab in other approved adjuvant settings, when all the deaths (due to AEs and outcome events for efficacy evaluation) are counted, the number of patients who died in the pembrolizumab arm is lower compared to placebo.

## 3.7.2. Balance of benefits and risks

Adjuvant 1-year therapy with pembrolizumab resulted in an improved benefit over placebo that can be considered to outweigh the toxicities of the treatment in the indication of patients with high risk of recurrence [Stage IB (T2a≥4cm), II and IIIA, per AJCC 7 th  ed] NSCLC following resection and prior adjuvant platinum-based chemotherapy.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall B/R of Keytruda is positive in the adjuvant treatment of patients with high risk of recurrence [Stage IB (T2a ≥ 4cm), II and IIIA, per AJCC 7th ed] NSCLC following resection and prior adjuvant platinum-based chemotherapy.

The following measures are considered necessary to address issues related to efficacy, in accordance with the Commission Delegated Regulation (EC) No 357/2014, (a) an initial efficacy assessment that is based on surrogate endpoints, which requires verification of the impact of the intervention on clinical outcome or disease progression or confirmation of previous efficacy assumptions:

Post-authorisation efficacy study (PAES): in order to further characterise the efficacy of Keytruda for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence, the MAH should submit the results of the final OS analysis of study KEYNOTE-091. The MAH should

<div style=\"page-break-after: always\"></div>

submit updated data on treatment post-progression, and particularly on the uptake and activity of anti-PD(L)1 in patients previously treated with adjuvant pembrolizumab.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include Keytruda as monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy based on study KEYNOTE-091; an ongoing Phase 3, randomized, tripleblinded, placebo-controlled, multicentre study of pembrolizumab versus placebo in patients with earlystage NSCLC after resection and completion of standard adjuvant therapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are being updated and the Annex II and the Package Leaflet are updated in accordance. An updated RMP version 39.0 was also submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I, II and IIIB and to the Risk Management Plan are recommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

<div style=\"page-break-after: always\"></div>

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Due date   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Post-authorisation efficacy study (PAES): In order to further characterise the efficacy of Keytruda for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence, the MAH should submit the results of the final OS analysis of study KEYNOTE-091. The MAH should submit updated data on treatment post-progression, and particularly on the uptake and activity of anti- PD(L)1 in patients previously treated with adjuvant pembrolizumab - Final Study Report | 3Q 2026    |

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Keytruda-H-C-003820-II-0121'